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ABSTRACT 
Non-steroidal anti-inflammatory drugs (NSAIDs) are known to be the major 
class of agents responsible for adverse effects in the elderly population. Age-related 
alterations in drug disposition are well established and are probably a contributory factor 
to adverse reactions in the elderly. However, the majority of NSAIDs are used as 
racemic mixtures and little is known concerning the influence of ageing on the 
stereochemical aspects of drug disposition. These studies were therefore initiated to 
investigate the stereoselective disposition of ibuprofen and flurbiprofen in young and 
elderly volunteers. Although, both of these drugs are members of the 2-arylpropionic 
acid family of NSAIDs, they display considerable differences in their stereoselective 
disposition and pharmacodynamics. 
Enantiospecific analysis of ibuprofen in serum and urine was based on the indirect 
approach to chiral chromatography, involving derivatization with (R)-1-(naphthen-l-yl) 
ethylamine to yield diastereomeric amides followed by reversed-phase HPLC. Protein 
binding of the individual enantiomers was performed using equilibrium dialysis 
followed by direct resolution using a derivatized cellulose CSP (Chiracel OD). 
Determination of the stereochemical composition of its major metabolites, hydroxy- and 
carboxyibuprofen, in urine was carried out by sequential achiral-chiral chromatography 
using a derivatized amylose CSP (Chiralpak AD). Simultaneous enantiospecific analysis 
of flurbiprofen and its metabolites, 4'-hydroxy- and 3'-hydroxy-4'-methoxyflurbiprofen, 
in urine was by chiral-phase chromatography using the derivatized amylose CSP. 
Modification in the mobile phase composition allowed the analysis of flurbiprofen and 
4'-hydroxyflurbiprofen in serum. This CSP was also used to isolate sufficient quantities 
of the individual enantiomers of both flurbiprofen metabolites for chiroptical 
characterization. 
Following the administration of the racemic drugs to both young and elderly 
volunteers enantioselective disposition was displayed by both compounds, the more 
prominent enantiomeric differences observed with ibuprofen. The serum kinetics of 
ibuprofen showed statistically significant differences (p<0.05) with (S)-ibuprofen 
showing greater CL, Vd and tl/2, Z and unbound fraction in comparison to the R- 
enantiomer in both age groups. Similarly, examination of the urinary composition of 
ibuprofen and its metabolites showed preferential elimination of products with the S- 
configuration. However with flurbiprofen, the S-enantiomer had a significant lower CL, 
1 
greater AUC and tli2, Z in comparison to the R-enantiomer in the elderly group. Similar 
trends were observed in the young, although only t112,, showed statistical significance. 
Furthermore urinary excretion of flurbiprofen and its metabolites, in contrast to 
ibuprofen, displayed a more modest preference for the R-enantiomer. 
Age-associated alterations in the disposition of ibuprofen were evident for the S- 
and not the R-enantiomer. As a consequence of a higher unbound fraction and reduced 
unbound clearance, which was largely due to reduced clearance via oxidative 
metabolism, the elderly had a greater exposure to the free levels of the 
pharmacologically more potent (S)-ibuprofen leading to a 25% increase in unbound 
AUC with age. Pharmacodynamic studies, based on monitoring the inhibition of TXB2 
formation, showed that ibuprofen activity is closely correlated with unbound (S)- 
ibuprofen concentration. Age-related differences in the pharmacokinetics of flurbiprofen 
seem to stem primarily from a reduction in clearance as a result of a general decline in 
metabolic activity. Consequently, the elderly have a greater exposure to both 
enantiomers of the drug with enantiomeric AUCs typically 60% higher in this age group 
in comparison to the young. These age-related alterations in the disposition of ibuprofen 
and flurbiprofen may contribute to the adverse reactions in this population sub-group. 
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Chirality of drug substances has received inadequate attention in the past and we 
have learned through experience that we ignore this aspect of molecular structure at our 
peril. In other words, the stereochemical genie has finally escaped from the medical 
prison in which it has been confined for too long. Advances over the last two decades in 
the area of stereospecific analysis, with parallel developments in stereoselective 
synthesis, have provided us with the tools to realise the potential significance of the 
pharmacodynamic and pharmacokinetic properties of the enantiomers of chiral drugs. 
This general increase in awareness is reflected in the attitude of regulatory authorities 
around the world. Although, geometrical isomers have long been regarded as different 
compounds, it is becoming increasing apparent that regulatory bodies also take this view 
when dealing with the enantiomers of a chiral drug (Caldwell, 1999). The initial 
sections in this chapter are designed to provide the reader with a brief overview of 
stereochemistry and its role in drug action and disposition. As the studies presented in 
this thesis are concerned with investigating the influence of ageing on the 
stereoselective disposition of 2-arylpropionic acids, the remainder of this chapter is 
devoted to a review of the literature on the stereoselective pharmacology and methods of 
enantiospecific analysis of this important sub-group of non-steroidal anti-inflammatory 
drugs (NSAIDs). 
1.2. Stereochemistry 
Stereochemistry is concerned with the three dimensional spatial arrangement of 
the atoms within a molecule. The prefix stereo originating from the Greek stereos 
meaning solid or volume. The origins of stereochemistry stem 
from the leap of intuition 
made by Louis Pasteur in 1849 concerning the 
"handedness" he noted in crystal 
structure (Drayer, 1993). By crystallisation of sodium ammonium tartrate 
from aqueous 
solutions, he obtained two types of 
hemihydric crystals with facets arranged such that 
non-superimposible species were 
formed. After separating the crystals by hand, he re- 
dissolved them individually and found that one solution rotated the plane of plane 
polarised light to the left ((-)-tartrate) and 
the other to the right ((+)-tartrate). This led 
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him to the conclusion that optical activity was a characteristic of the molecule and that 
the individual molecules of (-)- and (+)-tartaric acid are stereochemically dissymmetric, 
related to each other as non-superimposible mirror images and expressed as hemihydric 
crystals in their sodium ammonium salt form. The two forms are known as 
enantiomorphs or enantiomers (Greek enantios, opposite; morph, form). Compounds 
which display this behaviour are said to be chiral (Greek chiros, handed), because like 
an individual's hands, the individual stereoisomers are not superimposible with their 
mirror images (Hutt, 1998). 
1.2.1 Enantiomers and diastereoisomers 
The chirality of biologically-significant compounds generally arises as a result of 
the presence of a tetravalent carbon atom in a molecule to which four different atoms or 
groups are bonded, such atoms are known as centres of asymmetry or chiral centres 
(Figure 1.1). In addition to carbon, other atoms such as nitrogen, phosphorus and 
sulphur to which four different groups are bonded also generate chiral molecules of 
pharmacological importance (Hutt, 1998). The presence of one chiral centre (n=1) in a 
molecule gives rise to a pair of enantiomers, whereas n such different centres yields 2' 
stereoisomers and half as many pairs of enantiomers (Figure 1.1). Those isomers that are 
not enantiomeric are diastereomeric. It is also noteworthy, that molecules which do not 
possess an asymmetric centre may still exist in enantiomeric forms as a result of an axis 
or plane of chirality, however such systems are not often encountered in compounds of 
pharmacological interest. 
In a pair of enantiomers the distances between nonbonded atoms are identical and 
so enantiomers tend to have identical physiochemical properties except that they rotate 
the plane of polarised light by equal amounts but in opposite direction. Thus, they have 
essentially identical melting and boiling points, 
lipid solubilities, chromatographic 
characteristics and spectra. The energy differences 
between enantiomers are so little as 
to make distinction between them extremely 
difficult unless they are placed in a chiral 
environment, and this has profound 
importance in terms of both pharmacology and 
analytical chemistry. When two chiral molecules 
interact, either by the formation of a 
covalent or ionic bond or other weaker attractive 
forces, the physiochemical differences 
between the formed diastereomeric compounds or complexes are considerably more 
distinct. Diastereoisomers tend to have different energy contents unlike enantiomers, 
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since distances between nonbonded atoms are not identical, and hence they can be 
expected to be more easily discriminated by their different chromatographic properties, 






















Figure 1.1: Relationship between enantiomers and diastereoisomers (X denotes chiral centre). 
1.2.2 Nomenclature 
The traditional approach used to distinguish between a pair of enantiomers relied 
upon their differential interactions with plane polarised light. Under a particular set of 
experimental conditions, the isomer which rotates light to the right being termed 
dextrorotatory (d- or (+)-) and conversely, the isomer which rotates light to the left 
being designated levorotatory (1- or (-)-). A racemic mixture, a 1: 1 mixture of the 
enantiomers, being indicated by either d, 1- or (±)- prefix to the name of the compound. 
This notation describes a physical property of the molecule and indicates whether a 
single isomer or mixture is present but does not describe the actual spatial arrangement 
of the atoms or groups around the chiral centre, 
i. e. provides no information on its 
absolute configuration. 
At the end of the 19th century, the means to determine spatial three dimensional 
arrangement of the atoms or groups within a molecule, 
i. e. the absolute configuration, 
4 
Chapter 1 Introduction 
were not available and it was realised that reference standards were required. The 
carbohydrate, (+)-glyceraldehyde, was arbitrarily assigned the D-configuration when 
drawn as a Fischer projection (Figure 1.2) and any compound which could be 
synthesised from (+)-glyceraldehyde without inversion of the chiral centre was, by 
definition, the D-isomer; conversely, compounds related to (-)-glyceraldehyde were 
designated the L-isomer. It was not until the 1950s that X-ray crystallographic studies 
had established that the assigned configuration for (+)-glyceraldehyde was, in fact, 
correct (Shah et al., 1998). In a similar manner, D-(+)- and L-(-)-serine have also been 
used for the assignment of relative configurations (Figure 1.2). Due to the difficulty of 
chemical transformation, the confusion between the lower and upper case notations 
(D and d, L and l) and the difficulties in applying the system in many situations, the use 
of the D, L notation has largely been restricted to defining the stereochemistry of 
















Figure 1.2: Fischer projections of the enantiomers of glyceraldehyde and serine. 
The most widely used system to designate stereoisomers is the sequence rule 
system, which is also referred to as the Cahn, 
Ingold and Prelog convention (Cahn et al., 
1956). Following establishment of the three dimensional structure of the compound, by 
techniques such as X-ray crystallography, nuclear magnetic resonance or circular 
dichroism, the four substituent atoms directly attached to the chiral centre are placed in 
order of priority according to their atomic number, with 
the highest atomic number 
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being assigned the highest priority. If attached atoms are equivalent then the decision on 
priority is based on the atom an extra bond away and so on until the rank order for the 
four groups has been established. The molecule under examination is then viewed from 
the side opposite to the group of lowest priority (Figure 1.3). The arrangement of the 
remaining three groups is defined as either a R- or S- absolute configuration, depending 
on whether the decreasing priority order is clockwise (R, rectus) or anticlockwise (S, 
sinister). This convention can be used to rapidly and unambiguously specify the 
configuration of a chiral centre and is extremely useful for describing diastereoisomers. 
In the latter case, each chiral centre is designated independently and the configuration of 






Figure 1.3: Assignment of absolute stereochemical configuration according to the Cahn, Ingold 
and Prelog convention, where the priority order is [1] >[2] > [3] > [4]. 
1.3. Stereoselectivity in drug action and disposition 
1.3.1 Stereoselective pharmacodynamics 
Biological systems at a molecular level are homochiral environments with 
structural, functional and catalytic components composed of 
biomolecules, e. g proteins, 
glycolipids and polynucleotides, built from the chiral precursors of 
L-amino acids and 
D-carbohydrates. It is therefore not surprising to expect differential interactions between 
chiral biological macromolecules, such as receptors and enzymes, and the enantiomers 
of a chiral drug. The first recorded observations of the 
difference in pharmacodynamic 
activity of drug enantiomers was attributed to 
Cushny, who demonstrated that (-)- 
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hyoscyamine was more potent than the (+)-enantiomer and that (-)-adrenaline had 
greater activity than its (+)-antipode (Hutt, 1998). According to the Easson and Stedman 
model (Easson and Stedman, 1933), stereochemical differences in pharmacological 
activities are due to the differential binding of enantiomers to a common site on an 
enzyme or receptor surface (Figure 1.4). The model proposed that the more potent 
enantiomer has a minimum of three intermolecular interactions with the enzyme or 
receptor surface, whereas the less potent isomer may interact only at two sites. Such a 
model, although useful, is a rather simplistic representation of a complex bimolecular 
interaction process. The model assumes the drug molecule has to adopt a particular 
orientation when interacting with complementary binding sites and can not account for 
the possible involvement of mutually induced conformational adjustments of the drug 
and macromolecule. However, a dynamic model of the chiral recognition procedure has 
been recently proposed by Booth et al. (1997), which is based upon molecular chiralities 
rather than three-point interactions. This so-called "conformation-driven" chiral 
recognition process involves the initial formation of the complex, followed by 
conformational adjustment of the two elements, activation of the complex through 
additional binding interactions and "expression of the molecular chiralities" of the two 












Figure 1.4: Interaction of two enantiomers with a receptor site. The enantiomer on the left is the 
more potent, with three molecular interactions while 
that on the right interacts at two points only. 
The differential pharmacodynamic activity of a pair of enantiomers has resulted in 
additional terminology such that the enantiomer with 
the greater affinity or activity is 
termed the eutomer and that with the lower affinity or activity 
is referred to as the 
distomer (Lehmann et al., 1976). The ratio of their activities, the eudismic ratio is a 
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measure of the stereoselectivity of the system. It is important to appreciate that the 
above terms apply to a single drug activity and thus for a dual-action drug, the eutomer 
for one activity may be the distomer for the other. A variety of differential enantiomer 
contributions to the biological effects of a drug administered as a racemate are therefore 
possible and these are outlined below: 
Pharmacological activity resides in only one enantiomer. Although highly desirable, 
it is uncommon for the pharmacological activity to reside in a single enantiomer with 
the antipode totally devoid of activity. However, one such example is a-methyldopa 
(Figure 1.5), the antihypertensive activity resides solely in the S-enantiomer (Gillespie et 
al. , 
1962) and this agent is marketed as a single isomer. 
Figure 1.5: Structure of a-methyldopa (* denotes chiral centre). 
Both enantiomers have similar activities and potencies. The enantiomers of 
flecainide (Figure 1.6) display equipotency with regards to antiarrthymic activity and 
action on cardiac sodium channels; and also appear to 
have indifferent pharmacokinetic 
properties (Kroemer et al., 1989). Both enantiomers of the antihistamine promethazine 
(Figure 1.6) have similar pharmacological and toxicological profiles, and interestingly 
the loss of chirality in the dimethylaminoethyl side chain 
is associated with a 50 % 
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Both enantiomers have similar activities but different potencies. This is the most 
common situation for racemic drugs. The ß-blocking activity of propranolol (Figure 1.7) 
and other aryloxypropanolamine ß-antagonists resides principally in the S-enantiomers 
and the eudismic ratios vary from 100 for propranolol to 10 for atenolol (Walle et al.. 
1988). Another well known example is warfarin (Figure 1.7), whose S-enantiomer is 





Figure 1.7: Structure of (a) propranolol and (b) warfarin. 
(b) 
Both enantiomers are marketed with different indications. Recognition some years 
ago of the different spectrum of activity of the enantiomers of propoxyphene (Figure 
1.8) resulted in the development of two enantiomerically pure drugs: dextro- 
propoxyphene (Darvon), an analgesic and levopropoxyphene (Novrad), an antitussive. 
The trade names are, quite appropriately, mirror images of each other. 
* 
Figure 1.8: Structure of propoxyphene. 
Toxicological activity resides predominantly in one enantiomer. 
There are several 
examples where one enantiomer contributes 
little to therapeutic efficacy but is mainly 
responsible for undesirable side-effects. 
Penicillamine (Figure 1.9) is used for the 
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reactions such as nephritis are attributed to the L-enantiomer and, therefore, only the D- 
enantiomer is used (Williams, 1990). Ketamine (Figure 1.9) is a useful anaesthetic with 
analgesic properties and does not cause circulatory or respiration depression. However, 
(R)-ketamine is three to four fold less potent than its antipode and is responsible for the 
excitatory and hallucinogenic effects on emergence from anaesthesia (White et al., 
1980). Clearly, it would seem preferable to use (S)-ketamine, i. e. the more potent and 
less toxic enantiomer, rather than the racemic mixture and recently the single isomer 
product has been approved in Germany (Tucker, 2000). In a similar manner, 
bupivacaine (Figure 1.9), a long-acting amide local anaesthetic, has been re-marketed as 




















Figure 1.9: Structures of (a) penicillamine, (b) ketamine and (c) bupivacaine. 
The enantiomers have opposite effects. Picenadol (Figure 1.10) is a phenylpiperidine 
derivative that has both opioid agonist and antagonist activity. (+)-(3S, 4R)-Picenadol 
has a strong agonist activity at the µ receptor whilst the (-)-(3R, 45)-antipode has a weak 
antagonistic activity at the same receptor. The racemate therefore 
has moderate 
analgesic activity and acts as a partial agonist 





Figure 1.10: Structure of picenadol. 
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Toxicological activity of one enantiomer antagonised by other. Nebivolol (Figure 
1.11) is a recently introduced ß-blocker used for the treatment of hypertension. The (+)- 
isomer, which has the S, R, R, R configuration, is highly selective and has a long half-life. 
The (-)-isomer with the R, S, S, S configuration, has no ß-blocking activity but is reported 
to moderate the negative inotropic effects of (+)-nebivolol (Van de Water et al., 1988). 
Figure 1.11: Structure of nebivolol. 
1.3.2 Stereoselective pharmacokinetics 
Differences between the pharmacological activity of enantiomers may be of a 
pharmacokinetic as well as of a pharmacodynamic origin (Caldwell et al., 1988b; Jamali 
et al. , 1989; Tucker and Lennard, 
1990; Levy and Boddy, 1991). Stereoselectivity may 
occur in virtually all phases of drug disposition, i. e. absorption, distribution, metabolism 
and excretion since many of these processes involve interaction of the drug enantiomers 
with chiral biological macromolecules. The magnitude of the differences between 
stereoisomers with respect to their pharmacokinetic parameters tends to be relatively 
modest, frequently one to three fold compared with those observed with respect to 
pharmacodynamic properties; however, they are of clinical significance. 
i) Absorption 
Drug absorption through the gastrointestinal tract, skin or the pulmonary system is 
for the majority of compounds a passive process which depends on factors such as 
lipophilicity, pKa and molecular size, and therefore the rate and extent of absorption do 
not differ between a pair of enantiomers as they have the same physicochemical 
properties. However, stereoselective differences may arise if the drug is a substrate 
for 
active or carrier-mediated transport systems. For example, the absorption of 
L-dopa and 
L-methotrexate is favoured over their respective antipodes (Wade et al., 1973; Hendel 
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and Brodthagen, 1984) as the L-isomers are absorbed by active transport mechanisms 
while the D-isomers are absorbed by passive diffusion. 
Additional biochemical or pharmacological factors may influence the 
stereo selectivity of drug absorption. For example, the (-)-isomer of bupivacaine has a 
lower systemic absorption and longer-lasting local-anaesthetic activity than its antipode 
following intradermal injection, as consequence of its vasoconstrictor effect leading to a 
decrease in localised blood flow (Alps and Reynolds, 1978). In the case of terbutaline, 
the greater oral bioavailability of the more active (-)-isomer has been associated with 
stereoselective first-pass metabolism and may also be due to the (-)-isomer increasing 
intestinal membrane permeability (Brogstrom et al., 1989). 
However, stereoselective absorption of passively absorbed drugs can also occur if 
the enantiomers have difference dissolution profiles as a result of enantioselective 
intermolecular interactions with chiral excipients in the dosage form. For example, the 
release of propranolol from a formulation containing hydroxypropylmethylcellulose is 
stereoselective (Duddu et al., 1993) and verapamil dissolution from modified release 
dosage forms can favour the R-enantiomer (Aubry and Wainer, 1993). 
It is noteworthy, that so far little or no attention has been drawn to the relevance 
and stereoselectivity of the inverse transport (counter-transport) mechanisms of the 
gastrointestinal tract mediated by P-glycoprotein. Recent in vivo and in vitro data 
supports the hypothesis that (S)-talinolol is a slightly better substrate than the 
R-enantiomer for P-glycoprotein (Wetterich et al., 1996). Hence, net absorption of 
(S)-talinolol into systemic circulation is reduced, and plasma concentrations are lower in 
comparison to its R-antipode (Wetterich et al., 1996). 
ii) Distribution 
The extent of distribution of drugs is essentially governed by plasma protein 
binding, tissue protein binding and lipophilicity. As the latter is a physical property, the 
partition of a drug into various sites is not expected to be enantioselective, but the extent 
of binding of a pair of enantiomers however, may differ substantially. 
The plasma protein binding of a drug is an important factor influencing both 
pharmacodynamics and pharmacokinetics since only the 
drug in the unbound-form is 
responsible for pharmacological action and available 
for distribution to tissues and 
clearance. For highly protein 
bound drugs, minor enantiomeric differences in binding 
leads to much larger differences in the enantiomeric composition of the unbound 
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fraction. The majority of drugs bind in a reversible manner to plasma proteins, notably 
to human serum albumin (HSA) and /or al-acid glycoprotein (AGP). Acidic drugs bind 
preferentially to HSA, with binding at site II (benzodiazepine site) on the protein 
generally displaying greater enantiomeric differences than at site I (warfarin site) 
(Fehske et al., 1981). Example of stereoselective plasma protein binding for acidic 
drugs include ibuprofen, indacrinone, phenprocoumon, warfarin, mephobarbitone and 
pentobarbitone (Hutt, 1998). Basic drugs predominately bind to AGP and 
stereoselective binding has been reported for numerous drugs including chloroquine, 
disopyramide, methadone, mexiletine and verapamil (Hutt, 1998). Stereo selectivity in 
binding may vary for different proteins, e. g. the protein binding of propranolol to AGP 
is stereoselective for the S-enantiomer, whereas binding to HSA favours the R-antipode 
(Hutt, 1998). In whole plasma the binding to AGP is dominant such that the free 
fraction of (R)-propranolol is greater than that of (S)-propranolol (Hutt, 1998). 
Competition for plasma protein binding sites is a common cause of 
pharmacokinetic complications. For example, enantiomer-enantiomer interactions in the 
concentration-dependent plasma protein binding of disopyramide following 
administration of the racemate, exposed enantiomeric differences in disposition that 
were not evident following separate administration of the enantiomers (Giacomini et al., 
1986). The co-administration of another drug can also influence the protein binding of a 
chiral drug, e. g. phenylbutazone administration causes a greater displacement of 
(R)- compared to (S)-warfarin from plasma protein binding sites but concomitantly 
inhibited oxidative metabolism of the S-enantiomer to a larger extent. The cumulative 
effect is an increased total clearance of (R)-warfarin; but more significantly, a reduced 
clearance of active (S)-warfarin leading to enhanced pharmacological activity (Hutt, 
1998). 
Enantioselective tissue binding, which is in part a consequence of enantioselective 
plasma protein binding, has been reported. For example, the transport of ibuprofen into 
both synovial and blister fluids is preferential for the S-enantiomer owing to the higher 
free fraction of this enantiomer in plasma (Seideman et al., 1994). In addition the 
affinity of stereoisomers for binding sites 
in specific tissues may also differ and 
contribute to stereoselective tissue 
binding, e. g. (S)-leucovorin accumulates in tumour 
cells in vitro to a greater degree than the 
R-antipode (Mader et al., 1994). The uptake of 
ibuprofen into lipids is stereoselective in favour of the R-enantiomer, but this is as a 
13 
Chapter I Introduction 
result of stereospecific formation of the acyl-CoA thioester followed by incorporation as 
hybrid triglycerides (see section 1.4.2). 
iii) Metabolism 
Metabolism tends to exhibit the greatest degree of stereoselectivity of all the processes 
contributing to drug disposition, with both phase I and II reactions potentially capable of 
discriminating between enantiomers (Caldwell et al., 1988b). The chirality of both the 
parent drug and metabolite have to be considered when stereoselective metabolism is 
discussed, five scenarios are possible: 
Prochiral to chiral transformations, where a prochiral molecule is metabolised to 
preferentially form one of two possible enantiomers. An example of this type of reaction 
is the p-oxidation of the antiepileptic drug phenytoin, which displays significant product 
selectivity in favour of the formation of (S)-4-hydroxyphenytoin in man (Figure 1.12) 
(Poupaert et al., 1975). Whereas in the dog, phenytoin undergoes oxidation to yield the 
R-enantiomer of the m-hydroxylated product (Maguire et al., 1978) and thus the reaction 







Figure 1.12: Prochiral to chiral transformation, oxidation of phenytoin. 
Chiral to chiral transformations, in which the two enantiomers of a drug are 
differentially metabolised at a site remote from the chiral centre. With warfarin, 
aromatic oxidation to form the 7-hydroxy metabolite 
is highly selective for the more 
active S-enantiomer in man (Figure 







Figure 1.13: Chiral to chiral transformation, aromatic oxidation at the 7-position of warfarin. 
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Chiral to achiral transformations, where the chiral substrate undergoes metabolism 
leading to loss of asymmetry. Although, not frequently encountered, it is nevertheless 
important especially if substrate stereoselectivity is observed. For example nivadipine, 
which has a dihydropyridine structure, undergoes cytochrome P450-mediated oxidation 
to yield the corresponding achiral pyridine analogue (Figure 1.14); the reaction is 
stereoselective for the (-)-enantiomer of the drug in man (Hutt, 1998). 
HgC COOCH(CH3)2 H3C COOCH(CH3)2 
101 7 HN 
N02 NC COOCH3 NC COOCH3 
Figure 1.14: Chiral to achiral transformation, aromatization of nilvadipine. 
Chiral to diastereoisomer transformations, where either phase I or phase II 
metabolism introduces a second chiral centre into the molecule. An example of the first 
type is the keto-reduction of warfarin to yield diastereomeric alcohols (Figure 1.15), this 
reaction shows substrate selectivity for (R)-warfarin and 
favours the S-configuration at 
the new chiral centre (Hutt, 1998). Phase II metabolic reaction of a chiral substrate with 
a chiral conjugating agent, such as 
D-glucuronic acid, glutamine and glutathione, will 
inevitably produce diastereomeric products. In man, oxazepam conjugation with 
D-glucuronic acid shows preference for the S-enantiomer of the drug (Figure 1.15) 


















oxazepam oxazepam glucuronide 
Figure 1.15: Chiral to diastereoisomer transformations, (a) keto-reduction of warfarin and 
(b) glucuronidation of oxazepam. 
Chiral inversion, where one enantiomer of the substrate is biochemically converted 
into its antipode with no other alterations in structure. Such a transformation is relatively 
rare since it necessitates the breaking of a bond between the chiral centre and a group 
directly attached before subsequent reformation of the bond in the alternative 
configuration. The reaction was first observed with the 2-arylpropionic acid NSAIDs, 
with the inactive R-enantiomers undergoing selective inversion to their active 
S-antipodes in many animal species including man (Hutt and Caldwell, 1983). The 
mechanism is thought to proceed via formation of (R)-profenyl-CoA-thioesters that 
subsequently epimerize and hydrolyse to liberate both enantiomers of the drug. The 
S-enantiomer is unable to undergo thio-esterification and so the inversion process is 
unidirectional (Nakamura et al., 1981). The chiral inversion of 2-arylpropionic acid 
drugs will be examined in detail in section 1.4.2. 
iv) Renal excretion 
Renal excretion is the composite effect of glomerular filtration, active secretion and 
passive and active reabsorption. Apparent stereoselectivity in renal clearance may arise 
as a consequence of stereoselective protein binding leading to enantiomeric differences 
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in glomerular filtration and/or passive reabsorption. Active renal tubular secretion has 
been associated with stereoselective clearance of some basic drugs including terbutaline, 
disopyramide, chloroquine and pindolol (Hutt, 1998). It is also possible that 
enantiomeric differences may originate from stereoselectivity in active reabsorption or 
renal metabolism. However, stereoselective renal elimination tends to have little impact 
on the disposition of the enantiomers unless this is a major clearance pathway of the 
drug. 
As a result of stereoselectivity in the various processes of drug disposition 
outlined above, the pharmacokinetic profile of a pair of enantiomers may differ 
markedly. Thus an estimation of pharmacokinetic parameters and concentration-effect 
relationships based on total drug concentrations are of limited value and potentially 
misleading, and have been described as "sophisticated nonsense" (Ariens, 1984). 
Furthermore, whilst a considerable number of enantioselective pharmacokinetics studies 
have been performed, little is known about the influence of various patient factors, e. g. 
age, sex, disease state and pharmacogenetics, on stereochemical aspects of drug 
disposition. 
1.3.3 Current implications of drug stereochemistry 
From the above it is apparent that individual enantiomers may differ markedly in 
their pharmacodynamic and pharmacokinetic profiles and thus their presence in a 
racemic mixture can not be viewed simply as a 50: 50 mixture of an active drug and an 
inert component. The use of racemates is regarded by some as "polypharmacy", with the 
proportions in the mixture being dictated by chemical rather than therapeutic 
considerations; such agents are also regarded as compounds containing 50% impurity 
(Ariens, 1984; 1986). To date there is a large body of information regarding the 
stereoselective differences in the action and disposition of chiral drugs which supports 
the view that the use of racemic mixtures may have important pharmacological and 
toxicological implications. The strength of evidence has prompted regulatory agencies 
to promote the use of single isomer preparations for new chemical entities unless it can 
be proven that the racemate gives therapeutic benefits over the single enantiomer or that 
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the preparation of a single isomer is not technically feasible on an industrial scale 
(Langaniere, 1997; Williams et al., 1998). 
Furthermore, a re-evaluation of drugs marketed as racemates has led to a few 
successful "chiral switches", i. e. commercialisation of a single enantiomer product from 
a previously marketed racemate (Tucker, 2000). Situations where a racemate-to- 
enantiomer switch may be appropriate include: drugs where there are problems 
associated with the racemate or it would be therapeutically advantageous to use the 
single isomer, pharmacological activity resides in one isomer, the mode of action 
established for the racemate is valid for the single isomer and synthesis or resolution of 
the desired isomer is feasible at the appropriate scale (Caldwell, 1999). In terms of drug 
group, the most significant switches have been observed for the 2-arylpropionic acid 
NSAIDs with the S-enantiomer of ibuprofen available in Austria and Switzerland, and 
(S)-ketoprofen marketed in Spain and recently introduced in the United Kingdom. 
However as yet, the majority of the drugs in this group continue to be marketed and 
used as racemic preparations. Therefore, an examination of stereochemical aspects of 
the pharmacodynamic and pharmacokinetic properties of such drugs is essential for their 
rational therapeutic re-assessment, especially since they display stereoselectivity in 
action, protein binding, chiral inversion and metabolism. Moreover, 2-arylpropionic acid 
drugs are most widely used in the elderly population where there are likely to be age- 
related alterations in drug handling, and co-morbid disease conditions and multiple drug 
therapies are likely to be more prominent. 
1.4. The 2-arylpropionic acid group of anti-inflammatory drugs 
Non-steroidal anti-inflammatory drugs (NSAIDs) are extensively prescribed for 
alleviating pain and inflammation associated with a wide range of 
joint and 
muscoskeletal disorders. As a group, the 
NSAIDs encompass a variety of structural 
classes including salicylates, pyrazoles, oxicams, 
fenamates, arylacetic acids and 
arylpropionic acids. Of these subcategories, 
the 2-arylpropionic acids are the most 
frequently used agents and have been the backbone of anti-inflammatory 
drug treatment 
since ibuprofen became commercially available 
in 1969 in the UK (Williams et al., 
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1993). Subsequently, numerous analogues have been developed and the structures of 
























Drugs belonging to the 2-arylpropionic acid class have certain common structural 
components essential for anti-inflammatory activity. These include a carboxylic acid 
functionality and a substituted aromatic group attached to the a-carbon atom, and 
arrangement of the four different substituents around the a-carbon must be in the 
S-configuration to afford activity. Indeed, it was the early recognition that activity 
resided in the one enantiomer which prompted the development of the successful 
enantiomerically pure drug, (S)-naproxen, in the early 1970s. The majority of these 
agents are still used in their racemic form; however, as outlined above, the current 




It has been generally accepted that the 2-arylpropionic acids and other NSAIDs 
exert most of their pharmacological and toxicological effects by inhibiting the binding 
of arachidonic acid to cyclooxygenase (COX), thus preventing the formation of pro- 
inflammatory prostaglandins such as prostaglandin E2 (PGE2; Figure 1.17) (Vane, 1971; 
Fereira and Vane, 1979). The in vitro COX inhibitory activity of the 2-arylpropionic 
acids resides principally in the enantiomer of the S-configuration, as reflected by high 
eudismic ratios. Comparison of the relative potencies of the enantiomers in in vivo test 
systems however show that the large eudismic ratios observed in vitro are diminished 
such that in some cases, e. g. ibuprofen and fenoprofen, both enantiomers display 
approximately equal activity (Table 1.1). These disparities arise due to in vivo chiral 
inversion, which involves the metabolism of the relatively inactive R-enantiomer of the 
drug to the pharmacologically active antipode. In fact, a large difference between in vivo 
and in vitro eudismic ratios is a good indicator that metabolic chiral inversion has 
occurred (Adams et al., 1976). 
Recently, COX has been shown to be encoded by two genes giving rise to two 
distinct forms of this enzyme, namely COX-1 and COX-2 (Vane et al., 1998; Wu, 
1998). COX-1 is expressed in most tissues under normal physiological conditions and is 
associated with cellular homeostatic, i. e. normal "housekeeping", functions in for 
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example the gastrointestinal tract and kidneys (Vane et al., 1998). In contrast, COX-2 is 
chiefly produced in inflammatory cells in response to tissue trauma and inflammation 
and is also expressed constitutively in brain neurons and regions of the kidney (Vane et 
al., 1998). Therefore, the prostaglandins generated following stimulation of COX-2 
activity are most likely to be responsible for pain and tissue damage (Dray and Bevan, 
1993). 



























Figure 1.17: The arachidonic acid cascade (adapted from Vane et aL, 1998). 
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Table 1.1: Relative activity of the enantiomers of 2-arylpropionic acid NSAIDs in in vitro and in 
vivo test systems (adapted from Hutt, 1998). 
Drug Ratio SIR Test System 
in vitro in vivo 
Carprofen > 24 prostaglandin synthesis inhibition 
14 acute adjuvant arthritis 
Fenoprofen 35 platelet aggregation inhibition 
1 carrageenin paw oedema 
Flurbiprofen 200 platelet aggregation inhibition 
2 to 16 guinea-pig anaphylaxis 
Ibuprofen 160 prostaglandin synthesis inhibition 
1.1 ultraviolet induced erythema 
Naproxen 130 prostaglandin synthesis inhibition 
28 carrageenin paw oedema 
Following the identification of COX-1 and COX-2, the degree to which NSAIDs 
differentially inhibit the two isoforms has been evaluated in a wide variety of in vitro 
test systems. However, a major drawback has been the variability in results between 
different assay methods in terms of both the degree of COX-inhibition and the COX-2 
to COX-1 selectivity. Recently, Warner et al. (1999) developed an improved COX 
selectivity assay method which took into consideration a number of important criteria 
for optimum reliability, these were: (1), the use of both isoforms from a common 
species (preferably human); (2), common incubation times of drugs with both COX 
systems and (3), equivalent levels of substrate being available to both isoforms. The 
COX-2 to COX-1 selectivity, in terms of the ratio of IC80 values, determined for aspirin 
and various 2-arylpropionic acids using this novel method are presented in Figure 1.18. 
The degree of COX selectivity was quite varied between the different 2-arylpropionic 
acids, although all showed preference towards inhibiting COX-1. 
It has been suggested that selective COX-2 inhibition, at the expense of COX-1 
blockade would be a logical therapeutic goal, thereby limiting the well recognised 
gastrointestinal adverse effects of 2-arylpropionic acids and other 
NSAIDs. Indeed, 
numerous in vitro investigations of the COX-selectivity of 
NSAIDs have shown that 
agents with less inhibitory activity 
for COX-1 are less likely to cause gastrointestinal 
toxicity (Hayller and Bjarnason, 1995; Kawai et al., 
1998; Warner et al., 1999). Such in 
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vitro observations should be related with caution to the clinical situation, in view of the 
multifactorial nature of the pathophysiology of NSAID-induced adverse effects and also 
the fact that in vivo, other factors such as enantioselective disposition have to be 
considered. The situation could be further complicated by recent in vitro evidence which 
suggests that the coenzyme-A thioester of (R)-ibuprofen, which is an intermediate of the 
chiral inversion process, also possesses significant COX-2 inhibitory activity (Neupert 
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log [IC8o ratio (COX-2/COX-1)] 
Figure 1.18: Relative activities against COX-1 versus COX-2 for aspirin and some 2-arylpropionic 
acids (adapted from Warner et al., 1999). 
Nevertheless, recent randomised double-blind trials of two COX-2 specific 
inhibitors, i. e. celecoxib (Simon et al., 1999) and rofecoxib (Langman et al., 1999), 
showed that treatment with these drugs was associated with a lower incidence of 
gastrointestinal complications than treatment with non-specific NSAIDs. However, only 
widespread use will confirm or refute their utility over traditional NSAIDs and the 
premise that selective COX-2 inhibitors will not affect the gastrointestinal tract 
has 
already been challenged. In three experimental models, 
COX-2 selective drugs were 
observed to inhibit angiogenesis, i. e. formation of new capillary 
blood vessels, which is 
required for ulcer healing (Jones et al., 1999). To 
further support the notion, it was 
demonstrated that L-745,337, a selective COX-2 inhibitor, delayed the healing of gastric 
ulcers partly through the inhibition of angiogenesis 





Although the anti-inflammatory action of 2-arylpropionic acids and other NSAIDs 
appears to result from inhibition of COX, several recent reports suggest that non-COX 
mechanisms may also be important in the analgesic action of these drugs (Brune et al., 
1991,1992; Geisslinger et al., 1994a; Lötsch et al., 1995; Neugebauer et al., 1995; 
Geisslinger and Schaible, 1996, Buritova and Besson, 1998). These reports focus on the 
fact that in different models of animal and human nociception, the pure R-enantiomer of 
flurbiprofen, an ineffective COX inhibitor, possesses substantial analgesic activity. 
These findings are pivotal since (R)-flurbiprofen undergoes little if any chiral inversion 
when given to rats or humans. Further support for the pharmacological benefits of the 
poorly inverted R-enantiomers of 2-arylpropionic acids, is provided by the effectiveness 
of (R)-ketoprofen as an analgesic in the treatment of post-operative dental pain (Cooper 
et al. , 1998) and the suggestion that (R)-ketoprofen is a more effective analgesic than its 
antipode (Ghezzi et al., 1998). Highly lipid soluble drugs such as flurbiprofen and 
ketoprofen are likely to have the ability to cross the blood-brain barrier and central 
mechanisms of analgesic activity have been proposed. These include the ability to 
interfere with central opioid mechanisms, inhibition of serotonin activity and inhibitory 
activity on excitatory amino acids or NMDA receptors (Cashman, 1996). 
In addition to inhibiting the synthesis of prostaglandins, NSAIDs in general exert a 
range of COX-independent biological actions, some of which may be important 
contributors to the pharmacological profile of the drug. Such activities include the 
ability to reduce in vitro sulphated glycosaminoglycan synthesis in articular cartilage, 
the ability to suppress neutrophil aggregation and degranulation, inhibition of 
inflammatory oedema by action on polymorphonuclear leukocytes and inhibition of 
mitochondrial ß-oxidation (Evans, 1996). It is thought that many of these prostaglandin 
independent effects arise from interference with normal cell signalling processes due to 
their ability to partition into cellular phospholipid bilayer and disrupt G protein- 
dependent events. Membrane partitioning is unlikely to be enantioselective and so these 
COX-independent actions are invariably non-discriminatory between drug enantiomers. 
This is supported by a report of equipotent in vitro inhibition of human 
polymorphonuclear cell function by (R)-, (S)- and (R, S)-ibuprofen 







Among the general pharmacokinetic features of the 2-arylpropionic acids is the 
rapid and efficient oral absorption of conventional doses. For example, the oral 
bioavailability of (R, S)-ibuprofen and (R, S)-flurbiprofen have been estimated to be 
approximately 0.95 and 0.94 respectively, indicating virtually complete absorption from 
the gastrointestinal tract and insignificant first-pass metabolism (Hall et al., 1993; 
Szpunar et al., 1987). As absorption of these drugs is governed by passive diffusion, 
enantiomeric differences in the systemic availability of 2-arylpropionic acids is unlikely 
(Evans, 1992). 
Distribution 
Once in the systemic circulation, the 2-arylpropionic acids are extensively bound 
(> 99%) to plasma proteins, predominately to albumin (Lin et al., 1987). For ibuprofen, 
indoprofen and 2-phenylpropionic acid, plasma protein binding is greater for the 
R-enantiomer (Lapicque et al., 1993). Whilst conflicting results have been reported for 
flurbiprofen (Knadler et al., 1989; Blouin et al., 1993) and ketoprofen (Hayball et al., 
1991; Dubois et al., 1993a). By virtue of their extensive binding to plasma proteins, the 
2-arylpropionic acids have rather small volumes of distribution, usually between 7 to 
14 L in man (Evans, 1992). The high plasma protein binding also restricts the rate of 
movement of the 2-arylpropionic acids into the synovial fluid, and presumably, the 
central nervous system. Indeed the slow passage of ibuprofen enantiomers in and out of 
the joint may be responsible, in part, for the dampened and sustained concentration 
profiles in synovial fluid when compared to the plasma profiles (Day et al., 1988). As 
trans-synovial transport appears to be a diffusion-controlled process, the higher 
concentrations of the S-enantiomer of ibuprofen in the synovium is likely to be partly 
reflective of the higher unbound concentrations of this enantiomer in circulation (Day et 
al., 1988). In patients with rheumatoid arthritis who took (R, S)-flurbiprofen every 
twelve hours, the enantiomeric ratio (S/R) of the drug within synovial fluid increased 
from 1.8,3 hours after the last dose to 1.47 at the end of the dosage interval, reflecting 
similar changes in the enantiomeric composition of the drug in plasma (Young et al.. 
1991). As would be expected, the flurbiprofen enantiomers also had longer half-lives for 




The 2-arylpropionic acids have the ability to undergo unidirectional metabolic 
Introduction 
chiral inversion from the less active R-enantiomer to their more active S-antipodes (Hutt 
and Caldwell, 1983). It appears that this reaction is a general feature of the disposition 
of the 2-arylpropionic acids, although there can be substantial differences in both the 
rate and extent of inversion, which appears to vary with both the substrate and the 
species (Hutt and Caldwell, 1983,1984; Caldwell et al. 1988a, 1988b). Thus, in man the 
degree to which inversion occurs may be negligible, as is the case with flurbiprofen 
(Jamali et al., 1988); intermediate, for example ibuprofen (Lee et al., 1984) or 
essentially complete, as with fenoprofen (Rubin et al., 1985). As a result of a number of 
in vitro and in vivo investigations, the biochemical mechanism of the chiral inversion 
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Figure 1.19: Mechanism of the metabolic chiral inversion of 
2-arylpropionic acid derivatives. 
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The initial thioesterification of the R-enantiomer of the 2-arylpropionic acid with 
coenzyme A (CoA) via an adenylate intermediate is catalysed by a microsomal and 
mitochondrial enzyme, which has been characterised as long-chain acyl-CoA synthetase 
(Tracy et al., 1993; Menzel et al., 1994; Brugger et al., 1996). The undirectional 
formation of the respective adenylates and/or the CoA thioester by the R-enantiomers is 
the stereoselective step of the inversion. Subsequently, the resulting R-profenyl-CoA 
thioester undergoes epimerisation of the chiral centre in the profenyl moiety, which is 
thought to proceed via an enolate intermediate to yield the corresponding S-profenyl- 
CoA thioester (Chen et al., 1991; Tracy and Hall, 1992). The epimerase enzyme has 
been isolated from the cytosolic and mitochondria fractions of rat liver (Shieh and Chen, 
1993; Reichel et al., 1995) and a cDNA clone coding for the rat liver cytosolic enzyme 
has recently been isolated and the protein expressed in E. coli (Reichel et al., 1997). 
Hydrolysis of either of the acyl-CoA thioesters results in the liberation of the free acid. 
An alternative pathway to the hydrolysis of the acyl-CoA thioesters is transfer of 
the acyl group into glycerolipids; for example, both ibuprofen and fenoprofen have been 
shown to be incorporated into adipocyte triacylglycerols, forming "hybrid" glycerides 
(Williams et al., 1986, Sallustio et al., 1988). These hybrid glycerides accumulate in 
adipose tissue forming "long-lasting" stores and have been shown to interfere with 
various aspects of lipid biochemistry and membrane function; including inhibition of 
endogenous lipid synthesis, disruption of lipid ß-oxidation and alteration of membrane 
structure (Hall and Xiaotao, 1994; Mayer, 1996). The toxicological implications of these 
pathways for man is at present unclear, but as the formation of the acyl-CoA derivatives 
is essentially stereospecific for the (R)-2-arylpropionic acids a case may be made for 
those drugs which undergo inversion to be used as the single S-enantiomers. 
Other metabolic routes 
All of the 2-arylpropionic acids are excreted in the urine, mainly in the form of 
oxidative metabolites and as conjugates of amino acids or glucuronic acid. Although 
glucuronidation is the dominant metabolic pathway for most 2-arylpropionic acids, 
functional oxidation appears to play a more significant role in the cases of ibuprofen and 
flurbiprofen. Ibuprofen is oxidised to form two major metabolites, hydroxy- and 
carboxyibuprofen in man, accounting 
for approximately 26 and 35 % of the 
administered dose excreted in urine 
(Mills et al., 1973). The observation that both the 
oxidation products were 
dextrorotatory, irrespective of the stereochemical form of 
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ibuprofen administered, i. e. either of the enantiomers or the racemate, ultimately 
resulted in the discovery of the chiral inversion reaction (Mills et al., 1973; Hutt and 
Caldwell, 1983). In man, flurbiprofen undergoes aromatic oxidation to yield 
4'-hydroxyflurbiprofen, the major metabolite accounting for ca. 48 % of the dose 
recovered in urine, and 3', 4'-dihydroxyflurbiprofen followed by methylation to 
3'-hydroxy-4'-methoxyflurbiprofen (Szpunar et al., 1987). Mean urinary recovery 
studies of (R)- and (S)-flurbiprofen and its 4'-hydroxy metabolite suggested a lack of 
stereo selectivity of the oxidative reaction (Small et al., 1990). However, another 
investigation revealed that the urinary metabolites of flurbiprofen had an S/R ratio of 
0.80, which prompted the authors to suggest that enantioselectivity exists in the 
oxidation and conjugation reactions (Knadler and Hall, 1989). 
There is increasing evidence that cytochrome P450 2C9 (CYP 2C9) is the 
important metabolising enzyme in the oxidative metabolism of 2-arylpropionic acids. 
Sulphaphenazole and/or tolbutamide inhibition along with kinetic studies utilising 
recombinant CYP 2C9 indicate that this isoform is probably the major contributor to the 
human hepatic 2- and 3- hydroxylation of (R)- and (S)-ibuprofen and solely responsible 
for the 4'-hydroxylation of (R)- and (S)-flurbiprofen (Mancy et al., 1995; Tracy et al., 
1995; Hamman et al., 1997). Similar approaches have demonstrated that CYP 2C9 is 
involved in O-demethylation of (S)-naproxen and hydroxylation of the thiophene ring of 
suprofen (Mancy et al., 1995; Miners et al., 1996; Rodrigues et al., 1996). 
The 2-arylpropionic acids and their major oxidative metabolites undergo varying 
degrees of phase II glucuronidation. Principally these compounds form 1-O-ß-acyl 
(ester) conjugates with optically active D-glucuronic acid from the glucuronosyl donor, 
uridine diphosphoglucuronic acid (UDPGA). This transfer is catalysed by a microsomal 
enzyme, UDP-glucuronosyltransferase. In vitro investigations using microsomes from 
rabbit, rhesus monkey and human liver described enantioselective glucuronidation of 
ibuprofen, benoxaprofen and naproxen in favour of the S-enantiomer (El Mouelhi et al., 
1987). Additionally, preferential glucuronidation of the R-enantiomer of flunoxaprofen, 
flurbiprofen, indoprofen, pirprofen, benoxaprofen, carprofen and cicloprofen has been 
observed using rat liver microsomes (Hayball, 1995). Furthermore, in vitro studies 
indicate that (R)-flurbiprofen is a better substrate that its antipode for glucuronidation in 
humans (Hamdoune et al., 1995). 
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The acyl glucuronides formed are intrinsically chemically reactive species and in 
the presence of plasma proteins may hydrolyse and release the parent molecule into the 
systemic circulation, this may also occur in the bladder and this reversible process is 
referred to as futile recycling (Meffin et al., 1983). It is also important to note that this 
reaction can also display enantioselectivity, Knadler and Hall (1991) reported 
preferential hydrolysis of the conjugates of (S)-flurbiprofen in both plasma and albumin 
solutions and relatively little (nonstereoselective) conjugate hydrolysis in buffer alone. 
In conditions of renal dysfunction, accumulation of glucuronides occurs due to reduced 
elimination and the effect of futile recycling is to regenerate the free drug and maybe 
also to amplify chiral inversion for those drugs subject to this process, leading to an 
accumulation of the active S-enantiomer (Hayball, 1995). Consistent with this systemic 
cycling hypothesis, is the selective accumulation of (S)-ketoprofen and its glucuronide 
in chronic haemodialysis patients (Grubb et al., 1999). Acyl glucuronides may also 
undergo intramolecular rearrangement by acyl group migration to yield positional 
isomers which remain sensitive to chemical hydrolysis but are resistant to enzymatic 
hydrolysis by ß-glucuronidase (Faed, 1984; Caldwell and Hutt, 1986). In addition to 
hydrolysis and isomerisation reactions, the electrophilic character of acyl glucuronides 
enables them to covalently bind to appropriate nucleophilic sites on biological 
macromolecules and potentially cause immunotoxicological responses (Faed, 1984, 
Spahn-Lannguth and Benet, 1992). The formation of such complexes has been observed 
in vitro for benoxaprofen (Van Breemen and Fenselau, 1985), fenoprofen (Volland et 
al., 1991), ketoprofen (Dubois et al., 1993b) and carprofen (Iwakawa et al., 1990). 
Renal excretion 
Renal excretion of the unchanged species is typically a minor elimination pathway 
for 2-arylpropionic acids, which is reflective of their high lipohilicity (Williams et al., 
1993). 
1.5. Enantiospecific bioanalysis of 2-arylpropionic acids 
Analytical methodology suitable for both the determination of enantiomeric purity 
and stereochemical composition 
in biological fluids is obviously an essential pre- 
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requisite for evaluation of the eudismic ratio and the pharmacokinetic profile of a drug 
administered as a racemate. A number of analytical techniques provide stereochemical 
information (Table 1.2), but those most appropriate for the bioanalyst are based on 
separation sciences since they provide a means of discriminating between the analyte 
and the complex, often chiral, biological media. Enantioselective separation methods 
based on gas chromatography are rather limited due to the need for high column 
temperatures, volatility of analyte and the non-feasibility of large-scale preparative 
separations. In recent years, advances in capillary electrophoresis and supercritical fluid 
chromatography have seen increasing applications to enantiomeric resolution, although 
as yet there are few reports of their use in stereospecific bioanalysis (Lynam and 
Nicolas, 1993; Wilson, 1994; Ward and Ward, 1997; Hutt and Patel, 1998; Soo et al., 
1999). The most frequently used technique is high-performance liquid chromatography, 
with chiral resolution achieved using either a indirect or direct approach. Both 
approaches will be described below, including brief details of their application in the 
enantiomeric analysis of 2-arylpropionic acids. 
Table 1.2: Common enantiospecific analytical methodologies (adapted from Hutt et al., 1994; 
Hutt and Patel, 1998). 
Approach Method * 
Physical polarimetry, circular dichroism 
pseudoracemic mixture of enantiomers labelled with 
either stable or radioisotope 
NMR spectroscopy in the presence of chiral shift 
reagent, solvating or derivatising agents 
Separation science chromatographic : GC, HPLC, SFC 
capillary electrophoresis : FSCE, MEKC 
Biological enantiospecific radioimmunoassay 
radioreceptor assays 
* Key: NMR= nuclear magnetic resonance, GC= gas chromatography, HPLC= 
high performance liquid chromatography, 
FSCE= free solution capillary electrophoresis, MEKC= micellar electrokinetic chromatography. 
Indirect approach 
This approach is based on derivatization of the analyte enantiomers with a 
homochiral derivatizing agent (HDCA) to produce stable diastereoisomers. The formed 
derivatives, owing to their different physicochemical properties, can 
be separated using 
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conventional chromatographic stationary phases. The advantage of this approach is that 
appropriate selection of the HCDA in relation to the available detection systems, offers 
the opportunity to enhance analytical sensitivity, specificity and selectivity. This 
approach is also favoured since achiral stationary phases are utilised and these are often 
more robust, stable, efficient and economical than chiral stationary phases (CSPs). 
However, this approach does have a number of limitations including: presence of optical 
impurity in the HCDA, racemisation of the analyte or HCDA during derivatization, 
stereoselective derivatization (i. e. kinetic resolution), low product yield and differential 
detector responses to the two diastereoisomers. Of fundamental significance is a 
knowledge of the purity of the HCDA employed, since only if the HCDA is 100 % 
enantiomerically pure and kinetic resolution is not a factor, will the diastereomeric ratio 
be representative of the enantiomeric composition in the original analytical sample. 
Otherwise, the enantiomeric purity of the HCDA would have to be taken into 
consideration to avoid errors in the calculated values as detailed by Allenmark (1988), 
Wozniak et al. (1991) and Hutt et al. (1994). 
It is obviously essential for this approach to be applicable that the analyte(s) under 
investigation contain a suitable functionality which may undergo derivatization. In the 
case of 2-arylpropionic acids, the carboxyl group can be readily transformed into an 
ester or amide moiety (Figure 1.20). Methods involving the formation of esters using 
(S)-2-octanol (Lee et al., 1984), (R)-2,2,2-trifluoro-l-(9-anthryl)ethanol (Zhao et al., 
1994) and (1R, 2S, 5R)-menthol (Chen and Chen, 1994) as HCDAs have been reported 
for ibuprofen, and (S)-octanol has also been applied in a method for the determination of 
the enantiomeric purity of naproxen (Johnson et al., 1979). However, this approach 
is 
generally not favoured due to the instability of esters in comparison to amides 
(Testa, 












Figure 1.20: Formation of ester and amide 
derivatives of 2-arylpropionic acids. 
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Numerous chiral amines have been utilised as HCDAs, the most widely used 
being (R)- and (S)-amphetamine, L-leucinamide, (R)- and (S)-1-phenylethylamine and 
(R)- and (S)-1-(naphthen-1-yl)ethylamine (Davies, 1997). These HCDAs are readily 
available in very high and reliable enantiomeric purity. Furthermore, derivatization of 
the 2-arylpropionic acid with 1-(naphthen-1-yl)ethylamine, which is a strong 
fluorophore, has the added advantage of enhancing detection. The formation of the 
amide derivatives requires activation of the carboxyl group of the 2-arylpropionic acid 
to enable coupling with the chiral amine, the four main chemical activation approaches 
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Figure 1.21: Amide formation pathways for 2-arylpropionic acids. 
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The early GC assays of ibuprofen (Brooks and Gilbert, 1974), and 
indoprofen 
(Tosolini et al., 1974) were based on reaction with thionyl chloride to 
form the 
corresponding acyl chloride 
before reaction with either (R)- or (S)-1-phenylethylamine. 
However, this activation agent has been associated with side reactions 
(Kaiser et al., 
1976) and so its use has been superseded 
by other reagents. A popular activating agent is 
1,11-carbonyldiimidazole which coverts the carboxyl moiety 
into the corresponding 
imidazolide derivative (Maitre et al., 1984; 







major drawbacks with use of this activation pathway are uncertainty of the optimal 
coupling conditions, which often require high temperatures; and the possibility of 
forming of N, N-disubstituted urea derivatives (Hutt, 1990; Davies, 1997). Activation 
using carbodiimides has been employed for the enantiomeric analysis of pirpofen, 
carprofen and 2-phenylpropionic acid (Hutt et al., 1986) and ibuprofen (Avgerinos and 
Hutt, 1987; Tan et al., 1997a); but this approach tends to require long derivatization 
times of up to two hours (Hutt et al., 1986). The fourth method of activation involves 
the use of ethylchloroformate in the presence of an organic base, which has been widely 
applied for coupling 2-arylpropionic acids to various chiral amines (Bjorkman, 1985; 
Spahn, 1987; Palylyk and Jamali, 1991; Wright et al., 1992; Lemko et al., 1993). This 
approach is favoured for the short reaction times, which are typically between two to 
three minutes. The suitability of ethylchloroformate in combination with L-leucinamide 
as the HCDA for the resolution of 2-arylpropionic acid derivatives was reported to be a 
"generally applicable" method (Spahn, 1987). However, subsequent studies have show 
that the use of the mixed anhydride method was associated with racemization of 
tiaprofenic acid (Hutt et al., 1994), ibuprofen (Ahn et al., 1994), ketoprofen and 
flurbiprofen (Wright and Jamali, 1993). The extent of racemization seems to be 
influenced by the concentration of chloroformate (Wright and Jamali, 1993), the nature 
of the organic base (Hutt et al., 1994) and the solvent (Ahn et al., 1994). 
Direct approach 
The direct approach to enantiomeric analysis involves the formation of transient 
diastereomeric complexes via interaction of the chiral analyte(s) with the 
chromatographic sorbent support, i. e. chiral stationary phase (CSP) or a homochiral 
solvent, i. e. chiral mobile phase additive (CMPA). 
i) Chiral stationary phases 
The mechanism of enantiomeric resolution using CSPs is generally attributed to 
the "three-point" fit model of Dalgliesh (1952). For chiral recognition, one of the 
enantiomers of the analyte must 
be involved in three simultaneous interactions, one of 
which is stereochemically 
dependent, with complementary sites on the CSP and the 
antipode may only interact at two such sites. 
Consequently, the enantiomer forming the 
more stable diastereomeric complex will 
be retained longer by the CSP. The types of 
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interactions involved depend on the nature of the CSP and may include hydrogen 
bonding, dipole-dipole interactions, charge transfer complexes, inclusion complex 
formation, hydrophobic interactions and steric repulsion (Wainer, 1987). It is important 
to note, that the three interactions do not have to be attractive forces for discrimination 
to occur, e. g. one may be steric repulsion leading to destabilisation of the complex and 
in this case the enantiomer with the three-point interaction will be eluted from the 
column first (Wainer, 1987; Hutt et al., 1994). The HPLC CSPs have been classified by 
Wainer (1987) into five groups based on a combination of their resolution mechanism 
and structural features of the chiral selector (Table 1.3). However, some of the 
comparatively modern chiral selectors, such as chiral crown ether phases and the 
macrocyclic antibiotic phases, do not directly fit these categories. 
Table 1.3: Classification of chiral stationary phases (adapted from Wainer, 1987). 
Type Phase Interactions Examples 
I Brush type hydrogen bonding (R)-N-(3,5-dinitrobenzoyl)- 
it-donor /acceptor phenylglycine 
dipole-dipole stacking urea derivatives 
steric ergoline skeleton 
II Derivatized polysaccharide hydrogen bonding 
7c-donor /acceptor 
dipole-dipole stacking 
partial inclusion complexes 
synthetic ether, ester or 
carbamate derivatives of 
cellulose (e. g. Chiralcel OD) or 
amylose (e. g. Chiralpak AD) 
III Inclusion complex 




reversible formation of 
complexes between metal 





a, ß, y -cyclodextrins 
amino acids bound to silica via 
a 3-glycicloxypropyl spacer 
group 
ai-acid glycoprotein 
bovine/human serum albumin 
ovomucoid 
riboflavin binding proteins 
The advantage of using CSPs is that, 
in most situations, pre-column derivatization 
of the analyte(s) is not necessary. 
However, should derivatization be required for any 
purpose; e. g. to enhance 
detection, to introduce an aromatic moiety complementary to 
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the aromatic function in the CSP or to attenuate the polarity of the functional group in 
the analyte to reduce individual polar interactions; the derivatizing agent need not be 
chiral. Therefore, problems of enantiomeric purity, racemization and differential 
detector responses are avoided (Hutt et al., 1994). 
However, the application of CSPs in quantitative bioanalysis methods has a 
number of limitations. CSPs do not have the versatility of conventional stationary 
phases since their range of applications are often limited, chromatographic conditions 
tend to be restricted and peak asymmetry can mean higher limits of detection. 
Furthermore, the presence of endogenous contaminants, frequently present in samples of 
biological origin, may have marked effect on both analyte retention and resolution and 
may also degrade a potentially expensive CSP (bucharme et al., 1996; Hutt and Patel, 
1998). Additional problems may arise, as while the enantioselectivity of a CSP may be 
satisfactory, the chemical selectivity may be relatively poor such that structurally-related 
metabolic products may co-elute with the drug enantiomers (Hutt and Patel, 1998). One 
approach to overcome this problem is to use sequential achiral-chiral chromatography. 
The total drug or metabolite content of a sample is determined using the achiral phase 
and the mobile phase eluate containing the appropriate analyte is collected for 
subsequent enantiomeric analysis on the CSP (Hutt and Patel, 1998). 
One of the initial reports of the use of a CSP for the enantiomeric resolution of 
2-arylpropionic acids employed a Brush-type "Pirkle" column (Wainer and Doyle, 
1984) However, optimal separation on this (R)-N-(3,5-dinitrobenzoyl)phenylglycine 
column required pre-column derivatization of the drug with 1-naphthenemethylamine. 
A 
chiral recognition model was developed, based on these experiments, which suggested 
involvement of stacking of amide dipoles, it-n interactions between aromatic groups of 
the dinitrophenyl ring on the CSP and the drug, together with 
hydrogen bonding. 
Resolution of flurbiprofen enantiomers using a similar approach was consistent with this 
chiral recognition model (McDaniel and 
Snider, 1987). However, the validity of this 
model has been challenged 
by a proposed model of antiparellel amide stacking with 
hydrogen bonding, n-n interactions between the naphthyl group of the analyte 
derivative and the dinitrophenyl ring of the 
CSP and between the analyte aromatic ring 
and the unsubstituted phenyl group 
of the CSP (Nicoll-Griffith, 1987). The use of 
Pirkle-type phases for the bioanalysis of 
2-arylpropionic acids has been reported by 
Crowther et al. (1984), Sioufi et al. 




cases pre-column derivatization was essential. Direct separation of several 2-aryl- 
propionic acids by HPLC with amide and urea derivatives bonded to silica gel as CSPs 
has also been described (Oi et al., 1995). In addition, the use of an ergot alkaloid based 
stationary phase, packed in microbore columns, for the resolution of the enantiomers of 
several NSAIDs has potential for application in bioanalysis (Castellani et al., 1994, 
Olsovska et al., 1999). 
Numerous polysaccharide CSPs are available with the tris(3,5-dimethylphenyl 
carbamate) derivatives of cellulose (Chiralcel OD) and amylose (Chiralpak AD) 
appearing to be the most versatile (Okamoto and Yashima, 1998). Analyte interactions 
with these phases are primarily via attractive forces and formation of inclusion 
complexes, with stereoselectivity based upon steric fit of the analyte into the chiral 
cavities. The direct enantiomeric resolution of flurbiprofen, tiaprofenic acid and 
ketoprofen has been reported for the Chiralpak AD phase; however, ibuprofen 
enantiomers could only be resolved as their methyl esters (Okamoto et al., 1989). This 
CSP has also more recently been applied in a sequential achiral-chiral method for the 
analysis of ibuprofen metabolites in urine (Tan et al., 1997b). The main disadvantage of 
these phases is the restricted choice of mobile phases that may be selected since they are 
incompatible with chlorinated and aqueous phases. Novel phases are being developed 
such that the polysaccharide is chemically bonded rather than coated onto the support, 
which will enable the use of more polar solvents (Enomoto et al., 1996). 
A ß-cyclodextrin bonded phase, i. e. a type III CSP, where separation is based on 
the formation of inclusion complexes has been successfully employed to resolve 
underivatized ibuprofen enantiomers following isolation from biological fluids 
(Giesslinger et al., 1989). However, enantiomeric resolution was not complete and the 
phase displayed temperature sensitivity and batch-to-batch variability. 
Several direct resolutions of underivatized 2-arylpropionic acids have been 
described using protein affinity CSPs. These were based on either bovine serum albumin 
(Allenmark and Andersson, 1989), human serum albumin (Nocter et al., 1991), 
ovomucoid (Miwa et al., 1987; 
Haginaka et al., 1993), al-acid glycoprotein 
(Hermansson and Eriksson, 1986), avidin (Oda et al., 1991) or egg yolk riboflavin 
binding protein (Massolini et al., 1995; De 
Lorenzi and Massolini, 1999). The main 
advantages of protein phases 
for bioanalytical applications are that they are used in the 
reversed-phase mode and show considerable 
versatility. However, they tend to have 





extremely sensitive to subtle modifications in mobile phase composition (Hutt and 
Patel, 1998). 
ii) Chiral mobile phase additives 
The use of a CMPA enables enantiomeric resolution if the formed labile 
diastereomeric complexes differ in their distribution between the mobile phase and the 
achiral stationary phase. The main advantages of this approach are the use of 
conventional efficient achiral phases and the limited cost of most CMPAs. Possible 
disadvantages include the fact that some CMPAs possess chromophores and thus 
impose a limitation on their usefulness and removal of the CMPA from the eluate may 
be a problem if the analyte is required in the pure form (Armstrong, 1987). 
Enantiomeric resolution of naproxen and other 2-arylpropionic acids has been 
investigated using quinine as a CMPA with normal-phase columns (Pettersson, 1984). 
Separation efficiency was dependent on the nature of the stationary phase, i. e. whether 
silica diol or cyano bonded phases were employed. However, the applicability of this 
approach for bioanalysis is limited by the presence of strong chromophores in quinine 
which would adversely influence analytical sensitivity. The use of ß-cyclodextrin as a 
CMPA proved to be unsatisfactory for the resolution of ibuprofen and pirprofen (Hutt 
and Caldwell, 1988). However, the enantiomers of fenoprofen and ketoprofen have 
recently been resolved using a nonporous reversed-phase column with hydroxypropyl 
ß-cyclodextrin as a CMPA, with the approach being subsequently developed into an 
assay for the determination of the enantiomeric composition of ketoprofen in serum 
(Ameyibor and Stewart, 1997,1998). 
1.6. Aims and objectives 
NSAIDs, with the 2-arylpropionic acids being the major sub-group, are among the 
most widely used therapeutic agents today, with approximately 
20 million prescriptions 
dispensed for NSAIDs per year in the UK at a cost of over £180 million (Bateman and 
Kennedy, 1995). However, their use also represents an 
important cause of morbidity and 
mortality and is a major 
drain on resources in both primary and secondary health care 
(Garcia Rodriguez and Jick, 1994; Langman et al., 
1994). Epidemiological studies have 
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shown that the elderly population are the most frequent users of NSAIDs and at the most 
at risk of adverse effects; which in part could be attributed to age-related alterations in 
disposition (Henry et al., 1993; Garcia Rodriguez and Jick, 1994). 
It is therefore the more surprising that little data is available in the literature on the 
pharmacokinetics of NSAIDs in this target population, with most studies performed 
using relatively young healthy volunteers. Furthermore, those few studies which have 
investigated the influence of ageing on the pharmacokinetics of NSAIDs have tended to 
be of deficient study design and have not considered stereochemical factors, despite the 
fact that the majority of NSAIDs possess a chiral centre and are marketed as racemates 
(Davies and Skjodt, 2000). Examination of potential age associated alterations in the 
disposition of NSAIDs in the elderly, particularly if such alterations are stereoselective, 
may provide some insight into the observed adverse reaction profile in this age group. In 
addition, such investigations have the potential to contribute to the more rational use of 
these agents in this ever increasing population sub-group. 
The problems of non-stereospecific drug analysis in comparing age-related 
differences in pharmacokinetics following administration of racemic drugs may be 
illustrated by the report of Chandler et al. (1988) who examined the disposition of 
hexobarbitone. Following the administration of the racemic drug to young and elderly 
volunteers no differences were observed in the oral clearance of the total drug between 
the two groups. However, on examination of the individual enantiomers the clearance of 
the (-)-isomer was found to be twice as fast in the young volunteers as in the elderly 
group. It is also noteworthy, that the situation can be complicated by age-related gender 
differences in enantiomeric disposition as has been previously observed for 
methylphenobarbitone, see section 3.4 for further details (Hooper and Qing, 1990). 
Nevertheless, in some cases age-related alterations in disposition may not display 
stereoselectivity, for example the elderly have a lower oral clearance for both 
enantiomers of propranolol than the young with no effect on the enantiomeric 
composition in serum (Zhou et al., 1992). 
It was therefore proposed to examine the enantioselective disposition and 
pharmacokinetics of two 2-arylpropionic acid drugs, namely ibuprofen and flurbiprofen, 
following the administration of the racemic form of the drugs to healthy young and 
elderly volunteers. These two drugs although structurally related were selected as they 
have considerably different pharmacological properties, and thus it is possible that 
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advancing age has a differential influence. Differences in the pharmacodynamic profile 
between the two drugs is not only likely to be due to their S-enantiomers displaying 
different COX-1 to COX-2 selectivities, but also due to the varied role played by their 
respective R-enantiomers. For example, with ibuprofen the R-enantiomer is essentially a 
pro-drug which contributes to anti-inflammatory activity, not only by significant 
metabolic inversion to (S)-ibuprofen but also via inhibition of induction of COX-2 
mediated by (R)-ibuprofenoyl-CoA thioester (Neupert et al., 1997). In contrast, the R- 
enantiomer of flurbiprofen does not undergo unidirectional inversion in man but may 
contribute therapeutically via central antinociceptive effects (Brune et al., 1992). 
Differences in enantioselective disposition between ibuprofen and flurbiprofen, as 
would be expected, most probably stem from the contrasting significance of the chiral 
inversion process; but other important influencing factors are likely to be differences in 
stereo selectivity for protein binding and/or for metabolism via oxidation and 
conjugation pathways. 
In order to examine the stereoselectivity of the disposition of ibuprofen and 
flurbiprofen validated HPLC analytical methods for monitoring the enantiomeric 
composition of the drugs, and their metabolites, in biological fluids are an essential 
prerequisite. Appropriate analytical methodologies for the enantiospecific analysis of 
ibuprofen in serum and urine and for the stereospecific analysis of its two major 
metabolites, hydroxy and carboxyibuprofen, in urine have been previously developed 
within the laboratory (Tan et al., 1997a, 1997b); the applicability of these methods for 
clinical studies will be assessed. Numerous methods have been published which 
describe the enantiospecific bioanalysis of flurbiprofen, but only one of these also 
considers the determination of the enantiomeric composition of its two major 
metabolites, 4'-hydroxy and 3'-hydroxy-4'-methoxyflurbiprofen (Knadler and Hall, 
1989). However, this particular methodology is unable to analyse all three analytes in a 
single chromatographic run and was thus deemed inappropriate for routine use. 
Therefore various chromatographic approaches, both direct and indirect, will be 
investigated for their ability to simultaneously separate and resolve the enantiomers of 
flurbiprofen and its metabolites. Subsequently, the chromatographic system which 
displays the desired separation profile will be adapted into methodologies suitable for 
the determination of the enantiomeric composition of flurbiprofen and the two 
metabolites in urine and serum. As authentic reference samples of the enantiomers of 
the two flurbiprofen metabolites are not available, an attempt will be made to isolate the 
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individual isomers using semi-preparative chromatography and assignment of 
stereochemistry by chiroptical spectroscopic methods will be performed to establish the 
chromatographic elution order. 
Furthermore, the influence of age on the pharmacodynamic properties of 
ibuprofen following the administration of the racemate have not been reported 
previously. For this purpose, inhibitory activity of the drug on cyclooxygenase function 
will be monitored in blood samples obtained from both young and elderly volunteers 
during the pharmacokinetic study by measurement of thromboxane A2 generation and 
function. These latter investigations will be performed in association with the 
Department of Pharmacology, King's College London. 
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CHAPTER 2 
Stereospecific analysis of ibuprofen and its 




Ibuprofen : Stereospecific bioanalysis 
Ibuprofen undergoes extensive unidirectional chiral inversion in humans from the 
relatively inactive R-enantiomer to its active S-antipode as outlined in Chapter One 
(Mills et al., 1973; Wechter et al., 1974; Kaiser et al., 1976). In addition to inversion the 
metabolism of ibuprofen involves conjugation with glucuronic acid and oxidation of the 
isobutyl group at the 2- and 3- positions to yield hydroxy and carboxyibuprofen 
respectively (Figure 2.1; Mills et al., 1973). Following oral administration of racemic 
ibuprofen, approximately 60% of the dose is recovered in a 24 hour urine collection as 
these metabolites, both free and conjugated with glucuronic acid (Mills et al., 1973). 
The observation that both the oxidation products were dextrorotatory, regardless of the 
stereochemical form of ibuprofen administered, i. e. the racemate or either enantiomer, 
ultimately resulted in the discovery of the metabolic chiral inversion reaction (Mills et 
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Figure 2.1: Major oxidative metabolic pathways of ibuprofen (* denotes chiral centre). 
The considerable interest in the chiral inversion process and stereochemical 
aspects of ibuprofen disposition has led to the publication of a vast number of 
enantiospecific assay methods, based on both direct and indirect approaches, for this 
first-generation and important 2-arylpropionic acid drug. The direct approach, utilising 
al-acid glycoprotein phases (Menzel-Soglowek et al., 1990; Geisslinger et al., 1990; 
Pettersson and Olson, 1991; De Vries et al., 1994) and ß-cyclodextrin phases 
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(Geisslinger et al., 1989; Naidong and Lee, 1994) have been employed for the 
determination of ibuprofen enantiomers in plasma and urine. Other chiral stationary 
phases (CSPs) used for the enantiospecific analysis of ibuprofen include Pirkle-type 
(Wainer and Doyle, 1984; Nicoll-Griffith et al., 1988,1993; Li et al., 1993) and 
derivatized polysaccharide phases (Okamoto et al., 1989; Van Overbeke et al., 1994); 
these methods however required pre-column derivatization of ibuprofen to obtain 
acceptable resolution. 
Some indirect methods for the determination of ibuprofen enantiomers have 
employed alcohols as homo-chiral derivatizing reagents (HCDAs), e. g. (S)-octanol (Lee 
et al., 1984), (R)-2,2,2-trifluoro-l-(9-anthryl)ethanol (Zhao et al., 1994) and (1 R, 2S, 5R)- 
menthol (Chen et al., 1991; Chen and Chen, 1994); but this approach is generally not 
favoured due to the labile nature of the ester derivatives (Testa, 1986). Moreover, 
indirect methods have been based on the formation of relatively stable diastereomeric 
amides after derivatization with optically pure chiral amines such as L-leucinamide 
(Foster and Jamali, 1987; Pehourcq et al., 1995), (R)- and (S)-1-phenylethylamine (Rudy 
et al., 1990; Wright et al., 1992), (R)- and (S)-amphetamine (Singh et al., 1986; Jack et 
al. , 1992), 
(R)- and (S)-1-(naphthen-l-yl)ethylamine (Avgerinos and Hutt, 1987; Mehvar 
et al., 1988; Lemko et al., 1993; Lau, 1996) and (-)-2-[4-(1-aminoethyl)phenyl]-6- 
methoxybenzoxazole (Kondo et al., 1994). These chiral amines often have strong 
chromophores or fluorophores which aid the analysis by increasing assay sensitivity. 
Recently, a reliable, sensitive enantiospecific assay for the determination of ibuprofen in 
serum and urine based on reversed phase high-performance liquid chromatography 
(HPLC) has been developed within our laboratory (Tan et al., 1997a). The use of (R)- 
1-(naphthen-l-yl)ethylamine as a chiral derivatizing agent in combination with 
fluorescence detection enabled the approach to be adapted for the determination of the 
free drug enantiomer concentrations in serum following equilibrium dialysis (Tan et al., 
1997a). 
In comparison to the parent drug there are relatively few reports concerned 
with the determination of the stereochemical composition of the two major oxidation 
products. The enantiomers of hydroxyibuprofen have been resolved by both gas 
chromatography and HPLC following derivatization with the HCDAs 1-phenyl- 
ethylamine (Kaiser et al., 1976; Young et al., 1986; Baille et al., 1989; Rudy et al., 
1990) and (1 R, 2S, 5R)-menthol (Chen et al., 1991; Chen and Chen, 1994) and using a 
(R)-N-(3,5-dinitrobenzoyl)phenylglycine CSP (Nicoll-Griffith et al., 1988). However, 
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formation of carboxyibuprofen results in the introduction of a second chiral centre into 
the molecule (Figure 2.1) and the chromatographic resolution of the four stereoisomers, 
via either derivatization using an HCDA or CSP, has proved to be problematical. The 
only successful chromatographic resolution was that of Rudy et al. (1990) which was 
based on the indirect approach following derivatization with (S)-1-phenylethylamine 
and HPLC using a C8 stationary phase. Due to the lack of stereochemically defined 
authentic standards, the assignment of the chromatographic elution order of the 
carboxyibuprofen stereoisomers was based on that published by Kaiser et al. (1976), 
which was itself empirical. However, more recently within our laboratory, Tan et al. 
(1997c) were able to resolve the stereoisomers of carboxyibuprofen using the 
derivatized amylose CSP, amylose tris (3,5-dimethylphenylcarbamate) (Chiralpak AD) 
and determine their elution order by a combination of both metabolic and synthetic 
approaches. Subsequently, the above methodology was adapted to develop a sequential 
achiral-chiral chromatographic technique for the determination of the stereochemical 
composition of carboxy and hydroxyibuprofen in urine (Tan et al., 1997b). Total 
metabolite concentrations are determined by achiral normal-phase chromatography, 
followed by collection of the column eluates containing the individual metabolites prior 
to the determination of their stereochemical composition using the CSP. 
The "in-house" development of novel HPLC methods for the enantiospecific 
analysis of ibuprofen in serum and urine and for the stereospecific analysis of the two 
major metabolites in urine have been outlined above. The objectives of this chapter are 
to describe in detail the analytical methodology employed, as well as any modifications 
made to the published methods, and to describe the validation experiments performed 
prior to their application in clinical investigations (Chapter 3). 
Carboxyibuprofen is chemically designated as 2-[4-(2-carboxypropyl)phenyl] 
propionic acid and thus both chiral centres are indicated as being in the 2-position of the 
two side chains. In this thesis, the chiral centre introduced by metabolic oxidation of the 
isobutyl group of ibuprofen is indicated as the 2'-position, whereas the original chiral 




2.2.1 Chemicals and reagents 
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Acetonitrile, dichloromethane, ethanol, ethyl acetate, hexane and isopropanol 
(HPLC grade) were purchased from Rathburn (Walkerburn, UK). Sodium chloride, 
sodium dihydrogen phosphate, disodium hydrogen phosphate, trifluoroacetic acid 
(TFA), diethylether (Analar grade), and other solvents were purchased from BDH 
(Poole, Dorset, UK). Human serum albumin (type Fraction V, HSA), 1-(3-dimethyl- 
aminopropyl)-3 -ethylcarbodiimide hydrochloride (CDI), (R)-1-(naphthen-l-yl)ethyl- 
amine ((R)-NEA) and 4-chlorophenoxyacetic acid were purchased from Sigma 
Chemicals (Poole, Dorset, UK). 1-Hydroxybenzotriazole (HOBT) was purchased from 
Fluka Chemicals (Poole, Dorset, UK). (R, S)-, (R)-, (S)-Ibuprofen, (R, S)-hydroxy- 
ibuprofen and (R, S)-flurbiprofen were the generous gifts of Boots Company PLC 
(Nottingham, UK). "Racemic" carboxyibuprofen was synthesised as described 
previously (Tan et al., 1997c). Solid phase extraction (SPE) silica cartridges (100 mg) 
were prepared using Merck silica gel (40-63 µm) obtained from BDH (Poole, Dorset, 
UK) and empty Bond-elut SPE cartridges and frits purchased from Anachem Ltd. 
(Luton, Beds, UK). The SPE cartridges were activated by elution with methanol (1 ml) 
and subsequent drying at 100°C for 1 hour prior to use. Phosphate buffered saline (pH 
7.4; PBS) was prepared with 0.067 M disodium hydrogen phosphate, 0.067 M sodium 
dihydrogen phosphate and sodium chloride. Dialysis membranes (Spectropor 2, 
molecular weight cut-off 12,000-14,000) were obtained from Pierce and Warriner 
(Chester, UK). The membranes were cut into discs (diameter, 3 cm), washed with 
purified water and then soaked in PBS overnight. Protein Assay reagents based on the 
Coomasie blue method were obtained from Bio-Rad (Herts, UK). Radiolabelled 
[14C] -ibuprofen with specific activity of 21.6 mCi g-1 was generously donated by Knoll 
Pharmaceuticals (Nottingham, UK). The liquid scintillation cocktail used was 
Quickscint flow 302 (Zinsser Analytical, Berkshire, UK). 
2.2.2 Chromatographic columns 
The C18 column, a Waters Resolve C18 column (150 x 3.9 mm, 5 µm), was 
obtained from Anachem Ltd. (Luton, Beds., UK); and used in conjunction with a 
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refillable guard column (10 x 2.1 mm) packed with pellicular C 18 (40-60 µm) both were 
obtained from Alltech Associates (Carnforth, Lancs., UK). The normal-phase column, a 
Partisil silica column (250 x 4.6 mm, 5 µm) was obtained from Whatman (Maidstone, 
UK) and was used with a refillable guard column (10 x 2.1 mm) packed with pellicular 
silica (40-63 µm) both were obtained from Alltech Associates (Carnforth, Lancs., UK). 
The chiral columns, a Chiralcel OD (cellulose tris (3,5-dimethylphenylcarbamate)) 
column (250 x 4.6 mm, 10 µm) and a Chiralpak AD (amylose tris (3,5-dimethylphenyl- 
carbamate)) column (250 x 4.6 mm, 10 µm), used with their respective guard columns 
(5 x 4.6 mm, 10 pm), were supplied by HPLC Technology Ltd. (Macclesfield, UK). 
2.2.3 Instrumentation and apparatus 
Reverse-phase HPLC was performed using an LDC Constametric 3000 pump 
(Stone, Staffs., UK) linked to a Merck-Hitachi spectrofluorometer (Poole, Dorset, UK) 
and a LDC CI-4000 computing integrator (Stone, Staffs., UK). Samples were introduced 
on-column using a Rheodyne 7125 injection valve (Cotati, Cal., USA) fitted with a 
50 µl sample loop. Normal-phase HPLC was performed using an LDC Constametric 
3000 pump linked to an LDC Spectromonitor 3000 UV detector and a LDC CI-4000 
computing integrator (Stone, Staffs., UK). Samples were introduced on-column using a 
Rheodyne 7125 injection valve (Cotati, Cal., USA) fitted with a 100 µl sample loop. 
Chiral-phase HPLC was performed using an LDC Constametric 3000 pump linked to an 
LDC Spectromonitor 3100 UV detector and a LDC CI-4100 computing integrator 
(Stone, Staffs., UK). Samples were injected on column using a Perkin Elmer ISS-100 
autosampler (Beaconsfield, Bucks., UK). Equilibrium dialysis cells of 2.5 ml total 
capacity were constructed from perspex in the Department of Pharmacy Workshop, 
King's College London. Liquid scintillation spectrometry was performed using an LKB 
1209 Wallac Rackbeta liquid scintillation spectrometer (Milton Keynes, UK). 
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2.2.4 Enantiospecific analysis of ibuprofen in serum 
Sample preparation 
Aliquots of serum (0.5 ml) were added to 15 ml extraction tubes along with 
1.0 µg (20 µl of a 0.05 mg/ml solution in acetonitrile) of (R, S)-flurbiprofen as internal 
standard. The samples were acidified by the addition of hydrochloric acid (1.0 M; 100 
µl) and buffered to pH 3.8 with 1 ml of sodium phosphate buffer (pH 3.8; 1.0 M). 
Diethylether (3 ml) was then added and the samples mixed on a test-tube rocker for 20 
minutes. Following centrifugation at 1000g for 5 minutes, the diethylether layers were 
transferred into clean tubes and evaporated to dryness under a stream of nitrogen at 
40°C on a dry block heater. 
Derivatization 
The extracted samples or standards were derivatized by the addition of 100 µg 
each of CDI, HOBT and (R)-NEA (100 µl each of 1 mg/ml solutions in dichloro- 
methane). The contents were briefly mixed and the reaction allowed to proceed at room 
temperature for two hours. The reaction mixtures were then loaded onto SPE silica 
cartridges (100 mg) prewetted with dichloromethane and the eluate collected. The 
cartridges were further eluted twice with dichloromethane: acetonitrile (1 ml, 9: 1 v/v) 
and the pooled eluate dried under nitrogen gas at 40°C. The residue was reconstituted in 
100 µl mobile phase and 50 µl injected into the reverse phase HPLC system. 
Chromatographic analysis 
Chromatography was carried out using a Waters Resolve C 18 (150 x 3.9 mm, 
5 µm) column protected by a guard column (10 x 2.1 mm) filled with pellicular C 18. The 
mobile phase used was phosphate buffer (pH 3.5,0.01 M): acetonitrile (50: 50 v/v) at a 
flow rate of 1.5 ml/min at ambient temperature. Column eluate was monitored by 
fluorescence detection with excitation and emission wavelengths of 290 and 330 nm 
respectively. 
Validation of the assay procedure 
A stock solution of (R, S)-ibuprofen (10 mg/ 100ml) was prepared in acetonitrile. 
Into six separate 10 ml volumetric flasks were pipetted 0.02,0.05,0.1,0.2,1.0 and 
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2.0 ml aliquots of the stock solution. The solutions were evaporated gently under a 
stream of nitrogen and drug free serum added to the flasks q. s. 10 ml to give final 
solutions containing 0.1,0.25,0.5,1.0,5.0 and 10 µg/ml of each enantiomer in the 
respective flasks. Aliquots (0.5 ml) of these standards were transferred into different 
tubes and stored at -20°C. On each day of analysis one set of these tubes were analysed 
together with the samples. Calibration curves were constructed by plotting peak area 
ratios (ibuprofen enantiomer: (S)-flurbiprofen) against the concentration of each 
enantiomer and subjecting the data to linear regression analysis. The concentration of 
each enantiomer in serum samples was determined by comparing their respective peak 
area ratios to the calibration curves prepared. 
The accuracy and within day variation of the assay was assessed by analysing six 
serum standards with the following ibuprofen enantiomer concentrations: 0.1,1.0 and 
10 µg/ml. The precision and accuracy of the assay was determined for each enantiomer 
by calculation of the percentage coefficient of variation (standard deviation/mean x 100) 
and mean percentage difference ([mean concentration-actual concentration]/ actual 
concentration x 100) respectively. 
The between day variation of the assay was determined by analysing serum 
standards of the same concentrations for six consecutive days. The precision and 
accuracy were calculated as described above. 
2.2.5 Determination of unbound concentrations of ibuprofen enantiomers in 
serum 
Purification of [14C] -ibuprofen 
[14C]-Ibuprofen (3 mg) was dissolved in acetonitrile (1 ml) and 50 µl aliquots 
were injected onto a reversed-phase Waters Resolve C 18 column (150 x 4.6 mm, 5µm) 
with a mobile phase of acetonitrile: water (50: 50 v/v), with the pH adjusted to 3.5 with 
hydrochloric acid (1.0 M), at a flow rate of 1.0 ml/min. Detection was by UV, set at 
220 nm. The eluate containing ibuprofen was collected from the detector outlet into a 
100 ml pear shaped flask. The combined eluate (from 20 injections) was then pooled 
and the solvent evaporated to half its volume under nitrogen gas at 
40°C. 
Hexane: isopropanol (9: 1 v/v; 25 ml) was added as extraction solvent and the mixture 
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shaken. The solvent mixture was allowed to separate and the supernatant organic layer 
transferred into a 50 ml pear shaped flask and evaporated to dryness under nitrogen. The 
chemical purity of the product was subsequently determined by redissolving a portion of 
the residue in mobile phase and reinjecting it into the HPLC system. 
Equilibrium dialysis 
The equilibrium dialysis cell consisted of two 1.25 ml chambers separated by a 
single layer of Spectrapor 2 dialysis membrane. Aliquots of serum (1 ml) were placed 
into three dialysis cells and 20 µl of purified [14C] -ibuprofen (0.35 mg/ml) dissolved in 
HSA solution (4% w/v in PBS) added to each. Into the complimentary chambers on the 
opposite side of the membranes were transferred 1 ml aliquots of PBS. The cells were 
sealed and placed in a shaking water bath (30 strokes per minute) at 37°C for a 
pre-determined equilibrium time of 8 hours. After incubation, 400 µl aliquots of serum 
and PBS were removed from the cells and placed into separate scintillation vials along 
with 12.5 ml scintillation cocktail. The radioactivity, expressed as disintegrations per 
minute (dpm), within the buffer (dpm B) and serum (dpm P) were determined. 
Sample preparation 
To the dialysate buffer (2.5 ml; the contents of three cells combined) was added 
(R, S)-ibuprofen as a carrier (0.1 mg/ml in acetonitrile, 25 µl), followed by hydrochloric 
acid (1.0 M; 500 µl), phosphate buffer (pH 3.8,1. OM, 2 ml), and hexane: isopropanol 
(9: 1, v/v; 5 ml) as extraction solvent. The mixture was then extracted and solvent 
evaporated as described previously. The dried residue was reconstituted in 50 µl mobile 
phase and 30 µl injected into the Chiralcel OD CSP. 
Chromatographic resolution 
Enantiomeric resolution of ibuprofen was achieved using a Chiralcel OD CSP 
(250 x 4.6 mm, 10 µm) connected to a guard column containing similar material (50 x 
4.6 mm, 10 µm). The mobile phase consisted of hexane: isopropanol (100: 1.1 v/v) 
containing TFA (0.1 % v/v) as modifier, at a flow rate of 1.0 ml/min. The UV detector 
was operated at 220 nm. The eluate fractions corresponding to (R)- and (S)- ibuprofen 
were collected between 12.0-13.2 minutes and 15.4-17.2 minutes respectively into 
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individual scintillation vials and the radioactivity of each fraction (dpm BR and dpm BS 
respectively) was determined. 
An aliquot (200 µl) of the equilibrated serum was put through the extraction and 
chromatographic procedures along with the corresponding buffer sample to determine 
dpm PR and dpm Ps. 
Calculation of unbound fraction 
The unbound fraction of (R)-ibuprofen (f'uR) was determined as: 
f 'uR = 
dpm Bx dpm BR / (dpm BR + dpm Bs) 
dpmP dpmPR/(dpmPR+dpmPS) 





dpm Bs / (dpm BR + dpm Bs) 
dpm Ps / (dpm PR + dpm Ps) (Eqn. 2.2) 
The unbound fractions were then corrected for volume shifts using the following 
equation: 
fu = f'u. F/( f'u. F + 1- f'u) (Eqn. 2.3) 
where F is the ratio of the serum protein concentration post- and pre-dialysis, 
determined using the Coomasie blue procedure (Bio-Rad Protein Assay kit), and fu is 
the unbound fraction after volume shift correction (Huang, 1983). Free enantiomer 
concentrations were calculated by multiplying the respective corrected unbound 
fractions by the total (bound and unbound) serum concentrations. 
Validation 
Standards were prepared in drug free serum at concentrations of 5.0,10 and 20 
µg/ml of each ibuprofen enantiomer for the validation experiment. Five aliquots (i. e. 5x 
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[3x1 ml]) of each of these serum standards were put through the dialysis procedure and 
analysed to assess the reproducibility of the method at the different concentrations. 
2.2.6 Enantiospecific analysis of ibuprofen in urine 
Sample preparation 
Free: For the quantification of unconjugated ibuprofen, 0.5 ml aliquots of urine 
were used. To these samples were added 1 µg (20 µl of a 50 µg/ml solution in 
acetonitrile) of (R, S)-flurbiprofen as internal standard. The samples were then acidified 
by the addition of hydrochloric acid (1.0 M; 100 µl) and buffered to pH 3.8 with 1.5 ml 
of phosphate buffer (pH 3.8; 1.0 M). Hexane: isopropanol (9: 1, v/v; 5 ml) was added and 
the extraction tubes were then tightly capped and mixed on a test-tube rocker for 20 
minutes. Phase separation was achieved by centrifugation for 5 minutes at 1000g. The 
organic layer was then separated into a clean glass tube and evaporated under a gentle 
stream of nitrogen at 40°C on a dry heating block. 
Base hydrolysis: For the determination of total concentrations (i. e., free and acyl 
glucuronide) of ibuprofen, 0.1 ml aliquots of urine were used. To the samples were 
added (R, S)-flurbiprofen (1 µg) followed by NaOH (1.0 M; 20 µl) for hydrolysis of the 
acyl glucuronic acid conjugates. The hydrolysis reaction was left to proceed for 2 hours 
at room temperature. Subsequently, HC1 (1.0 M; 40 µl), sodium phosphate buffer (pH 
3.8; 1.0 M; 200 µl) and hexane: isopropanol (9: 1, v/v; 1.0 ml) were added. The samples 
were mixed and extraction carried out as before. 
Derivatization and chromatographic conditions 
The derivatization procedure and chromatographic analysis of the dried urine 
extracts were performed as described for the serum assay. 
Validation of the assay procedure 
A series of calibration standards were prepared in drug free urine at concentrations 
of 0.1,0.25,0.5,1.0,5.0 and 10 µg/ml of each ibuprofen enantiomer. Calibration 
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curves, within and between day variation were determined as described above for the 
serum samples. 
2.2.7 Stereospecific analysis of carboxyibuprofen and hydroxyibuprofen in urine 
Sample preparation 
Free: For the quantification of unconjugated carboxyibuprofen and hydroxy- 
ibuprofen, 0.5 ml aliquots of urine were used. To these samples were added 25 µg (50 µl 
of a 0.5 mg/ml solution in acetonitrile) of 4-chlorophenoxyacetic acid as internal 
standard. The samples were then acidified by the addition of hydrochloric acid (1.0 M; 
100 µl) and buffered to pH 3.8 with 1.5 ml of phosphate buffer (pH 3.8; 1.0 M). 
Dichloro-methane: ethyl acetate (14: 1 v/v; 5 ml) was added and the extraction tubes 
were then tightly capped and mixed on a test-tube rocker for 20 minutes. Phase 
separation was achieved by centrifugation for 5 minutes at 1000g. The lower organic 
layer was then separated into a clean glass tube and evaporated under a gentle stream of 
nitrogen at 40°C on a dry heating block. The residue was reconstituted in 150 µl mobile 
phase and 50 µl was injected into the achiral HPLC system. 
Base hydrolysis: For the determination of total concentrations (i. e., free and 
conjugated) of carboxyibuprofen and hydroxyibuprofen, 0.1 ml aliquots of urine were 
used. To the samples were added 4-chlorophenoxyacetic acid (25 µg) followed by 
NaOH (1.0 M; 20 µl). The hydrolysis reaction was left to proceed for 2 hours at room 
temperature. Subsequently, HCl (1.0 M; 40 µl), sodium phosphate buffer (pH 3.8; 1.0 
M; 200 µl) and dichloromethane: ethyl acetate (14: 1 v/v; 1.0 ml) were added. The 
samples were then extracted, dried and reconstituted as before. 
Achiral chromatographic analysis and fraction collection 
The achiral phase used was a Partisil silica column (250 x 4.6 mm, 5µm) 
protected by a guard column (10 x 2.1 mm) filled with pellicular silica. The mobile 
phase consisted of hexane: ethanol (98.2: 1.8 v/v) containing TFA (0.05% v/v) as 
modifier, at flow rate of 2.0 ml/min. The UV detector was set at 220 nm. 
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The column eluate from the HPLC containing carboxy (tr, 12.6 min; fraction 
collected between 12.2 and 13.0 min) and hydroxyibuprofen (tr, 15.8 min; fraction 
collected between 15.3 and 16.3 min) were individually collected from the detector 
outlet. The fractions were gently evaporated under a stream of nitrogen gas at 40°C and 
the residues reconstituted in 100 jd mobile phase and 50 .d aliquots subjected to 
chiral-phase analysis. 
Chiral-phase analysis 
The metabolites present in the reconstituted residues were separated into their 
individual isomers using a Chiralpak AD column (250 x 4.6 mm, 10 µm) connected to a 
guard column containing similar material (50 x 4.6 mm, 10 µm). The mobile phase 
consisted of hexane: ethanol (92: 8 v/v) containing TFA (0.05% v/v) as modifier, run at a 
flow rate of 1.0 ml/min. The detection wavelength was set at 220 nm. 
The enantiomeric composition of hydroxyibuprofen was determined as follows: 
Peak area of enantiomer 
Enantiomeric composition = 
Sum of peak areas for both enantiomers (Eqn. 2.4) 
Individual concentrations of each enantiomer were calculated by multiplying their 
enantiomeric composition by the corresponding metabolite concentrations obtained 
from achiral (normal-phase) analysis. For carboxyibuprofen, the same approach was 
adopted, the sum of peak areas being for all four stereoisomers. 
Validation of the assay procedure 
A series of calibration standards containing 10,20,40,80,160 and 320 µg/ml of 
each metabolite were prepared in drug free urine. On each day of analysis, 0.5 ml of 
these standards were analysed together with volunteer samples. Calibration curves were 
constructed based on the data obtained following achiral analysis. The accuracy and 
within day variation for each metabolite was determined by analysing the calibration 
samples of 10,80 and 320 µg/ml concentrations repeatedly (n = 
6). Between day 
variation was determined by analysing the same standards over six separate 
days. 
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The HPLC eluate from the above validation experiments were collected and 
subjected to chiral-phase analysis to establish whether the approach could determine 
accurate stereochemical compositions over a wide range of concentrations. 
2.3. Results and Discussion 
2.3.1 Enantiospecific analysis of ibuprofen in serum 
The assay procedure used to determine the concentrations of ibuprofen 
enantiomers in serum was based upon the reversed-phase HPLC resolution of the 
fluorescent diastereomeric amides formed on reaction with (R)-NEA (Tan et al., 1997a). 
The derivatization procedure is based on that original developed and optimised by 
Avgerinos and Hutt (1987), with derivatization of the carboxyl group being carried out 
using the carbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (CDI), and 
1-hydroxybenzotriazole (HOBT) as coupling agents (Figure 2.2). Although the reaction 
time for derivatization is relatively long, the procedure has a high derivatization yield 
and is essentially quantitative (Avgerinos and Hutt, 1987). Further purification, using 
solid phase extraction, is essential following derivatization to remove the excess 
(R)-NEA reagent and also serves as an addition clean-up step by removing a large 
portion of co-extracted endogenous material. 
Typical chromatograms of an authentic standard, extracts of drug free serum and 
serum obtained from a volunteer following the administration of 400 mg of racemic 
ibuprofen are shown in Figure 2.3. No interfering peaks were observed in the 
chromatogram for the extract of drug free serum at the retention times of the analyte and 
internal standard derivatives. However, the chromatogram obtained following analysis 
of volunteer serum post drug administration revealed the presence of peaks, possibly 
corresponding to carboxyibuprofen, that co-eluted with the derivative of 
(R)-flurbiprofen and so quantitative analysis was performed using the (S)-flurbiprofen 
derivative peak as the internal standard. The values for extraction recoveries from serum 
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Figure 2.2: Derivatization of (R, S)-ibuprofen with (R)-1-(naphthen-1-yl)ethylamine ((R)-NEA) in 
the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (CDI) and 1-hydroxybenzotriazole 
(HOBT). 
Validation of assay procedure 
The calibration curves for the analysis of ibuprofen enantiomers isolated from 
serum were linear between 0.1-10 µg/ml using fluorescence detection (excitation and 
emission wavelengths of 290 and 330 nm respectively) and are shown in Figure 2.4. 
Linear regression analysis of the calibration curves routinely gave correlation 
coefficients greater than 0.997. 
Analytical precision and accuracy were established by adding known quantities of 
ibuprofen at three different concentrations to serum and analysing aliquots on a single 
day (n =6) and on six different assay days, and the results are presented in Table 2.1. 
The coefficient of variation of the analytical method for within- and between-day studies 
was generally less than 10 %, indicating the precision of the assay at all concentrations 
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Figure 2.3: Chromatograms of (a) standard solution of (R, S)-ibuprofen derivatized with 
(R)-NEA, extracts of (b) blank serum and (c) a volunteer serum sample obtained 2hr post oral 
administration of the racemic drug. Peaks : (R)-1-(naphthen-1-yl)ethylamides of 1, (R)- 
flurbiprofen; 2, (S)-flurbiprofen (I. S. ); 3, (R)-ibuprofen and 4, (S)-ibuprofen. [Mobile phase, 
phosphate buffer (pH 3.5,0.01M): acetonitrile (50: 50 v/v); Flow rate, 1.5 mu min; Detection, 














Figure 2.4: A typical calibration curve prepared for the quantification of the enantiomers of 
ibuprofen as their (R)-1-(naphthen-l-yl)ethylamides following extraction of the 
drug from serum. 
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investigated was greater than 90 %. The mean difference of the analytical method for 
within- and between-day studies was also less than 10 %, indicating the accuracy of the 
assay at all the concentrations examined was greater than 90 %. 
Table 2.1: Within-day and between-day analytical variation and accuracy of ibuprofen 
enantiomers in "spiked" serum samples (mean ± s. d.; n=6) *. 
Concentration Enantiomer Concentration C. V. M. D. 
(mcg/ml) determined (mcg/ml) (%) (%) 
Within-day 
0.1 R 0.097 ± 0.005 5.63 -3.0 
S 0.098 ± 0.006 5.78 -2.0 
1.0 R 1.05 ± 0.03 3.09 5.0 
S 1.07±0.04 3.76 7.0 
10.0 R 10.08±0.26 2.56 0.8 
S 10.09 ± 0.28 2.81 0.9 
Between-day 
0.1 R 0.095 ± 0.008 8.74 -5.0 
S 0.096 ± 0.007 7.48 -4.0 
1.0 R 1.02±0.04 4.40 2.0 
S 1.03 + 0.06 5.64 3.0 
10.0 R 10.01 ±0.35 3.54 0.1 
S 10.04 ± 0.33 3.30 0.4 
* C. V. = coefficient of variation; M. D. = mean difference. 
2.3.2 Determination of unbound concentrations of ibuprofen enantiomers in 
serum 
The enantioselective plasma protein binding of ibuprofen was investigated using 
equilibrium dialysis and required the use of radiolabelled ibuprofen. The dialysis 
method employed was essentially that detailed by Tan et al. (1997a) and was based on 
an original method developed by Evans et al. (1989). Equilibrium dialysis was preferred 
over other methods of determining free concentrations since it is relatively cheap to 
perform and required the use of non-specialised instrumentation. The use of 
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radiolabelled drug is often necessitated as drugs which are highly protein bound, like the 
2-arylpropionic acids, require free drug assays to be very sensitive as extremely low 
concentrations are encountered (Rowland, 1980: Wright et al., 1996). Before utilisation 
in the dialysis experiments, the radiolabelled ibuprofen was purified by semi-preparative 
HPLC to remove low protein binding radiochemical impurities as their presence, even 
in small amounts, can lead to spurious estimates of unbound fractions (Bjornsson et al., 
1981). Based on the collection of timed fractions and radiochemical analysis, the 
purities pre- and post-chromatographic purification were about 96 % and 99 % 
respectively. 
Separation of the ibuprofen enantiomers, following isolation from post-dialysis 
buffer and serum, was carried out using a direct chromatographic approach with a CSP, 
rather than using the indirect methods previously employed (Evans et al., 1989; Tan et 
al. , 
1997a). In this manner, higher throughput could be achieved and also loss of sample 
by additional manipulation could be minimised. The resolution was performed using a 
derivatized cellulose CSP, cellulose tris (3,5-dimethylphenylcarbamate) (Chiralcel OD), 
and under the experimental chromatographic conditions (R)- and (S)-ibuprofen had 
retention times of 12.5 and 15.9 minutes respectively with separation (a) and resolution 
factors (Rs) of 1.23 and 1.28 respectively. Chromatograms of an ibuprofen standard, and 
post-dialysis extracts of dialysate and serum are shown in Figure 2.5; the addition of 
carrier non-radiolabelled (R, S)-ibuprofen during sample preparation ensured 
visualisation of the ibuprofen peaks and minimised potential sorptive losses of the 
radiolabelled drug. 
Volume shifts in equilibrium dialysis occur as a result of the movement of water 
from the recipient to the donor chamber causing dilution of the binding protein 
concentration and if uncorrected, will result in an overestimation of the unbound 
fraction (Lockwood and Wagner, 1983; Lima et al., 1983). Correction for volume shift 
is especially significant if the unbound fraction of the drug is small (Huang, 1983). The 
volume shifts obtained for the dialysis experiments were typically less than 10 % and 
the unbound fractions calculated were routinely corrected for volume shift based on 
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Figure 2.5: The (a) chiral-phase chromatograms and (b) radioactivity of (i) standard solutions of 
(R,, S)-ibuprofen, post-dialysis extracts of (ii) buffer and (iii) "spiked" serum (10 gg/ml). Peaks : 1, 
(R)-ibuprofen; 2, (S)-ibuprofen [Mobile phase, hexane: isopropanol (100: 1.1 v/v) with TFA (0.1 % 
v/v); Flow rate, 1.0mi/min; Detection, UV A, = 220 nm]. 
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The reproducibility of the entire procedure for determining the unbound fractions 
of ibuprofen enantiomers was assessed at various analyte concentrations in serum and 
the results are presented in Table 2.2. In general the variation is greater than that seen 
for the serum assay validation experiments, this is not unexpected as much lower 
concentrations are involved and even a maximum coefficient of variation of 16 % is still 
within acceptable limits. Thus, although several steps are involved in the performance of 
this method, the overall reproducibility is acceptable. 
Table 2.2: Precision data for the determination of the unbound fraction (%) for ibuprofen 
enantiomers (mean ± s. d.; n=5) *. 
Enantiomeric Enantiomer Unbound C. V. 
Concentration (mcg/ml) fraction (%) (%) 
5R0.24 ± 0.023 9.6 
S 0.66±0.021 3.2 
10 R 0.25±0.039 15.6 
S 0.68±0.035 5.1 
20 R 0.28±0.043 15.4 
S 0.70 ± 0.069 9.9 
* C. V. = coefficient of variation. 
These results also demonstrate that the protein binding of ibuprofen enantiomers 
to plasma protein is stereoselective, with the R-enantiomer binding to a greater extent 
than its S-antipode (Table 2.2). The extent of binding and degree of stereoselectivity was 
consistent with the observations of Evans et al. (1989). It is also worth noting that at the 
different concentrations assessed, which is expected to represent the typical therapeutic 
serum concentration range following the single oral administration of 400 mg ibuprofen 
(see Chapter 3), the enantiomeric binding was not significantly different and thus 
concentration-dependent protein binding is not anticipated to be an influential factor in 
the volunteer study. 
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2.3.3 Enantiospecific analysis of ibuprofen in urine 
The method adopted to determine the concentrations of ibuprofen enantiomers in 
urine was essential identical to that employed for the serum assay (Tan et al., 1997a). 
The only significant difference being that an alternative extraction solvent system, i. e. 
hexane: isopropanol (9: 1, v/v), was used as diethylether was found to result in the 
co-extraction of large quantities of endogenous materials from urine. High extraction 
efficiencies was also achieved, with recovery values typically greater than 90 % for both 
enantiomers (Tan et al., 1997a). 
The determination of total (free plus conjugated) concentrations required the use 
of smaller aliquots of urine samples since liberation of ibuprofen from its conjugate was 
expected to result in much higher levels present in the samples. The hydrolysis of the 
ester glucuronides was performed using the base hydrolysis procedure optimised and 
utilised by Tan et al. (1997a). The use of alkaline rather than enzymatic hydrolysis of 
acyl glucuronides circumvents analytical problems associated with the intramolecular 
acyl migration of the carboxylic acid moiety to yield ß-glucuronidase-resistant 
glucuronic acid esters (Faed, 1984; Caldwell et al., 1983). Typical chromatograms of a 
standard, extracts of drug free urine and non-hydrolysed and hydrolysed volunteer urine 
samples are shown in Figure 2.6 and illustrate the absence of interfering peaks at the 
retention times of the derivatives of (R)- and (S)-ibuprofen and (S)-flurbiprofen, the 
internal standard. 
Validation of the assay procedure 
Single enantiomer calibration curves for ibuprofen (range: 0.1-10 µg/ml) typically 
yielded correlation coefficients greater than 0.997 and are shown in Figure 2.7. The 
within-day and between-day precision and accuracy values for the enantiomers of 
ibuprofen, as presented in Table 2.3, are generally good with coefficients of variation 
and mean differences less than 9% at the different concentrations examined. These 
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Figure 2.6: Chromatograms of (a) standard solution of (RS)-ibuprofen derivatized with 
(R)-NEA, extracts of (b) non-hydrolysed and (c) hydrolysed blank urine and (d) non-hydrolysed 
and (e) hydrolysed volunteer 24 hour pooled urine samples following oral administration of the 
racemic drug. Peaks, (R)-1-(naphthen-1-yl)ethylamide derivatives of : 1, (R)-flurbiprofen; 2, (S)- 
flurbiprofen (I. S. ); 3, (R)-ibuprofen and 4, (S)-ibuprofen [Mobile phase, phosphate buffer (pH 3.5, 
0.01M): acetonitrile (50: 50, v/v); Flow rate, 1.5 ml/min; Detection, fluorescence Xex = 290 nm and 
Xem = 330 nm]. 
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Figure 2.7: A typical calibration curve prepared for the quantification of the enantiomers of 
ibuprofen as their (R)-1-(naphthen-1-yl)ethylamides following extraction of the drug from urine. 
Table 2.3: Within-day and between-day analytical variation and accuracy of ibuprofen 
enantiomers in "spiked" urine samples (mean ± s. d.; n=6) *. 
Concentration Enantiomer Concentration C. V. M. D. 
(Meg/ml) determined (mcg/ml) (%) (%) 
Within-day 
0.1 R 0.094 ± 0.005 5.36 -6.0 
S 0.096 ± 0.006 6.08 -4.0 
1.0 R 0.99 ± 0.04 3.57 -1.0 
S 1.00 ± 0.03 2.96 0.0 
10.0 R 10.01 ± 0.29 2.86 0.1 
S 10.03 ± 0.25 2.45 0.3 
Between-day 
0.1 R 0.094 ± 0.008 8.31 -6.0 
S 0.097 ± 0.007 6.99 -3.0 
1.0 R 0.99±0.04 4.34 -1.0 
S 0.98±0.03 3.14 -2.0 
10.0 R 10.05 ± 0.32 3.21 0.5 
S 10.06 ± 0.30 2.97 0.6 
* C. V. = coefficient of variation; M. D. = mean 
difference. 
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2.3.4 Stereospecific analysis of carboxyibuprofen and hydroxyibuprofen in urine 
A sequential achiral-chiral HPLC method was adopted for the stereospecific 
analysis of carboxyibuprofen and hydroxyibuprofen in urine; the metabolite 
concentrations are determined on the achiral-phase and the appropriate fraction of the 
eluate transferred to a CSP for the determination of stereochemical composition (Tan et 
al. , 1997b). Achiral chromatography is used as a first-step separation to obtain good 
resolution between the structurally similar metabolites and to minimise the exposure of 
the CSP to co-extracted contaminants which could potentially effect its stability or 
modify its separation properties (Ducharme et al., 1996; Hutt and Patel, 1998). 
Achiral chromatography was performed using a silica stationary phase, as the 
normal-phase conditions are compatible with those of the CSP and facilitate sample 
manipulation in that the collected eluate can be readily evaporated to concentrate the 
analyte before introduction onto the CSP. Typical chromatograms of a standard, extracts 
of drug free urine and non-hydrolysed and hydrolysed volunteer urine samples are 
shown in Figure 2.8. No interfering peaks were observed in the chromatograms at the 
retention times of either metabolite or the internal standard owing to endogenous 
constituents of urine either before or after alkali treatment to hydrolyse the ester 
glucuronide conjugates. Extraction recoveries were generally greater than 90 % and 
93 % for carboxyibuprofen and hydroxyibuprofen respectively (Tan et al., 1997b). 
Chiral chromatography was carried out using a derivatized amylose CSP, amylose 
tris (3,5-dimethylphenylcarbamate) (Chiralpak AD), under chromatographic conditions 
used previously for the resolution and characterisation of the stereoisomers of 
carboxyibuprofen (Tan et al., 1997c). Chromatograms of a carboxyibuprofen standard 
and of eluate fractions collected following achiral analysis of extracts of drug free urine 
and non-hydrolysed and hydrolysed volunteer urine samples are shown in Figure 2.9. 
The same mobile phase conditions were also used for the analysis of hydroxyibuprofen 
and typical chromatograms are shown in Figure 2.10. As would 
be expected the chiral- 
phase chromatograms of the metabolites, following their separate collection using 
normal-phase chromatography, were extremely clean with the chromatograms 
for the 
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Figure 2.8: Normal-phase chromatograms of (a) reference standards, extracts of (b) non- 
hydrolysed and (c) hydrolysed blank urine and (d) non-hydrolysed and (e) hydrolysed volunteer 24 
hour pooled urine samples following oral administration of the racemic drug. Peaks : 1, p-chloro- 
phenoxyacetic acid (I. S. ); 2, carboxyibuprofen and 3, hydroxyibuprofen [Mobile phase, 
hexane: ethanol (98.2: 1.8 v/v) with TFA (0.05% v/v); Flow rate, 2.0 ml/min; Detection, UV ?. = 220 
nm]. 
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Figure 2.9: Chiral-phase chromatograms of (a) carboxyibuprofen standard, normal-phase HPLC 
eluate collections from (b) non-hydrolysed and (c) hydrolysed blank urine and (d) non-hydrolysed 
and (e) hydrolysed volunteer 24 hour pooled urine samples following oral administration of the 
racemic drug. Peaks : 1, (2'S, 2R)-; 2, (2'R, 2R)-; 3, (2'R, 2S)- and 4, (2'S, 2S)- [Mobile phase, 
hexane: ethanol (92: 8 v/v) with TFA (0.05% v/v); Flow rate, 1.0 ml/min; Detection, UV X= 220 nm]. 
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Figure 2.10: Chiral-phase chromatograms of (a) hydroxyibuprofen standard, normal-phase HPLC 
eluate collections from (b) non-hydrolysed and (c) hydrolysed blank urine and (d) non-hydrolysed 
and (e) hydrolysed volunteer 24 hour pooled urine samples following oral administration of the 
racemic drug. Peaks : 1, (R)-hydroxyibuprofen and 2, (S)-hydroxyibuprofen [Mobile phase, 
hexane: ethanol (92: 8 v/v) with TFA (0.05% v/v); Flow rate, 1.0 ml/min; Detection, UV X= 220 nm]. 
67 
Chapter 2 Ibuprofen : Stereospecific bioanal sis 
Validation of the assay procedure 
The calibration curves for the quantification of carboxy and hydroxyibuprofen 
extracted from urine were linear in the range of 10-320 µg/ml and are shown in Figure 
2.11. Linear regression analysis of the data produced correlation coefficients greater 
than 0.997 for both metabolites. The achiral-phase analytical procedure showed 
acceptable precision, accuracy and between-day variability for both analytes at the three 
concentration levels examined, with coefficients of variation and mean differences less 
than 8% and 3% respectively (Tables 2.4 and 2.5). 
The chiral-phase method was validated by analysing the material in the eluate 
collected from the above normal-phase validation experiments. These further validation 
studies are fundamental to determine whether the chiral assay is able to reproduce the 
expected stereochemical compositions throughout the complete analytical procedure and 
over a wide range of analyte concentrations. The precision and accuracy values of the 
calculated stereochemical compositions for both metabolites are presented in Tables 2.6 
and 2.7. The results indicate that there was little variation from the expected 
stereochemical compositions over a wide range of concentrations, which suggests that 
metabolite concentration does not result in chiral discrimination using the sequential 
chromatographic approach. Thus, the measurement of the stereochemical composition 
of the metabolites in the eluate from the normal-phase system can be determined with 
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Figure 2.11: Typical calibration curves prepared for the quantification of carboxyibuprofen and 
hydroxyibuprofen using the normal-phase HPLC assay. 
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Table 2.4: Within-day and between-day analytical variation and accuracy of carboxyibuprofen 
in "spiked" urine samples (mean ± s. d.; n=6) 
Concentration Concentration C. V. M. D. 
(Meg/ml) determined (mcg/ml) (%) (%) 
Within-day 
10 9.96 ± 0.416 4.18 -0.40 
80 80.45 f 2.27 2.82 0.56 
320 322.3 f 9.2 2.84 0.72 
Between-day 
10 10.11 ± 0.616 6.10 1.10 
80 81.68 f 4.27 5.22 2.33 
320 323.7 ± 12.1 3.75 1.16 
* C. V. = coefficient of variation; M. D. = mean difference. 
Table 2.5: Within-day and between-day analytical variation and accuracy of hydroxyibuprofen 
in "spiked" urine samples (mean ± s. d.; n=6) *. 
Concentration Concentration C. V. M. D. 
(mcg/ml) determined (mcg/ml) (%) (%) 
Within-day 
10 10.19 ± 0.545 5.35 1.90 
80 80.53 ± 3.29 4.08 0.66 
320 322.9 ± 9.9 3.05 0.91 
Between-day 
10 9.93 ± 0.641 6.46 -0.70 
80 81.74±4.19 5.13 2.18 
320 318.1 ± 25.2 7.93 -0.59 
* C. V. = coefficient of variation; M. D. = mean difference. 
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Table 2.6: Within-day and between-day analytical variation and accuracy of stereochemical 
compositions determined by the analysis of eluate from normal-phase chromatography of urine 
samples "spiked" with carboxyibuprofen (mean ± s. d.; n=6) *. 
"Total" concentration Isomer Stereochemical C. V. M. D. 
(mcg/ml) composition (%) (%) (%) 
Within-day 
10 2'. C2R ýSn1+111 aaa nnn ý)ý+ V. V1 - 1.11 T. TT V. VT 
2'R, 2R 25.08 ± 1.52 6.06 0.32 
2'R, 2S 25.03 ± 1.35 5.39 0.12 
2'S, 2S 24.89 ± 1.94 7.79 -0.44 
80 2'S, 2R 25.04 ± 0.84 3.36 0.16 
2'R, 2R 25.04 ± 1.12 4.47 0.16 
2'R, 2S 24.98 ± 1.43 5.72 -0.08 
2'S, 2S 24.94 ± 1.66 6.66 -0.24 
320 2'S, 2R 25.03 ± 1.21 4.83 0.12 
2'R, 2R 25.01 ± 0.74 2.96 0.04 
2'R, 2S 24.98 ± 1.10 4.40 -0.08 
2'S, 2S 24.99 ± 1.84 7.36 -0.04 
Between-day 
10 2'S, 2R 24.99 ± 1.44 5.76 -0.04 
2'R, 2R 25.02 f 1.65 6.59 0.08 
2'R, 2S 25.02 ± 1.54 6.16 0.08 
2'S, 2S 24.98 ± 1.98 7.93 -0.08 
80 2'S, 2R 25.05 ± 0.33 1.32 0.20 
2'R, 2R 24.97 ± 1.61 6.45 -0.12 
2'R, 2S 25.04 ± 1.09 4.35 0.16 
2'S, 2S 24.93 ± 1.86 7.46 -0.28 
320 2'S, 2R 25.08 ± 0.73 2.91 0.32 
2'R, 2R 25.03 ± 1.03 4.12 0.12 
2'R, 2S 24.94 ± 1.23 4.93 -0.24 
2'S, 2S 24.95 ± 0.92 3.69 -0.20 
* C. V. = coefficient of variation; M. D. = mean difference. 
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Table 2.7: Within-day and between-day analytical variation and accuracy of enantiomeric 
compositions determined by the analysis of eluate from normal-phase chromatography of urine 
samples "spiked" with hydroxyibuprofen (mean ± s. d.; n=6) *. 
"Total" concentration Enantiomer Enantiomeric C. V. M. D. 
(mcg/ml) composition (%) (%) (%) 
Within-day 
10 R 50.02 ± 1.72 3.44 0.04 
S 49.98 ± 1.73 3.46 -0.04 
80 R 50.04 ± 1.23 2.46 0.08 
S 49.96 ± 1.23 2.46 -0.08 
320 R 50.00 ± 0.93 1.86 0.00 
S 50.00 ± 0.93 1.86 0.00 
Between-day 
10 R 50.11 ± 2.82 5.62 0.22 
S 49.89 ± 2.81 5.63 -0.22 
80 R 50.01 ± 1.32 2.64 0.02 
S 49.99 ± 1.32 2.64 -0.02 
320 R 50.07 ± 1.19 2.38 0.14 
S 49.93 ± 1.18 2.36 -0.14 
* C. V. = coefficient of variation; M. D. = mean difference. 
2.4. Summary 
In summary, this chapter has described HPLC methods for the stereospecific 
analysis of ibuprofen and its major metabolites in biological fluids. Enantiospecific 
analysis of ibuprofen in serum and urine was based on the indirect approach to chiral 
chromatography, involving derivatization with (R)-1-(naphthen-l-yl)ethylamine to yield 
fluorescent diastereomeric amides which can be resolved using reversed-phase HPLC. 
Free, non-protein bound, ibuprofen was determined in serum by equilibrium dialysis 
using radiolabelled ibuprofen and the direct resolution of the enantiomers on a 
derivatized cellulose CSP. Determination of the stereochemical composition of carboxy 
and hydroxyibuprofen in urine was performed by sequential achiral-chiral 
chromatography, the metabolites were separated and quantified using a normal-phase 
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HPLC system and the respective eluates collected for determination of stereochemical 
composition using a derivatized amylose CSP. Validation experiments were performed 
for all the assays and showed that they were suitable for utilisation in quantitative 
analysis. The application of the analytical methodologies to human pharmacokinetic 
studies following the oral administration of racemic ibuprofen to healthy young and 
elderly volunteers is presented in the following Chapter. 
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CHAPTER 3: 
Stereoselective disposition and 
pharmacodynamics of ibuprofen 
in young and elderly volunteers 
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3.1. Introduction 
Clinical investigations into the disposition of ibuprofen enantiomers need to take 
into consideration three major aspects; namely, chiral inversion, metabolite formation 
and protein binding. As ibuprofen is predominately used as the racemate, the 
unidirectional chiral inversion of the relatively inactive R-enantiomer to the active 
S-antipode is essentially a form of metabolic activation, the extent of which needs to be 
investigated to estimate the effective dose of the active agent. Variability in chiral 
inversion will also influence other stereoselective transformations and may cause 
significant differences in enantiomeric disposition (Caldwell et al., 1988a). 
In addition to chiral inversion, ibuprofen undergoes functional oxidative and 
conjugative metabolism. The principal metabolic pathway is oxidation of the isobutyl 
side-chain to yield hydroxyibuprofen and carboxyibuprofen. The formation of the 
carboxy metabolite introduces a second chiral centre into the molecule and due to the 
chromatographic resolution problems outlined in the previous chapter it has been 
difficult to discern the substrate or product enantioselectivity of the reaction. Excretion 
of ibuprofen as the acyl glucuronide is quantitatively a relatively minor metabolic 
pathway, accounting for only 10 % of the dose. However, in vitro experiments have 
revealed glucuronidation to be stereoselective, favouring (S)-ibuprofen as the substrate 
(El Mouelhi et al., 1987). 
Ibuprofen, in common with most NSAIDs, is extensively bound to plasma 
proteins with unbound fractions of typically less than 0.01 (Gallo et al., 1986; Lin et al., 
1987). In vitro and in vivo studies have also shown the plasma protein binding to be 
stereo selective, with the S-enantiomer having a significantly higher unbound fraction 
(Evans et al. 1989; Lapicque et al., 1993; Paliwal et al., 1993; Hage et al., 1995). 
Furthermore, each ibuprofen enantiomer has been shown to display non-linear protein 
binding and over the range of concentrations found clinically, was able to displace its 
optical antipode from protein binding sites (Evans et al., 1990; Paliwal et al., 1993). In 
terms of pharmacokinetics, the protein binding will have an influence on distribution 
and elimination. The enantiomers of ibuprofen would be expected to 
have relatively 
small volumes of distribution since their strong association with plasma proteins 
confines them to vascular spaces (Lin et al., 1987). 
For a low clearance drug like 
ibuprofen, the rate of hepatic metabolism is low, such that binding is a limiting 
factor in 
clearance. The clearance of each enantiomer of 
ibuprofen is, therefore, directly 
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proportional to their respective free fractions in blood (Lin et al., 1987). Thus, 
pharmacokinetic studies based on unbound concentrations are essential to yield 
information on the enantioselectivity of the underlying dispositional processes. 
However, such studies are often not performed due to the difficulties associated with 
developing methods capable of detecting very low unbound concentrations. 
The first study on the pharmacokinetics of ibuprofen enantiomers in man reported 
a difference in plasma elimination half lives for the R- and S-enantiomers and the 
predominance of (S)-ibuprofen in urine (Van Giessen and Kaiser, 1975). Since then, the 
considerable interest in the stereochemical aspects of its disposition, together with the 
possible implications of the chiral inversion reaction has lead to the publication of 
numerous other enantioselective dispositional studies of ibuprofen. A recent review 
article concerned with the clinical pharmacokinetics of ibuprofen cited no less than 40 
different stereospecific studies (Davies, 1998). However, the vast majority of these 
studies are not comprehensive and only addressed some of the important issues outlined 
above. Furthermore, very little attention has been paid to studying the effect of ageing 
on the enantioselectivity of ibuprofen disposition, which is rather surprising considering 
the use of NSAIDs by the elderly is three fold that of the young (Baum et al., 1985). 
In general, studies of the influence of age on the pharmacokinetics and disposition 
of ibuprofen are scarce and have been predominantly based on non-stereospecific 
analysis. In the study of Albert et al. (1984), the pharmacokinetics of ibuprofen were 
evaluated after single oral doses of 400,800 and 1200 mg to 17 elderly volunteers (age 
range: 65-78 years) and the data obtained compared with parameters determined from a 
previous study involving 15 young healthy male volunteers (age range: 22-35 years). No 
age-related differences were observed for total and unbound pharmacokinetic 
parameters suggesting that no dose adjustment is necessary in the elderly. Another study 
by Greenblatt et al. (1984) investigated the pharmacokinetics of a single 600 mg dose of 
ibuprofen in healthy elderly (age range: 60-88 years) and young (age range: 22-44 years) 
volunteers and the results obtained gave a conflicting picture. Ibuprofen elimination 
half-life was longer and clearance reduced in elderly males compared with young male 
subjects. A more recent pharmacokinetic comparison of ibuprofen involving the 
administration of a sustained release tablet formulation, to younger (age range: 
19-60 
years) and elderly (age range: 65-85 years) patients for a two week period 
demonstrated 
comparable pharmacokinetics without appreciable 
drug accumulation (Kendall et al., 
1990). 
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The main limitation of the above age-related pharmacokinetic studies is that the 
enantiomeric composition of ibuprofen in plasma has not been taken into consideration. 
As ageing can affects various pharmacokinetic parameters which exhibit stereo- 
selectivity, e. g. protein binding, hepatic metabolism and renal elimination, it is thus 
conceivable that the disposition of ibuprofen may display age-related stereoselective 
differences in these mechanisms. A relatively recent investigation of the enantiomeric 
disposition of racemic ibuprofen in healthy young volunteers (age range: 24-34 years), 
healthy elderly volunteers (age range: 65-80 years) and elderly patients with renal 
impairment (age range: 66-87 years) showed a stereoselective increase in the unbound 
fraction of (S)-ibuprofen in both elderly groups (Rudy et al., 1995). In addition, the 
pharmacokinetics of (S)-ibuprofen were significantly different in the renally imparied 
group compared to the young, the elimination half-life was increased and unbound 
clearance decreased. 
Furthermore, no studies are present in the literature which have investigated the 
effects of age on pharmacodynamic responses to ibuprofen. Pharmacodynamic activity 
has been shown to relate closely to plasma concentrations of unbound (S)-ibuprofen 
rather than total levels since only unbound drug is available for pharmacological 
interactions with enzymes (Lin et al., 1987). Since age associated differences in 
(S)-ibuprofen plasma protein binding has been reported (Rudy et al., 1995), it is possible 
that pharmacodynamic responses may differ between the young and elderly. As outlined 
in Chapter One, the primary pharmacological activity of (S)-ibuprofen is to decrease the 
bio-synthesis of prostaglandins and thromboxanes by inhibiting the enzyme 
cyclooxygenase. In platelets, cyclooxygenase activity is stimulated following platelet 
activation which occurs in response to a variety of physiological processes including 
haemostasis and inflammation. The activity of ibuprofen in vivo can therefore be 
determined by monitoring end-points of the enzyme's activity, i. e. by following 
biochemical (e. g. thromboxane B2) and functional (e. g. platelet aggregation) markers 
(Evans et al., 1991). 
The main objective of the current investigation is to examine the disposition of 
ibuprofen enantiomers following the oral administration of the racemic drug (400 mg) to 
healthy young and elderly volunteers; important issues that will be addressed 
include the 
extent and variability of chiral inversion, stereoselectivity of the major metabolic 
pathways as well as stereoselectivity in protein 
binding. In addition, the effect of age on 
the pharmacodynamic activity of ibuprofen, 
i. e. inhibition of cyclooxygenase, will be 
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investigated by determining ex vivo thromboxane concentrations in clotting blood and 
monitoring platelet aggregability. 
3.2. Experimental 
3.2.1 Clinical study protocol 
Volunteers 
Two groups of subjects were studied : a) eight young healthy volunteers aged from 
20 to 31 years (mean ± s. d., 24.1 ± 3.7 years), four male and four female; and b) eight 
elderly healthy volunteers aged from 66 to 84 years (75.6 ± 6.8 years), seven male and 
one female; their demographic data is shown in Appendix 1. Volunteers were judged to 
be in good health on the basis of case history, physical examination, ECG, and routine 
laboratory data including blood pressure and pulse. The study was approved by the 
Research Ethics Committee of the School of Medicine and Dentistry, King's College 
London. Volunteers were fully informed about the investigational procedure and the use 
of ibuprofen. In compliance with the Declaration of Helsinki, written informed consent 
was obtained from each participant before enrolment in the study. 
Study design 
The volunteers were required to abstain from any alcohol, caffeine-based products 
and medication for at least 24 hours prior to the study. The volunteers were fasted for at 
least 8 hours overnight before a single 400mg oral dose of racemic ibuprofen (Brufen®) 
was administered with 150m1 of water. Food and drink were withheld for at least 3 
hours after drug administration. 
Blood samples were collected immediately before drug administration and at 0.25, 
0.5,0.75,1.0,1.5,2.0,3.0,3.5,4.0,6.0,8.0,10 and 24 hours post dosing in plain 
silicone coated vacutainer tubes. The volume of blood collected was 10 ml except at 
0, 
2,4 and 8 hours where an additional 10 ml of blood was required for use in platelet 
aggregation studies, 1.5 ml aliquots of all the samples collected were reserved 
for 
determination of thromboxane concentrations. The venous blood samples were drawn 
for the initial 10 hour period via an indwelling cannula, to avoid repeated venipuncture, 
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placed in a convenient vein in the arm of the volunteer. The cannula was flushed after 
each sample collection with 0.9% NaCI solution B. P. to avoid clotting in the cannula. 
Samples were allowed to clot for two hours and serum obtained after centrifugation (10 
min at 2000 g). Urine samples were collected every two hours for the first 10 hours and 
then at 24 hours post drug administration. The individual urine volumes were recorded 
and a pooled 24 hour sample was prepared from the individual collections. Serum and 
urine samples were frozen at -20°C until required for analysis. 
3.2.2 Serum and urine analysis 
(R)- and (S)-Ibuprofen concentrations in serum and pooled urine were determined 
by the indirect chromatographic methods described in sections 2.2.4 and 2.2.6 
respectively. The enantiomeric and diastereomeric composition of hydroxy- and 
carboxyibuprofen in pooled urine were determined using the achiral-chiral method 
detailed in section 2.2.7. All samples were analysed in duplicate and a set of appropriate 
calibration standards analysed on each day. 
3.2.3 Serum protein binding 
The fraction unbound for the enantiomers of ibuprofen was determined for five 
replicates using the equilibrium dialysis methodology described in section 2.2.5, 
following the pooling of serum samples obtained at 0.5,1.0 2.0,3.0 and 4.0 hours post- 
administration for each volunteer. The mean values for unbound fractions of (R)- and 
(S)-ibuprofen determined from these five replicate were used to calculate unbound 
enantiomeric serum concentrations. 
3.2.4 Pharmacodynamic Studies 
Thromboxane concentrations in serum 
Thromboxane B2 (TXB2) concentrations in blood samples were determined using 
a validated radioimmunoassay by Dr 
Grazyna Kinkowska of the Department of 
Pharmacology, King's College London. Briefly, blood samples (250 µl; n= 4) taken 
prior to and at each collection point post-dosing were allowed 
to clot at 37°C for one 
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hour and TXB2 extracted by mixing with ethanol (250 µl), formic acid (1 M; 250 µl) 
and ethyl acetate (1.75 ml). Following centrifugation, an aliquot of ethyl acetate (25 µl) 
was evaporated and TXB2 concentrations determined using a TXB2-specific antibody 
and [3H]-TXB2 by ß-scintillation counting. Calibration curves were generated using 
standard solutions of TXB2. 
Platelet aggregation 
Ex vivo platelet aggregation studies were performed by Dr Linda Chirrey of the 
Clinical Age Research Unit (CARU), School of Medicine and Dentistry, King's College 
London, for blood samples taken pre and 2,4 and 8 hours post drug administration. 
Briefly, aliquots of freshly generated platelet rich plasma (250 µl) in the presence of a 
range of adenosine diphosphate (ADP) concentrations (25 µl of 0,1,2,5 and 10 µM) 
were assessed using a platelet aggregometer. Platelet aggregation data was expressed as 
percentages of theoretical maximum at each collection time point. 
3.2.5 Pharmacokinetic and data analysis 
Determination of pharmacokinetic parameters was performed by conventional 
non-compartmental analysis of the enantiomeric serum concentration-time profiles of 
ibuprofen (Rowland and Tozer, 1995). 
Maximum serum concentrations (Cm) and the corresponding times (Tm) were 
determined by examination of the individual serum concentration-time curves for each 
volunteer. The terminal elimination half-life (t112, Z) was determined using : 
tli2, Z = In 2/? 
(Eqn. 3.1) 
where the elimination rate constant (A) is obtained by 
log-linear regression of the 
terminal phase of the serum concentration-time profile. The area under the curve 
(AUC) 
was calculated by : 
AUC = AUCoýt + AUCtý00 (Eqn. 3.2) 
where AUC upto the last measurable 
data point (AUCo, t) was determined using the 
trapezoidal rule and extrapolated to 
infinite time (AUCt--, 00) by dividing the last 
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measurable serum concentration by 2 z" The area extrapolated beyond the last data point 
typically constituted less than 2% of the total area. 
The fraction of (R)-ibuprofen undergoing inversion (Fi,,,, ) was calculated from an 
examination of the stereochemical composition of the drug and both major metabolites 
(free and conjugated) excreted in urine over the 24 hour collection period (Rudy et al., 
1991): 
S metabolites -%S administered dose Finv = 
R administered dose (Eqn. 3.3) 
where "% S administered dose" and the "% R administered dose" are the percent of the 
administered dose with the S and R configuration respectively, i. e. 50 % in each case; 
and "% S metabolites" is a summation of the molar amounts of metabolites excreted in 
urine with the S configuration in the propionic acid moiety, expressed as a percent of 
that recovered. 
Apparent total clearance (CL) and volume of distribution (Vd) of ibuprofen was 
calculated from the following expressions: 
CL = F. Dose/AUC 
Vd = F. Dose/A, Z. AUC 
(Eqn. 3.4) 
(Eqn. 3.5) 
where fraction of the dose reaching systemic circulation (F) can be assumed to be unity. 
This is a reasonable, as the bioavailability of (R)- and (R, S)-ibuprofen has been shown to 
be greater than 92% in comparative oral and intravenous (60-minute infusion) dosing 
studies (Hall et al., 1993). As a consequence of chiral 
inversion, the dose of 
(S)-ibuprofen applicable to equations 3.4 and 3.5 must include the amount formed from 
metabolic chiral inversion of the R-enantiomer, this can 
be estimated using: 
(S)-ibuprofen "dose" _ (1 + F;,, ß, ). 200 mg (Eqn. 3.6) 
Assuming all of a given metabolite 
formed is eliminated via renal excretion, the 
formation clearance (CLf) of the major metabolites of 
ibuprofen, i. e. the stereoisomeric 
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forms of hydroxyibuprofen, carboxyibuprofen and ibuprofen glucuronide, can be 
estimated by: 
CLf = Ae(pýAUCparent (Eqn. 3.7) 
where Ae(p) is the total urinary excretion (unconjugated plus conjugated) of the 
metabolite and AUCparent is the AUC of the enantiomer from which the product was 
derived (Rudy et al., 1995). 
Free enantiomer concentrations were calculated by multiplying the respective 
mean unbound fraction by the total (bound and unbound) serum concentrations. The 
half-life (t112,, u) and elimination rate constant (2 u) for each unbound concentration-time 
profile were determined by linear regression of the log-linear portion of the unbound 
enantiomer concentration versus time curves. The AUC for unbound drug (AUCH, ) was 
calculated as: 
AUCU = unbound fraction x AUC (Eqn. 3.8) 
Total body clearance (CLv) and volume of distribution (Vd) based on unbound 
concentrations were calculated as before: 
CL = F. Dose/AUC 
Vd = CL/XZ u 
(Eqn. 3.9) 
(Eqn. 3.10) 
The unbound inversion clearance of (R)-ibuprofen (CLR inv, u) can 
be calculated from: 
CLR inv, u = 
Finv. CLR u (Egn. 3.11) 
The unbound clearance of (R)-ibuprofen via non-inversion pathways 
(CLR other, u) can be 
established from: 
CLR other, u = CLR u- 
CLR inv, u (Eqn. 3.12) 
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The mean pharmacokinetic parameters derived from the total and unbound serum 
data and urinary excretion data for the enantiomers of ibuprofen and hydroxyibuprofen 
and the stereoisomers of carboxyibuprofen were tested for stereoselective differences 
using the Student's t-test for paired samples in both age groups. Age-associated 
differences in the enantiospecific pharmacokinetic data and urinary data were assessed 
using the Student's t-test for independent samples. 
3.3. Results 
3.3.1 Serum kinetics 
Enantioselective differences 
The mean serum concentration-time profiles for the enantiomers of ibuprofen 
following the oral administration of 400 mg of the racemate to eight healthy young 
volunteers are shown in Figure 3.1, and the individual serum level data is tabulated in 
Appendix 2. The pharmacokinetic parameters derived from the serum concentrations are 
presented in Table 3.1. Following administration of 400 mg of the racemate, the serum 
levels of the two enantiomers of ibuprofen were indifferent during the initial four hour 
post-dose period, which is reflected in values for C,,, ax and Tm displaying close 
correlation between the two enantiomers (Table 3.1). Subsequently, the serum 
concentrations of the S-enantiomer consistently exceeded those of its antipode such that 
the difference in enantiomeric concentrations reached statistical significance beyond 6 
hours. This gradual enrichment of (S)-ibuprofen in serum during the elimination phase 
is also apparent from the mean half-live of the S-enantiomer being significantly greater 
than that of the R-antipode (p < 0.05; Table 3.1). These findings are consistent with 
previously reported data (Van Giessen and Kaiser, 1975; Lee et al., 1985; Cox et al., 
1988; Avgerinos and Hutt, 1990; Tan, 1996; Suri et al., 1997). The longer tli2, Z for the 
S-enantiomer was primarily due to the significantly larger volume of distribution of this 
enantiomer; with enantioselective total clearance, favouring the faster clearance of 
(S)-ibuprofen rather than its R-antipode, playing a less prominent role (Table 3.1). In 
addition, the AUC of the S-enantiomer was significantly greater than that of the 
R-enantiomer. 
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Figure 3.1: Mean serum concentration-time profiles for ibuprofen enantiomers following the oral 
administration of (R, S)-ibuprofen (400 mg) to eight healthy young volunteers (mean ± s. d. ). 
83 
Chapter 3 Ibuprofen : Stereoselective disposition and pharmacodynamics 
Table 3.1: Pharmacokinetic parameters of ibuprofen enantiomers following the oral 
administration of the racemic drug (400 mg) to eight healthy young volunteers. 
(R)-ibuprofen 
Subject Cmaa Tmax t1/2, Z AUC CL Vd Fmv, 
Code (mcg/ml) (hr) (hr) (mcg/mI hr) (ml/min) (L) 
lyl 16.1 1.0 1.6 67.3 49.5 7.0 0.62 
Iy2 15.2 3.0 2.1 67.5 49.4 8.8 0.66 
1y3 14.9 1.5 1.4 55.3 60.3 7.0 0.74 
Iy4 15.8 2.0 2.0 75.3 44.3 7.5 0.69 
Iy5 23.0 2.5 1.4 80.6 41.4 4.9 0.66 
Iy6 11.3 6.0 1.2 45.0 74.1 8.0 0.73 
Iy7 11.6 2.5 1.5 42.9 77.7 9.8 0.68 
1y8 17.6 2.5 1.3 57.1 58.4 6.4 0.65 
Mean 15.7 2.6 1.6 61.4 56.9 7.4 0.68 
s. d. 3.7 1.5 0.3 13.6 13.4 1.5 0.04 
C. V. % 23.4 57.4 20.8 22.2 23.5 20.1 6.0 
(S)-ibuprofen 
lyl 16.8 1.0 1.8 71.6 75.4 11.8 
Iy2 16.1 3.5 2.1 77.2 71.7 12.9 
1y3 16.2 2.0 2.6 98.5 58.9 13.4 
1y4 14.9 2.0 2.5 84.3 66.8 14.2 
ly5 16.8 2.5 2.4 76.9 72.0 14.9 
Iy6 16.1 6.0 3.6 78.2 73.7 22.9 
Iy7 13.7 3.5 2.3 75.5 74.2 14.4 
Iy8 14.1 3.0 2.2 65.9 83.5 16.0 
Mean 15.6 2.9 2.4 78.5 72.0 15.1 
s. d. 1.2 1.5 0.5 9.7 7.1 3.4 
C. V. % 7.7 51.0 21.8 12.3 9.8 22.7 
p (R vs. S) * N. S. N. S. p<0.05 p<0.05 p<0.05 p<O. 
001 
* Comparison between the means for the enantiomers of ibuprofen were carried out using Student's t-test for paired samples 
(N. S. = p>0.05). 
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The fraction unbound of the individual R- and S-enantiomers of ibuprofen for each 
volunteer was determined ex vivo following the replicate analysis (n =5) of a pooled 
serum sample which incorporated samples selected along the absorption phase, at Cm 
when ibuprofen and metabolite concentrations would be high and during the elimination 
phase (Table 3.2). Such an approach is reasonable since nonlinear protein binding for 
the enantiomers of ibuprofen is not expected to be issue at the relatively low dose and 
serum concentrations of this study (Evans et al., 1989,1990; Hall et al., 1993). 
Table 3.2: Percentage unbound of ibuprofen enantiomers following the oral administration of the 
racemic drug (400 mg) to eight healthy young volunteers (mean ± s. d.; n=5). 
Ibuprofen : Stereoselective disposition and pharmacodynamics 
% unbound 
Subject R -isomer S-isomer 
Code mean ± s. d. mean ± s. d. 
lyl 0.25 ± 0.048 0.48 ± 0.041 
Iy2 0.25 ± 0.042 0.43 ± 0.050 
Iy3 0.19±0.024 0.41 ±0.024 
Iy4 0.21 ± 0.031 0.48 ± 0.029 
Iy5 0.21 ± 0.022 0.54 ± 0.045 
Iy6 0.21 ± 0.040 0.47 ± 0.026 
Iy7 0.24 ± 0.018 0.38 ± 0.037 
Iy8 0.23 ± 0.009 0.45 ± 0.008 
Mean ± s. d. 0.22 ± 0.022 0.46 ± 0.049 
The percentage unbound of the R-enantiomer was significantly less than that of 
the S-enantiomer in all volunteers, with the mean values of 0.22 and 0.46 % for (R)- and 
(S)-ibuprofen respectively comparing favourably with values of 0.33 and 0.55 % 
obtained by Evans et al. (1990). The slight differences may be in part due to 
overestimation of the unbound fractions in the previous study as the values had not been 
corrected for volume shifts that occur during equilibrium dialysis (Evans et al., 1990). 
Inter-subject variation in the enantiomeric binding ratio (percent unbound S/R) was 
large, varying approximately 60 % between 1.58 and 2.61, with a mean value of 
2.09 
which is within the range of values previously reported 
in in vitro studies (Evans et al., 
1990; Paliwal et al., 1993; Smith et al., 1994). The significance of the enantioselective 
protein binding in favour of the R-enantiomer 
is apparent from the serum unbound 
concentration-time curves, where the 
free serum levels of (S)-ibuprofen always 
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exceeded those of its antipode such that the difference reached statistical significance at 
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Figure 3.2: Mean serum unbound concentration-time profiles for ibuprofen enantiomers 
following the oral administration of (R, S)-ibuprofen (400 mg) to eight healthy young volunteers 
(mean ± s. d. ). 
The pharmacokinetic parameters obtained from the analysis of unbound serum 
concentrations for the young volunteers are presented in Table 3.3. When plasma 
protein binding is taken into account the significant enantioselectivity in volume of 
distribution disappears, but enantioselective differences in AUCU and tli2, Z, with the 
S-enantiomer displaying a higher AUCU and longer tli2,, are still observed. In contrast, 
unbound clearance exhibits enantioselectivity opposite to that of total clearance, with 
preference for the R-enantiomer rather than the S-enantiomer. Examination of the 
unbound clearance data for (R)-ibuprofen shows that this enantiomer is cleared 
predominately via inversion to its antipode, accounting for 69 % of the total unbound 
clearance. The unbound clearance of (R)-ibuprofen via other pathways was 
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approximately half the unbound clearance of (S)-ibuprofen, indicating that clearance 
through the oxidative and glucuronidation pathways was stereoselective for the 
S-enantiomer (Table 3.3). 
Table 3.3: Pharmacokinetic parameters based on unbound concentrations of ibuprofen 
enantiomers following the oral administration of the racemic drug (400 mg) to eight healthy young 
volunteers. 
unbound (R)-ibuprofen 
Subject % AUCu tli2z, u Vdu CLu CLmv, u CLother, u 
Code unbound (mg/ml hr) (hr) (L) (L/min) (L/min) (L/min) 
lyl 0.25 0.17 1.6 2796 19.8 12.3 7.5 
Iy2 0.25 0.17 2.1 3523 19.8 13.0 6.7 
Iy3 0.19 0.11 1.4 3708 31.7 23.5 8.3 
Iy4 0.21 0.16 2.0 3559 21.1 14.5 6.5 
Iy5 0.21 0.17 1.4 2319 19.7 13.0 6.7 
Iy6 0.21 0.09 1.2 3787 35.3 25.8 9.5 
Iy7 0.24 0.10 1.5 4092 32.4 22.0 10.4 
Iy8 0.23 0.13 1.3 2791 25.4 16.5 8.9 
Mean 0.22 0.14 1.5 3322 25.6 17.6 8.1 
s. d. 0.02 0.03 0.3 612 6.5 5.4 1.4 
C. V. % 9.83 24.82 20.3 18 25.5 30.5 17.8 
unbound (S)-ibuprofen 
lyl 0.48 0.34 1.8 2449 15.7 
Iy2 0.43 0.33 2.1 3002 16.7 
Iy3 0.41 0.40 2.6 3270 14.4 
Iy4 0.48 0.40 2.5 2965 13.9 
Iy5 0.54 0.42 2.4 2757 13.3 
Iy6 0.47 0.37 3.6 4863 15.7 
Iy7 0.38 0.29 2.3 3802 19.5 
Iy8 0.45 0.30 2.2 3581 18.6 
Mean 0.46 0.36 2.4 3336 16.0 
s. d. 0.05 0.05 0.5 755 2.2 
C. V. % 10.83 13.66 21.8 23 13.7 
p (R vs. S) * p<O. 001 p<O. 001 p<0.05 N. S. p<O. 01 
* Comparison between the means for the enantiomers of ibuprofen were carried out using Student's t-test for paired samples 
(N. S. = p>0.05). 
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The mean (R)- and (S)-ibuprofen serum concentration-time profiles following the 
administration of the racemic drug to eight healthy elderly volunteers are shown in 
Figure 3.3, and the individual serum level data is tabulated in Appendix 3. The 
pharmacokinetic parameters calculated from these data are presented in Table 3.4. In 
contrast to the young group, the serum levels of the R-enantiomer exceeded those of the 
S-antipode for the initial five hours following administration of the racemate to elderly 
volunteers; beyond this period the slower decline of (S)-ibuprofen, as also observed with 
the young, resulted in comparatively higher levels of the S-enantiomer in serum (Figure 
3.3). The differences in the serum concentration of the two enantiomers were 
statistically significant at all sampling time after the initial 15 minutes post dose. The 
mean pharmacokinetic parameters determined for the elderly volunteers displayed 
similar enantioselective differences in CL, Vd and tli2,, as those previously observed in 
the young, with the S-enantiomer having a greater CL and Vd and a longer tli2, Z. A 
statistically significant difference in AUC was not observed with the elderly, although a 
trend towards a larger AUC for the S-enantiomer was apparent. Furthermore, the 
predominance of (R)-ibuprofen in serum during the absorption phase is reflected in the 
R-enantiomer displaying a significantly greater Cmax than the S-antipode in this age 
group (Table 3.4). 
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Figure 3.3: Mean serum concentration-time profiles for ibuprofen enantiomers following the oral 
administration of (R, S)-ibuprofen (400 mg) to eight healthy elderly volunteers (mean ± s. d. ). 
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Table 3.4: Pharmacokinetic parameters of ibuprofen enantiomers following the oral 
administration of the racemic drug (400 mg) to eight healthy elderly volunteers. 
(R )-ibuprofen 
Subject Cm, 
a Tmax tli2, z AUC CL Vd Fin,, 
Code (mcg/ml) (hr) (hr) (mcg/ml hr) (mi/min) (L) 
Ie l 19.3 2.0 2.8 95.9 34.8 8.3 0.65 
1e2 14.8 1.5 1.7 77.8 42.8 6.4 0.71 
1e3 14.4 1.0 1.8 75.0 44.4 7.0 0.67 
1e4 15.5 2.0 1.2 71.4 46.7 4.9 0.72 
1e5 11.5 1.5 1.8 54.9 60.7 9.4 0.66 
1e6 12.0 2.5 1.7 49.8 66.9 10.1 0.64 
1e7 20.4 2.0 1.1 78.1 42.7 3.9 0.62 
1e8 21.4 1.5 1.6 109.4 30.5 4.3 0.61 
Mean 16.2 1.8 1.7 76.5 46.2 6.8 0.66 
s. d. 3.8 0.5 0.5 19.5 12.2 2.3 0.04 
C. V. % 23.4 26.5 30.0 25.5 26.4 34.5 6.0 
p(Yvs. E) N. S. N. S. N. S. N. S. N. S. N. S. N. S. 
(S)-ibuprofen 
lel 16.5 1.5 3.9 96.3 57.1 19.3 
1e2 14.0 2.0 4.3 101.7 56.0 20.9 
1e3 14.7 1.0 2.8 88.1 63.2 15.3 
1e4 14.1 2.0 2.9 96.6 59.4 14.9 
1e5 11.4 1.5 4.1 61.9 89.4 31.7 
1e6 10.3 2.5 2.5 55.1 99.2 21.5 
Ie7 13.2 2.0 2.7 72.8 74.2 17.3 
1e8 15.7 2.0 3.0 99.4 54.0 14.0 
Mean 13.7 1.8 3.3 84.0 69.1 19.4 
s. d. 2.1 0.5 0.7 18.2 17.0 5.7 
C. V. % 15.1 25.3 21.6 21.7 24.6 29.5 
p(R vs. S) * p<0.05 N. S. p<0.001 N. S. p<O. 0001 p<O. 0001 
p(Yvs. E) p<0.05 N. S. P<0.05 N. S. N. S. N. S. 
* Comparison between the means for the enantiomers of ibuprofen were carried out using Student's t-test for paired samples 
(N. S. = p>O. 05). t Comparison between respective means for young and elderly volunteers were carried out using Student's t-test 
for independent samples (N. S. = p>O. 05). 
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The serum protein binding of ibuprofen in the elderly volunteers displayed the 
same enantioselectivity as that observed in the young group, with mean percentage 
unbound values for (R)- and (S)-ibuprofen of 0.22 and 0.53 % respectively (Table 3.5). 
High inter-subject variability in the enantiomeric binding ratio (unbound S/R) is also 
evident in this age group with values ranging from 1.69 to 3.23 around a mean value of 
2.48. As observed with the young, the stereoselective protein binding is paralleled with 
serum concentrations of the free-form of (S)-ibuprofen being between 2 to 6 fold greater 
than those of the corresponding R-antipode concentrations (Figure 3.4). 
Table 3.5: Percentage unbound of ibuprofen enantiomers following the oral administration of the 
racemic drug (400 mg) to eight healthy elderly volunteers (mean ± s. d.; n=5). 
% unbound 
Subject R -isomer S-isomer 
Code mean ± s. d. mean ± s. d. 
lel 0.21 ±0.017 
Ie2 0.33 ± 0.061 
Ie3 0.24±0.010 
Ie4 0.25 ± 0.044 
1e5 0.19±0.028 
Ie6 0.17 ± 0.007 
Ie7 0.25 ± 0.047 
0.57 ± 0.042 
0.56 ± 0.054 
0.57 ± 0.015 
0.53 ± 0.063 
0.50 ± 0.036 
0.46 ± 0.023 
0.56 ± 0.048 
1e8 0.15±0.019 0.49±0.034 
Mean ± s. d. 0.22 ± 0.057 0.53 f 0.042 
The pharmacokinetic parameters base on unbound serum concentrations displayed 
the same enantioselectivity between (R)- and (S)-ibuprofen as 
found with the young 
group; i. e. the S-enantiomer has a significantly 
longer tli2, Z u, reduced CL and a larger 
AUCU than the R-antipode (Table 3.6). The clearance pattern observed in the young 
group is also still evident in the elderly, with 
(R)-ibuprofen cleared primarily via chiral 
inversion and clearance through other general metabolic pathways exhibiting substrate 
stereo selectivity in favour of (S)-ibuprofen. 
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Figure 3.4: Mean serum unbound concentration-time profiles for ibuprofen enantiomers 
following the oral administration of (R, S)-ibuprofen (400 mg) to eight healthy elderly volunteers 
(mean ± s. d. ). 
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Table 3.6: Pharmacokinetic parameters based on unbound concentrations of ibuprofen 
enantiomers following the oral administration of the racemic drug (400 mg) to eight healthy elderly 
volunteers. 
unbound (R)-ibuprofen 
Subject % AUCu ttnz, u Vd CL CL; ýv, u CLother, u 
Code unbound (mg/ml hr) (hr) (L) (L/min) (L/min) (L/min) 
lel 0.21 0.20 2.8 3941 16.6 10.8 5.8 
Ie2 0.33 0.26 1.7 1945 13.0 9.2 3.8 
1e3 0.24 0.18 1.8 2918 18.5 12.4 6.1 
Ie4 0.25 0.18 1.2 1956 18.7 13.5 5.2 
Ie5 0.19 0.10 1.9 5257 32.0 21.1 10.9 
Ie6 0.17 0.08 1.8 5966 39.4 25.2 14.2 
Ie7 0.25 0.20 1.1 1567 17.1 10.6 6.5 
Ie8 0.15 0.16 1.6 2884 20.3 12.4 7.9 
Mean 0.22 0.17 1.7 3304 21.9 14.4 7.5 
s. d. 0.06 0.06 0.5 1617 9.0 5.7 3.4 
C. V. % 25.39 33.86 29.3 49 40.9 39.4 45.1 
p(Yvs. E) N. S. N. S. N. S. N. S. N. S. N. S. N. S. 
unbound (S)-ibuprofen 
lel 0.57 0.55 4.0 3435 10.0 
Ie2 0.56 0.57 4.3 3726 10.0 
Ie3 0.57 0.50 2.8 2678 11.1 
Ie4 0.53 0.51 2.9 2792 11.2 
Ie5 0.50 0.31 4.1 6408 17.9 
Ie6 0.46 0.25 2.6 4874 21.6 
Ie7 0.56 0.41 2.8 3246 13.3 
Ie8 0.49 0.49 3.0 2862 11.0 
Mean 0.53 0.45 3.3 3753 13.3 
s. d. 0.04 0.12 0.7 1284 4.2 
C. V. % 7.94 25.73 20.9 34 31.9 
p(R vs. S) * p<O. 001 p<0.001 p<0.001 N. S. p<O. 0001 
p(Y vs. E) p<0.05 N. S. p<0.05 
N. S. N. S. 
rison *C between the means for the enantiomers of ibuprofen were carried out using 
Student's t-test for paired samples ompa 
(N. S. =p>0.05). t Comparison between respective means 
for young and elderly v olunteers were carried out using Student's t-test 
for independen t samples (N. S. = p>O. 05). 
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Age-associated differences 
Comparison between the young and elderly groups indicated age-related 
alterations in the stereo selectivity of ibuprofen disposition (Table 3.4). There were no 
differences in the pharmacokinetic parameters based on total serum concentrations for 
(R)-ibuprofen between the two age groups. But significant differences were observed in 
the case of the S-enantiomer indicating that the elderly have a lower Cm and a longer 
elimination half life for the active (S)-ibuprofen. There was also trends towards a larger 
Vd for the S-enantiomer in the elderly, but the difference between the two age groups did 
not achieve statistical significant (p = 0.09; Table 3.4). 
Examination of the unbound fractions for the individual enantiomers of ibuprofen 
in the two age groups reveals that ageing is associated with significant changes in the 
extent of serum protein binding of (S)- but not (R)-ibuprofen; such that the mean 
enantiomeric ratio (percent unbound S/R) increased from 2.07 ± 0.33 in the young to 
2.48 ± 0.47 in the elderly subjects (Tables 3.2 and 3.5). Pharmacokinetic parameters 
based on unbound serum concentrations displayed, as would be expected, no age-related 
differences for (R)-ibuprofen (Table 3.6). In the case of unbound (S)-ibuprofen a 
significant difference was only evident for tli2,, u between the two age groups which 
mirrored the age-related difference observed in the half-life of (S)-ibuprofen based on 
total serum concentrations, this is not surprising since in the presence of a constant 
fraction unbound values of half-life are not influenced by the use of unbound drug 
concentrations. However, it is also noteworthy that there is a trend towards a larger 
AUCH, for (S)-ibuprofen in the elderly, but the difference between the two age groups did 
not achieve statistical significant (p = 0.06; Table 3.6). 
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3.3.2 Urinary excretion 
Enantioselective differences 
Ibuprofen : Stereoselective disposition and pharmacodynamics 
The urinary excretion data for ibuprofen and its metabolites following the oral 
administration of the drug to young volunteers is summarised in Table 3.7 and the 
individual data tabulated in Appendices 4 to 6. The calculated inversion fractions and 
formation clearances are tabulated in Tables 3.1 and 3.8. The total amount of ibuprofen 
and metabolites recovered in the 0-24 hour urine collection period was 72.8 + 11.8 % 
which compares favourably with previously published values of 70 to 79 % (Evans et 
al., 1990; Smith et al., 1994; Rudy et al., 1995; Scheuerer et al., 1998). The principle 
pathway of ibuprofen elimination is via oxidative metabolism to form hydroxy- and 
carboxyibuprofen with recovery values of 21.2 and 39.4 % respectively. Elimination as 
ibuprofen conjugates is a relatively minor pathway, accounting for only 12.2 % of the 
administered dose excreted in urine (Evans et al., 1990; Smith et al., 1994; Scheuerer et 
al., 1998). 
The fraction of the administered dose of (R)-ibuprofen inverted to (S)-ibuprofen 
(F;,,, ), determined using urinary data, had a mean value of 0.68 which shows good 
agreement with previously reported values calculated by either separate administration 
of the R-enantiomer, by the urinary metabolite method, or by administration of a 
pseudoracemate (Lee et al., 1985; Rudy et al., 1991; Smith et al., 1994). The range of 
F1,,,, values was from 0.62 to 0.74 indicating limited inter-subject variability in the extent 
of chiral inversion, which is consistent with the observations made previously based on 
indirect evidence (Avgerinos and Hutt, 1990). 
Ibuprofen was present in urine almost exclusively as the acyl glucuronide of the 
S-enantiomer (recovery ratio S/R = 11.5; Table 3.7). This appears to be as a consequence 
not only of the metabolic chiral inversion of (R)- to (S)-ibuprofen but also the 
stereoselective clearance of (S)-ibuprofen as the glucuronide metabolite, which is 
indicated by the enantioselectivity observed in the formation clearances of ibuprofen 
glucuronides (Table 3.8). The presence of small amounts of free (R)- and (S)-ibuprofen 
in the urine, accounting for about 1% of the dose, is probably as a result of spontaneous 
hydrolysis of the glucuronide during sample manipulation rather than excretion of the 
unchanged drug (Lockwood et al., 1983; Lee et al., 
1985; Evans, 1992). 
95 
Chapter 3 Ibuprofen : Stereoselective disposition and pharmacodynamics 
Table 3.7: Urinary excretion (0-24 hr) of ibuprofen and its metabolites following the oral 
administration of the racemic drug (400 mg) to eight healthy young volunteers (data expressed as a 
mean percentage of the administered dose). 
R -isomer S -isomer 
Analyte mean ± s. d. mean ± s. d. 
Ibuprofen 
free: 0.06 ± 0.03 0.96 ± 0.46 
conjugate: 0.89 ± 0.16 10.24 ± 2.08 
total 0.95±0.16 11.20±2.15 * 
Hydroxyibuprofen 
free: 2.69±0.80 7.82±2.13 
conjugate: 0.62 ± 0.28 10.11 ± 1.48 
total 3.31 ± 0.82 17.92 ± 1.89 * 
Carboxyibuprofen, 2'R- 
free: 3.40 ± 0.40 10.76 ± 2.40 
conjugate: 1.20 ± 0.62 3.51 ± 1.93 
total 4.60 ± 0.70 14.27 ± 2.60 
Carboxyibuprofen, 2'S- 
free: 2.34 + 0.38 12.86 ± 2.73 
conjugate: 0.51 ± 0.30 
4.79 ± 2.09 
total 2.84 ± 0.55 
17.65 ± 2.91 
Total Recovery 11.71 ± 1.75 
61.04 ± 7.04 
*p<0.05 for comparison between the means of enantiomers using 
Student's t-test for paired samples. 
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Table 3.8: Formation clearances (ml/min) for (a) ibuprofen glucuronides, hydroxyibuprofen and 
carboxyibuprofen and (b) individual carboxyibuprofen stereoisomers following the oral 






RS 2'S, 2R + 2R, 2R 2'R, 2S + 2'S, 2S 
lyl 1.10 9.99 4.32 15.64 7.70 26.15 
Iy2 0.88 7.56 2.37 13.62 7.82 25.86 
Iy3 1.22 9.50 2.89 12.38 7.23 19.94 
Iy4 0.97 9.24 2.41 13.76 5.91 21.79 
1y5 0.68 10.91 3.70 17.20 8.13 34.90 
ly6 1.29 9.55 4.44 17.89 10.77 34.04 
1y7 1.04 6.74 5.31 16.46 11.31 29.25 
1y8 1.32 13.13 4.37 15.83 7.96 27.29 
Mean 1.06 9.58 3.73 15.35 8.35 27.40 
s. d. 0.22 1.96 1.07 1.92 1.80 5.28 
C. V. % 20.53 20.43 28.79 12.50 21.57 19.25 
p (R vs. S) * p<0.0005 p<0.0005 p<0.0005 
b) Subject 
Code 2'S, 2R 
carboxyibuprofen stereoisomers 
2'R, 2R 2'R, 2S rs, 2S 
lyl 2.69 5.00 11.94 14.21 
Iy2 3.22 4.60 11.00 14.86 
Iy3 2.57 4.67 9.12 10.82 
1y4 2.09 3.82 9.78 12.00 
Iy5 3.19 4.94 16.17 18.73 
Iy6 4.27 6.50 14.72 19.32 
Iy7 3.90 7.41 13.71 15.53 
Iy8 3.55 4.41 11.44 15.85 
Mean 3.19 5.17 12.24 15.17 
s. d. 0.72 1.19 2.44 2.94 
C. V. % 22.66 22.94 19.97 19.38 
p(271 vs. 2' S) * p<0.0005 p<0.0005 
* Comparison between the means of the enantiomers of ibuprofen and hydroxyibuprofen and that of the individual stereoisomers 
of carboxyibuprofen and the stereoisomers of carboxyibuprofen 
derived from (R)- and (S)-ibuprofen were performed using a 
Student's t-test for paired samples (N. S. =p>0.05). 
NOTE: data for carboxyibuprofen are presented for both the individual stereoisomers and also 
for the sum of the stereoisomers 
produced from an individual isomer of 
ibuprofen, i. e. the two diastereoisomers 2'S, 2R and 2'R, 2R arise via oxidation of 
(R)-ibuprofen whereas 2'R, 2S and 2'S, 2S arise from oxidation of the 
S-enantiomer. 
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Clearance of ibuprofen via oxidative metabolic pathways, i. e. via the formation of 
hydroxyibuprofen and carboxyibuprofen, also display substrate stereoselectivity towards 
(S)-ibuprofen as reflected in the formation clearances, which were significantly greater 
for the metabolites derived from the S-enantiomer compared to the R-antipode (S/R: 
hydroxyibuprofen = 4.1 and carboxyibuprofen = 3.3; Table 3.8). Furthermore, for both 
(R)- and (S)-ibuprofen the formation clearances were greater for carboxyibuprofen rather 
than hydroxyibuprofen indicating that oxidation has preference for the 3'-position rather 
than 2'-position of the isobutyl group. Thus, clearance via oxidative metabolism exhibits 
stereo selectivity in favour of the S-enantiomer and regioselectivity in favour of 
carboxyibuprofen formation, this pattern is reflected in the metabolite excretion data 
(Table 3.7). It is also apparent that formation of the carboxyibuprofen stereoisomers 
displays product, as well as substrate, stereoselectivity with the predominantly formed 
diastereoisomer having the same configuration at the metabolically introduced chiral 
centre as that in the substrate propionic acid moiety i. e. oxidation of (R)-ibuprofen 
favours (2'R, 2R)-carboxyibuprofen formation (2'R, 2R/2'S, 2R = 1.6) and (S)-ibuprofen 
favours the formation of (2'S, 2S)-carboxyibuprofen (2'S, 2S/2'R, 2S = 1.2; Table 3.8). 
In contrast to the situation with the parent drug, substantial amounts of the 
hydroxy and carboxy metabolites were excreted in urine in the non-conjugated, as well 
as conjugated, form (Table 3.7). Interestingly, (R)-hydroxyibuprofen is predominantly 
recovered as the free metabolite (conjugate/free = 0.23) whereas (S)-hydroxyibuprofen 
was excreted mainly as the conjugate (conjugate/free = 1.3), indicating that conjugation 
of hydroxyibuprofen displays enantioselectivity in favour of the S-enantiomer. In the 
case of carboxyibuprofen, all four stereoisomers were present in urine predominantly as 
the free metabolite, which might be as predicted on the basis of its high polarity. The 
individual conjugate/free ratios of 0.35,0.33,0.22 and 0.37 for the 2'R, 2R, 2'R, 2S, 
2'S, 2R and 2'S, 2S stereoisomers respectively, suggests that (2'S, 2R)-carboxyibuprofen is 
a poorer substrate for conjugation than the other three stereoisomers 
(Table 3.7). This is 
most probably as a consequence of stereoselective conjugation since recently 
it has been 
reported that carboxyibuprofen, like ibuprofen and 
hydroxyibuprofen, undergoes 
conjugation with glucuronic acid to form 
ß-1-O-acyl glucuronides at the carboxylic acid 
group of the propionic acid side chain and thus regioselectivity 
in conjugation is not an 
issue (Kepp et al., 1997). 
Metabolite formation clearances based on unbound rather than total serum 
concentrations of ibuprofen revealed more modest, 
but still significant, differences 
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between the enantiomers for all metabolic pathways (Table 3.9). Thus, the enantiomeric 
ratio (S/R) of the formation clearances for ibuprofen glucuronides decreased from 9.0 to 
4.4 when calculated from total and unbound enantiomer data respectively. Similarly, the 
corresponding values for the hydroxy metabolite decreased from 4.1 to 2.0 and those for 
the sum of the carboxy diastereoisomers derived from a particular ibuprofen enantiomer 
decreased from 3.3 to 1.6. However, the product selectivity ratios, i. e. the ratio for the 
carboxyibuprofen stereoisomers derived from a single enantiomer of ibuprofen, 
remained constant at 1.62 and 1.24 for 2'R, 2R/2'S, 2R and 2'S, 2S/2'R, 2S respectively; 
which is not surprising since the influence of unbound fraction is negated in these ratios. 
Therefore, even though the relative stereo selectivity of the individual pathways is 
reduced when based on unbound formation clearances, the data indicates inherent 
stereo selectivity of the associated metabolic pathways. So, the overall stereochemical 
composition of the metabolites in urine is reflective of stereoselectivity in both protein 
binding and metabolism, and possibly also of renal excretion. 
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Table 3.9: Unbound formation clearances (L/min) for (a) ibuprofen glucuronides, 
hydroxyibuprofen and carboxyibuprofen and (b) individual carboxyibuprofen stereoisomers 








2'S, 2R+2'R, 2R 2'R, 2S+2'S, 2S 
lyl 0.44 2.10 1.71 3.29 3.05 5.51 
1y2 0.35 1.77 0.94 3.19 3.11 6.05 
ly3 0.61 2.34 1.45 3.05 3.64 4.91 
ly4 0.45 1.95 1.13 2.90 2.78 4.59 
Iy5 0.32 2.00 1.75 3.15 3.85 6.39 
1y6 0.64 2.02 2.22 3.78 5.39 7.19 
Iy7 0.45 1.75 2.28 4.29 4.85 7.61 
Iy8 0.58 1.88 1.92 3.48 3.50 6.00 
Mean 0.48 1.98 1.68 3.39 3.77 6.03 
s. d. 0.12 0.19 0.48 0.45 0.91 1.04 
C. V. % 24.70 9.63 28.70 13.34 24.18 17.24 
p (R vs. S) * p<0.0005 p<0.0005 p<0.0005 
b) Subject 










1.07 1.98 2.51 2.99 
1.28 1.83 2.57 3.48 
1.29 2.35 2.25 2.67 
0.98 1.80 2.06 2.53 
1.51 2.34 2.96 3.43 
2.13 3.25 3.11 4.08 
1.67 3.18 3.57 4.04 
1.56 1.94 2.51 3.48 
carboxyibuprofen stereoisomers 
2'R, 2R 2'R, 2S 
Mean 
s. d. 










p(2 'R vs. 2' S) * p<0.0005 
p<0.0005 
* Comparison between the means of the enantiomers of ibuprofen and 
hydroxyibuprofen and that of the individual stereoisomers 
of carboxyibuprofen and the stereoisomers of carboxyibuprofen 
derived from (R)- and (S)-ibuprofen were performed using a 
Student's t-test for paired samples (N. S. =p>0.05). 
NOTE: data for carboxyibuprofen are presented 
for both the individual stereoisomers and also for the sum of the stereoisomers 
produced from an individual isomer of 
ibuprofen, i. e. the two diastereoisomers 2'S, 2R and 2'R, 2R arise via oxidation of 
(R)-ibuprofen whereas 2'R, 2S and 2'S, 
2S arise from oxidation of the S-enantiomer. 
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The urinary excretion data for ibuprofen and its metabolites for the elderly group 
is presented in Table 3.10 and the individual data tabulated in Appendices 7 to 9. The 
calculated inversion fraction and formation clearances are tabulated in Tables 3.4 and 
3.11. Approximately 66.8 ± 15.6 % of the ibuprofen dose was recovered in urine as 
ibuprofen or its metabolites over the 0-24 hour collection period. The hydroxy and 
carboxy metabolites formed 19.1 and 35.2 % of the administered dose recovered in 
urine, with the parent drug accounting for only 12.4 % (Table 3.10). The mean value for 
the Fi, was 0.66 which is in close agreement with the value obtained in the young and 
in a similar manner, there was little variability in the extent of inversion between the 
elderly volunteers. 
As with the young group, ibuprofen was excreted mainly as the acyl glucuronide 
of the S-enantiomer with an S/R recovery ratio of 11.0; which is paralleled with 
(S)-ibuprofen glucuronide having a significantly greater formation clearance than the 
R-antipode. Stereoselective clearance was also observed with the hydroxyibuprofen and 
carboxyibuprofen metabolites as reflected by the respective formation clearances, which 
were significantly greater for the metabolites derived from (S)-ibuprofen compared to 
those of the (R)-enantiomer (S/R: hydroxyibuprofen = 4.9, carboxyibuprofen = 3.5; 
Table 3.11). The formation of the carboxyibuprofen diastereoisomers displayed the 
same substrate related product stereoselectivity as that observed with the young 
volunteers, i. e. oxidation of (R)-ibuprofen preferentially yields (2'R, 2R)-carboxy- 
ibuprofen (2'R, 2R/2'S, 2R = 1.5) and (S)-ibuprofen preferentially forms (2'S, 2S)-carboxy- 
ibuprofen (2'S, 2S/2'R, 2S = 1.3; Table 3.11). 
The urinary excretion of the oxidative products, as free metabolites or as 
conjugates, showed a similar stereochemical pattern to that observed in the young 
(Table 3.10). Stereoselective conjugation of hydroxyibuprofen is indicated by the 
recovery of the S-enantiomer primarily as the conjugate (conjugate/free = 1.36) and the 
R-antipode mainly in the unconjugated form (conjugate/free = 0.17). In the case of the 
carboxy metabolite, the individual conjugate/free ratios of 0.35,0.33,0.23 and 0.37 for 
the 2'R, 2R, 2'R, 2S, 2'S, 2R and 2'S, 2S stereoisomers respectively, also suggests that 
(2'S, 2R)-carboxyibuprofen is a poorer substrate for conjugation than the other three 
stereoisomers in this age group (Table 3.11). 
In a similar manner to the young group, unbound formation clearances 
displayed 
more modest, but still significant, 
differences between the enantiomers (Table 3.12). 
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Table 3.10: Urinary excretion (0-24 hr) of ibuprofen and its metabolites following the oral 
administration of the racemic drug (400 mg) to eight healthy elderly volunteers (data expressed as a 
mean percentage of the administered dose). 
R -isomer S -isomer 
Analyte mean ± s. d. mean ± s. d. 
Ibuprofen 
free: 0.09 ± 0.04 1.02 f 0.70 
conjugate: 0.94 ± 0.28 10.32 f 3.42 * 
total 1.04±0.31 11.34±3.86 * 
Hydroxyibuprofen 
free: 2.57 ± 0.87 6.83 ± 2.17 * 
conjugate: 0.43 ± 0.20 9.31 ± 2.27 * 
total 3.00 ± 0.94 16.14 ± 3.86 
Carboxyibuprofen, 2'R- 
free: 3.24 ± 0.99 9.30 ± 2.35 
conjugate: 1.13 ± 0.92 3.03 ± 3.16 * 
total 4.37 ± 1.17 12.33 ± 2.98 
Carboxyibuprofen, 2'S- 
free: 2.46 + 0.71 11.29 ± 3.07 
conjugate: 0.57 ± 0.82 4.23 ± 3.60 
total 3.02±0.80 15.52±3.42 * 
Total Recovery 11.43 ± 2.69 55.33 ± 10.25 
*p<0.05 for comparison between the means of enantiomers using Student's t-test 
for paired samples. t p-value <0.05 for 
comparison between respective means for young and elderly volunteers using 
Student's t-test for independent samples 
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Table 3.11: Formation clearances (mu min) for (a) ibuprofen glucuronides, hydroxyibuprofen and 
carboxyibuprofen and (b) individual carboxyibuprofen stereoisomers following the oral 
administration of the racemic drug (400 mg) to eight healthy elderly volunteers. 
a) Subject conjugate hydroxyibuprofen carboxyibuprofen 
Code R S R S 2'S, 2R +2 'R, 2R 2'R, 2S + 2'S, 2S 
lei 0.52 7.66 2.02 10.55 6.44 23.97 
Ie2 0.97 8.53 1.49 8.26 4.07 12.07 
1e3 0.70 6.33 1.49 7.05 4.67 15.60 
1e4 1.29 12.93 2.84 12.77 5.76 18.88 
1e5 1.82 15.29 4.09 19.07 9.39 32.89 
1e6 0.84 8.19 4.79 23.97 12.32 42.38 
1e7 0.82 8.18 2.72 13.86 6.19 21.88 
1e8 0.71 6.43 2.75 13.96 5.80 21.72 
Mean 0.96 9.19 2.77 13.69 6.83 23.67 
s. d. 0.42 3.20 1.18 5.59 2.72 9.75 
C. V. % 43.30 34.84 42.37 40.87 39.81 41.17 
p (R vs. S) * p<0.0005 p<0.0005 p<0.0005 
p(Y vs. E) N. S. N. S. N. S. N. S. N. S. N. S. 
b) Subject carboxyibuprofen stereoisomers 
Code 2'S, 2R 2'R, 2R 2'R, 2S 2'S, 2S 
lei 2.75 3.69 10.97 13.00 
1e2 1.81 2.26 5.19 6.88 
1e3 2.04 2.60 6.82 8.78 
Ie4 1.97 3.79 8.57 10.30 
1e5 4.23 5.16 13.94 18.96 
1e6 4.44 7.87 19.37 23.01 
1e7 2.42 3.77 9.72 12.16 
Ie8 2.48 3.32 9.33 12.39 
Mean 2.77 4.06 10.49 13.19 
s. d. 1.02 1.77 4.44 5.33 
C. V. % 36.70 43.63 42.36 40.45 
p(2R vs. 2' S) * p<0.0005 p<0.0005 
p(y vs. E) N. S. N. S. N. S. N. S. 
* Comparison between the means of the enantiomers of ibuprofen and hydroxyibuprofen and that of the individual stereoisomers 
of carboxyibuprofen and the stereoisomers of carboxyibuprofen derived from (R)- and 
(S)-ibuprofen were performed using a 
Student's t-test for paired samples (N. S. =p>0.05). 
t Comparison between respective means for young and elderly volunteers 
were carried out using Student's t-test for independent samples 
(N. S. =p>0.05). 
NOTE: data for carboxyibuprofen are presented for both the individual stereoisomers and also 
for the sum of the stereoisomers 
produced from an individual isomer of ibuprofen, 
i. e. the two diastereoisomers 2'S, 2R and 2'R, 2R arise via oxidation of 
(R)-ibuprofen whereas 2'R, 2S and 2'S, 2S arise from oxidation of the 
S-enantiomer. 
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Table 3.12: Unbound formation clearances (L/min) for (a) ibuprofen glucuronides, 
hydroxyibuprofen and carboxyibuprofen and (b) individual carboxyibuprofen stereoisomers 








2'S, 2R + 2'R, 2R 2R, 2S + 2S, 2S 
lei 0.25 1.34 0.97 1.85 3.09 4.20 
Ie2 0.29 1.52 0.45 1.47 1.22 2.15 
1e3 0.29 1.12 0.62 1.24 1.93 175 
1e4 0.51 2.45 1.13 2.42 2.29 3.58 
1e5 1.00 3.05 2.25 3.81 5.15 6.57 
1e6 0.53 1.81 2.98 5.28 7.67 9.34 
1e7 0.32 1.45 1.06 2.46 2.42 3.88 
1e8 0.48 1.30 1.88 2.83 3.97 4.41 
Mean 0.46 1.76 1.42 2.67 3.47 4.61 
s. d. 0.25 0.66 0.87 1.33 2.10 2.32 
C. V. % 53.45 37.86 61.57 49.85 60.48 50.23 
p (R vs. S) * p<0.0005 p<0.0005 p<0.0005 
p(Y vs. E) t N. S. N. S. N. S. N. S. N. S. N. S. 
b) Subject 
Code 2'S, 2R 
carboxyibuprofen stereoisomers 
2'R, 2R 2'R, 2S 2'S, 2S 
le l 1.32 1.77 1.92 2.28 
1e2 0.54 0.68 0.93 1.23 
1e3 0.85 1.08 1.20 1.55 
1e4 0.78 1.50 1.62 1.95 
1e5 2.32 2.83 2.78 3.78 
1e6 2.77 4.90 4.27 5.07 
1e7 0.94 1.47 1.73 2.16 
1e8 1.70 2.27 1.89 2.51 
Mean 1.40 2.06 2.04 2.57 
s. d. 0.80 1.33 1.05 
1.26 
C. V. % 56.90 64.30 51.57 49.27 
p(2 'R ,, s. 2' S) " p<0.0005 p<0.0005 
P(Y vs. E) t N. S. 
N. S. N. S. N. S. 
* Comparison between the means of the enantiomers of ibuprofen and 
hydroxyibuprofen and that of the individual stereoisomers 
of carboxyibuprofen and the stereoisomers of carboxyibuprofen 
derived from (R)- and (S)-ibuprofen were performed using a 
Student 's t-test for paired samples (N. S. =p>0.05). 
1 Comparison between respective means for young and elderly volunteers 
were carried out using Student's t-test 
for independent samples (N. S. =p>0.05). 
NOTE: data for carboxyibuprofen are presented 
for both the individual stereoisomers and also for the sum of the stereoisomers 
produced from an individual isomer of 
ibuprofen, i. e. the two diastereoisomers 2'S, 2R and 2'R, 2R arise via oxidation of 
(R)-ibuprofen whereas 2'R, 2S and 2'S, 2S arise 
from oxidation of the S-enantiomer. 
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Thus, the enantiomeric ratio (S/R) of the formation clearances for ibuprofen 
glucuronides decreased from 9.6 to 3.8 when calculated from total and unbound 
enantiomer data respectively. Likewise, the corresponding values for the hydroxy 
metabolite decreased from 4.9 to 1.9 and those for the sum of the carboxy 
diastereoisomers derived from a particular ibuprofen enantiomer decreased from 3.5 to 
1.3. 
Age-associated differences 
A lower percentage of the dose, although not significant, was recovered over the 
24 hour urine collection period in the elderly (66.8% vs. 72.7%). This appears to be 
primarily due to a modest decrease in the recovery of the oxidative products of 
(S)-ibuprofen, with the amounts of material excreted as the parent drug, both free and 
conjugated, and as R-configuration oxidative metabolites essentially invariant between 
the two age groups (Tables 3.7 and 3.10). 
There was a trend for metabolite formation clearances based on total serum 
concentrations to be lower in the elderly volunteers (Table 3.8 and 3.11). But the 
differences did not achieve statistical significance, this could possibly be due to the 
large inter-subject variability in the values, especially within the elderly volunteer group. 
It is noteworthy, that for a given metabolic pathway the proportionate decrease in 
clearance with age was always to a lesser extent for the S-enantiomer. This pattern is 
probably reflective of the higher unbound fraction for (S)-ibuprofen in the elderly 
partially counteracting any age related decreases in the individual unbound formation 
clearances leading to less substantial changes in the associated formation clearances. 
Comparison of unbound formation clearances did suggest that the elderly volunteers 
were generally less able to metabolise (R)- and (S)-ibuprofen; however, the differences 
were largely trends with none reaching statistical significance. In contrast, to the 
observation with total formation clearances, decreases in unbound formation clearances 
were more apparent for metabolites derived from (S)-ibuprofen. For instance, the 
unbound formation clearances for (R)- and (S)-ibuprofen glucuronide were lower by 4.1 
% and 11.0 % respectively in the elderly. In a similar manner, the corresponding values 
for (R)- and (S)-hydroxyibuprofen decreased by 15.5 % and 21.2 %, and those for the 
sum of the carboxy diastereoisomers derived from (R)- and 
(S)-ibuprofen decreased by 
8.0 % and 23.6 %. respectively. Thus, it would appear that elimination of 
(S)-ibuprofen 
is more sensitive to decreased metabolic activity 
in the elderly and it is also interesting 
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to note that clearance via the glucuronidation pathway is least influenced by age. This 
pattern of age-related alteration in the metabolic activity is reflected in the elderly 
having a reduced unbound clearance for (S)-ibuprofen (Y: 16.0 vs. E: 13.3 L/min), 
although the difference between the two age groups did not statistical significance. 
3.3.3 Pharmacodynamic studies 
The mean serum thromboxane B2 (TXB2) concentrations at each sampling time 
following the oral administration of the racemic drug to the young and elderly 
volunteers is presented in Figure 3.5. In the young group, the inhibition of TXB2 
generation was greater than 80% from 2.5 to 8 hours post administration, initial peak 
activity was reached at 3hr with 86% inhibition then there was a slight rise in serum 
TXB2 levels before a secondary peak activity of 90% inhibition was observed at 6 hours. 
In comparison, with the elderly TXB2 synthesis was inhibited to a level greater than 
80% for a longer period, from 0.5 to 10 hours following dosing, with maximum 
inhibition at 93% achieved after only 2 hours. Furthermore, a residual inhibitory activity 
of about 25% was still evident in the elderly after 24 hours, whereas with the young 
TXB2 concentrations had returned to basal levels by this period. Comparison of the 
serum concentration versus time profiles of TXB2 with those of unbound (S)-ibuprofen 
suggest a close relationship (Figure 3.5b). The faster onset and longer-lasting action in 
the elderly is associated with a shorter Tmax and slower elimination of unbound 
(S)-ibuprofen in this age group. 
The inhibition of adenosine diphosphate (ADP)-induced platelet aggregation was 
also investigated for serum derived from blood samples collected at 0,2,4 and 8 hours 
post administration (Figure 3.6). However, it appears that ibuprofen's ability to suppress 
platelet aggregation is not as profound as its inhibitory activity on TXB2 generation and 
thus only subtle differences in aggregation were observed between samples times and 
between the two age groups. However, pairwise comparison of the 2 hr, 4 hr and 8 hr 
profiles with the initial pre-dose profile (0 hour) 
indicate optimal inhibition of platelet 
aggregation after 4 hr and 2 hr in the young and elderly respectively. 
Furthermore, 
comparison of the latter time profiles with the two 
hour sample in the elderly show a 
slow gradual recovery towards basal aggregation activity; e. g. platelet 
aggregation 
induced by 1 µM ADP was 41%, 38% and 25% lower than the 
basal value for the 2 hr, 4 
hr and 8 hr samples respectively. 
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Figure 3.5: (a) Ex vivo serum thromboxane B2 (TXB2) generation and (b) mean serum 
concentration versus time profiles of TXB2 and unbound (S)-ibuprofen following the oral 
administration of racemic ibuprofen (400 mg) to eight 
healthy young and eight healthy elderly 
volunteers. 
ý- (S)-ibuprofen (YOUNG) 
(S)-ibuprofen (ELDERLY) 
o- TXB2 (YOUNG) 
o TXB2 (ELDERLY) 
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Figure 3.6: Ex vivo platelet aggregation induced by adenosine diphosphate (ADP) following the 
oral administration of racemic ibuprofen (400 mg) to eight healthy young and eight 
healthy elderly 
volunteers (mean ± s. d. ). 
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3.4. Discussion 
Previous studies, either non-stereospecific or stereospecific, of ibuprofen 
disposition in elderly volunteers are rare and have in general suggested that advanced 
age has only minimal influence on the pharmacokinetics of ibuprofen. However, the 
conclusions of some of the non-stereo specific investigations may be misleading since, 
not only do they conceal possible enantiomeric differences, but were based on 
measuring total (free plus bound) drug concentrations (Greenblatt et al., 1984; Kendall 
et al., 1990). The importance of unbound serum data is highlighted by Upton et al. 
(1984), who reported that measuring only total concentrations masks an increase in the 
unbound fraction together with a concomitant decrease in unbound clearance of 
naproxen in the elderly. The purpose of the current study was to gain a more 
comprehensive understanding of the effect of age on the enantiomeric disposition and 
pharmacodynamic activity of ibuprofen. 
Enantioselective differences 
Clinical investigations into the enantiomeric disposition of ibuprofen in human are 
complicated by the major role played by the bioactivation of (R)-ibuprofen to the 
S-antipode. Pharmacokinetic characterisation of (S)-ibuprofen must take into account 
this inversion phenomenon and thus a knowledge of the fractional inversion (F;,,,, ) is 
absolutely essential. In the current study, the fraction inverted was calculated by 
determining the stereochemical content of the drug and its metabolites in urine. This 
approach is the most convenient for clinical studies involving the administration of the 
racemate since alternative methods, based on serum analysis, require the administration 
of (R)-ibuprofen, a pseudoracemate or the individual enantiomers on separate occasions 
(Lee et al., 1985; Baillie et al., 1989; Rudy et al., 1991). Implicit 
in the adopted method 
are the assumptions that all the dose is ultimately recovered 
in the urine and that the 
metabolites do not undergo inversion to an appreciable extent. 
Almost complete urinary 
recovery (95%) of an oral administered 
dose of radiolabelled ibuprofen has been 
observed (Lee et al., 1985) and thus 
it is possible that the 25 to 35 % of the dose not 
recovered and characterised 
in the current study may have an influence, albeit small, on 
the determined Fiv values. The second assumption 
is supported by in vitro evidence that 
neither the hydroxy- or carboxy- metabolites 
inhibit the formation of (R)-ibuprofenyl- 
CoA thioester (Hall et al., 1993; Tracy et al., 
1993). The estimates of the extent of 
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inversion were similar for the two age groups and fall within the range of 0.52 to 0.74 
reported in the literature (Lee et al., 1985; Baillie et al., 1989; Hall et al., 1993; Smith et 
al., 1994; Scheueuer et al., 1998). 
In addition to chiral inversion, stereoselectivity in protein binding will also have a 
major influence on the stereoselective disposition of ibuprofen. The observation of 
significantly higher unbound fractions of (S)-ibuprofen for both age groups is consistent 
with in vitro binding studies that indicate (R)-ibuprofen has a 2.3-fold higher binding 
constant than (S)-ibuprofen for the high affinity binding site, namely site II (diazepam 
binding site), on human serum albumin (Itoh et al., 1997). 
In general, most of the enantioselective differences observed in the in 
pharmacokinetic parameters, i. e. for volume of distribution (Vd), total clearance (CL) 
and elimination half-life (t112, Z), were evident in both age groups. When unbound serum 
concentrations of the ibuprofen enantiomers are considered, the enantioselectivity is lost 
for volume of distribution (Vd) and reversed for unbound clearance (CL), clearly 
emphasising the central importance of plasma protein binding. Furthermore, 
enantioselective differences were observed for unbound area under the curve (AUC) in 
both age groups; however, such enantioselectivity was observed to a lesser degree in the 
young or not evident at all in the elderly for AUC values based on total serum 
concentrations. 
The role played by stereoselective protein binding in (S)-ibuprofen having a 
significantly higher Vd than its antipode (Tables 3.1 and 3.4) 
is apparent from the 
following expression: 
Vd = VP-(1 + REn) + VT. (f/fT) (Eqn. 3.13) 
where Vp is the plasma volume, REA 
is the ratio of plasma binding protein in the 
extracellular fluid to plasma, VT is the volume of extravascular 
tissue and f and fT are 
the fractions of unbound drug in plasma and tissue respectively. 
Assigning physiological 
values to REA, Vp and VT of 1.4,3.0 
L and 30 L respectively followed by substitution into 
equation 3.13 yields (Oie and 
Tozer, 1979; Lin et al., 1987; Evans, 1992): 
Vd = 7.2 + 30. (f/fT) (Eqn. 
3.14) 
110 
Chapter 3 Ibuprofen : Stereoselective disposition and pharmacodynamics 
As tissue binding is of minor importance with ibuprofen, it is therefore clear that the 
larger Vd of the S-enantiomer is a result of the higher unbound fraction in plasma. This 
is corroborated by the fact that this enantiomeric difference disappears when ff, is not an 
issue as with the case of VdU, i. e. the unbound Vd are not significantly different between 
the two enantiomers (Tables 3.3 and 3.6). 
While the total CL of (S)-ibuprofen was significantly greater than that of the 
R-enantiomer, the reverse situation was observed when unbound clearance values were 
examined, i. e. CLu R>S, indicating that the apparent higher total CL for the 
S-enantiomer was due to the higher free serum concentrations. The reversal of the 
enantioselective preference from CL to CL is reflected in AUCU displaying 
considerably greater enantioselectivity than evident for AUC, i. e. the mean enantiomeric 
ratios (S/R) for AUC and AUC were 1.3 and 2.6 respectively in the young, and 1.1 and 
2.7 in the elderly. As expressed above, both the Vd and CL parameters exhibit 
enantiomeric differences having higher values for the S-enantiomer, however the 
magnitude of the enantioselectivity is greater for Vd such that the apparent half-life of 
(S)-ibuprofen is significantly longer than that of (R)-ibuprofen in both age groups (Table 
3.1 and 3.4). 
The unbound clearance for (R)-ibuprofen is predominantly due to clearance by 
inversion (CL;,,,,,, ) which is of similar magnitude to the unbound clearance of the 
S-enantiomer and approximately 2.2-fold larger than clearance via alternative, non- 
inversion, pathways (CL other,,, ). These findings contradict those of 
Rudy et al. (1991) 
who reported that CL;,, v and CLother of (R)-ibuprofen were of equal significance. 
However, in vitro data using rat hepatocytes (Xiaotao and Hall, 1993) and subsequent 
human dispositional studies are consistent with our findings that CL;,, v is the main 
pathway for clearance of (R)-ibuprofen (Hall et al., 1993; Smith et al., 1994; Rudy et 
al., 1995; Scheueuer et al., 1998). 
In addition to the metabolic inversion pathway, the principle pathways of 
ibuprofen elimination involve the formation of ibuprofen glucuronide and oxidation to 
yield hydroxyibuprofen and carboxyibuprofen. 
The formation clearances for these 
metabolites all displayed stereoselectivity 
in favour of the S-enantiomer, which is 
consistent with the higher CL 
for (S)-ibuprofen. Unbound formation clearances also 
showed significant preferences 
for (S)-ibuprofen, although the magnitude of the 
stereo selectivities were 
less than the corresponding values for total formation clearance. 
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Thus, as well as the stereoselective protein binding, inherent enantioselectivity in 
functional oxidation and conjugation makes a major contribute to the enantiomeric 
disposition of ibuprofen. The stereoselectivity observed for oxidation is in agreement 
with in vitro studies which have shown that cytochrome P450 2C9 (CYP 2C9), the 
major enzyme mediating 2'- and 3'-position oxidation of ibuprofen, shows substrate 
stereo selectivity in favour of (S)-ibuprofen. As stated in the introduction, in vitro studies 
have also shown glucuronidation to be stereoselective (El Mouelhi et al., 1987); 
however, the situation in vivo is complicated by the possibility of stereoselective 
hydrolysis of the unstable acyl glucuronide conjugate and thus the enantioselectivity 
observed is possibly reflective of a net effect (Faed 1984; Knadler and Hall, 1991). The 
predominance of elimination products having the S-configuration, as a result of chiral 
inversion and stereoselectivity in both protein binding and metabolism, is reflected in 
















(2'S, 2R)- and (2'R, 2R)-carboxyibuprofen 
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Figure 3.7: Schematic representation of the enantioselective clearance of 
ibuprofen. The line 
thickness of the arrows indicate the relative 
importance of the pathway. 
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Age-associated differences 
Age-associated differences in drug disposition are well established, and age 
related alterations in enzyme expression may influence the pharmacokinetics of the 
enantiomers of a racemic drug differently. For example, the oral clearance of (-)-hexo- 
barbitone is about 2-fold greater in young compared with elderly subjects, whereas the 
clearance of the (+)-enantiomer shows no age-related effects (Chandler et al., 1988). In 
contrast, the oral clearance of both propranolol enantiomers in young subjects was about 
1.5-fold higher than that observed in elderly volunteers, with no effect on the 
enantiomeric composition of the drug in plasma (Zhou et al., 1992). Age related gender 
differences have also been observed in enantiomeric disposition (Hooper and Qing, 
1990). Examination of the enantiomeric disposition of mephobarbitone in both male and 
female, young and elderly volunteers indicated the faster elimination of the 
R-enantiomer compared with the S-antipode in all groups. However, the oral clearance 
of (R)-mephobarbitone in young males was significantly greater than that observed in 
either young or elderly females or elderly males, indicating that the clearance of the R- 
enantiomer is both age and gender dependent. No significant differences were evident 
between young and elderly females or between elderly males and females. In contrast, 
(S)-mephobarbitone has a significantly shorter elimination half life in young males 
compared with the other volunteer groups, this appears to be as a consequence of 
differences in distribution since no differences in oral clearance were found between the 
groups. 
Such changes in enantiomeric disposition with age may influence therapeutic 
response, depending upon whether the eutomer or the distomer is most affected, and 
may contribute to the observed differences in drug sensitivity, either enhanced 
pharmacological activity or adverse effects, found in the elderly. 
The present investigation has shown that following the oral administration of a 
single dose of racemic ibuprofen to young and elderly volunteers age-related 
differences 
were observed in the disposition of the S-enantiomer 
but not its R-antipode. Such 
changes in the handling of the S-enantiomer appear to originate 
from a 15% greater 
unbound fraction and a 17% reduction 
in the unbound clearance in the elderly. In terms 
of the pharmacokinetics of (S)-ibuprofen, this 
is reflected by a significantly lower Cm 
and longer tl/2, Z in the advanced age group; 
furthermore, there was also a trend towards 
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the elderly having a greater Vd and, as would be expected, larger AUC for this 
enantiomer. 
In the case the R-enantiomer, it would have been expected that any prominent age 
related changes would have most likely stemmed from differences in the extent of chiral 
inversion between the two age groups, since clearance via this route is ca. two fold more 
important than other metabolic pathways. However, the mean inversion fraction for the 
two age groups showed good correlation (Tables 3.3 and 3.6). It is also worth noting, 
that the inter-subject variability in the fractional inversion is relatively small, indicating 
that the chiral inversion appears to be a relatively "stable" process, i. e. the fraction of the 
dose presented to the body in the active form is relatively predictable in healthy 
individuals. Other major influential factors, such as protein binding and total unbound 
clearance, also displayed no age associated effect and therefore it is not surprising that 
age-dependent alterations in the disposition of (R)-ibuprofen are not apparent. 
This study indicates that ageing stereo selectively increased the unbound fraction 
of (S)-ibuprofen without any alteration in the binding of the R-antipode. Whilst it is 
generally accepted that increases in unbound fraction may be due to lower serum 
albumin concentrations in the elderly (Wallace and Verbeeck, 1987; Grandison and 
Boudinot, 2000), this appears not to be applicable in the present study since the 
determined serum albumin concentrations for the two volunteer groups were not 
significantly different (see Appendix 1). This is similar to the observations of Upton et 
al. (1984), where a small difference in serum albumin levels between the young and 
elderly volunteers could not account for the larger difference in plasma protein binding 
of naproxen. Furthermore, any general reduction in albumin concentrations would have 
expected to cause a parallel decrease in the binding of (R)-ibuprofen. It has also been 
suggested that the increase in unbound (S)-ibuprofen in the elderly may 
be due to 
accumulated oxidative metabolites acting as selective displacers 
(Rudy et al., 1995). 
However, it is unlikely this is the case since the unbound formation clearances of the 
metabolites tended to be lower in the elderly. 
Examination of the unbound formation clearances suggest that the trend towards a 
lower unbound clearance of (S)-ibuprofen 
in the elderly is largely due to a reduction in 
oxidative metabolic function. Recent 
in vitro investigations have suggested that CYP 
2C8 may also play a significant role alongside 
the principle metabolising enzyme, 
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CYP2C9, in the oxidative metabolism of ibuprofen (Hamman et al., 1997). It is interest 
to note that the CYP2C8 displays opposing enantioselectivity to CYP 2C9 and favours 
the formation of products with the R-configuration. It is likely that age has a relatively 
lower influence on CYP 2C8 than CYP 2C9-mediated metabolism, explaining why the 
clearance of (R)-ibuprofen via the oxidative pathways was altered to a lesser extent 
between the two age groups. Clearance via the minor glucuronidation pathway was 
comparatively indifferent between the young and elderly, which is agreement with 
previous suggestions that glucuronidation is generally not affected by ageing (Mooney et 
al., 1985). 
However, as the changes in protein binding and unbound clearance appear to 
operate in opposite directions no apparent age-related difference is observed in the total 
clearance of (S)-ibuprofen, i. e. the increase in fraction unbound with age (young, 0.46% 
and elderly, 0.53%) negates the observed decrease in unbound clearance (young, 16.0 
L/min and elderly, 13.3 L/min). Thus, at steady state the total serum concentrations of 
(S)-ibuprofen would appear to be similar between the two groups, but this would mask 
the fact that the elderly have exposure to higher unbound concentrations. This can best 
be appreciated by the observation that the total AUC was similar between the two age 
groups (young, 78.5 mcg/ml hr and elderly 84.0 mcg/ml hr), whereas the unbound AUC 
was 25% greater in the elderly (young, 0.36 mg/ml hr and elderly 0.45 mg/ml hr). The 
increase in the unbound fraction with age is paralleled with a trend towards a higher 
volume of distribution and this results in the elderly exhibiting a significantly longer 
half life for (S)-ibuprofen than the young group. 
The clinical implications of the stereoselective increase in the exposure of the 
elderly to the free levels of the active enantiomer of ibuprofen can not 
be fully 
appreciated solely on pharmacokinetic knowledge. Aside from the concentration of the 
drug at its site of action, the magnitude of a drug effect 
depends on the number of 
receptors in the target organ, the capability of the cells to respond to specific occupation 
of the receptors (signal transduction) and the counterregulatory processes operating 
in 
the body. Hence, in addition to pharmacokinetics, drug pharmacodynamics may 
be 
changed in the elderly (Hammerlein et al., 
1998). For example, both animal and human 
studies suggest that there is an 
inverse relationship between advancing age and 
gastrointestinal prostaglandin 
levels and thus it has been postulated that NSAIDs cause 
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more gastropathy in older individuals due to lower basal levels of prostaglandins 
(Solomon and Gurwitz, 1997). 
To monitor the pharmacodynamic activity of ibuprofen on platelet cyclooygenase, 
the amount of thromboxane A2 (TXA2) generated in response to endogenous thrombin 
formation (i. e clot formation) was assessed by measuring the concentration of its stable 
breakdown product, thromboxane B2 (TXB2), in the harvested serum (Figure 3.5). The 
potent activity of ibuprofen is clearly evident with near complete inhibition of serum 
TXB2 (>90 %) in both age groups, which is in good agreement with the extent of 
inhibition observed by Evans et al. (1991). The close transitory relationship between 
inhibition of TXB2 generation and serum unbound (S)-ibuprofen concentration in both 
the young and elderly groups is consistent with the close proximity of the biological 
receptor (platelet cyclooxygenase) to the sampling compartment (serum). The time 
course of inhibition is in keeping with the fact that the binding of ibuprofen to platelet 
cyclooxygenase is a reversible process (Cashman, 1996). In contrast, the function of 
platelets which have been exposed to aspirin cannot be restored, since this drug 
irreversibly acetylates the active site on the cyclooxygenase (Flower et al., 1985). 
Comparison of the TXB2 profiles for the young and elderly groups mirror the 
differences evident in the unbound (S)-ibuprofen kinetic profiles and thus suggest that 
inhibitory activity has faster onset and is longer-lived in the elderly. It is interesting to 
note that the serum TXB2 concentration was 25 % below the pre-treatment value at 24 
hr in the elderly. Whereas with the young, TXB2 concentrations had returned to basal 
activity as has been observed previously for four healthy young males (Evans et al., 
1991). The maintenance of such a significant degree of activity in the elderly at 24 hour 
post dosing is unlikely to be solely related to differences in serum concentrations of 
unbound (S)-ibuprofen. The elderly have an increased proportion of body fat (Dawling 
and Crome, 1989) so it is possible that the prolonged activity could be associated with 
the leaching of (S)-ibuprofen from adipose stores (Evans, 1991). Alternatively, it could 
be reflective of the fact that the elderly are more sensitivity to the effects of 
ibuprofen, 
this could be investigated through pharmacokinetic-pharmacodynamic modelling, 
however this is beyond the scope of the current investigation. 
Platelet aggregation studies were also performed using platelet rich plasma and 
adenosine diphosphate (ADP) as an external stimulus 
for aggregation (Figure 3.6). Age 
related differences were more 
difficult to define, however there was a trend consistent 
with the findings of the TXA2 study suggesting 
that activity was observed faster and for 
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a longer period in the elderly group. The main disadvantage of the platelet aggregation 
studies is that they are time-consuming and need to be performed using freshly isolated 
plasma from recently drawn blood, since they are dependent on the viability of the 
arachidonic acid pathway in the platelets, and so only a restricted number of sampling 
times can be assessed. 
3.5. Conclusions 
Similar stereoselective differences were observed in the pharmacokinetics of the 
enantiomers of ibuprofen following the administration of the racemic drug to healthy 
young and elderly volunteers. Stereoselective protein binding favouring higher serum 
unbound (S)-ibuprofen concentrations led to enantiomeric differences in Vd and the 
unbound AUC. (R)-Ibuprofen was cleared predominately through chiral inversion and 
clearance through the oxidation and glucuronidation metabolic pathways, exhibited 
substrate stereoselectivity in favour of the S-enantiomer. Metabolite formation 
clearances indicate that the stereoselectivity in these metabolic pathways is as a result, 
not only of the stereoselective protein binding, but also inherent stereoselectivity in the 
metabolic reactions. 
Age-related alterations were only evident in the disposition of (S)- and not 
(R)-ibuprofen. As a consequence of a higher unbound fraction and reduced unbound 
clearance, which was largely due to reduced clearance via oxidative pathways, the 
elderly had a greater exposure to the free levels of the active (S)-ibuprofen. 
Pharmacodynamic studies, based on monitoring the inhibition of platelet TXA2 
generation, shows that activity is in close correlation with serum concentrations of 
unbound (S)-ibuprofen. This would suggest that age-related changes in the disposition 
of (S)-ibuprofen could have significant clinical implications and necessitate dose 
reduction in the elderly. 
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CHAPTER 4: 
Chromatographic separation and enantiomeric 
resolution of flurbiprofen and its metabolites 
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4.1. Introduction 
Since the first reported enantiospecific analytical methods became available in the 
early 1970s, a wide range of methods and techniques have been developed for the 
enantiospecific analysis of chiral NSAIDs. The indirect chromatographic approach, i. e. 
involving the formation of stable diastereomeric derivatives is the more popular 
technique in terms of validated assays published in the literature (Davies, 1997). The 
number of commercially available homo-chiral derivatizing reagents (HCDAs), many of 
which are available in very high and reliable enantiomeric purity, has increased in recent 
years and several compilations of both reagents and derivatization methods have been 
published (Hutt, 1990; Gal, 1993; Skidmore, 1993; Görög and Gazdag, 1994; Buschges 
et al., 1997). Direct methods, utilising chiral stationary phases (CSPs) or chiral mobile 
phase additives (CMPAs), are still relatively new and their application in bioanalysis is 
more limited. But their potential is certainly evident and they are becoming increasing 
employed as novel phases and modifications to existing phases, with improvements in 
both selectivity and versatility, continue to be introduced (Major, 1999; Terfloth, 1999). 
It is therefore the more surprising that there remains a lack of published 
enantiospecific assays for flurbiprofen, one of the most popular and widely used 2-aryl- 
propionic acid drugs. Indirect methods for the determination of flurbiprofen enantiomers 
have been based on the formation of diastereomeric amides after derivatization with 
optically pure chiral amines such as (S)-1-phenylethylamine (Maitre et al., 1984; Adams 
et al., 1988; Knadler and Hall, 1989) and L-leucinamide (Berry and Jamali, 1988). The 
direct approach, utilising the protein CSPs, al-acid glycoprotein (Geisslinger et al., 
1992) and ovomucoid (Fukuhara et al., 1996), have been employed for the determination 
of flurbiprofen in plasma; and the resolution of the methyl esters of flurbiprofen was 
achieved using a cellulose tris (4-methylbenzoate) phase by Aboul-Enein and Bakr 
(1992). Recently, a sequential achiral-chiral method has been used for the enantiomeric 
quantification of flurbiprofen in rat plasma based on pre-column derivatization with the 
nonchiral fluorogenic reagents, 4-[N, N-dimethylamino)sulphonyl]-7-piperazino-2,1,3- 
benzoxadiazole or 4-[[N-hydrazinoformyl)methyl]-NV methyl]amino-7-[N, N-dimethyl- 
amino)sulphonyl]-2,1,3-benzoxadiazole and chiral resolution carried out using a 
cellulose tris (3,5-dimethyphenylcarbamate) CSP (Fukushima et al., 1997). 
The major metabolites of flurbiprofen, namely 4'-hydroxyflurbiprofen and 3'- 
hydroxy-4'-methoxyflurbiprofen, retain the asymmetric centre and therefore may also 
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exist in the R- and S-configurations (Figure 4.1). Of all the assays outlined above, only 
one methodology considers the quantification of the individual enantiomers of the 
metabolites as well as those of the parent drug (Knadler and Hall, 1989). However, due 
to their different polarities, flurbiprofen and its metabolites could not be analysed using 
a single isocratic system on a achiral C18 column and changes in the mobile phase were 
required. Furthermore, the quantification of flurbiprofen in urine required both 
fluorescence and UV detection since the internal standard had negligible fluorescent 
activity. Due to the lack of authentic standards of the individual enantiomers of the 
metabolites the stereochemical elution orders were defined by analysing urine obtained 








4'-Hydroxyflurbiprofen HO H 
3'-Hydroxy-4'-methoxyflurbiprofen CH3O HO 
Figure 4.1: Chemical structures of flurbiprofen and its major metabolites (* denotes chiral 
centre). 
It is clear from the above that there is a need for a simple chromatographic 
separation method which is able to resolve the enantiomers of flurbiprofen and its 
metabolites in a single chromatographic run and which can be routinely employed in 
bioanalytical studies. In the present study a variety of chromatographic methods were 
investigated for their suitability : (a) indirect separation on an achiral reversed-phase 
system following the formation of diastereomeric derivatives using (R)-1-(naphthen-l- 
yl)ethylamine, (b) direct separation using hydroxypropyl-ß-cyclodextrin as a CMPA in a 
reversed-phase HPLC system, (c) direct separation on a al-acid glycoprotein CSP via 
reversed-phase HPLC and (d) direct separation on a amylose tris (3,5-dimethyl- 
phenylcarbamate) CSP via normal-phase HPLC. These various approaches present 
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different mechanisms for chiral discrimination and the advantages and limitations of 
each will be outlined. 
The technique which displayed optimal separation characteristics was selected for 
further evaluation for it clinical applicability, this is presented in Chapter 5. 
Furthermore, this method with modifications in mobile phase composition was used for 
the semi-preparative isolation of the individual enantiomers of the metabolites for 
stereochemical assignment using circular dichroism (CD). 
4.2. Experimental 
4.2.1 Chemicals and reagents 
Acetonitrile, dichloromethane, ethanol, hexane, isopropanol and methanol (HPLC 
grade) were purchased from Rathburn (Walkerburn, UK). Trifluoroacetic acid (TFA) 
and sodium hydrogen phosphate (GPR grade) were purchased from BDH (Poole, 
Dorset, UK). N, N-Dimethyloctylamine (DMOA) was obtained from Aldrich Chemicals 
(Gillingham, Dorset, UK), 1-(3-dimethyl-aminopropyl)-3-ethylcarbodiimide hydro- 
chloride (CDI) and (R)-1-(naphthen-l-yl)ethylamine ((R)-NEA) were purchased from 
Sigma Chemicals (Poole, Dorset, UK). 1-Hydroxybenzotriazole (HOBT) was purchased 
from Fluka Chemicals (Poole, Dorset, UK). Hydroxypropyl-ß-cyclodextrin 
preparations: HP-ß-CD-I (Molar substitution = 0.6, average MW = 1380) from Aldrich 
Chemicals (Gillingham, Dorset, UK); HP-ß-CD-II (pharmaceutical grade) and HP-(3- 
CD-III (standard grade) were the generous gifts of Wacker Chemicals Ltd (Egham, 
Surrey, UK). (R, S)-, (R)-, (S)-Flurbiprofen, (R, S)-4'-hydroxyflurbiprofen and (R, S)-3'- 
hydroxy-4'-methoxyflurbiprofen were the generous gifts of Boots Company PLC 
(Nottingham, UK) 
4.2.2 Chromatographic columns 
Waters Resolve C18 column (150 x 3.9 mm, 5 µm) was obtained from Anachem 
Ltd. (Luton, Beds., UK), and used with a refillable guard column (10 x 2.1 mm) packed 
with pellicular C 18 (40-60 µm) both were obtained from Alltech Associates (Carnforth, 
Lancs, UK). Waters Symmetry C 18 column (75 x 4.6 mm, 3.5 µm) and Waters Sentry 
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Guard, fitted with a Symmetry C 18 cartridge (10 x 4.6 mm, 3.5 p m), were purchased 
from Phase Separations Ltd. (Deeside, Flints., UK). The Chiral-AGP (al-acid 
glycoprotein) column (100 x 4.0 mm, 5 µm) with a guard column (10 x 3.0 mm, 5 µm) 
filled with the same material, both were obtained from ChromTech AB (Norsborg, 
Sweden). The Chiralpak AD (amylose tris (3,5-dimethylphenylcarbamate)) column (250 
x 4.6 mm, 10 pm) used with a matching guard column (50 x 4.6 mm, 10 µm) was 
supplied by HPLC Technology Ltd. (Macclesfield, UK). 
4.2.3 Instrumentation 
Reversed-phase HPLC was performed using an LDC Constametric 3000 pump 
linked to an LDC Spectromonitor 3000 UV detector and a LDC CI-4000 computing 
integrator (Stone, Staffs., UK). Samples were introduced on-column using a Rheodyne 
7125 injection valve (Cotati, Cal., USA) fitted with a 20 µl sample loop. When 
fluorescence detection was required a Kontron SFM 25 fluorescence detector (Watford, 
Herts., UK) was connected in series, prior to, the UV detector. 
HPLC utilising the Chiralpak AD CSP was performed using an LDC Constametric 
3000 pump linked to an LDC Spectromonitor 3100 UV detector and a LDC CI-4100 
computing integrator (Stone, Staffs., UK). Samples were injected on column using a 
Perkin Elmer ISS-100 autosampler (Beaconsfield, Bucks., UK). 
Circular dichroism (CD) spectra were recorded using a Jasco J600 
spectropolarimeter (Halstead, Essex, UK). 
4.2.4 Development of a chromatographic methods for the resolution of the 
enantiomers of flurbiprofen and its major metabolites 
Various enantiospecific chromatographic approaches were investigated for the 
resolution of the enantiomers of flurbiprofen , 4'-hydroxyflurbiprofen and 3'-hydroxy-4'- 
methoxyflurbiprofen. 
Method 1: Chromatographic separation after pre-column derivatization 
The derivatization procedure is similar to that described for ibuprofen in section 
2.2.4, which utilised flurbiprofen as an internal standard. Standard solutions of 
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flurbiprofen, 4'-hydroxyflurbiprofen or 3'-hydroxy-4'-methoxyflurbiprofen were 
prepared in dichloromethane (1 mg/ l Oml). To 10 µl aliquots of the standard solutions 
were added 100 p. g each of CDI, HOBT and (R)-NEA (100 µl each of a1 mg/ml solution 
in dichloromethane). The tubes were tightly capped and the derivatization procedure 
performed as before. 
Chromatography was carried out using a Waters Resolve C18 (150 x 3.9 mm, 
5 µm) column protected by a guard column (10 x 2.1 mm) filled with pellicular C18. The 
mobile phase used was phosphate buffer (pH 3.5,0.01M) : acetonitrile (50: 50 v/v) at a 
flow rate of 0.8 ml/min. Column eluate was monitored by UV detection at 254 nm or by 
fluorescence detection with excitation and emission wavelengths of 290 and 330 nm 
respectively. Derivatized standards were reconstituted in 50 µl mobile phase and 20 µl 
aliquots injected into the HPLC. 
Method 2: Direct chromatographic separation using a CMPA 
Chromatography was performed using a Waters Symmetry C18 column (75 x 4.6 
mm, 3.5 µm) protected by a Waters Sentry Guard fitted with a Symmetry C18 cartridge 
(10 x 4.6 mm, 3.5 µm). The mobile phase consisted of aqueous TFA (pH 3.5; 0.1 % v/v) 
: methanol (60: 40 v/v) containing HP-ß-CD (1.1 % w/v), at a flow rate of 1.0 ml/min at 
ambient temperature. Detection was by UV absorbance at 254 nm. Samples were 
injected onto the system as 20 µl of 1 mg/ l Oml solutions in mobile phase. 
Method 3: Direct chromatographic separation using a Chiral-AGP CSP 
Chromatography was carried out using a Chiral-AGP column (100 x 4.0 mm, 
5µm) linked to a matching guard column (10 x 3.0 mm, 5 µm). The mobile phase 
consisted of phosphate buffer (pH 6.5,0.01 M): isopropanol (98.5: 1.5 v/v) containing 
DMOA (1.0 mM). The flow rate was set at 0.5m1/min and detection was by UV 
absorbance at 254 nm. The system was used in an air-conditioned room at 23°C. 
Standard solutions of flurbiprofen and its metabolites (1 mg/lOml) were prepared in 
mobile phase and 20 µl aliquots where subjected to analysis. 
Method 4: Direct chromatographic separation using a Chiralpak AD CSP 
Chromatography was carried out using a Chiralpak AD column (250 x 4.6 mm, 
10 µm) linked to a matching guard column (50 x 4.6 mm, 10 µm). The mobile phase 
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consisted of hexane: ethanol (90: 10 v/v) containing trifluoroacetic acid (0.05% v/v) as 
modifier, run at a flow rate of 1.0ml/min. Detection was by UV absorbance at 254 nm. 
Standard solutions of flurbiprofen and its metabolites (1 mg/ l Oml) were prepared in 
mobile phase and 20 µl aliquots where subjected to analysis. 
Characterisation of chromatographic separations 
In order to evaluate the chromatographic performance of the various approaches in 
the enantioseparation of flurbiprofen and its metabolites, several factors were 
investigated. The retention factors (k'), the separation factor ((x) and the resolution value 
(Re) were calculated for each analyte using the following equations: 
k' = Or - to) / to (Eqn. 4.1) 
where tr is the retention time of the enantiomer and to is the column dead time 
determined by the injection peak; 
cc =k2/k'1 (Eqn. 4.2) 
where k'1 and k'2 are the capacity factors of the first and second eluting enantiomers 
respectively. 
Rs=2(t2-tl)/(Wl+w2) (Eqn. 4.3) 
where tl and t2 are the retention times of the first and second enantiomers respectively 
and w1 and W2 are the peak widths at the base of the first and second enantiomers 
respectively. RS is a measure of the extent of overlap of the two peaks and ideally should 
be greater than 1.5 (indicating baseline resolution) if the chromatographic separation is 
to be used for quantitative analysis (Gal, 1993). 
4.2.5 Semi-preparative chromatographic resolution of the enantiomers of 
4'-hydroxyflurbiprofen 
In order to obtain sufficient quantities of each 4'-hydroxyflurbiprofen enantiomer 
for analyte characterisation, repeated injections (50 x 20 µl) of a concentrated analyte 
solution (20 mg/ml) in ethanol were made onto the Chiralpak AD CSP. The mobile 
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phase used was hexane: ethanol (87: 13 v/v) containing 0.05% v/v trifluoroacetic acid, at 
a flow rate of 1.0 ml/min. The eluate was monitored by UV detection at 254 nm. The 
first eluting peak was collected between 8.9 and 10.9 min and the second between 12.5 
and 15.5 min. The mobile phase was evaporated under a stream of nitrogen and the 
enantiomeric purities of the individual enantiomers then determined by re-examination 
of an aliquot of each using the CSP. 
4.2.6 Semi-preparative chromatographic resolution of the enantiomers of 
3'-hydroxy-4'-methoxyflurbiprofen 
Repeated injections (50 x 20 µl) of a concentrated 3'-hydroxy-4'-methoxy- 
flurbiprofen solution (20 mg/ml) in ethanol were made onto the Chiralpak AD CSP. The 
mobile phase used for separation of the enantiomers was hexane: ethanol (85: 15 v/v) 
containing 0.05% v/v trifluoroacetic acid, run at a flow rate of 1.0 ml/min. The eluate 
was monitored by UV detection at 254 nm. The first eluting peak was collected between 
16.0 and 18.0 min and the second between 22.0 and 25.0 min. The mobile phase was 
evaporated under a stream of nitrogen and the enantiomeric purities of the individual 
enantiomers confirmed by re-injection. 
4.2.7 Chiroptical characterization of 4'-hydroxyflurbiprofen and 3'-hydroxy-4'- 
methoxyflurbiprofen 
Solutions in acetonitrile (enantiomers of flurbiprofen and 4'-hydroxyflurbiprofen) 
and in methanol (enantiomers of flurbiprofen and 3'-hydroxy-4'-methoxyflurbiprofen) 
were prepared at analyte concentration of 0.01 mg/ml. Circular dichroism (CD) spectra 
were recorded over the range 200-320 nm in a cell of pathlength 1 cm at 25°C. In each 
case a solvent baseline was recorded and subtracted from the analyte spectrum before 
converting to molar ellipticity (Ac). UV spectra were recorded using the same 
instrument over the corresponding wavelength range. 
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4.3. Results and Discussion 
4.3.1 Derivatization method 
Flurbiprofen : Enantiomeric resolution and chiroptical characterisation 
For chiral arylpropionic non-steroidal anti-inflammatory drugs, the presence of a 
reactive carboxylic acid moiety allows for facile pre-column derivatization with chiral 
derivatization reagents and this technique has enjoyed extensive application. Chiral 
amine reagents have been used more frequently than chiral alcohols as reagents since the 
chromatographic behaviour of diastereomeric amides is often superior to that of 
respective esters and perhaps because of the greater stability of amides over esters. The 
majority of amines utilised for derivatization reactions have been 1-substituted 
ethylamines with a bulky residue such as phenyl, naphthyl or dimethylaminonaphthyl 
since these agents have the asymmetric centre directly bonded with both the bulky 
moiety and the reactive amine function. The resulting diastereomeric amides have the 
ideal properties for optimal separation since the distance between the chiral centres is 
limited to two atoms and the presence of the bulky substituent encourages 
conformational rigidity (Görög and Gazdag, 1994). 
The enantiomers of 1-(naphthen-1-yl)ethylamine (NEA) are readily available 
commercially with high optical purity and because of their fluorescent properties have 
been widely used in biological investigations. (S)-NEA was used by Hutt et al. (1986) in 
the derivatization of 2-phenylpropionic acid, ibuprofen, carprofen and pirprofen, and in 
the analysis of 2-phenylpropionic acid in urine. All derivatives were baseline resolved 
on a silica-gel radial compression column with hexane-ethyl acetate as a mobile phase. 
Derivatization with (S)-NEA was used for enantiospecific pharmacokinetic studies 
following the repeated oral administration of ibuprofen (Avgerinos and Hutt, 1987). 
Subsequently a number of other plasma assay methods based on the formation of the 
(S)-1-(naphthen-l-yl)ethylamide diastereoisomers of ibuprofen have been published 
(Mehvar et al., 1988; Lemko et al., 1993; Ahn et al., 1994 and Lau, 1996). The 
derivatives of flurbiprofen and ketoprofen could in addition be conveniently resolved 
using the method of Mehvar et al. (1988), however as yet the assay has not been applied 
for these profens. The determination of the enantiomers of suprofen in plasma by 
capillary gas chromatography-mass spectrometry was also based on the pre-column 
derivatization with this agent (Shinohara et al., 1990). The antipode (R)-NEA was 
employed in the stereospecific determination of the active metabolite of loxoprofen in 
plasma of humans and dogs (Takasaki and Tanaka, 1992). Recently, Tan et al., (1997a) 
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published a sensitive enantiospecific assay for the determination of ibuprofen in serum 
based on the formation of (R)-1-(naphthen-1-yl)ethylamide diastereoisomers, which 
enabled the methodology to be adapted for the determination of the free enantiomer 
concentrations in serum following equilibrium dialysis. 
Activation of the carboxyl groups in flurbiprofen and its metabolites prior to 
reaction with (R)-NEA was essentially the coupling reaction adopted by Tan et al. 
(1997a). The activation agent employed was the carbodiimide, 1-(3-dimethyl- 
aminopropyl)-3-ethylcarbodiimide (CDI) in the presence of 1-hydroxybenzotriazole 
(HOBT), agents originally reported for their use in peptide synthesis. The addition of 
HOBT is effective not only in suppressing the formation of N-acylisourea by-products 
but also in enhancing the reaction rates and yields, which is advantageous for the 
prevention of racemisation (Windridge and Jorgensen, 1971; Benoiton and Kuroda, 
1981). The derivatization reaction (Figure 4.2) was allowed to proceed at ambient 
temperatures for a period of two hours, which is the optimised conditions used previous 
for the ibuprofen assay methods (see Chapter 2). 
Previously, the (R)-1-(naphthen-l-yl)ethylamide diastereoisomers of both 
ibuprofen and flurbiprofen, which had been used as an internal standard, were 
successfully resolved using a reversed-phase HPLC system (see Chapter 2). Using the 
same stationary phase, Waters Resolve C18 column, the system was investigated by 
alteration of the mobile-phase composition and/or flow rate to determine if the 
diastereoisomeric derivatives of flurbiprofen and its major metabolites, 4'-hydroxy- 
flurbiprofen and 3'-hydroxy-4'-methoxyflurbiprofen, could all be separated in a single 
chromatographic run. The chromatogram obtained using a mobile phase of phosphate 
buffer (pH 3.5, O. O1M): acetonitrile (50: 50 v/v) at a flow rate of 0.8 ml/min using UV 
detection is shown in Figure 4.3a. Each pair of analyte derivatives showed baseline 
separation, as indicated by Rs values > 1.5 (Table 4.1). However, (R)-3'-hydroxy-4'- 
methoxyflurbiprofen was not completely resolved from (S)-4'-hydroxyflurbiprofen 
(Figure 4.3a). Decreasing the flow rate further, or reducing the proportion of organic 
modifier to complete separation would probably result in run times unsuitable for 
routine analysis. 
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Figure 4.2: Derivatization of 2-arylpropionic acids with 1-(naphthen-1-yl)ethylamine (NEA) in the 
presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (CDI) and 1-hydroxybenzotriazole 
(HOBT). 
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Figure 4.3: Chromatograms of flurbiprofen and its major metabolites following derivatization 
with (R)-NEA using (a) UV detection and (b) fluorescence detection. Peaks : (R)-1-(naphthen-1-yl) 
ethylamide derivatives of 1, (R)-4'-hydroxyflurbiprofen; 2, (R)-3'-hydroxy-4'-methoxyflurbiprofen; 
3, (S)-4'-hydroxyflurbiprofen; 4, (S)-3'-hydroxy-4'-methoxyflurbiprofen; 5, (R)-flurbiprofen and 6, 
(S)-flurbiprofen. [Stationary phase, Resolve C18 column (150 x 3.9 mm, 5 µm); Mobile phase, 
phosphate buffer (pH 3.5,0.01M): acetonitrile (50: 50 v/v); Flow rate, 0.8 ml/min] 
Table 4.1: Chromatographic parameters for the separation of the (R)-1-(naphthen-1-yl) 
ethylamide diastereoisomers of flurbiprofen and its metabolites on a Waters Resolve C18 column *. 
Analyte k1k2a Rs 
Flurbiprofen 10.76 13.58 1.26 2.76 
4'-Hydroxyflurbiprofen 2.69 3.68 1.37 2.19 
3'-Hydroxy-4'-methoxyflurbiprofen 3.27 4.37 1.34 2.00 
* Mobile phase phosphate buffer (pH 3.5,0.01 M): acetonitrile (50: 50 v/v. ) 
Elution order : R- before S-enantiomer for all three analytes. 
The fluorescent properties of the (R)-1-(naphthen-1-yl)ethylamide derivatives are 
advantageous for increasing the sensitivity and selectivity of the approach for use in the 
analysis of biological fluids. Figure 4.3b shows a typical chromatogram obtained when 
the column eluate was monitored by a fluorescence detector (kex: 290nm and k em: 
330nm) connected in series, prior to the UV detector. For all three analytes it was 
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observed that the two diastereomeric derivatives exhibited unequal fluorescence 
intensities. The R/S peak-area ratios for the derivatives of flurbiprofen, 4'-hydroxy- 
flurbiprofen and 3'-hydroxy-4'-methoxyflurbiprofen were 0.82,0.43 and 0.35 
respectively. Furthermore, adjustment of the fluorescence condition to those previously 
employed by Knadler and Hall (1989) to monitor the (S)- l -phenylethylamides of the 
metabolites of flurbiprofen, i. e. with excitation and emission wavelengths of 260 and 
320 nm respectively, also showed unequal fluorescent activity between diastereomeric 
derivatives; with R/S peak-area ratios for the derivatives of flurbiprofen, 4'-hydroxy- 
flurbiprofen and 3'-hydroxy-4'-methoxyflurbiprofen of 0.95,0.38 and 0.32 respectively 
Among the potential causes of this phenomenon are unequal rates of formation of the 
two derivatives (i. e. kinetic resolution) and unequal response by the detector employed. 
However, when UV absorption at 254nm was used to monitor the column eluate, it was 
found that the difference between the diastereomeric responses were negligible in all the 
cases, with the peak areas for each pair of analyte derivatives essentially reverting to a 
1: 1 ratio. It is clear therefore, that unequal peak areas were not the result of differing 
formation rates of the diastereomeric derivatives, but arise as a consequence of the 
diastereoisomers differing in their fluorescence properties. These observations were 
unexpected and the magnitude of the differences in fluorescence intensities were 
considerably greater than those of examples found in the literature. For instance, in the 
investigation of a wide range of drugs after derivatization with (-)-(S)-flunoxaprofen 
isocyanate reagent and using a fluorescence detector, the R/S peak-area ratios ranged 
between 0.97 and 1.03 in most instances, but the ratio was 1.23 for mexiletine and 1.09 
for tranylcypromine (Martin et al., 1989). In another study, the R, R, R/S, R, R peak-area 
ratio of the diacetyl tartrate derivatives of the enantiomers of propranolol was 1.08 when 
using a UV detector and 1.25 when a fluorescence detector was used (Linder et al., 
1989). Furthermore, diastereomeric isoindole derivatives formed by reaction of primary 
amine drugs with ortho-phthaldialdehyde and a homo-chiral thiol, often display unequal 
detector response and interesting, in several cases, unequal response was observed with 
UV detection rather than fluorescence detection (Desai and Gal, 1993). 
Clearly an equal response to the derivatives is highly preferable, and this is one of 
the factors that make the direct approach to enantiospecific analysis superior in principle 
to the indirect method. It should be noted, however, that an unequal detector response 
does not necessarily render an indirect separation invalid because in quantitative 
analysis it is usually necessary to base the quantification on individual calibration curves 
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for the diastereomeric derivatives of the analyte enantiomers. Nevertheless in this case, 
the substantial, rather than subtle, differences observed in response between the 
diastereoisomeric pairs would make the approach seem impractical and analytical 
validation more complex, even if it were possible to separate all the derivatives in a 
single chromatographic run. 
4.3.2 Chiral mobile phase additive method 
The introduction of a chiral selector into the mobile phase of an achiral 
chromatographic system offers a number of benefits for enantiomeric analysis including 
flexibility, a wide choice of possible additives, avoidance of the disadvantages 
associated with the indirect approach and such an approach is often more cost-effective 
than an equivalent chiral stationary phase. Cyclodextrins are cyclic chiral oligomers of 
D-(+)-glucose bonded thorough a-(1,4) linkages and are extensively used as chiral 
mobile phase additives. The secondary hydroxyl groups are located on the wider side of 
the cavity and the primary hydroxyl groups on the narrower end. Thus, the cyclodextrin 
structure is shaped like a truncated cone with a relatively hydrophobic interior and a 
hydrophilic exterior as depicted in Figure 4.4. The most commonly used cyclodextrins 
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However, the application of cyclodextrins as chiral additives for the resolution of 
2-arylpropionic acid non-steroidal anti-inflammatory drugs has largely been in the field 
of capillary electrophoresis (Guttman and Cooke, 1994; Rawjee and Vigh, 1994; Fanali 
and Aturki, 1995; Fillet et al., 1996; Nair and Armstrong, 1997; O'Keeffe et al., 1997 
and Zhu et al., 1999), with limited use in liquid chromatography. The enantiomeric 
resolution of fenoprofen, ketoprofen and ibuprofen by HPLC was investigated, using 
native and derivatized ß-cyclodextrins as chiral mobile phase additives by Ameyibor 
and Stewart (1997). Resolutions were achieved for fenoprofen and ketoprofen using a 
nonporous reversed-phase octadecylsilane column with hydroxypropyl-ß-cyclodextrin 
(HP-ß-CD) in the mobile phase, this approach was then used for the analysis of 
ketoprofen in human serum (Ameyibor and Stewart, 1998). The enantiomers of 
ibuprofen were only partially separated using this system and none of the compounds 
were resolved with native ß-cyclodextrin (Ameyibor and Stewart, 1997). In reversed- 
phase applications, the resolution mechanism of ß-cyclodextrins is thought to be the 
result of the formation of inclusion complexes in which the analyte is included into the 
cavity of the cyclodextrin. For enantiomers, resolution is possible if these inclusion 
complexes have different binding constants. In addition, the mouth of the cyclodextrin 
hydrophobic cavity is surrounded by secondary hydroxyl groups which are locked into 
position and are considered to be important in chiral recognition (Armstrong et al., 1986 
and Stalcup et al., 1990). In the derivatized cyclodextrin some of these hydroxyls are 
substituted with freely rotating hydroxypropyl groups. This flexibility may allow for a 
closer approach between the hydroxyl groups and any hydrogen bonding moiety present 
in fenoprofen and ketoprofen, leading to stronger or more stereoselective interactions 
than are possible with the native ß-cyclodextrin (Stalcup et al., 1990). As well as the 
two aromatic rings which form inclusion complexes with the cyclodextrin, both these 
compounds have carboxylic acid groups at the chiral center that could participate in 
additional interactions with the rim hydroxypropyl groups. Ibuprofen is only partially 
resolved which may be due to its smaller molecular size, having a single aromatic ring 
structure, is unable to form a "tight" inclusion complex within the cyclodextrin cavity. 
The structural similarities between flurbiprofen, and its metabolites, to fenoprofen 
and ketoprofen would suggest that HP-ß-CD could also be applied for their 
enantiomeric resolution and so this was investigated using a short length Waters 
Symmetry C18 column. The column selected offers high efficiency and short analysis 
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times which is advantageous for minimising the organic modifier content of the mobile 
phase and thus circumventing problems associated with the limited solubility of 
cyclodextrins. The influence of organic modifier concentration, HP-ß-CD concentration 
and different commercial preparations of HP-ß-CD were investigated to try and achieve 
ideal separation characteristics. 
The influence of the methanol content in the mobile phase on the retention and the 
enantioseparation of flurbiprofen and its metabolites is presented in Table 4.2. None of 
the analytes were baseline resolved with any of the mobile phase compositions 
investigated. However, partial resolution was observed for flurbiprofen and reduction of 
the alcohol content to 45% v/v or less resulted in limited enantioseparation of 
3'-hydroxy-4'-methoxyflurbiprofen. A decrease in methanol concentration, as could be 
expected in reversed-phased systems, resulted in an increase in retention and also a 
slight improvement in enantioselectivity. It appears that at these high proportions, 
methanol acts as displacing agent from the hydrophobic environment of the cyclodextrin 
chiral cavity, thus weakening the strength of the inclusion complexes formed between 
the analytes and the cyclodextrin (Munoz de la Pena et al., 1991). 
Table 4.2: Influence of the organic modifier concentrations on retention and enantioseparation 
of flurbiprofen and its metabolites on a Waters Symmetry C18 column *. 
Methanol Analyte k'1 k2a RS 
(°ý° v/v) 
50 Flurbiprofen 15.28 15.41 1.01 < 0.2 
4'-Hydroxyflurbiprofen 3.13 3.13 1.00 - 
3'-Hydroxy-4'-methoxyflurbiprofen 4.70 4.70 1.00 - 
45 Flurbiprofen 21.93 22.97 1.05 0.49 
4'-Hydroxyflurbiprofen 3.83 3.83 1.00 - 
3'-Hydroxy-4'-methoxyflurbiprofen 5.08 5.29 1.04 0.29 
40 Flurbiprofen 25.97 29.61 1.14 0.64 
4'-Hydroxyflurbiprofen 4.61 4.61 1.00 - 
3'-Hydroxy-4'-methoxyflurbiprofen 6.15 6.45 1.05 0.37 
* Mobile phase : aqueous TFA (pH 3.5; 0.1 % v/v): methanol, containing 
HP-BCD (1. I% w/v) 
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A chromatogram of the separation achieved using a mobile phase containing 40 % 
methanol outlining the lack of enantioseparation and also illustrating the relative long 
retention and poor peak shape, of the flurbiprofen enantiomers is shown in Figure 4.5. 
Investigations using lower methanol concentrations were not performed as this would 
have resulted in long run times with further band broadening of the flurbiprofen peaks. 
Substitution of the trifluoroacetic acid (0.1 % v/v) solution in the mobile phase with a 
phosphate buffer (pH 3.5,0.01M) did not improve the separation or resolution profiles. 
Retention Time (min) 
Figure 4.5: Chromatographic separation of flurbiprofen and its major metabolites using 
HP-ß-CD as a mobile phase additive. Peaks : 1, (R, S)-4'-hydroxyflurbiprofen; 2 and 3, enantiomers 
of 3'-hydroxy-4'-methoxyflurbiprofen; 4, (R)-flurbiprofen; 5, (S)-flurbiprofen. [Stationary phase, 
Symmetry C18 column (75 x 4.6 mm, 3.5 µm); Mobile phase, aqueous TFA (pH 3.5; 0.1% v/v) 
methanol (60: 40 v/v) containing HP-ß-CD (1.1 % w/v); Flow rate, 1.0 mu min; Detection, UV ?. _ 
254 nm]. 
The effect of HP-ß-CD concentration in the mobile phase on the enantiomeric 
separation of the analytes is presented in Table 4.3. The best separation profile was 
observed using 1.1% v/v HP-ß-CD in the mobile phase (Figure 4.5) with partial 
resolution of the enantiomers of flurbiprofen and 3'-hydroxy-4'-methoxyflurbiprofen. 
Further increases in the HP-ß-CD concentration in the mobile phase resulted in faster 
elution of the analytes and a reduction in enantioseparation. Reduction 
in the mobile 
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phase content of HP-ß-CD to less than 1.1% w/v increased the retention times of the 
analytes with little influence on resolution. 
Table 4.3: Influence of the HP-ß-CD concentrations on retention and enantioseparation of 
flurbiprofen and its metabolites on a Waters Symmetry C18 column *. 
HP-ß-CD Analyte k'1 k2a RS 
(% w/v) 
0.9 Flurbiprofen 33.02 37.31 1.13 0.63 
4'-Hydroxyflurbiprofen 4.99 4.99 1.00 - 
3'-Hydroxy-4'-methoxyflurbiprofen 6.82 7.22 1.06 0.38 
1.1 Flurbiprofen 25.97 29.61 1.14 0.64 
4'-Hydroxyflurbiprofen 4.61 4.61 1.00 - 
3'-Hydroxy-4'-methoxyflurbiprofen 6.15 6.45 1.05 0.37 
1.3 Flurbiprofen 24.29 25.63 1.06 0.42 
4'-Hydroxyflurbiprofen 4.32 4.32 1.00 - 
3'-Hydroxy-4'-methoxyflurbiprofen 5.43 5.43 1.00 - 
1.5 Flurbiprofen 19.51 20.51 1.05 0.36 
4'-Hydroxyflurbiprofen 4.12 4.12 1.00 - 
3'-Hydroxy-4'-methoxyflurbiprofen 5.08 5.08 1.00 - 
* Mobile phase . aqueous TFA (pH 3.5; 0.1 % v/v): methanol (60: 40 w/v), containing HP-BCD 
During the course of these studies, two other HP-ß-CD preparations (denoted as 
preparations II and III) became available and their separation capabilities were 
compared to those of the original HP-ß-CD (preparation I). As indicated in Table 4.4, 
there was considerable variability in the enantiomeric resolution capabilities of the 
different HP-ß-CD preparations. Substituting HP-ß-CD-I in the mobile phase with 
HP-ß-CD-II resulted in an improved peak shape and resolution of the enantiomers of 
flurbiprofen (Rs = 0.84) but there was a complete loss of the partial resolution of 
3'-hydroxy-4'-methoxyflurbiprofen. Using HP-ß-CD-III in the mobile phase resulted in 
a loss of resolution for both flurbiprofen and 3'-hydroxy-4'-methoxyflurbiprofen. It is 
not surprising that these different preparations exhibited differing enantioresolution 
properties since HP-ß-CDs are not pure compounds but impure mixtures of closely 
related homologs and isomers. The variability 
in the degree of substitution between 
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derivatized cyclodextrin preparations has been shown to have a significant effect on 
resolution of enantiomers (Valko et al., 1994 and Szeman et al., 1996). When using 
HP-ß-CD as a CMPA it has been found that as the degree of substitution on the 
derivatized cyclodextrin increases, it can sometimes affect the binding process as well as 
the enantioselectivity. It is probable that the hydroxypropyl groups partially occlude the 
mouth of the cyclodextrin cavity and sterically influence the formation of inclusion 
complexes (Stalcup et al., 1990). It is interesting to note that the descriptions supplied 
with HP-ß-CD preparations II and III, provided no details with regards to the degree of 
substitution. 
Table 4.4: Influence of different HP-ß-CD preparations on retention and enantioseparation of 
flurbiprofen and its metabolites on a Waters Symmetry C18 column *. 
HP-ß-CD Analyte k'1 k2a RS 
preparation t 
I Flurbiprofen 25.97 29.61 1.14 0.64 
4'-Hydroxyflurbiprofen 4.61 4.61 1.00 - 
3'-Hydroxy-4'-methoxyflurbiprofen 6.15 6.45 1.05 0.37 
II Flurbiprofen 25.94 27.64 1.07 0.84 
4'-Hydroxyflurbiprofen 5.84 5.84 1.00 - 
3'-Hydroxy-4'-methoxyflurbiprofen 6.03 6.03 1.00 - 
III Flurbiprofen 19.32 19.32 1.00 - 
4'-Hydroxyflurbiprofen 5.16 5.16 1.00 - 
3'-Hydroxy-4'-methoxyflurbiprofen 5.64 5.64 1.00 - 
*Mobile phase : aqueous TFA (pH 3.5; 0.1 % v/v): methanol (60: 40 w/v) with HP-ß-CD (1.1 % w/v) 
HP-ß CD preparations: I= Aldrich (Molar sub. = 0.6, average MW = 1380) 
11 = Wacker Chemicals Ltd. (Pharmaceutical grade) 
III= Wacker Chemicals Ltd. (Standard grade) 
In conclusion the use of HP-ß-CD as a CMPA for the enantiomeric resolution of 
flurbiprofen and its metabolites proved to be of little success with none of the analytes 
being baseline resolved. However, these investigations did highlight the variability in 
enantioselectivities between different HP-ß-CD preparations and hence the importance 
of using well characterised cyclodextrins in the development of separation methods. In 
addition, it is more than likely that better enantioseparation would have been observed if 
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a octyladecylsilane phase that required relatively low organic modifier concentrations 
had been available; for instance the novel nonporous column used by Ameyibor and 
Stewart (1997) was only able to demonstrate enantioselectivity for fenoprofen and 
ketoprofen when the acetonitrile concentration in the mobile phase was less than 6%. 
The use of native ß-cyclodextrin as a CMPA, instead of HP-ß-CD, showed no 
resolution capabilities for any of the three analytes (unpublished). 
4.3.3 Chiral-AGP column 
al-Acid glycoprotein (AGP), or orosomucoid, is a human plasma protein having a 
molecular weight of 41,000 to 45,000 and consists of a linear polypeptide with 
branching chains of carbohydrate. It has been demonstrated that immobilised AGP 
contains one high affinity binding site and at least one other site which binds the solute 
molecules with lower affinity (Enquist and Hermansson, 1990). The binding sites are 
built up by the peptide chain and they contain a large number of potential chiral binding 
moieties. The presence of different types of highly stereoselective interaction sites 
renders these CSPs very versatile, but the loading capacity is low due to the limited 
number of interaction sites (Hermansson and Schill, 1988). Several kinds of interaction 
can be involved in the retention mechanism, such as hydrophobic, hydrogen-bonding 
and ionic interactions (Schill et al., 1986; Hermansson and Schill, 1988; Allenmark, 
1989). 
The use of an AGP-column for the resolution of 2-arylpropionic acids was initially 
investigated by Hermansson and Eriksson (1986). With the use of N, N-dimethyl- 
octylamine (DMOA) as a charged modifier in 2% v/v isopropanol (IPA) in phosphate 
buffer, enantiomeric resolution of ibuprofen, ketoprofen and naproxen was achieved. 
AGP columns have been used in stereospecific assays for fenoprofen (Menzel-Soglowek 
et al. , 
1990), flurbiprofen (Geisslinger et al., 1992), ibuprofen (Menzel-Soglowek et al., 
1990; Petterson and Olsson 1991; de Vries et al., 1994), ketoprofen (Menzel-Soglowek 
et al., 1990), naproxen (Andersen and Hansen, 1992) and the taurine conjugate of 2-[4- 
(3-methyl-2-thienyl)phenyl]propionic acid, a new orally effective anti-inflammatory 
agent, in dog urine (Konishi et al., 1998). The fact that this CSP is used in the reversed- 
phase mode offers the possibility of direct injection of aqueous samples but moreover 
allows for greater flexibility in the mobile phase composition to try and in order to 
obtain baseline resolution (Hermansson and Eriksson, 1986). The effects of pH, DMOA 
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concentration and the content of IPA were investigated to optimise enantiomeric 
resolution of flurbiprofen and its metabolites on a Chiral-AGP column. 
The influence of the mobile phase pH on the enantioseparation of flurbiprofen and 
its metabolites is presented in Table 4.5. With the mobile phase conditions investigated, 
there was no resolution of 3'-hydroxy-4'-methoxyflurbiprofen and partial resolution of 
4'-hydroxyflurbiprofen. Flurbiprofen eluted considerably later than its metabolites and 
demonstrated baseline resolution at all pH values investigated. However, 
(S)-flurbiprofen, the later eluting peak, always had a retention time greater than 70 
minutes and tended to exhibit extremely poor peak shape with increased broadness and 
loss of symmetry. Thus monitoring chromatographic performances was restricted to an 
arbitrary period of 70 minutes. 
Table 4.5: Influence of the mobile phase pH on retention and enantioseparation of flurbiprofen 
and its metabolites on a Chiral-AGP CSP *. 
pH Analyte k'1 V2 a RS 
7.0 Flurbiprofen 13.74 N. D. -- 
4'-Hydroxyflurbiprofen 2.35 2.87 1.22 1.07 
3'-Hydroxy-4'-methoxyflurbiprofen 5.03 5.03 1.00 - 
6.5 Flurbiprofen 27.10 N. D. -- 
4'-Hydroxyflurbiprofen 4.82 5.40 1.12 0.84 
3'-Hydroxy-4'-methoxyflurbiprofen 7.20 7.20 1.00 - 
6.0 Flurbiprofen 38.45 N. D. -- 
4'-Hydroxyflurbiprofen 6.05 6.84 1.13 0.72 
3'-Hydroxy-4'-methoxyflurbiprofen 9.96 9.96 1.00 - 
* Mobile phase : phosphate buffer (0. OJM) : IPA (99: 1 v/v) containing 1.0 mMDMOA. 
N. D. = not determinedd, since retention time > 70 minutes. 
As can be seen from the data presented in Table 4.5, the capacity factors of the analytes 
increased with decreasing pH from 7.0 to 6.0. It is not surprising that pH is a 
fundamental parameter when using a Chiral AGP since under the pH range investigated 
both the analytes and the AGP will be charged. AGP is an acidic protein with an 
isoelectric point of 2.7 and so decreasing the pH generates a larger number of positive 
charges (protonated amino groups) within the protein and therefore carboxylate anions 
are retained more strongly (Hermansson and 
Schill, 1988; Allenmark, 1989). It has also 
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been postulated that a change of pH can give rise to conformational changes that can 
have a strong effect on the bonding properties of the protein (Hermansson and Schill, 
1988). The change in pH did not seem to have a significant influence on the 
enantioselectivity of 4'-hydroxyflurbiprofen, which is consistent with the findings 
observed for other 2-arylpropionic acids (Hermansson and Eriksson, 1986). 
In an attempt to improve the separation profile the concentration of DMOA, a 
cationic modifier, in the mobile phase at pH 6.5 was increased from 1.0 mM to 5.0 mM. 
The increase in DMOA concentration resulted in faster elution of the analytes with a 
modest improvement on the enantioselectivity of 4'-hydroxyflurbiprofen and a slight 
decrease in the resolution factor (Table 4.6). 
Table 4.6: Influence of the DMOA concentration on retention and enantioseparation of 
flurbiprofen and its metabolites on a Chiral-AGP CSP *. 
DMOA Analyte k'1 V2 a RS 
(mM) 
1.0 Flurbiprofen 27.10 N. D. -- 
4'-Hydroxyflurbiprofen 4.82 5.40 1.12 0.84 
3'-Hydroxy-4'-methoxyflurbiprofen 7.20 7.20 1.00 - 
5.0 Flurbiprofen 19.83 N. D. -- 
4'-Hydroxyflurbiprofen 4.36 5.49 1.26 0.62 
3'-Hydroxy-4'-methoxyflurbiprofen 5.65 5.65 1.00 - 
* Mobile phase : phosphate buffer (pH 6.5,0. O1 M) : IPA (99: 1 v/v) containing DMOA. 
N. D. = not determined, since retention time > 70 minutes. 
These finding are consist with those previously observed by Hermansson and Eriksson 
(1986) and Hermansson and Hermansson (1994), who showed for a series of 2-aryl- 
propionic acids that the k'1-values were unchanged or slightly reduced with increasing 
DMOA concentration, whereas all k'2-values increased, yielding improved 
enantioselectivity. It is postulated that solutes are distributed as ion-pairs with DMOA to 
the stationary phase and that the bulky DMOA ion-pair of one enantiomer in a pair fits 
better in the chiral binding site of the protein due to conformational reasons 
(Hermansson and Eriksson, 1986). However, it should be noted that decrease in 
retention times with increasing concentrations of ion-pairing agents has also been 
observed using other protein-based columns (Ceccato et al., 1998). Thus, the effect from 
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ion-pairing (charged) mobile phase additives on k'- and a-values is rather difficult to 
predict. 
The presence of IPA, an uncharged modifier, in the mobile phase is essential to 
reduce the degree of hydrophobic interactions between the analytes and the AGP 
(Enquist and Hermansson, 1990). As reported in Table 4.7, increasing the content of 
IPA resulted in faster elution of the analytes and decreased enantioselectivity. Having 
1.5% v/v IPA in the mobile phase reduced the retention time of (S)-flurbiprofen to less 
than 70 minutes. A further increase to 5% resulted in a dramatic decrease in capacity 
factors, with (S)-flurbiprofen having a retention time of only 13.6 minutes and still 
exhibiting baseline resolution from its antipode, but such conditions result in 
insufficient retention of the enantiomers of 4'-hydroxyflurbiprofen and resolution is lost 
for this analyte. To obtain acceptable enantiomeric resolutions for both flurbiprofen and 
4'-hydroxyflurbiprofen in a single isocratic run would require the use of 0.3% v/v IPA in 
the mobile phase, however the last eluting peak has a retention time of ca. 140 minutes 
and shows poor peak shape (Figure 4.6). 
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Figure 4.6: Chromatographic separation and resolution of flurbiprofen and its major metabolites 
using a Chiral-AGP CSP. Peaks :1 and 2, enantiomers of 4'-hydroxyflurbiprofen; 3, (R, S)-3'- 
hydroxy-4'-methoxyflurbiprofen; 4, (R)-flurbiprofen; 5, (S)-flurbiprofen. [Mobile phase, phosphate 
buffer (pH 6.5,0.01M): IPA (99.7: 0.3 v/v) containing 1.0 mM DMOA; Flow rate, 0.5ml/min; 
Detection, UV X= 254 nmJ. 
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Clearly such conditions are not suitable for routine and quantitative applications. The 
use of alternative organic modifiers, such as acetonitrile and ethanol, did not improve 
the resolution for any analyte. 
Table 4.7: Influence of the organic modifier concentration on retention and enantioseparation of 
flurbiprofen and its metabolites on a Chiral-AGP CSP *. 
IPA (%) Analyte k11 k2a RS 
0.3 Flurbiprofen 31.52 180.00 5.71 9.00 
4'-Hydroxyflurbiprofen 4.89 6.55 1.34 1.27 
3'-Hydroxy-4'-methoxyflurbiprofen 7.53 7.53 1.00 - 
1.0 Flurbiprofen 27.1 N. D. - - 
4'-Hydroxyflurbiprofen 4.82 5.40 1.12 0.84 
3'-Hydroxy-4'-methoxyflurbiprofen 7.20 7.20 1.00 - 
1.5 Flurbiprofen 19.84 77.97 3.93 7.10 
4'-Hydroxyflurbiprofen 3.98 4.89 1.23 0.65 
3'-Hydroxy-4'-methoxyflurbiprofen 6.52 6.52 1.00 - 
3.0 Flurbiprofen 10.08 29.64 2.94 5.20 
4'-Hydroxyflurbiprofen 3.01 3.01 1.00 - 
3'-Hydroxy-4'-methoxyflurbiprofen 4.55 4.55 1.00 - 
5.0 Flurbiprofen 6.59 16.79 2.56 2.51 
4'-Hydroxyflurbiprofen 2.05 2.05 1.00 - 
3'-Hydroxy-4'-methoxyflurbiprofen 3.60 3.60 1.00 - 
* Mobile phase : phosphate buffer (pH 6.5,0. O1 M) : IPA containing 1.0 mM DMOA 
N. D. = not determinedd, since retention time > 70 minutes. 
In summary, it was not possible to obtain enantiomeric resolution of flurbiprofen 
and it's two major metabolites in a single chromatographic run using a Chiral-AGP CSP 
since this column was unable to discriminate between the enantiomers of 3'-hydroxy-4'- 
methoxyflurbiprofen. Furthermore the analysis time 
(150 minutes) required to obtain 
optimal enantioseparation of flurbiprofen and 4'-hydroxyflurbiprofen 
in a single run was 
not practical for enantiospecific bioanalysis. 
However, this problem could possibly be 
overcome by the use of gradient elution or 
by separately analysing flurbiprofen and 
4'-hydroxyflurbiprofen. Typical chromatograms for the individual analysis of 
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flurbiprofen and 4'-hydroxyflurbiprofen with their optimised chromatographic 
conditions are presented in Figure 4.7. Of all the parameters investigated in an attempt 
to obtain the desired separation profile, only IPA concentration in the mobile phase had 
a significant influence on the enantioselectivity of flurbiprofen and 4'-hydroxy- 
flurbiprofen and thus it would seem that the hydrophobic interactions between the 
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Figure 4.7: Chromatographic resolution using a Chiral-AGP CSP of (a) flurbiprofen. Peaks : 1, 
(R)-flurbiprofen; 2, (S)-flurbiprofen [Mobile phase, phosphate buffer (pH 6.5,0.01M): IPA (95: 5 
v/v) containing 1.0 mM DMOA; Flow rate, 0.5ml/min; Detection, UV X= 254 nm] and (b) 
4'-Hydroxyflurbiprofen. Peaks :3 and 4, enantiomers of 4'-hydroxyflurbiprofen [Mobile phase, 
phosphate buffer (pH 6.5,0.01M): IPA (99.8: 0.2 v/v) containing 1.0 mM DMOA; Flow rate, 
0.5ml/min; Detection, UV A. = 254 nm]. 
4.3.4 Derivatized amylose (Chiralpak AD) CSP 
Derivatized polysaccharide-based high-performance liquid chromatographic 
stationary phases are a key class of chiral stationary phases owing to their wide 
versatility and robustness (Okamato and Yashima, 1998). In particular, the CSP based 
on the tris (3,5-dimethylphenylcarbamate) derivative of amylose (Chiralpak AD) has 
been found to show high chiral recognition and been widely used to separate a broad 
range of racemic compounds and drugs (Yashima and 
Okamato, 1997; Okamoto and 
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Yashima, 1998). Derivatization of amylose with tris (3,5-dimethylphenylcarbamate) 
moieties facilitates the distribution of the solute to the CSP through hydrogen bonding 
to the amino and carbonyl groups and also via dipole-dipole interactions with the 
carbonyl group. In addition, the presence of the methyl substituents on the phenyl 
groups increase the electron density at the carbonyl oxygen atom of the carbamates and 
so encourage stronger hydrogen bonding interactions (Okamoto and Yashima, 1998). 
Besides these polar interactions, the lt-7t interaction between the phenyl group of the 
CSP and aromatic group of the analyte also play a significant role in chiral recognition 
(Okamoto and Yashima, 1998) 
The use of an amylose tris (3,5-dimethylphenylcarbamate) (Chiralpak AD) phase 
for the chromatographic separation of 2-arylpropionic acid enantiomers was initially 
demonstrated by Okamoto et al. (1989), baseline separation was obtained for 
flurbiprofen, ketoprofen and tiaprofenic acid. However, the application of this CSP in 
bioanalysis has been confined to the analysis of ketoprofen in human plasma and urine 
(Carr et al., 1995; Lovlin et al., 1996), analysis of tiaprofenic acid in plasma (Vakily and 
Jamali, 1996) and the stereospecific analysis of the major metabolites of ibuprofen in 
urine (Tan et al., 1997b; see Chapter 2). The main disadvantage of this phase is the 
limited choice of mobile phases that can be used since chlorinated and aqueous solvents 
are prohibited as they may swell or dissolve the amylose-coat on the silica support 
(Enomoto et al., 1996). Furthermore, biological sample work-up tends to be more 
critical to avoid the extraction of polar impurities that may interfere with the elution of 
the analytes or cause damage to the phase. 
The optimal use of the Chiralpak AD phase requires an understanding of how 
chiral recognition occurs on this CSP. Booth and Wainer (1996) have described a 
"conformational driven" chiral recognition mechanism, rather than the standard "three- 
point interaction" model, for the separation of a-alkylarylcarboxylic acids on the 
Chiralpak-AD phase. The results from quantitative structure-enantioselective retention 
relationships and molecular modelling studies indicate that the enantioselective 
discrimination of the a-alkylarylcarboxylic acids on the AD-CSP is a three step process. 
These steps are : (a) "tethering" of the analyte to the CSP through hydrogen bonding 
interactions between the acid moiety of the analyte and the amine moieties on the CSP; 
(b) conformational adjustments of the analytes and insertion of the aromatic portion of 
the analyte into a "ravine" on the CSP; (c) stabilisation of the analyte-CSP complex via 
electrostatic and hydrogen bonding interactions within the "ravine". 
Both enantiomers 
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of the analyte form identical hydrogen bonding interactions and presumably the same 
hydrophobic interactions as well (Figure 4.8). Chiral discrimination arises due to the 
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Figure 4 8: Proposed mechanism of binding between the amylose tris(3,5-dimethylphenyl- 
carbamate) chiral stationary phase and (S)-benoxaprofen, a model a-alkylarylcarboxylic acid 
(adapted from Booth and Wainer, 1996). 
The separation of enantiomers on polysaccharide-based CSPs is essentially 
performed using a mobile phase of hexane containing an alcohol modifier, such as 
ethanol, methanol or isopropanol. The Chiralpak AD column that was to be evaluated 
for the analysis of flurbiprofen had previously been applied in our laboratory for the 
resolution of sulindac (Sloväkovä et al., 1998) and the separation of the stereoisomers of 
the metabolites of ibuprofen (Tan et al., 1997b, 1997c; see Chapter 2). These 
separations had been performed using hexane-ethanol mixtures and required the 
addition of 0.05 % v/v trifluoroacetic acid (TFA) to suppress peak tailing and shorten 
the retention of the acidic drug analytes (Tang, 1996). The TFA present in the mobile 
phase reduced the hydrogen-bonding interactions of the acidic moiety of the analyte 
with the free silanol groups on the silica surface and also suppressed ionisation of the 
moiety. Therefore, using the same mobile-phase components and by altering the ethanol 
content, the Chiralpak AD phase was investigated to accomplish enantiomeric 
resolution of flurbiprofen and its metabolites within a reasonable run time. The 
chromatogram obtained using the mobile phase of hexane: ethanol (90: 10 v/v) 
containing trifluoroacetic acid (0.05% v/v) at a flow rate of 1. Oml/min is shown in 
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Figure 4.9. The three analytes, were separated and enantiomerically resolved with high 
separation and resolution factors (Table 4.8). Furthermore there was no co-elution 
between any of the analytes, which is often a problem since CSPs tend to have good 
enantioselectivity but poor chemical selectivity (Hutt and Patel, 1998). It is also 
noteworthy that as this CSPs is used under normal-phase conditions unlike the other 
approaches investigated, the polar metabolites elute after, rather than before, the parent 
compound. The overall run time was limited to about 45 minutes which is acceptable for 
application in bioanalysis. 
Table 4.8: Chromatographic parameters for the enantioseparation of flurbiprofen and its 
metabolites on a Chiralpak AD column *. 
Analyte KI k2a is 
Flurbiprofen 0.68 1.16 1.71 1.67 
4'-Hydroxyflurbiprofen 2.69 4.44 1.65 3.67 
3'-Hydroxy-4'-methoxyflurbiprofen 7.13 10.30 1.44 3.44 
* Mobile phase : hexane : ethanol (90: 10 v/v) containing tr fuoroacetic acid (0.05% v/v) 
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Figure 4.9: Chromatographic separation and resolution of flurbiprofen and its major metabolites 
using a Chiralpak AD CSP. Peaks : 1, (R)-flurbiprofen; 2, (S)-flurbiprofen; 3 and 4, enantiomers of 
4'-hydroxyflurbiprofen; 5 and 6, enantiomers of 3'-hydroxy-4'-methoxyflurbiprofen. [Mobile phase 
hexane: ethanol (90: 10 v/v) containing trifluoroacetic acid (0.05% v/v); Flow rate, 1. Oml/min; 
Detection, UV X= 254 nm]. 
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Thus it is clearly evident that the direct approach using the Chiralpak AD phase 
was the only one able to achieve the objective of baseline resolution of flurbiprofen and 
its metabolites in a single isocratic run and thus worthy of further evaluation for its 
application in bioanalytical studies (see Chapter 5). For such use it is essential that the 
stereochemical elution order of the analytes is established. However there is a lack of 
authentic chemical standards of the individual enantiomers of 4'-hydroxyflurbiprofen 
and 3'-hydroxy-4'-methoxyflurbiprofen and therefore these needed to be isolated by 
semi-preparative chromatography and characterised by circular dichroism spectroscopy. 
4.3.5 Semi-preparative chromatographic resolution of the enantiomers of 
4'-hydroxyflurbiprofen and 3'-hydroxy-4'-methoxyflurbiprofen. 
The semi-preparative isolation of the enantiomers of 4'-hydroxyflurbiprofen was 
performed using the Chiralpak AD column with a modification in the mobile phase 
composition. The ethanol content was increased to 12% in order to minimise the run 
time without significantly compromising the resolution, as indicated by a and Rs values 
of 1.62 and 1.85 respectively (Figure 4.10a). Following multiple injections (n=50) of 
4'-hydroxyflurbiprofen (0.4 mg per injection) approximately 9 mg of each enantiomer 
was isolated. Repeated analysis on the CSP indicated 98.2 % and 98.3 % enantiomeric 
purities for the first- and second-eluting enantiomers respectively (Figure 4.10 b and c). 
The individual enantiomers of 3'-hydroxy-4'-methoxyflurbiprofen were collected 
using the Chiralpak AD phase in a similar manner. The mobile phase employed had an 
ethanol content of 15 %, which is the upper limit for this CSP, and resulted in baseline 
separation of 3'-hydroxy-4'-methoxyflurbiprofen with a and Rs values of 1.45 and 2.43 
respectively (Figure 4.11 a). Similar yields were obtained as for 4'-hydroxyflurbiprofen 
and the first and second eluting enantiomers had enantiomeric purities of 99.1 % and 
99.0 % respectively (Figure 4.11 b and c). 
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Figure 4.10: (a) Semi-preparative resolution of the enantiomers of 4'-hydroxyflurbiprofen using 
the Chiralpak AD CSP. Repeat chromatographic analysis of (b) first-eluting enantiomer and (c) 
second-eluting enantiomer [Mobile phase hexane: ethanol (87: 13 v/v) containing trifluoroacetic acid 
(0.05% v/v); Flow rate, 1.0 ml/min; Detection, UV X= 254 nm]. 
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Figure 4.11: (a) Semi-preparative resolution of the enantiomers of 3'-hydroxy-4'-methoxy- 
flurbiprofen using the Chiralpak AD CSP. Repeat chromatographic analysis of (b) first-eluting 
enantiomer and (c) second-eluting enantiomer [Mobile phase hexane: ethanol (85: 15 v/v) containing 
trifluoroacetic acid (0.05% v/v); Flow rate, 1.0 ml/min; Detection, UV X= 254 nm). 
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4.3.6 Chiroptical properties of the enantiomers of 4'-hydroxyflurbiprofen and 
3'-hydroxy-4'-methoxyflurbiprofen 
An important aspect of assigning absolute configuration by circular dichroism 
(CD) is the spectroscopic assignment of the CD sign to a particular electronic transition. 
The UV absorption spectrum (Figure 4.12a) of (R, S)-flurbiprofen in acetonitrile is 
dominated by three n Tc * transitions at 275,246 and < 210 nm which are associated 
with the biphenyl chromophore. The CD spectra (Figure 4.12b) provides evidence for 
optical activity at 275,240,220 and < 210 nm. The prominent 240 and 220 nm CD 
features must, by comparison with the UV absorption spectra, be associated with the 
carboxyl chromophore which is expected to have a minimal contribution to the UV 
spectrum. The sign of the CD of the carboxyl related transitions in a-alkylphenylacetic 
acid derivatives correlates with their absolute stereochemistry such that negative and 
positive signals correspond to the R- and S- absolute configurations respectively (Barth 
et al., 1970). The negative and positive CD of (R)- and (S)-flurbiprofen (Figure 4.12b) 
correspond with those observed for (R)- and (S)-ibuprofen and related 2-arylpropionic 
acids (Barth et al., 1970; Teulon et al., 1978; Tan et al., 1997c: Hoult et al., 1999). 
Hydroxylation of flurbiprofen to yield 4'-hydroxyflurbiprofen causes a red shift 
in the UV spectrum (Figure 4.12a) of the aromatic transitions with features at 285 and 
258 nm and a shoulder appears at 218 nm. The wavelengths of the prominent CD 
features remain relatively unchanged (Figure 4.12c), the carboxyl assignment with CD 
sign in the 260 to 215 nm region remaining unaffected. The negative signal observed in 
this region for the first eluting enantiomer of 4'-hydroxyflurbiprofen and the positive 
signal seen with the second eluting enantiomer would suggest that the order of elution 
on the chiral stationary phase is (R)- before (S)-4'-hydroxyflurbiprofen, i. e. the same as 
that observed for flurbiprofen. 
Unfortunately 3'-hydroxy-4'-methoxyflurbiprofen is not sufficiently soluble in 
acetonitrile and measurements had to be carried out in methanol. Optical activity can be 
very sensitive to solvent and stereochemical correlations need to be made with respect to 
the reference compound in the chosen solvent. The UV absorption spectrum of 
flurbiprofen was found to be effectively unchanged in either acetonitrile or methanol 
(compare Figures 4.12a and 4.13a). However, considerable changes are observed in the 
CD spectra (Figures 4.12b and 4.13b). For (R)-flurbiprofen the 
CD pattern remains 
positive at < 210 nm, negative at 220 nm and positive at 
270 nm; however, the CD in 
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Figure 4.12: (a) UV spectra of flurbiprofen and 4'-hydroxyflurbiprofen; CD spectra determined in 
acetonitrile of (b) (R)- and (S)-flurbiprofen and (c) 
first and second eluting enantiomers of 
4'-hydroxyflurbiprofen. 
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Figure 4.13: (a) UV spectra of flurbiprofen and 3'-hydroxy-4'-methoxyflurbiprofen; 
CD spectra 
determined in methanol of (b) (R)- and (S)-flurbiprofen and (c) 
first and second eluting enantiomers 
of 3'-hydroxy-41-methoxyflurbiprofen. 
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the 225 to 260 nm region has apparently changed sign with a red shift to 248 nm 
matching the UV maximum at 248 nm. An obvious interpretation is that in methanol the 
CD spectra in this region is dominated by a positive biphenyl based transition whereas 
in acetonitrile the CD is dominated by a carboxyl based transition. This competition 
between negative carboxyl CD and positive biphenyl CD in the 225 to 260 nm region 
may account for the differences observed in acetonitrile between flurbiprofen and 
4'-hydroxyflurbiprofen. 
Increased substitution of the biphenyl ring system to form 3'-hydroxy-4'- 
methoxyflurbiprofen induces a further red shift of the UV absorption spectrum (Figure 
4.13a) with features clearly observed at 292 and 260 nm and a more prominent signal at 
225 nm. It appears that below 225 nm, the CD of 3'-hydroxy-4'-methoxyflurbiprofen is 
derived from two transitions: a carboxyl related signal remaining relatively unchanged at 
219 nm and a biphenyl related signal of the opposite sign. As the biphenyl transition 
red-shifts with substitution, the CD in this region is effectively cancelled (Figure 4.13c). 
The configurational assignment of the enantiomers of 3'-hydroxy-4'-methoxy- 
flurbiprofen therefore has to be performed using a secondary comparison. The CD in the 
260 nm region remains dominated by the biphenyl contribution as for the unsubstituted 
flurbiprofen and so by comparison of this region, the first eluting enantiomer of 
3'-hydroxy-4'-methoxyflurbiprofen exhibits a positive signal as observed with 
(R)-flurbiprofen and the second-eluting enantiomer shows a negative signal like 
(S)-flurbiprofen. Thus the chromatographic elution order is (R)- before (S)-3'-hydroxy- 
4'-methoxyflurbiprofen. 
4.4. Summary and conclusions 
In order to separate the enantiomers of flurbiprofen, 4'-hydroxyflurbiprofen and 
3'-hydroxy-4'-methoxyflurbiprofen using liquid chromatography, four different 
approaches were selected : reversed-phase HPLC after pre-column derivatization with 
(R)-NEA, reversed-phase HPLC using HP-ß-CD as a CMPA, reversed-phase HPLC 
using an al-acid glycoprotein CSP (Chiral-AGP) and normal-phase 
HPLC using an 
amylose tris (3,5-dimethylphenylcarbamate) CSP (Chiralpak 
AD). 
The (R)- 1-(naphthen-1-yl)ethylamide diastereoisomers of flurbiprofen and its two 
major metabolites could all be baseline resolved using a reversed-phase system. 
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However, this approach had the disadvantages that a run time greater than 45 minutes 
would have been required to achieve simultaneous separation and resolution of all three 
analyte derivatives and the use of fluorescence detection to enhance analytical 
sensitivity would not have been permitted due to the unequal florescent properties 
shown by diastereomeric derivatives. 
The adoption of a direct method using HP-ß-CD as a CMPA proved to be of 
limited success with only partial resolution observed for flurbiprofen and its 3'-hydroxy- 
4'-methoxy metabolite. This set of experiments also highlighted the lack of robustness 
of the approach with considerable variability observed in enantioselectivity between 
difference grades and brands of HP-ß-CDs. 
Baseline resolution of flurbiprofen and 4'-hydroxyflurbiprofen could be achieved 
using a Chiral-AGP CSP; but simultaneous analysis would have required a run time 
greater than 150 minutes, which is clearly not practical for quantitative and routine use. 
Furthermore, this column was unable to discriminate between the enantiomers of the 
3'-hydroxy-4'-methoxy metabolite. 
Of all the approaches, only the direct method using the Chiralpak AD CSP 
demonstrated separation and enantiomeric resolution of all three analytes within an 
acceptable run time of 45 minutes. Resolution values of 1.67,3.67 and 3.44 were 
obtained for flurbiprofen, 4'-hydroxyflurbiprofen and 3'-hydroxy-4'-methoxyflurbiprofen 
respectively. Semi-preparative isolation of the individual enantiomers of both 
metabolites, followed by CD analysis, revealed that the elution order on the CSP was 
R- before S-enantiomer for both compounds and maintained the same order as that 
observed for flurbiprofen. The metabolite elution order was subsequently confirmed on 
the analysis of urine samples obtained from a healthy volunteer following oral 
administration of the individual drug enantiomers (see Chapter 5). 
The above chiral-phase chromatographic system is the first to separate and resolve 
the enantiomers of flurbiprofen and its major metabolites in a single chromatographic 
run. The application of this methodology to the development of analytical methodology 
for the enantiospecific determination of flurbiprofen and its metabolites in urine and 
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Stereospecific analysis of flurbiprofen and its 
two major metabolites in biological fluids 
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5.1. Introduction 
Flurbiprofen, unlike ibuprofen, does not appear to undergo enantiomeric inversion 
in humans and is eliminated predominantly through metabolic oxidation and 
conjugation reactions (Risdall et al., 1978; Szpunar et al., 1987; Jamali et al., 1988). 
Flurbiprofen undergoes oxidation to yield 4'-hydroxy- and 3', 4'-dihydroxyflurbiprofen, 
the latter undergoing methylation to form 3'-hydroxy-4'-methoxyflurbiprofen, all of 
which retain the chiral centre (Figure 5.1). These metabolites, in addition to the parent 
compound are subjected to conjugation by either glucuronidation or in the case of the 



















Figure 5.1: Metabolism of flurbiprofen in humans (* denotes chiral centre). 
Urinary recovery studies by Szpunar et al. (1987) indicate that approximately 
22% flurbiprofen, 48 % 4'-hydroxyflurbiprofen, 7% 3'-hydroxy-4'-methoxyflurbiprofen 
and less than 1% 3', 4'-dihydroxyflurbiprofen are excreted 
in urine, primarily as 
conjugates, following a 100mg oral 
dose. Comparable data was also obtained by 
Knadler and Hall (1989). Only flurbiprofen and 
4'-hydroxyflurbiprofen have been 
detected in human serum or plasma, with the 4'-hydroxy metabolite 
being present at 
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concentrations 10 to 20 times less than those of the parent drug (Adams et al., 1987; 
Szpunar et al., 1987). 
Clearly the pathways associated with the formation and elimination of these 
metabolites may exhibit enantioselectivity and therefore to obtain a comprehensive 
picture of the enantiospecific disposition of flurbiprofen, investigations should not be 
solely based on the quantitative analysis of the enantiomers of the parent drug but also 
of its metabolites. Having said that, the achiral chromatographic analysis of the 
metabolites of flurbiprofen in biological fluids has received little attention in the 
literature (Adams et al., 1987; Szpunar et al., 1987) and the development of 
enantiospecific methods been restricted due to the difficulties associated with the 
chromatographic separation and resolution of flurbiprofen and its metabolites, coupled 
with the lack of authentic standards of the individual enantiomers of the metabolites. 
The indirect approach based on HPLC adopted by Knadler and Hall (1989) for the 
analysis of the enantiomers of flurbiprofen and its metabolites in plasma and urine, 
circumvented chromatographic separation difficulties by employing different methods 
for the analysis of (R)- and (S)- flurbiprofen and for the enantiospecific analysis of 
4'-hydroxyflurbiprofen and 3'-hydroxy-4'-methoxyflurbiprofen. Furthermore, the 
determination of flurbiprofen in plasma or urine required different conditions, the 
analysis of urine extracts required an adjustment in the mobile phase composition to 
allow for the simultaneous measurement of 3', 4'-dihydroxyflurbiprofen and needed the 
use of fluorescence detection, rather than UV, to minimise interference from 
endogenous compounds. However, it is worth noting that UV detection was still 
essential for the monitoring of the internal standard in this assay. 
The previous chapter outlined the chromatographic separation and resolution of 
flurbiprofen and its major metabolites, 4'-hydroxyflurbiprofen and 3'-hydroxy-4'- 
methoxyflurbiprofen on a amylose tris (3,5-dimethylphenylcarbamate) CSP (Chiralpak 
AD) and by a combination of semi-preparative isolation and chiroptical characterisation 
established the enantiomeric elution order for the metabolites. 
The ability to resolve all 
three analytes within a reasonable run time would 
indicate that this method is ideally 
suited for application in enantiospecific 
bioanalysis. This chapter therefore describes the 
development and validation of assays based on the Chiralpak AD CSP for the 
quantification of flurbiprofen and 
its metabolites in urine and serum. The utility of these 
assay methods for dispositional 
investigations was assessed by performing some 
preliminary urinary recovery studies 
following the oral administration of the drug to 
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three healthy male volunteers and the establishment of a serum concentration-time 
profile for one of these volunteers. 
5.2. Experimental 
5.2.1 Chemicals and reagents 
Acetonitrile, dichloromethane, ethanol, ethyl acetate, hexane and isopropanol 
(HPLC grade) were purchased from Rathburn (Walkerbum, UK). Trifluoroacetic acid 
(TFA) and sodium hydrogen phosphate (GPR grade) were purchased from BDH (Poole, 
Dorset, UK). Sodium acetate pHix Buffer (4.0 M, pH 5.5 + 0.03 at 25°C) was purchased 
from Pierce (Rockford, Illinois, USA). ß-Glucuronidase (EC 3.2.1.31) type H-5, with 
530 units of ß-glucuronidase and 30 units of sulphatase activity per mg solid, was 
purchased from Sigma Chemicals (Poole, Dorset, UK). (S)-Naproxen was obtained from 
Aldrich Chemicals (Gillingham, Dorset, UK). (R, S)-Benoxaprofen was kindly supplied 
by Lilly Research Centre Ltd. (Windlesham, Surrey, UK) and (R, S)-, (S)-, (R)- 
flurbiprofen, (R, S)-4'-hydroxyflurbiprofen and (R, S)-3'-hydroxy-4'-methoxy-flurbiprofen 
were the generous gifts of Boots Company PLC (Nottingham, UK). 
5.2.2 Chromatographic column 
The Chiral stationary phase was a Chiralpak AD (amylose tris (3,5-dimethyl- 
phenylcarbamate)) column (250 x 4.6 mm, 10 pm) used with a matching guard column 
(50 x 4.6 mm, 10 µm) and was supplied by HPLC Technology Ltd. (Macclesfield, UK). 
5.2.3 Instrumentation 
Chiral-phase HPLC was performed using an LDC Constametric 3000 pump linked 
to a Kontron SFM-25 fluorescence detector (Watford, Herts., UK) and a LDC 
Spectromonitor 3100 UV detector integrator (Stone, Staffs., UK). Data from the two 
detectors was acquired using a LDC CI-4000 computing integrator and a LDC CI-4100 
computing integrator (Stone, Staffs., UK). Samples were injected on column using a 
Perkin Elmer ISS-100 autosampler (Beaconsfield, Bucks., UK). 
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5.2.4 Enantiospecific analysis of flurbiprofen and its metabolites in urine 
Sample preparation 
Free: For the quantification of unconjugated flurbiprofen, 4'-hydroxy- 
flurbiprofen and 3'-hydroxy-4'-methoxyflurbiprofen, 1.0 ml aliquots of urine were used. 
To these samples were added 2.5 pg (50 µl of a 50 µg/ml solution in acetonitrile) of 
(S)-naproxen as internal standard. The samples were then acidified by the addition of 
hydrochloric acid (1.0 M; 100 µl) and buffered to pH 3.8 with 1.0 ml of phosphate 
buffer (pH 3.8; 1.0 M). Hexane: isopropanol (95: 5, v/v; 6 ml) was added and the 
extraction tubes were then tightly capped and mixed on a test-tube rocker for 20 
minutes. Phase separation was achieved by centrifugation for 5 minutes at 1000g. The 
organic layer was then separated into a clean glass tube and evaporated under a gentle 
stream of nitrogen at 40°C on a dry heating block. The residue was then reconstituted in 
150 µl mobile phase and 100 µl injected into the chiral phase HPLC system. 
Base hydrolysis: For the determination of the free plus acyl glucuronide 
concentrations of flurbiprofen, 4'-hydroxyflurbiprofen and 3'-hydroxy-4'-methoxy- 
flurbiprofen, 0.1 ml urine samples were used and diluted to 1.0 ml with distilled water. 
These samples were treated with sodium hydroxide (1.0 M; 200 µl) and the hydrolysis 
reaction was left to proceed for 2 hours at room temperature. Subsequently, the base was 
neutralised and the samples acidified by the addition of hydrochloric acid (1.0 M; 
300 µl). Then (S)-naproxen (2.5 µg), 1.0 ml of phosphate buffer (pH 3.8; 1.0 M) and 
hexane: isopropanol (95: 5 v/v; 6 ml) added before the samples were extracted as 
described above for the free samples. The quantity of an analyte excreted as acyl 
glucuronide was subsequently calculated by subtraction of the urinary concentration of 
the free analyte from the determined concentration following base hydrolysis. 
Enzymatic and base hydrolysis: For the determination of total concentrations 
(i. e., free, acyl glucuronide and phenolic conjugates) of flurbiprofen, 4'-hydroxy- 
flurbiprofen and 3'-hydroxy-4'-methoxyflurbiprofen, 0.1 ml aliquots of urine were used. 
To these, for optimal hydrolysis of phenolic conjugates, were added ß-glucuronidase 
(EC 3.2.1.31) type H-5 (1000 units of ß-glucuronidase plus 57 units of sulphatase) in 
0.9 ml acetate buffer (pH 5.0; 0.05 M) and incubated at 37°C for 16 hours. Following 
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this the samples were treated with NaOH (1.0 M; 200 µl) and the procedure followed as 
described above for base hydrolysis. 
Optimisation of enzymatic hydrolysis conditions 
Before determination of the conjugated levels of flurbiprofen and its metabolites 
in urine, optimal assay conditions for ß-glucuronidase (EC 3.2.1.31) enzyme activity 
were established. This partially purified enzyme has 530 units of ß-glucuronidase and 
30 units of sulphatase activity per mg solid and, hereafter the activity of the enzyme 
system will be referred to solely in terms of ß-glucuronidase activity to maintain 
simplicity. 
In order to determine the appropriate amount of enzyme required, 0.1 ml samples, 
from a 4-6 hr urine collection obtained from a volunteer following the oral 
administration of 100 mg of the racemic drug, were incubated with 500,1000,2000, 
4000 and 6000 units of ß-glucuronidase in 0.9 ml acetate buffer (pH 5.0; 0.05 M). The 
hydrolysis was performed in duplicate at 37°C for a period of 4 hours and 24 hours for 
each of the enzyme concentrations. Enzyme activity was terminated by placing the 
incubates on ice and the samples prepared, as described above for free drug and 
metabolites, prior to analysis. 
Upon establishing the most suitable quantity of enzyme (1000 units), a time 
course experiment was performed to determine the incubation time period which would 
be sufficient to completely liberate the phenolic and 1-O-acyl-glucuronides and sulphate 
conjugates of the drug and metabolites. Samples (0.1 ml) of the volunteer's 4-6hr urine 
collection were incubated in duplicate with 1000 units of 3-glucuronidase in 0.9 ml 
acetate buffer (pH 5.0; 0.05 M) at 37°C for 0,2,4,6,8,10,12,14,16,20 and 24 hours 
and then analysed as before. 
Chromatographic analysis 
The column used was a Chiralpak AD CSP (250 x 4.6 mm, 10 µm) connected to a 
guard column containing similar material (50 x 4.6 mm, 10 µm). The mobile phase 
consisted of hexane: ethanol (90: 10, v/v) containing TFA (0.05% v/v) as modifier, at a 
flow rate of 1.0 ml/min. The fluorescence detector was set at excitation and emission 




Validation of the assay procedure 
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A stock solution containing (R, S)-flurbiprofen (10 mg/ 100ml), (R, S)-4'-hydroxy- 
flurbiprofen (20mg/ 100ml) and (R, S)-3'-hydroxy-4'-methoxyflurbiprofen (2mg/ 100ml) 
was prepared in acetonitrile. Into nine separate 20 ml volumetric flasks were pipetted 
0.02,0.04,0.1,0.2,0.4,1.0,2.0,3.0 and 4.0 ml of the stock solution. The solutions 
were evaporated gently under nitrogen gas. Blank drug free urine was added to the 
flasks q. s. 20 ml to give final solutions containing 0.05,0.1,0.25,0.5,1.0,2.5,5.0,7.5 
and 10 p g/ml of each flurbiprofen enantiomer; 0.1,0.2,0.5,1.0,2.0,5.0,10.0,15.0 and 
20 µg/ml of each 4'-hydroxyflurbiprofen enantiomer and 0.01,0.02,0.05,0.1,0.2,0.5, 
1.0,1.5, and 2.0 p g/ml of each 3'-hydroxy-4'-methoxyflurbiprofen enantiomer in the 
respective flasks. Aliquots (1.0 ml) of these standards were transferred into different 
tubes and stored at -20°C. On each day of analysis one set of these tubes were analysed 
together with the samples. Ultraviolet detection at 254 nm was used for monitoring 
flurbiprofen, 4'-hydroxyflurbiprofen and the higher concentrations of 3'-hydroxy-4'- 
methoxyflurbiprofen (calibration range: 0.1-2.0 µg/ml for each enantiomer). However, 
fluorescence detection was used for lower concentrations of 3'-hydroxy-4'-methoxy- 
flurbiprofen (calibration range: 0.01-1.0 pg/ml for each enantiomer) the excitation 
wavelength was 288 nm and the emission cut-off filter was 340 nm. Calibration curves 
were constructed by plotting peak area ratios (analyte enantiomer: (S)-naproxen) against 
the concentration of each enantiomer and subjecting the data to linear regression 
analysis. The concentration of each analyte enantiomer in urine samples were 
determined by comparing their respective peak area ratios to the calibration curve 
prepared. 
The within day variation of the assay for flurbiprofen, 4'-hydroxyflurbiprofen 
and 3'-hydroxy-4'-methoxyflurbiprofen was assessed by analysing six standard samples 
each of nominal high, medium and low concentrations (refer to Tables 5.2 to 5.4). The 
precision and accuracy of the assay was determined for each analyte by calculation of 
the percentage coefficient of variation (standard deviation/mean x 100) and mean 
percentage difference ([mean-actual concentration] /actual concentration x 100) 
respectively. The extraction efficiencies for flurbiprofen and the metabolites were 
estimated by comparing peak areas against theoretical 100 % values obtained by 
analysis of standard solutions prepared in hexane: ethanol (90: 10, v/v), containing an 
equivalent quantity of analyte on column. 
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The between day variation of the assay was determined by analysing urine 
standard samples of the same concentrations for six consecutive days. The precision and 
accuracy were calculated as described above. 
In order to determine whether the analytical procedure could produce accurate 
data with respect to the enantiomeric composition of flurbiprofen over a wide range of 
concentrations, a series of "spiked" standards of varying concentration and enantiomeric 
composition were prepared using the individual flurbiprofen enantiomers. "Total" 
flurbiprofen concentrations of 0.5,2.0 and 10 µg/ml were prepared in urine with the 
following enantiomeric compositions; R: S; 1: 4; 2: 3; 3: 2 and 4: 1 for each concentration. 
The samples were extracted and analysed in triplicate and the precision and accuracy of 
the method was determined for each enantiomeric composition at the chosen 
concentrations as described above. 
The applicability of the de-conjugation methodologies for quantitative analysis 
was assessed by determining the precision following the replicate analysis (n=6) of a 
volunteer's 4-6 hr post-dose urine collection, hydrolysed using the enzyme plus base 
approach and the base approach. 
5.2.5 Enantiospecific analysis of flurbiprofen and 4'-hydroxyflurbiprofen in 
serum 
Sample preparation 
To serum samples (1.0 ml) were added 0.25 µg (50 µl of a 5.0 µg/ml solution in 
acetonitrile) of (R, S)-benoxaprofen as internal standard. The samples were then acidified 
by the addition of hydrochloric acid (1.0 M; 100 µl) and buffered to pH 3.8 with 1.0 ml 
of phosphate buffer (pH 3.8; 1.0 M). Hexane: ethyl acetate (90: 10 v/v; 6 ml) was added 
and the extraction tubes were then tightly capped and mixed on a test-tube rocker for 20 
minutes. Phase separation was achieved by centrifugation for 5 minutes at 1000 g. The 
organic layer was then separated into a clean glass tube and evaporated under a gentle 
stream of nitrogen at 40°C on a dry heating block. The residue was then reconstituted in 
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The column used was a Chiralpak AD CSP (250 x 4.6 mm, 10 µm) connected to a 
guard column containing similar material (50 x 4.6 mm, 10 µm). The mobile phase 
consisted of hexane: ethanol (87: 13, v/v) containing TFA (0.05% v/v) as modifier, at a 
flow rate of 1. Oml/min. The fluorescence detector was set at excitation and emission 
wavelengths of 288 and 340 nm respectively. 
Validation of the assay procedure 
A stock solution containing (R, S)-flurbiprofen (10 mg/ 100ml) and (R, S)-4'- 
hydroxyflurbiprofen (1.0 mg/ 100ml) was prepared in acetonitrile. Into nine separate 
20 ml volumetric flasks were pipetted 0.04,0.08,0.16,0.24,0.32,0.4,0.8,1.6 and 2.4 
ml of the stock solution. The solutions were evaporated gently under nitrogen gas. drug 
free serum was added to the flasks q. s. 20 ml to give final solutions containing 0.1,0.2, 
0.4,0.6,0.8,1.0,2.0,4.0 and 6 µg/ml of each flurbiprofen enantiomer and 0.01,0.02, 
0.04,0.06,0.08,0.1,0.2,0.4 and 0.6 pg/ml of each 4'-hydroxyflurbiprofen enantiomer 
in the respective flasks. Aliquots (1.0ml) of these standards were transferred into 
different tubes and stored at -20°C. On each day of analysis one set of these tubes were 
analysed together with the samples. Calibration curves were constructed by plotting 
peak height ratios (analyte enantiomer : first eluting enantiomer of benoxaprofen) 
against the concentration of each enantiomer and subjecting the data to linear regression 
analysis. The concentration of each analyte enantiomer in serum samples were 
determined by comparing their respective peak height ratios to the calibration curve 
prepared. 
The within day variation of the assay for flurbiprofen and 4'-hydroxyflurbiprofen 
was assessed by analysing six standard samples each of nominal high, medium and low 
concentrations (refer to Tables 5.8 and 5.9). The precision and accuracy of the assay was 
determined for each analyte by calculation of the percentage coefficient of variation 
(standard deviation/mean x 100) and mean percentage difference ([mean-actual 
concentration]/actual concentration x 100) respectively. The extraction efficiencies for 
flurbiprofen and the metabolites were estimated by comparing peak areas against 
theoretical 100 % values obtained by analysis of standard solutions prepared in 
hexane: ethanol (87: 13 v/v), containing an equivalent quantity of analyte on column. 
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The between day variation of the assay was determined by analysing serum 
standard samples of the same concentrations for six consecutive days. The precision and 
accuracy were calculated as described above. 
In order to determine whether the analytical procedure could produce accurate 
data with respect to the enantiomeric composition of flurbiprofen over a wide range of 
concentrations, a series of "spiked" standards of varying concentration and enantiomeric 
composition were prepared using the individual flurbiprofen enantiomers. "Total" 
flurbiprofen concentrations of 0.5,2.0 and 6 µg/ml were prepared in serum with the 
following enantiomeric compositions; R: S; 1: 4; 2: 3; 3: 2 and 4: 1 for each concentration. 
The samples were extracted and analysed in triplicate and the precision and accuracy of 
the method was determined for each enantiomeric composition at the chosen 
concentrations as described above. 
5.2.6 Preliminary urinary excretion studies following the administration of (R, S)- 
flurbiprofen, (S)-flurbiprofen or (R)-flurbiprofen 
Three healthy male volunteers (volunteers A, B and C: aged 48,35 and 28 years, 
weight 68,81 and 70 kg respectively) were given a single oral dose of racemic 
flurbiprofen (1 x 100 mg Froben® tablet) with 150 ml water following an overnight fast. 
Volunteer A was also administered 50 mg (R)-flurbiprofen and 50 mg (S)-flurbiprofen 
with a washout interval between each dose of at least 2 weeks. 
A blank, drug-free, urine sample was obtained prior to drug administration and 
sequential samples were collected at two hourly intervals up to 12 hours post dosing, 
together with a 12-24 h sample. The individual urine volumes were recorded and the 
samples analysed using the procedures described in section 5.2.4. 
5.2.7 Preliminary serum study following the administration of (R, S)-flurbiprofen 
Blood samples were also taken from volunteer A following the administration of 
the 100mg racemic dose. A venous blood sample (10 ml) was collected prior to 
flurbiprofen dosing and at 0.25,0.50,0.75,1,1.5,2,2.5,3,3.5,4,6,8,10 and 24 h post 
administration. Blood drawn by a plastic syringe was immediately transferred into glass 
tubes and allowed to clot at room temperature for two hours. Serum was separated by 
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centrifugation (10 min at 2000 g) and analysed using the procedure described in section 
5.2.5. 
5.3. Results and Discussion 
5.3.1 Enantiospecific analysis of flurbiprofen and its metabolites in urine 
The achievement of the desired chromatographic separation profile is only an 
initial preliminary step in the development of a quantitative enantiospecific urine assay 
method. Some of the critical, and often more challenging, issues that need to be 
addressed include selection of an appropriate detection method, the choice of an internal 
standard, the development of a suitable sample extraction procedure and adaptation of 
the methodology for the quantitative analysis of drug conjugates and metabolite 
conjugates. 
The presence of the drug and metabolites at widely different concentration ranges 
in urine, make it almost impossible to use a single detector with acceptable sensitivity 
for the analysis of all the analytes. However, the fluorescent nature of flurbiprofen and 
its metabolites allow for the use of tandem fluorescence and UV detectors to overcome 
this problem. The fluorescence detector was set at excitation and emission wavelengths 
of 288 nm and 340 nm respectively to provide optimum response for the detection of 
3'-hydroxy-4'-methoxyflurbiprofen, the enantiomers of this analyte are present at the 
lowest concentrations in urine samples and being the later eluting-peaks on the 
Chiralpak AD CSP exhibit the poorer peak shapes in terms of band broadening. The UV 
detector was used at 254 nm and was of sufficient sensitivity to allow for the 
simultaneous analysis of the enantiomers of flurbiprofen, 4'-hydroxyflurbiprofen and 
also higher concentrations of 3'-hydroxy-4'-methoxyflurbiprofen (> 0.1 µg/ml for each 
enantiomer in urine). 
Selection of an appropriate internal standard for chiral-phase bioanalysis is often 
difficult since CSPs tend to show poor separation characteristics for structurally similar 
compounds and furthermore in this case the choice is restricted by the need that 
candidates possess acceptable fluorescence and UV-absorbing properties under the 
experimental conditions employed. Therefore the compounds investigated as potential 
internal standards were other highly conjugated 2-arylpropionic acids and of these only 
164 
Chapter 5 Flurbiprofen : Stereospecific bioanalysis 
(S)-naproxen met the desired criteria. As shown in Figure 5.2, (S)-naproxen having a 
retention time of 10.1 minutes was baseline resolved between the peaks of 
(S)-flurbiprofen and (R)-4'-hydroxyflurbiprofen and could be readily detected using both 
detection systems. 
The operation of the Chiralpak AD stationary phase under normal-phase 
conditions makes it not ideally suited for applications in bioanalysis since most 
potentially interfering compounds derived from the biological matrix are polar and can 
be strongly retained on the chromatographic support. The presence of these 
contaminants may cause problems in analyte retention, resolution and column stability 
(Ducharme et al., 1996; Hutt and Patel, 1998); and therefore it is essential that 
extremely clean extracts are obtained. Initial `scouting' examinations of various 
extraction solvents for the isolation of flurbiprofen and its metabolites from urine were 
performed with the use of an achiral reversed-phase separation method rather than the 
CSP. From these preliminary studies it was deemed that a hexane: isopropanol (95: 5 v/v) 
mixture was the most appropriate for evaluation and determination of extraction 
efficiencies on the chiral stationary phase. Typical chromatograms obtained using the 
Chiralpak AD CSP for extracts from a blank urine sample and a "spiked" urine standard 
are shown in Figure 5.2. The stable baseline observed after the initial solvent front for 
the extract of blank urine illustrates the effectiveness of the extraction method as a 
clean-up process; and as expected the chromatogram obtained using fluorescence 
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Figure 5.2: Chiral-phase chromatograms of (i) reference standards, extracts of (ii) blank drug 
free urine and (iii) "spiked" urine; using (a) UV detection and (b) fluorescence detection. Peaks : 1, 
(R)-flurbiprofen; 2, (S)-flurbiprofen; 3, (S)-naproxen (I. S. ); 4, (R)-4'-hydroxyflurbiprofen; 5, 
(S)-4'-hydroxyflurbiprofen; 6, (R)-3'-hydroxy-4'-methoxyflurbiprofen and 7, (S')-3'-hydroxy-4'- 
methoxyflurbiprofen [Mobile phase hexane : ethanol (90: 10 v/v) containing trifluoroacetic acid 
(0.05% v/v); Flow rate, 1.0ml/min]. 
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Extraction efficiencies were determined at three different concentrations for each 
of the analytes and the results are presented in Table 5.1. The calculated percentages are 
based on theoretical 100 % values determined by analysis of standards containing 
equivalent quantities of the analytes. Essentially by employing this extraction system, 
high recovery of the polar metabolites is sacrificed for the maintenance of "contaminant- 
free" extracts. 
Table 5.1: Liquid-liquid extraction efficiencies for the enantiomer of flurbiprofen and its 
metabolites from urine using a hexane: isopropanol (95: 5 v/v) mixture (mean ± s. d.; n=6). 
Analyte Enantiomeric Extraction Efficiency (%) 
Concentration (mcg/ml) R -isomer S-isomer 
Flurbiprofen 0.10 89.5 ± 6.8 88.9 ± 5.9 
0.50 89.2 ± 2.5 89.0 ± 2.7 
5.00 86.8 ± 1.9 86.5 ± 1.6 
4'-Hydroxyflurbiprofen 0.20 74.5 ± 4.8 74.2 ± 3.8 
1.00 75.2±2.8 74.9±2.8 
10.0 75.4±1.1 75.1±1.3 
3'-Hydroxy-4'-methoxyflurbiprofen 0.02 78.3 ± 6.8 77.8 ± 7.7 
0.10 79.1 ±4.8 78.8+4.2 
1.00 77.4 ± 2.1 77.1 ±2.2 
Optimisation of enzymatic hydrolysis conditions 
Previous assay methods have quantified the conjugates of flurbiprofen, and its 
metabolites, by using either base (Adams et al., 1987) or acid hydrolysis (Knadler and 
Hall, 1989). However, in addition to acyl glucuronidation, the metabolites of 
flurbiprofen undergo phenolic conjugation to form ether glucuronides and sulphate 
conjugates and the disadvantage of the above methodologies is that they do not 
differentiate between conjugation at the different sites. Therefore, we have employed a 
enzymatic-base hydrolysis combination method, in addition to a base hydrolysis 
procedure that allows for the quantification of both acyl- and phenolic-conjugation of 
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the flurbiprofen metabolites. Phenolic conjugates tend to be relatively stable and so mild 
basic conditions are suitable only for the liberation of the free acids from their ester 
conjugates, including any isomers that may have arisen from intramolecular 
rearrangement (acyl migration). A partially purified form of ß-glucuronidase, namely 
P-glucuronidase (EC 3.2.1.31) type H-5, was selected for enzymatic hydrolysis as it also 
contains sulphatase activity and so will hydrolyse both phenolic- and 1-O-acyl- 
glucuronides in addition the sulphate conjugates. But it is worth noting that the 
glucuronides derived via acyl migration are not susceptible to enzymatic hydrolysis 
(Caldwell et al., 1983). 
The enzymatic hydrolysis of the enantiomers of flurbiprofen and its metabolites 
was optimised with respect to the quantity of ß-glucuronidase and the incubation time 
required. The influence of quantity of ß-glucuronidase on hydrolysis was investigated by 
incubating volunteer urine samples with 500,1000,2000,4000 and 6000 units of 
P-glucuronidase for a period of 4 hours and 24 hours (Figure 5.3). Increasing the amount 
of ß-glucuronidase beyond 1000 units per incubate appeared to have minimal influence 
on the hydrolysis of any the analytes, whether it be for the 4 hr or 24 hr incubations. The 
effect of increasing the incubation period from 4 hours to 24 hours, with a 1000 units of 
ß-glucuronidase per incubate, was to improve the yields for the enantiomers of 
3'-hydroxy-4'-methoxyflurbiprofen by approximately 15 %, the increase in yields for the 
enantiomers of flurbiprofen and 4'-hydroxyflurbiprofen were not as significant and 
tended to be less than 5% (Figure 5.3). Evidently, the hydrolysis reaction is not complete 
within 4 hours and so its time course was followed, using 1000 units of P-glucuronidase 
per incubate, at regular intervals over a 24 hour period to establish the optimal 
incubation time. The data presented in Figure 5.4 shows that hydrolysis of flurbiprofen 
conjugates and 4'-hydroxyflurbiprofen conjugates was relatively rapid and essentially 
complete after 6 hours, however the reaction appeared to have slower kinetics for 
3'-hydroxy-4'-methoxyflurbiprofen and complete liberation of the aglycone is achieved 
after 14 hours. The enantiomeric composition of all three analytes remained essentially 
constant throughout the experiment, indicating that there was no stereoselective 
hydrolysis under the experimental conditions employed. (Figure 5.4). Upon this basis, 
hydrolysis of urine samples with a 1000 units of ß-glucuronidase for a duration of 16 
hours, which is a convenient time period for over-night incubation, was deemed most 
168 
Chapter 5 Flurbiprofen : Stereospecijic bioanalrsis 
appropriated for application in the urine assay method. The base-hydrolysis procedure is 
essentially that previously characterised and employed in the enantiospecific urine assay 



















0 1000 2000 3000 4000 5000 6000 0 

















1000 2000 3000 4000 5000 6000 
quantity of enzyme (units) 
24 hr 
--0- (R)-4'-hydroxyfl urbi rpofen 
-- (S)-4'-hydroxyflurbiprofen 
1000 2000 3000 4000 5000 6000 0 1000 2000 3000 4000 5000 6000 














- f- (R)-3'-hydroxy-4'-methoxyflurbirpofen 
(S)-3'-hydroxy-4'-methoxyflurbiprofen 
0 1000 2000 3000 4000 5000 6000 0 
quantity of enzyme (units) 
1000 2000 3000 4000 5000 6000 
quantity of enzyme (units) 
Figure 5.3: Effect of quantity of ß-glucuronidase on the hydrolysis of conjugates of the 
enantiomers of (a) flurbiprofen, (b) 4'-hydroxyflurbiprofen and (c) 3'-hydroxy-4'-methoxy- 
flurbiprofen over 4 hour and 24 hour incubation periods [Sample: 4-6 hr urine collection following 
oral administration of 100 mg racemic flurbiprofen to volunteer 
C; n=21. 
169 
















































äý ............. ý . w.. w ý........,................... .. 
"- - -f -- -"- - -f -- f- - -f -- -f- - -f -------. - ------ 
---0 flurbiprofen 
.......... -°"° 4'-hydroxyflurbiprofen 
--f-- 3'-hydroxy-4'-methoxyflurbiprofen 
048 12 16 20 24 
Incubation time (hr) 
Figure 5.4: Time course of hydrolysis for conjugates of (a) flurbiprofen, (b) 4'-hydroxy- 
flurbiprofen and (c) 3'-hydroxy-4'-methoxyflurbiprofen by ß-glucuronidase and (d) the 
corresponding R/S ratios [Sample: 4-6 hr urine collection following oral administration of 100 mg 
racemic flurbiprofen to volunteer A; n=2]. 
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Validation of urine assay procedure 
The calibration curves for the analysis of the enantiomers of flurbiprofen, 
4'-hydroxyflurbiprofen and 3'-hydroxy-4'-methoxyflurbiprofen isolated from urine, were 
linear between 0.05-10 µg/ml, 0.1-20 µg/ml and 0.1-2.0 . tg/ml respectively using UV 
detection and are shown in Figure 5.5. The optimisation of the fluorescence detector for 
3'-hydroxy-4'-methoxyflurbiprofen allowed for the sensitive analysis of its enantiomers 
between 0.01-1.0 µg/ml, a typical calibration curve is shown in Figure 5.6. Linear 
regression analysis of the calibration curves for all the analytes routinely gave 
correlation coefficients better than 0.998. 
Analytical precision and accuracy were established by adding known quantities of 
flurbiprofen, 4'-hydroxyflurbiprofen and 3'-hydroxy-4'-methoxyflurbiprofen at three 
different concentrations to urine and analysing aliquots on a single day (n=6) and on six 
different assay days, and the results are presented in Tables 5.2,5.3 and 5.4. The 
coefficient of variation of the analytical method for within- and between-day studies was 
generally less than 10 % for all the analytes, indicating the precision of the assay at all 
the concentrations examined was greater than 90 %. The mean difference of the 
analytical method for within- and between-day studies was also less than 10 % for all 
the analytes, indicating the accuracy of the assay at all the concentrations examined was 
greater than 90 %. 
The assay was further validated by analysing a series of samples "spiked" with 
mixtures of the individual enantiomers of flurbiprofen at three different concentration 
levels. This validation approach is necessary as biological samples from pharmaco- 
kinetic and metabolic studies will contain non-racemic mixtures of enantiomers due to 
stereoselectivity in drug metabolism and disposition (Hutt, 1991). The precision and 
accuracy values calculated for these analyses are shown in Table 5.5. The measured 
enantiomeric compositions were in good agreement with the expected values and the 
variation involved was within acceptable limits at all three "total" concentrations 
examined. These results indicate that racemization is not occurring during sample 
manipulation and that the concentration of flurbiprofen does not appear to affect the 
measured enantiomeric composition. Due to the unavailability of sufficient quantities of 
the individual enantiomers of the metabolites, this validation approach was not 
performed for 4'-hydroxyflurbiprofen and 3'-hydroxy-4'-methoxyflurbiprofen. 
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Figure 5.5: Typical calibration curves prepared for the quantification of the enantiomers of (a) 
flurbiprofen, (b) 4'-hydroxyflurbiprofen and (c) 3'-hydroxy-4'-methoxyflurbiprofen in urine 
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Figure 5.6: A typical calibration curve prepared for the quantification of the enantiomers of 
3'-hydroxy-4'-methoxyflurbiprofen in urine samples using fluorescence detection. 
Table 5.2: Within-day and between-day analytical variation and accuracy of flurbiprofen 
enantiomers in "spiked" urine samples (mean ± s. d.; n=6) *. 
Concentration Enantiomer Concentration C. V. M. D. 
(mcg/ml) determined (mcg/ml) (%) (%) 
Within-day 
0.1 R 0.108±0.008 7.47 8.0 
S 0.103 ± 0.007 6.39 3.0 
0.5 R 0.47 ± 0.02 4.05 -6.0 
S 0.50±0.02 3.49 0.0 
5.0 R 5.04±0.15 2.97 0.8 
S 5.03 ± 0.15 2.88 0.6 
Between-day 
0.1 R 0.103±0.011 10.51 3.0 
S 0.098±0.011 11.61 -2.0 
0.5 R 0.49 + 0.01 2.10 -2.0 
S 0.49±0.02 3.20 -2.0 
5.0 R 5.01±0.13 2.64 0.2 
S 4.98 + 0.10 2.02 -0.4 
* C. V. = coefficient of variation; M. D. = mean 
difference 
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Table 5.3: Within-day and between-day analytical variation and accuracy of 4'-hydroxy- 
flurbiprofen enantiomers in "spiked" urine samples (mean ± s. d.; n=6) *. 
Concentration Enantiomer Concentration C. V. M. D. 
(mcg/ml) determined (mcg/ml) (%) (%) 
Within-day 
0.2 R 0.211 + 0.009 4.25 5.5 
S 0.203 ± 0.008 3.98 1.5 
1.0 R 1.05±0.03 2.86 5.0 
S 1.04 ± 0.03 2.68 4.0 
10.0 R 10.10±0.29 2.84 1.0 
S 10.10±0.29 2.90 1.0 
Between-day 
0.2 R 0.207 ± 0.008 3.89 3.5 
S 0.201 ± 0.009 4.35 0.5 
1.0 R 1.02 ± 0.05 4.40 2.0 
S 0.99±0.06 5.86 -1.0 
10.0 R 9.88±0.41 4.15 -1.2 
S 9.87 ± 0.45 4.60 -1.3 
* C. V. = coefficient of variation; MD. = mean difference 
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Table 5.4: Within-day and between-day analytical variation and accuracy of 3'-hydroxy-4'- 
methoxyflurbiprofen enantiomers in "spiked" urine samples (mean ± s. d.; n=6) *. 
Concentration Enantiomer Concentration C. V. M. D. 
(mcg/ml) determined (mcg/ml) (%) (%) 
Within-day 
0.02 R 0.020 ± 0.001 6.32 0.0 
S 0.019 ± 0.001 6.10 -5.0 
0.1 R 0.099 ± 0.003 2.63 -1.0 
S 0.098 ± 0.002 2.54 -2.0 
1.0 R 1.05±0.04 3.86 5.0 
S 1.04±0.04 3.80 4.0 
Between-day 
0.02 R 0.021 ± 0.002 8.03 5.0 
S 0.020 ± 0.002 11.91 0.0 
0.1 R 0.098 ± 0.008 7.71 -2.0 
S 0.096 ± 0.007 7.62 -4.0 
1.0 R 1.03 ± 0.04 4.20 3.0 
S 1.02±0.05 4.52 2.0 
* C. V= coefficient of variation; M. D. = mean difference. 
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Table 5.5: Precision and accuracy data for the determination of a series of different enantiomeric 
compositions of flurbiprofen in urine at three different "total" concentrations (mean ± s. d.; n=3)*. 
Enantiomer Theoretical Measured C. V. M. D. 
concentration(mcg/ml) concentration(mcg/ml) (%) (%) 























0.1 0.111 ± 0.009 7.64 11.3 
0.4 0.431 ± 0.005 1.16 7.8 
0.2 0.209 ± 0.006 2.91 4.5 
0.3 0.318±0.007 2.10 5.9 
0.3 0.305±0.012 4.10 1.7 
0.2 0.217±0.005 2.08 8.3 
0.4 0.410±0.014 3.33 2.6 
0.1 0.109 ± 0.002 1.41 8.7 
0.4 0.402 f 0.008 2.07 0.4 
1.6 1.595 f 0.017 1.05 -0.3 
0.8 0.800 ± 0.012 1.52 0.0 
1.2 1.188 f 0.019 1.61 -1.0 
1.2 1.190 t 0.006 0.46 -0.9 
0.8 0.788 f 0.015 1.88 -1.5 
1.6 1.610±0.001 0.04 0.6 
0.4 0.390 ± 0.007 1.68 -2.5 
2.0 2.17±0.053 2.44 8.6 
8.0 7.89±0.193 2.44 -1.3 
4.0 3.94±0.100 2.54 -1.4 
6.0 5.99±0.151 2.52 -0.1 
R 6.0 6.02 ± 0.072 1.20 0.3 
S 4.0 4.01 ± 0.031 0.77 0.3 
R 8.0 7.94 ± 0.045 0.56 -0.7 
S 2.0 2.03±0.019 0.93 1.3 
* C. V= coefficient of variation; MD. = mean difference. 
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The methodologies established for the determination of the conjugates of 
flurbiprofen and its metabolites were assessed for their suitability by determining the 
precision following the replicate analysis (n=6 in each case) of a volunteer's urine 
sample after enzymatic plus base hydrolysis and base hydrolysis alone. As expressed in 
Table 5.6, the coefficient of variation was generally less than 6% for all the analytes 
following either de-conjugation procedure and thus indicated the utility of the 
approaches for quantitative analysis. It can also be observed from these validation 
experiments, the close correlation of the determined concentrations for flurbiprofen 
enantiomers between the two different hydrolysis methods, which is indicative of the 
fact that flurbiprofen cannot undergo phenolic conjugation. 
Table 5.6: Precision data for the determination of the enantiomers of flurbiprofen and its 
metabolites following enzymatic plus base hydrolysis and base hydrolysis (mean ± s. d.; n=6) *. 
Analyte Enantiomer Concentration C. V. 
determined (mcg/ml) (%) 
Enzymatic + base hydrolysis 
Flurbiprofen R 69.9 ± 1.9 2.66 
S 56.0± 1.5 2.70 
4'-Hydroxyflurbiprofen R 126.5 ± 4.3 3.40 
S 109.2±3.6 3.31 
3'-Hydroxy-4'-methoxyflurbiprofen R 7.33 ± 0.11 1.55 
S 8.72±0.15 1.72 
Base hydrolysis 
Flurbiprofen R 68.3 ± 1.5 2.22 
S 54.8 + 1.3 2.28 
4'-Hydroxyflurbiprofen R 124.0 ± 6.9 5.55 
S 108.8 ± 6.5 5.93 
3'-Hydroxy-4'-methoxyflurbiprofen R 0.83 ± 0.01 1.37 
S 1.33±0.03 2.15 
* C. V. = coefficient of variation. 
[Sample: 4-6 hr urine collection following oral administration of 100 mg racemicflurbiprofen to volunteer 
B]. 
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5.3.2 Enantiospecific analysis of flurbiprofen and 4'-hydroxyflurbiprofen in 
serum 
A preliminary investigation of volunteer serum samples using the methodology 
adopted for the analysis of urine samples indicated that the approach would require 
modification, in terms of the detection method, mobile phase composition and choice of 
internal standard, for application in serum analysis. 
Initial studies indicated that, under the optimised conditions for fluorescence 
detection, the enantiomers of 3'-hydroxy-4'-methoxyflurbiprofen could not be detected 
in serum samples of a volunteer following administration of racemic flurbiprofen, these 
observations are in accordance with the findings of Adams et al. (1987) and Knadler et 
al. (1992a). The development of the serum assay was consequently limited to the 
quantitative analysis of the enantiomers of flurbiprofen and 4'-hydroxyflurbiprofen. It 
was deemed that the use of a single detection method would be sufficient for this 
purpose and so the fluorescence detector was employed and set at an optimum 
sensitivity for 4'-hydroxyflurbiprofen, which was expected to be present at lower 
concentrations than the parent compound in serum. It is worth noting that 4'-hydroxy- 
flurbiprofen exhibited similar fluorescence excitation and emission maxima to those of 
3'-hydroxy-4'-methoxyflurbiprofen. 
In addition, close examination of the chromatograms obtained following analysis 
of extracts of volunteer serum post drug administration revealed the presence of a slight 
shoulder on the peak of (S)-4'-hydroxyflurbiprofen (Figure 5.7a). As the "shoulder" was 
not observed in chromatograms obtained using "spiked" serum standards, and extracts 
of blank serum did not show additional peaks in this region of the chromatogram, it was 
thought that the "shoulder" could be due to co-eluting drug-related material. Also if the 
peak is due to drug-related material, then as the drug is chiral it is highly likely that the 
unknown is also chiral and that two, rather than one, additional peaks may be present. It 
was therefore necessary to adjust the mobile phase composition in an attempt to separate 
the interfering component from (S)-4'-hydroxyflurbiprofen. Increasing the ethanol 
content of the mobile phase from 10 % to 13 % resulted in the separation of the two 
components with the additional peak eluting just after the tail of the (S)-4'-hydroxy- 
flurbiprofen peak (Figure 5.7b). Examination of hydrolysed and non-hydrolysed 
volunteer urine samples under these chromatographic conditions 
did not unmask a 
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similar peak after the peak of the (S)-4'-hydroxy metabolite, suggesting that this 
particular product was not detectable in urine. 
A consequence of the alteration in the mobile phase composition was partial 
coalescence between the peaks due to (R)-4'-hydroxyflurbiprofen and (S)-naproxen, the 
internal standard (Figure 5.7b); therefore it was necessary to find an alternative 
fluorescent internal standard for application in the serum assay. Racemic benoxaprofen 
displayed suitable chromatographic characteristics with baseline resolution of its 
enantiomers and elution after (S)-4'-hydroxyflurbiprofen (Figure 5.8a). Either 
enantiomer of benoxaprofen could have been applied for quantitative analysis thus the 
choice of the first eluting enantiomer as the internal standard was an arbitrary decision. 
Due to the non-availability of the individual enantiomers the elution order is unknown. 
However, previously it has been shown by Booth and Wainer (1996) that the elution 
order for a series of 2-arylpropionic acids, including flurbiprofen and benoxaprofen, was 
always the R-enantiomer before the S-antipode on the amylose tris (3,5-dimethylphenyl- 
carbamate) CSP and so a fair assumption would be that the (R)-benoxaprofen elutes 
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Figure 5.7: Chiral-phase chromatograms of extracts from a serum sample (8 hr) obtained from a 
volunteer following the oral administration of 100mg racemic 
flurbiprofen using a mobile phase 
composition of (a) hexane: ethanol (90: 10, v/v) with TFA 
(0.05%) and (b) hexane: ethanol (87: 13 v/v) 
with TFA (0.05%) Peaks : 1, (R)-flurbiprofen; 2, 
(S)-flurbiprofen; 3, (S)-naproxen (I. S. ); 4, (R)-4'- 
hydroxyflurbiprofen; 5, (S')-4'-hydroxyflurbiprofen; a and ß, additional unknown peaks. 
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for the isolation of flurbiprofen and the 4'-hydroxy metabolite from serum was based on 
"scouting" experiments performed using an achiral reversed-phase column. 
Employment of the same extraction solvent as used for urine samples was found to be 
unsuitable as it resulted in the co-extraction of a large amount of serum pigments. A 
hexane: ethyl acetate (90: 10 v/v) mixture displayed more suitable characteristics as it 
gave clean extracts and good recoveries. Typical chromatograms obtained using the 
Chiralpak AD CSP for extracts from a blank serum sample and a "spiked" serum 
standard are shown in Figure 5.8 and illustrate the absence of interfering peaks at the 
retention times of the analytes and internal standard. Extraction efficiencies, calculated 
by comparison of peak areas for extracted serum standards against theoretical 100 % 
values, for the enantiomers of flurbiprofen and 4'-hydroxyflurbiprofen were generally 
better than 85 % at the concentration levels investigated (Table 5.7). 
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Figure 5.8: Chiral-phase chromatograms of (a) reference standards, extracts of (b) blank serum 
and (c) "spiked" serum. Peaks : 1, (R)-flurbiprofen; 2, (S)-flurbiprofen; 
3, (R)-4'-hydroxy- 
flurbiprofen; 4= (S)-4'-hydroxyflurbiprofen and 5 and 6, enantiomers of benoxaprofen (I. S. ) 
[Mobile phase hexane : ethanol (87: 13 v/v) containing TFA (0.05% v/v); 
Flow rate, 1.0ml/min]. 
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Table 5.7: Liquid-liquid extraction efficiencies for flurbiprofen and 4'-hydroxyflurbiprofen 
enantiomers from serum using a hexane: ethyl acetate (90: 10 v/v) mixture (mean ± s. d.; n=6). 
Analyte Enantiomeric Extraction Efficiency (%) 
Concentration (mcg/ml) R -isomer S -isomer 
Flurbiprofen 0.20 90.4 ± 10.8 89.3 ± 11.2 
1.00 92.5±5.4 91.9±5.7 
5.00 91.4±2.7 91.0± 1.8 
4'-Hydroxyflurbiprofen 0.02 85.4 ± 8.8 86.0 ± 9.2 
0.10 86.4±6.3 85.9±5.8 
0.50 87.4± 1.6 87.1±1.6 
Validation of serum assay procedure 
Quantitative analysis of flurbiprofen and 4'-hydroxyflurbiprofen in serum was 
performed by determining peak-height ratios (analyte : internal standard) instead of 
peak-area ratios as peak height measurements are less likely to be influenced by the 
presence of slight overlap between neighbouring peaks, which may be an issue in the 
chromatographic analysis of volunteer serum extracts due to the exposure of the 
additional peak at the tail of the (S)-4'-hydroxyflurbiprofen peak. 
Single enantiomer calibration curves for flurbiprofen (range: 0.1-6.0 µg/ml) and 
4'-hydroxyflurbiprofen (range: 0.01-0.6 µg/ml) typically yielded correlation coefficients 
greater than 0.997 and are shown in Figure 5.9. The within-day and between-day 
precision and accuracy values for the enantiomers of flurbiprofen and 4'-hydroxy- 
flurbiprofen, as presented in Tables 5.8 and 5.9, are generally good with coefficient of 
variations and mean differences less than 6% at the different concentrations examined 
Additional validation using non-racemic mixtures of the individual enantiomers of 
flurbiprofen at various concentrations is shown in Table 5.10. There was good 
correlation between measured and theoretical enantiomeric compositions and the 
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Concentration (mcg/ml) 
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Figure 5.9: Typical calibration curves prepared for the quantification of the enantiomers of (a) 
flurbiprofen and (b) 4'-hydroxyflurbiprofen in serum samples using fluorescence detection. 
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Table 5.8: Within-day and between-day analytical variation and accuracy of flurbiprofen 
enantiomers in "spiked" serum samples (mean ± s. d.; n=6) *. 
Concentration Enantiomer Concentration C. V. M. D. 
(Meg/ml) determined (mcg/ml) (%) (%) 
Within-day 
0.2 R 0.199 + 0.00 3.96 -0.5 
S 0.197 ± 0.008 3.85 -1.5 
1.0 R 1.01 ± 0.03 3.04 1.0 
S 1.00 ± 0.03 3.41 0.0 
5.0 R 5.04±0.05 1.00 0.8 
S 5.04 ± 0.05 0.96 0.8 
Between-day 
0.2 R 0.203±0.011 5.36 1.5 
S 0.204 ± 0.008 3.77 2.0 
1.0 R 1.02±0.03 2.54 2.0 
S 1.01±0.02 2.29 1.0 
5.0 R 5.11 ± 0.07 1.46 2.2 
S 5.12±0.08 1.63 2.4 
* C. V. = coefficient of variation; M. D. = mean difference 
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Table 5.9: Within-day and between-day analytical variation and accuracy of 4'-hydroxy- 
flurbiprofen enantiomers in "spiked" serum samples (mean ± s. d.; n=6) *. 
Concentration Enantiomer Concentration C. V. M. D. 
(mcg/ml) determined (mcg/ml) (%) (%) 
Within-day 
0.02 R 0.021 ± 0.001 2.67 5.0 
S 0.021 ± 0.001 1.96 5.0 
0.1 R 0.099 ± 0.004 3.55 -1.0 
S 0.101 ± 0.005 4.82 1.0 
0.5 R 0.51 ± 0.01 1.78 2.0 
S 0.50±0.01 2.11 0.0 
Between-day 
0.02 R 0.021 ± 0.001 4.72 5.0 
S 0.021 ± 0.001 4.26 5.0 
0.1 R 0.099 ± 0.004 3.90 -1.0 
S 0.100 ± 0.005 5.26 0.0 
0.5 R 0.51 ± 0.01 2.06 2.0 
S 0.51 ± 0.01 2.18 2.0 
* C. V. = coefficient of variation; M. D. = mean difference 
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Table 5.10: Precision and accuracy data for the determination of a series of different enantiomeric 









Low concentration (0.5 mcg/ml) 
R 0.1 0.097 ± 0.002 1.79 -3.0 
S 0.4 0.393 ± 0.005 1.28 -1.7 
R 0.2 0.200 ± 0.007 3.26 0.0 
S 0.3 0.295 ± 0.005 1.60 -1.6 
R 0.3 0.316 ± 0.007 2.34 5.2 
S 0.2 0.203 ± 0.005 2.33 1.3 
R 0.4 0.409 ± 0.007 1.59 2.2 
S 0.1 0.105±0.007 6.78 4.7 














0.4 0.402 ± 0.006 1.37 0.6 
1.6 1.615±0.019 1.15 1.0 
0.8 0.811 ± 0.009 1.16 1.4 
1.2 1.202 ± 0.028 2.37 0.2 
1.2 1.193 ± 0.008 0.67 -0.6 
0.8 0.813±0.014 1.72 1.6 
1.6 1.615±0.009 0.56 1.0 
0.4 0.408 ± 0.006 1.47 2.0 
1.2 1.19 ± 0.007 0.60 -0.8 
4.8 4.82 ± 0.024 0.50 0.3 
2.4 2.40 ± 0.010 0.42 0.1 
3.6 3.63 ± 0.031 0.84 0.8 
R 3.6 3.61 ± 0.017 0.48 0.2 
S 2.4 2.39±0.010 0.40 -0.4 
R 4.8 4.80±0.009 0.19 0.0 
S 1.2 1.19 ± 0.005 0.42 -0.7 





5.3.3 Preliminary in vivo investigations 
Urinary excretion studies 
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The utility of the urine assay was demonstrated by analysing urine samples 
collected at 2 hour intervals from 0 to 12 hours followed by a pooled urine sample from 
12 to 24 hours for three healthy volunteers following the oral administration of 100 mg 
of racemic flurbiprofen. Typical chromatograms of extracts obtained from non- 
hydrolysed and hydrolysed urine samples from this study are shown in Figure 5.10. The 
presence of 4'-hydroxyflurbiprofen at much higher concentrations than 3'-hydroxy-4'- 
methoxyflurbiprofen in urine and the necessity for a dual detection approach is clearly 
illustrated by the large differences observed in the size of the peaks between the 
enantiomers of the two metabolites. 
The amounts of flurbiprofen and metabolites excreted in urine were determined in 
terms of free and both acyl- and phenol-conjugated levels for all the volunteers. 
Representative cumulative excretion profiles for a volunteer are shown in Figure 5.11 
and the mean urinary excretion data is presented in Table 5.11. Of the administered dose 
some 19.3 % was excreted as flurbiprofen, 30.4 % as 4'-hydroxyflurbiprofen and 3.0 % 
as 3'-hydroxy-4'-methoxyflurbiprofen over the 24 hour collection period, primarily as 
conjugates. These results are in good agreement with previously reported results 
(Szpunar et al., 1987; Knadler and Hall, 1989). It is noteworthy that the two metabolites 
have different preferential sites for conjugation; the 4'-hydroxy metabolite tends to form 
acyl-conjugates like the parent drug whereas the 3'-hydroxy-4'-methoxy metabolite is 
excreted mainly as phenol conjugates (see also Table 5.6). The formation of more stable 
phenol conjugates by 3'-hydroxy-4'-methoxyflurbiprofen maybe indicative of why it 
appeared to display slower kinetics during enzymatic hydrolysis. 
A larger percentage of the dose was recovered in the (R)-form over the 24 hour 
collection period with total flurbiprofen and total 4'-hydroxyflurbiprofen having S/R 
ratios of 0.84 and 0.85 respectively, these findings are consistent with the observations 
of Knadler and Hall (1989). However, the minor metabolite, 3'-hydroxy-4'-methoxy- 
flurbiprofen, seemed to display preferential excretion of the (S)-isomer with a SIR ratio 
of 1.25. The proportion of metabolite present in recovered material seems to remain 
fairly constant with increasing urinary collection for both R- and S- forms, as can be 
seen in Figure 5.11 d. In this case, the metabolite fractions for metabolites derived from 
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the (R)- and the (S)-enantiomers reached steady values of 0.62 and 0.65 respectively 
after 8 hours. The lack of variability in the metabolite fraction with increasing urinary 
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Figure 5.10: Chiral-phase chromatograms of (i) non-hydrolysed, (ii) base hydrolysed and (iii) 
enzymatic and base hydrolysed extracts of a urine sample from a volunteer obtained 4-6 hr 
following the oral administration of racemic flurbiprofen (100mg); using (a) UV detection and (b) 
fluorescence detection. Peaks : 1, (R)-flurbiprofen; 2, (S)-flurbiprofen; 3, (S)-naproxen (I. S. ); 4, (R)- 
4'-hydroxyflurbiprofen; 5, (S)-4'-hydroxyflurbiprofen; 6, (R)-3'-hydroxy-4'-methoxyflurbiprofen 
and 7, (S)-31-hydroxy-4'-methoxyflurbiprofen. 
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Figure 5.11: Cumulative urinary excretion profiles for (a) flurbiprofen, (b) 4'-hydroxyflurbiprofen 
and (c) 3'-hydroxy-4'-methoxyflurbiprofen following the oral administration of 100mg racemic 
flurbiprofen to a healthy volunteer and (d) corresponding metabolite fractions. 
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Table 5.11: Urinary excretion (0-24 hr) of flurbiprofen and its metabolites following the 
administration of the racemic drug (100mg) to three healthy volunteers (data expressed as a mean 
percentage of the administered dose ± s. d.; n=3). 
Analyte (R)-isomer (S)-isomer S/R ratio 
Flurbiprofen 
free: 0.56 ± 0.41 0.50 ± 0.41 0.89 
acyl-conjugate: 9.95 ± 3.24 8.33 ± 2.85 0.84 
4'-Hydroxyflurbiprofen 
free: 1.13 ± 1.25 1.25 ± 1.15 1.10 
acyl-conjugate: 13.17 f 0.83 11.32 ± 1.37 0.86 
phenol-conjugate: 2.10 ± 0.83 1.44 ± 0.67 0.69 
3'-Hydroxy-4'-methoxyflurbiprofen 
free: 0.004 ± 0.005 0.005 ± 0.005 1.25 
acyl-conjugate: 0.034 ± 0.026 0.041± 0.043 1.21 
phenol-conjugate: 1.30 ± 0.17 1.63 ± 0.43 1.25 
Total Recovery 28.24 ± 1.03 24.68 f 0.30 0.87 
In an additional exploratory study, one of the volunteers was also dosed orally 
with 50 mg (R)-flurbiprofen and 50 mg (S)-flurbiprofen with a washout interval between 
each dose of at least 2 weeks and urine samples collected and analysed as described 
previously. Comparison of the urinary excretion data following administration of the 
individual enantiomers with that following dosing with the racemate provides an insight 
into whether, or how, the presence of the antipode in a racemic preparation influences 
its disposition. In this particular study, the R-enantiomer was investigated in addition to 
the S-enantiomer since (R)-flurbiprofen contributes to the pharmacological profile of the 
drug due to its analgesic properties (Brune et al., 1991,1992; Geisslinger et al., 1994a; 
Lötsch et al., 1995; Neugebauer et al., 1995; Geisslinger and Schaible, 1996, Buritova 
and Besson, 1998). Typical chromatograms of extracts obtained from non-hydrolysed 
and hydrolysed urine samples following administration of both (R)- and (S)-flurbiprofen 
are shown in Figures 5.12 and 5.13. The products detected in the urine samples retained 
the same stereochemical configuration as the administered enantiomer. This highlights 
the lack of chiral inversion of flurbiprofen in humans and is consistent with the findings 
of Jamali et al., (1988) and Geisslinger et al. (1994b). 
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Figure 5.12: Chiral-phase chromatograms of (i) non-hydrolysed, (ii) base hydrolysed and (iii) 
enzymatic and base hydrolysed extracts of a urine sample from a volunteer obtained 4-6 hr 
following the oral administration of (R)-flurbiprofen (50mg); using (a) UV detection and (b) 
fluorescence detection. Peaks : 1, (R)-flurbiprofen; 2, (S)-naproxen (I. S. ); 3, (R)-4'-hydroxy- 
flurbiprofen; and 4, (R)-3'-hydroxy-4'-methoxyflurbiprofen [Mobile phase hexane: ethanol (90: 10 
v/v) containing trifluoroacetic acid (0.05% v/v); Flow rate, 1.0ml/min]. 
, ý. 
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Figure 5.13: Chiral-phase chromatograms of (i) non-hydrolysed, (ii) base hydrolysed and (iii) 
enzymatic and base hydrolysed extracts of a urine sample from a volunteer obtained 4-6 hr 
following the oral administration of (S)-flurbiprofen (50mg); using (a) UV detection and (b) 
fluorescence detection. Peaks : 1, (S)-flurbiprofen; 2, (S)-naproxen (I. S. ); 3, (S')-4'-hydroxy- 
flurbiprofen; and 4, (S)-3'-hydroxy-4'-methoxyflurbiprofen [Mobile phase hexane: ethanol (90: 10 
v/v) containing trifluoroacetic acid (0.05% v/v); Flow rate, 1.0ml/min]. 
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The total recoveries of flurbiprofen and its metabolites following administration of 
the single enantiomers and the racemate to a healthy volunteer are presented in Table 
5.12. It is worth noting that the recovery values following dosing with (R, S)-flurbiprofen 
are expressed as a percentage of the enantiomeric dose, rather than administered dose 
(as in Table 5.11), for ease of comparison. A greater proportion of the dose was 
recovered in 24 hours following administration of (R)-flurbiprofen than with 
(S)-flurbiprofen, this is in agreement with preferential elimination of products with the 
R-configuration following dosing with the racemate. The total recoveries of material in 
the R-isomeric form after administration of 50mg (R)-flurbiprofen and 100mg 
(R, S)-flurbiprofen were consistent and there was good correlation between the amounts 
of the individual products. Similar observations were also made for (S)-flurbiprofen 
with the only disparages being between the quantities of free (S)-flurbiprofen and acyl- 
conjugated (S)-4'-hydroxyflurbiprofen recovered. In general, this would suggests that 
there is little dispositional interaction between the enantiomers of flurbiprofen. 
Table 5.12: Urinary excretion (0-24 hr) of flurbiprofen and its metabolites following the 
administration of (R)-flurbiprofen (50mg), (R, S)-flurbiprofen (100mg) and (S)-flurbiprofen (50mg) 
to a healthy volunteer (data expressed as a mean percentage of the enantiomeric dose) *. 
Analyte 50mg 100mg racemate 50mg 
(R )-flurbiprofen (R )-isomer (S)-isomer (S)-flurbiprofen 
Flurbiprofen 
free: 0.52 0.36 0.26 2.61 
acyl-conjugate: 19.94 19.34 15.36 15.89 
4' -Hyd roxyflu rb ip rofen 
free: 0.94 0.68 1.50 4.30 
acyl-conjugate: 28.05 28.14 25.70 17.31 
phenol-conjugate: 0.73 3.64 2.64 1.3 
3'-Hyd roxy-4'-methoxyflu rb ip rofen 
free: N. D. 0.01 0.01 N. D. 
acyl-conjugate: N. D. 0.01 0.09 N. D. 
phenol-conjugate: 2.47 2.96 3.56 4.82 
Total Recovery 52.65 55.14 49.12 46.23 
* N. D. = not detected. 
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Serum study 
Following the administration of 100mg racemic flurbiprofen, blood samples as 
well as urine samples were collected from one of the volunteers. Serum was isolated and 
analysed using the methodology outlined in section 5.2.5 and typical chromatograms of 
a 3hr and a 8hr collection are shown in Figure 5.14. The additional peaks at 10.0 and 
13.2 minutes were not observed in pre-dose serum or serum standard extracts and 
appear to become more prominent with time. These peaks could possibly correspond to 
the enantiomers of the 3', 4'-dihydroxy- intermediate involved in the formation of 
3'-hydroxy-4'-methoxyflurbiprofen. However, an authentic sample of 3', 4'-dihydroxy- 
flurbiprofen was not readily available for confirmation and any further investigations of 
the suspected metabolite were not thought to be essential as it was considered to be 
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Figure 5.14: Chiral-phase chromatograms of serum samples (a) 3 hr and (b) 8 hr following oral 
administration of (R, S)-flurbiprofen (100mg) to a healthy volunteer. Peaks : 1, (R)-flurbiprofen; 2, 
(S)-flurbiprofen; 3, (R)-4'-hydroxy-flurbiprofen; 4, (S)-4'-hydroxyflurbiprofen; 5, (R)-benoxa- 
profen (I. S. ) and 6, (, S')-benoxaprofen; a and ß, additional unknown peaks [Mobile phase 
hexane: ethanol (87: 13 v/v) containing TFA (0.05% v/v); Flow rate, 1.0mI/min]. 
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Semilogarithmic plots of serum concentration-time profiles of flurbiprofen and 
4'-hydroxyflurbiprofen for the volunteer are shown in Figure 5.15. Visual examination 
of the profiles for (R)- and (S)-flurbiprofen suggested that the drug exhibited 
non-stereoselective pharmacokinetics and that disappearance of the drug from systemic 
circulation was biphasic. The enantiomers of the 4'-hydroxy metabolite were present in 
serum at concentrations between ten to twenty times less than simultaneous flurbiprofen 
concentrations and their rates of disappearance from serum appeared to be comparable 
to that of the parent enantiomers. 
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Figure 5.15: Serum concentration-time profiles for the enantiomers of flurbiprofen and 
4'-hydroxyflurbiprofen following the oral administration of (R, S)-flurbiprofen (100mg) to a healthy 
volunteer. 
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Pharmacokinetic data analysis of the serum concentrations were performed using 
the procedures described in Chapter 6 and the results are presented in Table 5.13. There 
were only small differences in the values of the parameters between (R)- and (S)- 
flurbiprofen and between (R)- and (S)-4'-hydroxyflurbiprofen, which reiterates that 
neither the drug or metabolite appear to undergo extensive stereoselective disposition in 
this individual. The observation that (R)- and (S)-flurbiprofen have equivalent terminal 
half-lives is consistent with the findings of Jamali et al. (1988). The AUC for the (S)-4'- 
hydroxy metabolite was 9.5 % of the AUC of (S)-flurbiprofen and the corresponding 
value for the antipode was 6.9 %, emphasising that the serum concentrations of the 
enantiomers of this metabolite are relatively low. The terminal half-lives for (R)- and 
(S)- 4'-hydroxy-flurbiprofen were essentially equivalent to those of the parent 
enantiomers suggesting that metabolite elimination is formation rate-limited (Rowland 
and Tozer, 1995). 
Table 5.13: Pharmacokinetic parameters for the enantiomers of flurbiprofen and 4'-hydroxy- 
flurbiprofen following the oral administration of (R, S)-flurbiprofen (100mg) to a healthy volunteer. 
Parameter flurbiprofen 4'-hydroxyflurbiprofen 
(units) R -isomer S-isomer R -isomer S-isomer 
Cmax (mcg/ml) 7.8 7.6 0.36 0.52 
Tmax (hr) 3.0 3.0 3.5 3.5 
ti/2, Z(hr) 5.5 
5.6 5.8 5.9 
AUC (mcg/ml hr) 45.0 46.3 3.1 4.4 
CL (ml/min) 18.5 18.0 -- 
Vd (L) 8.8 8.8 -- 
5.4. Summary and conclusions 
In summary, reliable, sensitive chiral-phase HPLC assays for flurbiprofen and its 
major metabolites in urine and serum have been developed and validated. The 
compounds being extracted from urine or serum using liquid-liquid extraction 
techniques prior to separation and resolution on an amylose tris (3,5-dimethylphenyl 
carbamate) CSP (Chiralpak AD). The use of a fluorescence detector and a UV detector 
in series allows for the concurrent determination of the enantiomers of 
flurbiprofen, 
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4'-hydroxyflurbiprofen and 3'-hydroxy-4'-methoxyflurbiprofen in urine extracts. The 
employment of a fluorescence detector is sufficient for the quantitative analysis of the 
enantiomers of flurbiprofen and the 4'-hydroxy metabolite in serum. 
The methods were applied in preliminary urinary excretion and serum disposition 
studies following the administration of flurbiprofen to healthy volunteers. The urinary 
recovery studies indicate that the acyl-conjugates of flurbiprofen and the 4'-hydroxy 
metabolite are the major components in urine the excretion profile of the drug shows 
modest enantioselectivity for products with the R-configuration. The analysis of serum 
samples from a volunteer suggest enantioselectivity in the disposition of flurbiprofen in 
humans is limited. 
To our knowledge this is the first report of methodology allowing simultaneous 
determination of the enantiomers of flurbiprofen and its major metabolites in biological 
fluids using chiral-phase chromatography. 
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CHAPTER 6: 
Stereoselective disposition of flurbiprofen 




Flurbiprofen : Stereoselective disposition 
Numerous studies have investigated the plasma pharmacokinetics of the 
enantiomers of flurbiprofen following either administration of the racemate or the 
individual enantiomers (Jamali et al., 1988,1991; Small et al., 1990; Cefali et al., 1991; 
Young et al., 1991; Knadler et al., 1992a, 1992b; Geisslinger et al., 1994b). Plasma 
concentrations of (S)-flurbiprofen were consistently higher than those of 
(R)-flurbiprofen in all these studies such that the area under the plasma concentration 
versus time curve of the S-enantiomer were significantly greater than that of the 
R-enantiomer. Statistically significant differences between flurbiprofen enantiomers 
were also found for systemic clearance (Jamali et al., 1988; Small et al., 1990; Young et 
al.. 1991; Knadler et al., 1992a, 1992b) and half-life (Jamali et al., 1991; Knadler et al., 
1992a; Geisslinger et al., 1994b), indicating the faster elimination of the R-enantiomer. 
In contrast with the above findings, a recent human serum study suggests that 
flurbiprofen does not exhibit enantioselective pharmacokinetics (Oelkers et al., 1997). 
In comparison to ibuprofen, flurbiprofen demonstrates modest enantioselectivity 
in its disposition in humans. This is not surprising, since the disposition of flurbiprofen 
in man, unlike other species, is not complicated by the significant unidirectional R- to S- 
inversion observed with ibuprofen (Menzel-Soglowek et al., 1992; Geisslinger et al., 
1994b). Flurbiprofen does not form a coenzyme A thioester in vitro (Knihinicki et al., 
1989; Knadler and Hall, 1990), a prerequisite for chiral inversion, and individual 
enantiomer administration to humans does not result in formation of its antipode (Jamali 
et al., 1988; Geisslinger et al., 1994b; Oelkers et al., 1997). Furthermore, the negligible 
mutual enantiomeric interactions displayed by flurbiprofen at doses commonly 
employed may contribute to the lack of complexity in its disposition (Knadler et al., 
1989). 
Differences in the disposition of flurbiprofen enantiomers are likely to arise due to 
enantioselectivity in plasma protein binding and elimination. The principle pathways of 
flurbiprofen elimination are through the formation of oxidation products and conjugates 
and therefore the stereoselectivity of these different processes need to be addressed. 
However, as a consequence of the difficulties associated with developing suitable 
methods for the enantiospecific bioanalysis of flurbiprofen with its metabolites, few 
human studies have considered this aspect of flurbiprofen disposition. The excretion of 
flurbiprofen as the acyl glucuronide accounts for about 20 % of the dose, and in vitro 
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experiments, using human hepatic microsomal preparations, reveal the glucuronidation 
to be stereoselective with (R)-flurbiprofen being a better substrate than (S)-flurbiprofen 
(Hamdoune et al., 1995). Quantitatively, the major metabolic pathway for flurbiprofen 
is via oxidation to yield 4'-hydroxyflurbiprofen. Small et al. (1990) using an 
unpublished analytical method, suggested there was a lack of stereoselectivity in the 
disposition of this product in humans following administration of the drug. Urinary 
excretion studies indicate a predominance of products with the R-configuration in the 
recovered material, as greater amounts of the R-enantiomer were found both as total 
flurbiprofen (conjugated and unconjugated) and 4'-hydroxyflurbiprofen (Knadler et al., 
1992a, 1992b). 
Studies on the influence of age on the pharmacokinetics and disposition of 
flurbiprofen in humans are scarce. In the study of Hamdy et al. (1980), the 
pharmacokinetics of flurbiprofen were evaluated after a single 50 mg dose of the 
racemate in 12 male osteoarthritis-patients (age range: 66-90 years, mean: 79 years) and 
12 female osteoarthritis-patients (age range: 74-94 years, mean: 85 years) and compared 
the data obtained with parameters determined from previous studies in undefined 
healthy younger volunteers (age range: 18-40 years). Limited pharmacokinetic 
parameters were calculated, e. g. peak serum concentration and area under the plasma 
concentration versus time curve, based on an undocumented analytical procedure and no 
differences in the disposition of "total" flurbiprofen between young and elderly subjects 
were observed. A more extensive study performed by Kean et al. (1992) investigated the 
pharmacokinetics of flurbiprofen in 13 elderly (age range: 65-83 years, mean: 73 years) 
and 12 younger (age range: 40-60 years, mean: 53 years) patients with rheumatoid 
arthritis at the beginning, mid-point and end of an eight day, 100 mg twice daily, 
multiple-dose regimen. Renal clearance was decreased significantly in the elderly; 
however, renal clearance averaged only 10 % of total body clearance in these patients 
and is only a minor pathway of drug elimination compared with metabolism. The above 
investigations would suggest that age has minimal influence on the handling of 
flurbiprofen in humans, but such conclusions may be misleading as the lack of 
stereochemical analysis may mask age-associated differences in enantiomeric 
disposition. 
The objective of the current investigation is to examine the disposition of 
flurbiprofen enantiomers and the formation of known metabolites following the oral 
administration of the racemic drug to healthy young and elderly volunteers. 
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Enantiospecific analysis will be performed using the analytical methodologies based on 
chiral phase HPLC described and validated in the previous Chapter. 
6.2. Experimental 
6.2.1 Clinical study protocol 
Volunteers 
Two groups of subjects were studied : a) four young healthy volunteers aged from 
24 to 29 years (mean ± s. d., 26.8 ± 2.2 years), two male and two female; and b) four 
elderly healthy volunteers aged from 72 to 87 years (78.5 ± 7.2 years), two male and two 
female; their demographic data is shown in Appendix 1O. Volunteers were judged to be 
in good health on the basis of case history, physical examination, electrocardiogram, and 
routine laboratory data including blood pressure and pulse. The study was approved by 
the Research Ethics Committee of the School of Medicine and Dentistry, King's College 
London. Volunteers were fully informed about the investigational procedure and the use 
of flurbiprofen. In compliance with the Declaration of Helsinki, written informed 
consent was obtained from each participant before enrolment in the study. 
Study design 
The volunteers were required to abstain from any alcohol, caffeine-based products 
and medication for at least 24 hours prior to the study. The volunteers were fasted for at 
least 8 hours overnight before a single 100mg oral dose of racemic flurbiprofen 
(Froberi tablet) was administered with 150m1 of water. Food and drink were withheld 
for at least 3 hours after drug administration. 
Blood samples (10 ml) were collected immediately before drug administration and 
at 0.5,1.0,1.5,2.0,3.0,4.0,5.0,6.0,7.0,8.0,10,12 and 24 hours post dosing in plain 
silicone coated vacutainer tubes. The venous blood samples were drawn for the initial 
12 hour period via an indwelling cannula, to avoid repeated venipuncture, placed in a 
convenient vein in the arm of the volunteer. The cannula was flushed after each sample 
collection with 0.9% NaCI solution B. P. to avoid clotting 
in the cannula. Samples were 
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allowed to clot for two hours and serum obtained after centrifugation (10 min at 2000g). 
Urine samples were collected every two hours for the first 12 hours and then at 22 and 
24 hours post drug administration. The individual urine volumes were recorded and a 
pooled 24 hour sample was prepared from the individual collections. Serum and urine 
samples were frozen at -20°C until required for analysis. 
6.2.2 Chromatographic analysis 
The enantiomeric composition of flurbiprofen and 4'-hydroxyflurbiprofen in 
serum and flurbiprofen, 4'-hydroxyflurbiprofen and 3'-hydroxy-4'-methoxyflurbiprofen, 
both free and conjugated, in urine were determined using the methodology described in 
Chapter 5. All samples were analysed in duplicate and a set of appropriate calibration 
standards analysed on each day. 
6.2.3 Pharmacokinetic and data analysis 
Determination of pharmacokinetic parameters was performed by conventional 
non-compartmental analysis of the enantiomeric serum concentration-time profiles of 
flurbiprofen and the 4'-hydroxy metabolite (Rowland and Tozer, 1995). 
Maximum serum concentrations (Cm) and the corresponding times (Tm) were 
determined by examination of the individual serum concentration-time curves for each 
volunteer. The terminal elimination half-life (t112, Z) was determined using : 
tln, Z In 2/XZ (Eqn. 6.1) 
where the elimination rate constant (kZ) is obtained by log-linear regression of the 
terminal phase of the serum concentration-time profile. The area under the curve (AUC) 
was calculated by : 
AUC = AUCo-, t + AUCt, ao (Eqn. 6.2) 
where AUC up to the last measurable data point (AUCo, t) was determined using the 
trapezoidal rule and extrapolated to infinite time (AUCt*co) by dividing the last 
measurable serum concentration by A. The average extrapolated area accounted 
for 8% 
201 
Chapter 6 Flurbiprojen : Stereoselective disposition 
and 16% of the total area for the enantiomers of flurbiprofen and 4'-hydroxyflurbiprofen 
respectively. Apparent total body clearance (CL) and volume of distribution (Vd) of 
flurbiprofen were calculated from the following expressions: 
CL = F. Dose/AUC 
where the fraction of the dose reaching systemic circulation (F) was assumed to be 
unity. This is reasonable, since previous studies have shown that greater than 95 % of 
orally administered 50 mg doses of the racemate were excreted in urine within 48 hours 
post dosing (Risdall et al., 1978) and the bioavailability of different tablet dosages 
relative to an oral solution averaged 94 % (Spzunar et al., 1987). 
The fraction of each flurbiprofen enantiomer converted to oxidation products 
(F0X), namely 4'-hydroxyflurbiprofen and 3'-hydroxy-4'-methoxyflurbiprofen, was 
calculated from an examination of the total recoveries (free and conjugated) of the 
individual enantiomers of flurbiprofen and metabolites in urine over 24 hours using: 
Vd = F. Dose/?. AUC 
(Eqn. 6.3) 
(Eqn. 6.4) 
oxidative metabolites FOX = 
total recovery (Eqn. 6.5) 
where "% oxidative metabolites" is the sum of the molar amounts of the 4'-hydroxy and 
3'-hydroxy-4'-methoxy metabolites excreted, both free plus conjugated, expressed as a 
percentage of the administered dose and "% total recovery" is the percentage of the dose 
recovered in urine. 
The clearance of 4'-hydroxyflurbiprofen (CLm) was estimated from : 
CLm = Fox. (F. Dose)/AUC. (Eqn. 6.6) 
where AUCn, is the area under the 4'-hydroxyflurbiprofen serum concentration-time 
curve corrected for molar equivalency to the parent 
drug. 
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When administered to humans, the major dispositional pathways of the 


























where the clearance superscripts refer to the "parent" compound, i. e. flurbiprofen (Fl) 
and 4'-hydroxyflurbiprofen (H), and the subscript to the elimination route, i. e. renal 
(ren), conjugation (con) and metabolism (met). Assuming these products are cleared 
exclusively via renal elimination, the associated formation clearances (CLf) may be 
determined by : 
CLf = Ae(p)/AUCparent (Eqn. 6.7) 
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where Ae(p) is the total amount of product recovered in urine either unchanged or 
conjugated, and in the case of the 4'-hydroxy product includes the amount undergoing 
further oxidation to the 3'-hydroxy-4'-methoxy metabolite; and AUCparent is the AUC of 
the compound from which the product was derived (Rowland and Tozer, 1995). 
The mean pharmacokinetic parameters derived from the serum data and urinary 
excretion data for the enantiomers of flurbiprofen, 4'-hydroxyflurbiprofen and 3'- 
hydroxy-4'-methoxyflurbiprofen were tested for stereoselective differences using the 
Student's t-test for paired samples in both age groups. Age-associated differences in the 
pharmacokinetic data and urinary data of both (R)- and (S)-flurbiprofen were assessed 
using the Student's t-test for independent samples. 
6.3. Results 
6.3.1 Serum kinetics 
Enantioselective differences 
The mean serum concentration-time profiles for the enantiomers of flurbiprofen 
and 4'-hydroxyflurbiprofen following the administration of 100 mg of the racemate to 
four healthy young volunteers are shown in Figure 6.1, and the individual serum level 
data are tabulated in Appendix 11. The pharmacokinetic parameters derived from the 
serum concentrations of the enantiomers of flurbiprofen and the magnitude of the 
enantiomeric differences for these parameters, expressed as S/R ratios, are presented 
in 
Tables 6.1 and 6.2 respectively. Likewise, the individual enantiomer pharmacokinetic 
parameters and corresponding S/R ratios for 4'-hydroxyflurbiprofen are shown 
in Tables 
6.3 and 6.4 respectively. 
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Figure 6.1: Mean serum concentration-time profiles for the enantiomers of flurbiprofen and 
4'-hydroxyflurbiprofen following the oral administration of (R, S)-flurbiprofen (100 mg) to four 
healthy young volunteers (mean ± s. d. ). 
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Table 6.1: Pharmacokinetic parameters of flurbiprofen e nantiomers following the oral 
administration of the racemic drug (100 mg) to four healthy young volunteers. 
(R)-flurbiprofen 
Subject Cmax Tma= tl/Z, z AUC CL 
CLren Vd F0 
Code (mcg/ml) (hr) (hr) (mcg/mI hr) (ml/min) (mi/min) (L) 
FyI 6.3 2.0 4.0 43.1 19.4 1.96 6.8 0.69 
Fy2 8.9 1.5 4.2 45.7 18.3 0.54 6.6 0.77 
Fy3 7.7 1.5 4.6 41.0 20.3 0.94 8.0 0.70 
Fy4 4.6 1.5 5.3 39.6 21.0 1.35 9.7 0.66 
Mean 6.9 1.6 4.5 42.3 19.7 1.20 7.8 0.71 
s. d. 1.8 0.3 0.6 2.6 1.2 0.61 1.4 0.05 
C. V. % 26.4 15.4 12.6 6.2 6.1 50.6 18.2 6.6 
(S)-flurbiprofen 
Fyl 5.5 3.0 4.7 43.4 19.2 1.85 7.8 0.66 
Fy2 8.3 1.5 4.8 54.9 15.2 0.39 6.4 0.77 
Fy3 7.5 2.0 5.1 46.7 17.8 0.66 7.8 0.73 
Fy4 4.8 3.0 6.3 52.9 15.8 0.85 8.5 0.68 
Mean 6.5 2.4 5.2 49.5 17.0 0.94 7.6 0.71 
A. 1.6 0.8 0.7 5.3 1.9 0.64 0.9 0.05 
C. V. % 25.2 31.6 13.7 10.8 10.9 67.9 12.0 7.0 
p(R vs. S) * N. S. N. S. p<0.005 N. S. N. S. N. S. N. S. N. S. 
* Comparison between the means for the enantiomers offlurbiprofen were carried out using Student's t-test for paired samples 
(N. S. =p>0.05). 
Table 6.2: Pharmacokinetic parameter ratios (SIR) of flurbiprofen following the oral 
administration of the racemic drug (100 mg) to four healthy young volunteers. 
ratio (SIR) 
Subject CmIX Tm ti/Z, z AUC 
CL CLren Vd Fox 
Code 
Fyl 0.87 1.50 1.16 1.01 0.99 0.94 1.15 0.96 
Fy2 0.94 1.00 1.15 1.20 0.83 0.72 0.96 1.00 
Fy3 0.97 1.33 1.11 1.14 0.88 0.70 0.98 1.04 
Fy4 1.04 2.00 1.17 1.33 0.75 0.63 0.88 1.03 
Mean 0.96 1.46 1.15 1.17 0.86 0.75 0.99 1.01 
s. d. 0.07 0.42 0.03 0.14 
0.10 0.14 0.11 0.04 
C. V. % 7.44 28.57 2.33 11.55 11.70 18.09 11.33 3.81 
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Table 6.3: Pharmacokinetic par ameters of 4'-hydroxyflurbiprofen enantiomers following the 
oral administration of (R, S)-flurbiprofen (100 mg) to four healthy young volunteers. 
(R)-4'-hydroxyflurbiprofen 
Subject CmAx Tmi tli2z AUC CL CLren 
Code (meg/mi) (hr) (hr) (mcg/ml hr) (mi/min) (mu min) 
Fyl 0.43 3.0 6.1 3.11 195.9 53.7 
Fy2 0.93 2.0 5.6 4.39 155.6 15.3 
Fy3 0.59 2.0 7.8 3.14 199.3 26.1 
Fy4 0.28 2.0 7.4 2.34 251.1 42.8 
Mean 0.56 2.3 6.7 3.25 200.5 34.5 
s. d. 0.28 0.5 1.1 0.85 39.1 17.1 
C. V. % 50.0 22.2 15.8 26.1 19.5 49.6 
(S)-4'-hydroxyflurbiprofen 
Fyl 0.59 2.0 12.8 5.77 101.6 26.1 
Fy2 1.33 2.0 7.4 6.04 112.8 9.9 
Fy3 0.95 2.0 10.1 5.68 113.6 14.1 
Fy4 0.39 2.0 12.1 3.97 150.9 23.6 
Mean 0.82 2.0 10.6 5.37 119.7 18.4 
s. d. 0.41 0.0 2.4 0.94 21.5 7.7 
C. V. % 50.8 0.0 23.1 17.6 18.0 41.8 
p(R vs. S) * p<0.05 N. S. p<0.05 p<0.005 p<O. 01 N. S. 
* Comparison between the means for the enantiomers of 4'-hydroxyflurbiprofen were carried out using Student's t-test for paired 
samples (N. S. = p>O. 05). 
Table 6.4: Pharmacokinetic parameter ratios (SIR) of 4'-hydroxyflurbiprofen following the oral 
administration of (R, S)-flurbiprofen (100 mg) to four healthy young volunteers. 
ratio (SIR) 
Subject Cmax Tm. ti/Z, z AUC CL 
CLren 
Code 
Fyl 1.37 0.67 2.10 1.86 0.52 0.49 
Fy2 1.43 1.00 1.32 1.38 0.72 0.65 
Fy3 1.61 1.00 1.29 1.81 0.57 0.54 
Fy4 1.39 1.00 1.62 1.70 0.60 0.55 
Mean 1.45 0.92 1.58 1.68 0.60 0.56 
s. d. 0.11 0.17 0.38 0.22 0.09 0.07 
C. V. % 7.5 18.2 23.8 12.8 14.5 12.2 
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Following administration of 100 mg of the racemate, the serum levels of (R)- 
flurbiprofen were greater than those of the S-enantiomer during the initial 3 hour post- 
dose period, i. e. mainly during the absorption phase; beyond this point, the serum 
concentrations of (S)-flurbiprofen were consistently higher those of its antipode. 
However, the differences between the serum concentrations of the enantiomers did not 
reach statistical significance at any sampling time during the 24 hour period. The (S)- 
flurbiprofen serum levels declined more slowly and this is reflected by the significantly 
longer half-life (t1/2, Z) values (p<0.005; Table 6.1). These findings are consistent with 
previously reported data (Jamali et al., 1991; Knadler et al., 1992a; Geisslinger et al., 
1994b). None of the other pharmacokinetic parameters were significantly different 
between the individual enantiomers and the lack of enantioselectivity in the 
pharmacokinetics of flurbiprofen in the young volunteers is highlighted by the modest 
deviations of S/R parameter ratios from unity (Tables 6.1 and 6.2). It is of interest to 
note that both enantiomers of flurbiprofen were cleared primarily by metabolism with 
renal clearance accounting for less than 6% of the total clearance (Table 6.1). 
The metabolite, 4'-hydroxyflurbiprofen, was also detectable in serum samples, the 
sensitivity of the analytical method was such that the concentrations of the metabolite 
enantiomers could be determined in the 24 hr sample. It is worth noting that the assay 
method previously employed by Knadler et al. (1992a) lacked sensitivity capable of 
quantifying the levels of both (R)- and (S)-4'-hydroxyflurbiprofen beyond 13 hours post 
dosing and consequently only limited pharmacokinetic parameters for this metabolite 
have been reported previously. 
The mean serum concentration-time curves for (R)- and (S)-4'-hydroxyflurbiprofen 
in comparison with those of (R)- and (S)-flurbiprofen for the young volunteers are 
shown in Figure 6.1. The enantiomers of the 4'-hydroxy metabolite were typically 
present in serum at concentrations between five to twenty fold less than those of the 
corresponding flurbiprofen concentrations and their elimination displayed a more 
prominent biphasic characteristic with the terminal half lives being larger than those of 
the parent enantiomers. In contrast to flurbiprofen, the serum levels of the S-enantiomer 
of 4'-hydroxyflurbiprofen always exceeded those of its antipode with the differences 
being statistically significant at all sampling times with the exception of those at 4 and 5 
hours. As a consequence, the area under the curve (AUC) and maximum serum 
concentration (Cmax) of (S)-4'-hydroxyflurbiprofen were significantly greater (p<0.05) 
than for (R)-4'-hydroxyflurbiprofen (Table 6.3). The terminal half-life (ä12, Z) and total 
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clearance (CL) also showed statistically significant differences, with (S)-4'-hydroxy- 
flurbiprofen having a longer tli2, Z and a smaller CL. 
The mean serum concentration-time profiles for the enantiomers of flurbiprofen 
and 4'-hydroxyflurbiprofen following administration of the racemic drug to four healthy 
elderly volunteers are shown in Figure 6.2, and the individual serum level data are 
tabulated in Appendix 12. The associated pharmacokinetic parameters and S/R ratios 
derived for flurbiprofen are presented in Tables 6.5 and 6.6 respectively; and likewise 
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Mean serum concentration-time profiles for the enantiomers of flurbiprofen and 
4'-hydroxyflurbiprofen following the oral administration of (R, S)-flurbiprofen (100 mg) to four 
healthy elderly volunteers (mean ± s. d. ). 
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Table 6.5: Pharmacokinetic parameters of flurbiprofen enantiomers following the oral 
administration of the racemic drug (100 mg) to four healthy elderly volunteers. 
(R )-flurbiprofen 
Subject Cmai Tmai t1/2, z AUC CL CLren Vd F01 
Code (mcg/ml) (hr) (hr) (mcg/ml hr) (ml/min) (ml/min) (L) 
Fe l 10.9 3.0 7.2 83.5 10.0 2.07 6.2 0.55 
Feg 5.6 3.0 7.7 57.0 14.6 1.00 9.7 0.71 
Fe3 8.1 1.0 8.0 74.5 11.2 0.21 7.7 0.68 
Fe4 8.9 2.0 5.7 63.0 13.2 2.49 6.6 0.66 
Mean 8.4 2.3 7.1 69.5 12.3 1.44 7.6 0.65 
s. d. 2.2 1.0 1.0 11.8 2.1 1.03 1.6 0.07 
C. V. % 26.5 42.6 13.9 17.0 16.9 71.7 21.1 10.7 
p(Y vs. E) f N. S. N. S. p<O. 01 p<0.05 p<0.005 N. S. N. S. N. S. 
(S)-flurbiprofen 
Fe l 10.2 3.0 9.7 98.0 8.5 1.39 7.1 0.57 
Fe2 5.1 3.0 10.2 64.2 13.0 0.69 11.5 0.74 
Fe3 7.7 1.0 10.6 84.2 9.9 0.15 9.1 0.66 
Fe4 8.2 2.0 7.9 70.9 11.8 1.96 8.1 0.63 
Mean 7.8 2.3 9.6 79.3 10.8 1.05 8.9 0.65 
s. d. 2.1 1.0 1.2 15.0 2.0 0.79 1.9 0.07 
C. V. % 26.7 42.6 12.4 18.9 18.4 75.6 21.1 10.9 
p(R vs. S) * N. S. N. S. p<O. 001 p<O. 01 p<0.005 N. S. p<0.05 N. S. 
p(Y vs. E) N. S. N. S. p<0.005 p<0.05 p<O. 01 N. S. N. S. N. S. 
* Comparison between the means for the enantiomers offlurbiprofen were carried out using Student's t-test for paired samples 
(N. S. =p>0.05). t Comparison between respective means for young and elderly volunteers were carried out using Student's t-test 
for independent samples (N. S. = p>0.05) 
Table 6.6: Pharmacokinetic parameter ratio (S/R) of flurbiprofen following the oral 
administration of the racemic drug (100 mg) to four healthy elderly volunteers. 
ratio (SIR) 
Subject Cmax TmH t112 AUC CL CLren Vd Fox 
Code 
Fe l 0.93 1.00 1.35 1.17 0.85 0.67 1.15 1.04 
Fe2 0.92 1.00 1.33 1.13 0.89 0.69 1.18 1.04 
Fe3 0.95 1.00 1.33 1.13 0.88 0.71 1.18 0.97 
Fe4 0.92 1.00 1.38 1.13 0.89 0.79 1.23 0.95 
Mean 0.93 1.00 1.35 1.14 0.88 0.72 1.18 1.00 
s. d. 0.01 0.00 0.02 0.02 0.02 0.05 
0.03 0.04 
C. V. % 1.48 0.00 1.70 2.06 2.02 7.09 2.68 4.48 
p(Y vs. E) t N. S. N. S. p<0.001 
N. S. N. S. N. S. p<0.05 N. S. 
t Comparison between respective means for young and elderly volunteers were carried out using 
Student's 1-test for independent 
samples (N. S. = p>0.05). 
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Table 6.7: Pharmacokinetic parameters of 4'-hydroxyflurbiprofen enantiomers following the 
oral administration of (R, S)-flurbiprofen (100 mg) to four healthy elderly volunteers. 
(R )-4'-hydroxyflurbiprofen 
Subject Cm&Z Tmax t1 12, z AUC CL CLr,. 
Code (Meg/ml) (hr) (hr) (mcg/ml hr) (ml/min) (ml/min) 
Fel 0.71 4.0 9.7 5.88 83.5 34.3 
Feg 0.48 5.0 12.0 5.54 113.8 22.8 
Fe3 0.63 3.0 9.5 6.74 89.9 5.1 
Fe4 0.49 3.0 9.5 4.51 129.2 65.0 
Mean 0.58 3.8 10.2 5.67 104.1 31.8 
s. d. 0.11 1.0 1.2 0.92 21.2 25.2 
C. V. % 19.4 25.5 11.7 16.3 20.4 79.2 
p(Y vs. E) fi N. S. p<0.05 p<0.01 p<0.01 p<O. 01 N. S. 
(S)-4'-hydroxyflurbiprofen 
Fe l 0.93 4.0 13.1 9.97 50.3 17.4 
Feg 0.61 5.0 15.6 7.63 86.6 15.2 
Fe3 0.77 2.0 11.7 7.92 73.7 3.4 
Fe4 0.62 3.0 14.4 6.79 82.5 35.2 
Mean 0.73 3.5 13.7 8.08 73.3 17.8 
s. d. 0.15 1.3 1.7 1.35 16.2 13.1 
C. V. % 20.6 36.9 12.4 16.7 22.1 73.8 
p(R vs. S) * p<0.01 N. S. p<0.01 p<0.05 p<0.05 N. S. 
p(Y vs. E) t N. S. N. S. N. S. p<0.05 P<0.05 N. S. 
* Comparison between the means for the enantiomers of 4'-hydroxyfurbiprofen were carried out using Student's t-test for paired 
samples (N. S. = p>0.05). t Comparison between respective means for young and elderly volunteers were carried out using 
Student's t-test for independent samples (N. S. = p>0.05). 
Table 6.8: Pharmacokinetic parameter ratios (SIR) of 4'-hydroxyflurbiprofen following the oral 
administration of (R, S)-flurbiprofen (100 mg) to four healthy elderly volunteers. 
ratio (SIR) 
Subject Cmax Tmax tvz, z AUC CL 
CLren 
Code 
Fel 1.31 1.00 1.35 1.70 0.60 0.51 
Feg 1.27 1.00 1.30 1.38 0.76 0.66 
Fe3 1.22 0.67 1.22 1.18 0.82 0.68 
Fe4 1.27 1.00 1.51 1.51 0.64 0.54 
Mean 1.27 0.92 1.35 1.44 0.71 0.60 
s. d. 0.04 0.17 0.12 0.22 0.10 0.09 
C. V. % 2.8 18.2 9.0 15.2 14.5 14.3 
p(Y vs. E) t p<0.05 N. 
S. N. S. N. S. N. S. N. S. 
t Comparison between respective means for young and elderly volunteers were carried out using 
Student's t-test for independent 
samples (N. S. =p>0.05). 
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Following the oral administration of 100mg racemic flurbiprofen, the relative 
serum concentration time profiles for (R)- and (S)-flurbiprofen followed a similar trend 
to that observed in the young group, however in this case the gradual enrichment of 
(S)-flurbiprofen in serum during the elimination phase resulted in statistical significant 
differences in the serum levels between the two enantiomers beyond 8 hours post dosing 
(Figure 6.2). As would be expected, the half live of (S)-flurbiprofen was also 
significantly longer than that of its antipode in this age group (Table 6.5). However, it 
appears that greater enantioselectivity is observed in the disposition of flurbiprofen in 
the elderly compared to the young since other statistically significant differences were 
observed between the individual enantiomers with (S)-flurbiprofen displaying a larger 
AUC, reduced CL, and a greater volume of distribution (Vd) than (R)-flurbiprofen 
(Table 6.5). An interesting observation in this age group is the notable consistency of 
the S/R ratio between individuals for a given pharmacokinetic parameter, the highest 
inter-subject variability observed being only 7% (Table 6.6). 
The serum concentration time profiles of (R)- and (S)- 4'-hydroxyflurbiprofen, 
following the administration of the drug to the elderly volunteers, mirrored the 
observations in the young group. The metabolite being present at concentrations up to 
20 fold less than the parent and the consistent predominance of the S-enantiomer in 
serum (Figure 6.2). This is reflected in the pharmacokinetic parameters determined for 
the 4'-hydroxy metabolite displaying the same enantioselective differences as those 
previously observed in the young, with the S-enantiomer having a higher Cm"', longer 
tli2,,, reduced CL and a larger AUC in comparison to (R)-4'-hydroxyflurbiprofen (Table 
6.7). 
Age-associated differences 
Comparison between the young and elderly groups indicated age-related 
differences with respect to the pharmacokinetics of (R)- and (S)-flurbiprofen (Table 6.5). 
The elderly volunteers exhibited significantly longer tli2,, and reduced CL for both 
enantiomers of the drug. The accumulation of flurbiprofen in the elderly is reflected 
in 
the group having significantly larger AUC values for (R)- and (S)-flurbiprofen 
in 
comparison to the corresponding values observed for the young volunteers. 
(Tables 6.1 
and 6.5). Age-associated differences were also observed 
in the pharmacokinetic 
parameters determined for 4'-hydroxyflurbiprofen with 
both enantiomers of the 
metabolite displaying significantly larger 
AUCs and a reduction in clearance in the 
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elderly volunteers (Tables 6.3 and 6.7). Additional differences between the two age 
groups were seen in the case of the R-enantiomer, i. e. the elderly exhibited significantly 
greater values of T,,, and tli2, Z for (R)-4'-hydroxyflurbiprofen. 
These age-related changes in the pharmacokinetics of the enantiomers of 
flurbiprofen and 4'-hydroxyflurbiprofen are associated with only modest alterations in 
enantioselectivity. This is evident from the majority of the parameter S/R ratios 
displaying good agreement between the two age groups (Tables 6.6 and 6.8). The 
observation of an enantioselective difference in the volume of distribution of 
flurbiprofen in the elderly (R: 7.6 vs. S: 8.9 L) which was not evident in the young 
(R: 7.8 vs. S: 7.6 L) is reflected in a significant difference in the S/R ratio for this 
parameter between the two groups (Tables 6.2 and 6.6). The significantly greater S/R 
ratio seen for ti/2,, of flurbiprofen in the elderly is probably as a result of this age-related 
appearance of enantioselectivity in the Vd, as age had no influence on the 
enantioselective clearance of the drug (Table 6.2 and 6.6). In addition a significant, but 
modest, change in the S/R ratio for Cm of 4'-hydroxyflurbiprofen was apparent, such 
that the elderly showed a reduced enantioselective difference (Table 6.4 and 6.8). 
6.3.2 Urinary excretion 
Enantioselective differences 
The urinary excretion data and formation clearance values for flurbiprofen and its 
metabolites for the young volunteer group are summarised in Tables 6.9 and 6.10 
respectively (the individual data are tabulated in Appendices 13 to 15). The total amount 
of flurbiprofen and metabolites recovered in the 0-24 hour collection period was 
72.3 ± 4.6 % and these values compare favourably with previously published values of 
65 to 79 % (Szpunar et al., 1987; Cefali et al., 1991; Knadler et al., 1992a). The 
principle pathways of flurbiprofen elimination involve the formation of flurbiprofen 
glucuronide and 4'-hydroxyflurbiprofen with recovery values of 15.7 % and 46.8 % 
respectively. The 3'-hydroxy-4'-methoxy metabolite is a minor component accounting 
for only 4.2 % of the administered dose excreted in urine (Table 6.9). In general, a larger 
percentage of the dose was recovered with products having the R-configuration 
(S/R = 0.87), which is in agreement with the findings of Knadler et al. (1992a, 1992b). 
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The excretion of flurbiprofen as the acyl glucuronide demonstrated a preference 
for the R-enantiomer conjugate (S/R = 0.86; Table 6.9). This pattern is reflected in all 
four volunteers displaying higher formation clearances for (R)-flurbiprofen compared to 
(S)-flurbiprofen glucuronidation, but the difference did not reach statistical significance 
(p = 0.07; Table 6.10). It is worth noting that (R)-flurbiprofen was also predominant in 
the amount of free drug excreted (S/R = 0.89), but the difference in renal clearance 
between the enantiomers did not achieve statistical significant (p = 0.06; Table 6.1). 
Enantioselective clearance of flurbiprofen via oxidation to 4'-hydroxyflurbiprofen 
is also evident from the formation clearances, which were significantly greater for the 
metabolite derived from the R-enantiomer compared to its S-antipode (Table 6.10). The 
excretion of 4'-hydroxyflurbiprofen is primarily as conjugates and the formation of these 
metabolites displays regioselectivity and enantioselectivity. That is, conjugation of the 
4'-hydroxy metabolite favours the generation of acyl glucuronides rather than phenolic 
conjugates (ratio acyl/phenol: S= 14.9; R= 14.0) and (R)-4'-hydroxyflurbiprofen acyl- 
glucuronide rather than (S)-4'-hydroxyflurbiprofen acyl-glucuronide (S/R = 0.83; Table 
6.9). The stereoselective clearance of (R)-4'-hydroxyflurbiprofen via conjugation is also 
indicated in the formation clearances, with the R-enantiomer being cleared significantly 
faster than the antipode (Table 6.10). As with the parent drug, a modest higher urinary 
recovery (S/R = 0.92), paralleled with a higher renal clearance, is observed for the 
R-enantiomer of the nonconjugated metabolite (Tables 6.3 and 6.9). However, relatively 
high inter-subject variability in the values of these parameters for both enantiomers 
resulted in the differences not achieving statistical significance. 
Clearance of 4'-hydroxyflurbiprofen through the formation of the 3'-hydroxy-4'- 
methoxy metabolite is a minor elimination pathway and appears to lack substrate 
enantioselectivity, however higher formation clearances for the R-enantiomer were 
observed in three of the four volunteers (Table 6.10). It is noteworthy, that conjugation 
of this metabolite may display opposing regioselectivity and stereoselectivity to that of 
the 4'-hydroxy metabolite, favouring the formation of phenolic conjugates of the 
S-enantiomer (Table 6.9). 
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Table 6.9: Urinary excretion (0-24 hr) of flurbiprofen and its metabolites following the oral 
administration of the racemic drug (100 mg) to four healthy young volunteers (data expressed as a 
mean percentage of the administered dose). 
R-enantiomer S-enantiomer S/R 















2.99 ± 1.55 2.67 ± 1.55 * 0.89 
8.43±1.51 7.26± 1.03 * 0.86 
11.42±2.34 9.92±2.19 * 0.87 
5.86±2.48 5.40±2.19 0.92 
18.18±1.84 15.05±1.60* 0.83 
1.30±1.34 1.01 ± 1.18 0.78 
25.33 t 1.45 21.46 ± 0.65 * 0.85 
0.021 ± 0.030 0.024 ± 0.004 1.14 
0.029 ± 0.034 0.022 ± 0.027 0.76 
1.87±0.27 2.20±0.33 1.18 
1.92±0.30 2.24±0.37 1.17 
Total Recovery 38.67 ± 2.63 33.63 ± 2.03 * 0.87 
*p <0.05 for comparison between the means of enantiomers using Student's t-test for paired samples. 
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Table 6.10: Metabolite formation clearances (ml/min) following the oral administration of racemic 
flurbiprofen (100 mg) to four healthy young volunteers. 
(a) Flurbiprofen 
Subject acyl glucuronide 4'-hydroxyflurbiprofen 
Code R S SIR ratio R S SIR ratio 
Fyl 3.00 2.82 0.94 10.88 9.04 0.83 
Fy2 2.56 1.89 0.74 10.36 7.50 0.72 
Fy3 3.43 2.43 0.71 10.28 8.19 0.80 
Fy4 4.43 2.72 0.61 11.43 7.45 0.65 
Mean 3.36 2.47 0.75 10.74 8.05 0.75 
s. d. 0.80 0.42 0.14 0.53 0.74 0.08 
C. V. % 23.84 16.94 18.29 4.96 9.25 10.61 
p (R vs. S) * N. S. p<0.05 
(b) 4'-Hydroxyflurbiprofen 
Subject conjugate(s) 3'-h ydroxy-4'-methoxyflurbiprofen 
Code R S SIR ratio R S S/R ratio 
Fyl 93.9 39.1 0.42 13.07 7.39 0.57 
Fy2 92.6 55.1 0.60 6.99 7.63 1.09 
Fy3 105.5 50.6 0.48 11.41 7.00 0.61 
Fy4 151.1 74.3 0.49 12.33 7.79 0.63 
Mean 110.8 54.8 0.50 10.95 7.45 0.73 
s. d. 27.5 14.6 0.07 2.73 
0.34 0.25 
C. V. % 24.83 26.72 14.93 24.89 4.61 33.85 
p(R vs. S) * p<0.01 
N. S. 
* Comparison between the means for the enantiomers were carried out using Student's Nest 
for paired samples (N. S. = p>O. 05). 
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The urinary excretion data and formation clearance values for flurbiprofen and its 
metabolites for the elderly volunteer group are summarised in Tables 6.11 and 6.12 
respectively (the individual data are tabulated in Appendices 16 to 18). The total amount 
of flurbiprofen and metabolites recovered in the 0-24 hour collection period was 
60.6 ± 10.7 %. The 4'-hydroxy and 3'-hydroxy-4'-methoxy metabolites accounting for 
36.0 and 2.9 % of the administered dose excreted in urine respectively. Flurbiprofen, 
was excreted in approximately equal amounts as the free drug (11.0 %) and the acyl 
glucuronide (10.6 %; ) accounting for 21.6 % of the administered dose (Table 6.11). 
The excretion of flurbiprofen in the elderly volunteers displayed similar 
enantioselectivity to that 
greater amounts of free 
R-configuration (free S/R 
of excretion is reflected 
glucuronide formation c1e 
6.12). 
observed in the young volunteer group, with significantly 
drug and acyl glucuronide recovered in urine having the 
= 0.83, acyl glucuronide S/R = 0.79; Table 6.11). This pattern 
in (R)-flurbiprofen displaying higher values for renal and 
arances than its antipode in all four volunteers (Table 6.5 and 
Examination of the formation clearances for 4'-hydroxyflurbiprofen arising from 
oxidation of either enantiomer of the drug indicates substrate selectivity favouring 
(R)-flurbiprofen (S/R = 0.71; Table 6.12). Renal excretion of the metabolite showed the 
same preference for the R-enantiomer as observed with the parent compound (Table 
6.11). As with the young, the elimination of the 4'-hydroxy metabolite via conjugation 
favours the formation of ester-glucuronides and the R-enantiomer (Tables 6.11 and 
6.12). The clearance of 4'-hydroxyflurbiprofen via further metabolism to 3'-hydroxy-4'- 
methoxyflurbiprofen showed a distinct enantioselectivity in favour of the R-enantiomer 
(Table 6.12). However, in contrast to the young group the elimination of the 3'-hydroxy- 
4'-methoxy metabolite as phenolic conjugates appeared to have a preference for the 
R- rather than the S-enantiomer (Table 6.11). 
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Table 6.11: Urinary excretion (0-24 hr) of flurbiprofen and its metabolites following the oral 
administration of the racemic drug (100 mg) to four healthy elderly volunteers (data expressed as a 
mean percentage of the administered dose). 
R-enantiomer S-enantiomer SIR 
Analyte mean ± s. d. mean ± s. d. ratio 
Flurbiprofen 
free: 6.03 f 4.59 5.00 ± 3.86 * 0.83 
acyl-conjugate: 5.93 f 2.02 4.66 ± 1.86 * 0.79 
total 11.96 f 4.23 9.66 ± 3.29 * 0.81 
4'-Hydroxyflu rbiprofen 
free: 9.23 f 6.20 7.82 ± 5.07 0.85 
acyl-conjugate: 9.73 f 4.38 7.42 ± 3.46 *t 0.76 
phenol-conjugate: 1.03 f 1.01 0.73 ± 0.57 0.71 
total 19.99 3.40 t 15.98±2.14*t 0.80 
3'-Hydroxy-4'-methoxyflurbiprofen 
free: 0.016 ± 0.031 0.013 f 0.027 0.81 
acyl-conjugate: 0.011 ± 0.022 0.009 f 0.018 0.82 
phenol-conjugate: 1.51 ± 0.42 1.38 f 0.31 t 0.91 
total 1.53 ± 0.44 1.40 f 0.31 t 0.91 
Total Recovery 33.49 ± 6.32 27.03 f 4.42 * 0.81 
* p-value <0.05 for comparison between the means of enantiomers using 
Student's t-test for paired samples. t p-value <0.05 for 
comparison between respective means for young and elderly volunteers using 
Student's Nest for independent samples. 
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Table 6.12: Metabolite formation clearances (ml/min) following the oral administration of racemic 





S SIR ratio R 
4'-hydroxyflurbiprofen 
S SIR ratio 
Fe l 1.36 0.83 0.61 4.24 2.89 0.68 
Fe2 1.30 0.84 0.65 5.60 4.47 0.80 
Fe3 1.87 1.43 0.76 4.45 3.04 0.68 
Fe4 1.09 0.78 0.72 6.84 4.69 0.69 
Mean 1.41 0.97 0.68 5.28 3.77 0.71 
s. d. 0.33 0.31 0.07 1.20 0.94 0.06 
C. V. % 23.55 31.73 10.12 22.68 24.88 8.06 
p (R vs. S) * p<0.005 p<O. 01 
p(Y vs. E) t p<0.05 p<0.005 N. S. p<0.001 p<0.0005 N. S. 
(b) 4'-Hydroxyflurbiprofen 
Subject conjugate(s) 3'-hydroxy-4'-methoxyflu rbiprofen 
Code RS SIR ratio RS SIR ratio 
Fe l 25.7 10.9 0.42 4.05 2.03 0.50 
Fe2 32.9 21.4 0.65 5.64 3.48 0.62 
Fe3 42.0 27.0 0.64 5.29 4.04 0.76 
Fe4 32.8 13.9 0.42 4.02 3.04 0.76 
Mean 33.4 18.3 0.53 4.75 3.15 0.66 
s. d. 6.7 7.3 0.13 0.84 0.85 0.13 
C. V. % 20.02 39.92 24.13 17.64 27.01 18.99 
p(R vs. S) * p<0.005 p<0.05 
p(Yvs. E) fi p<0.01 p<0.01 N. S. p<0.05 p<0.001 
N. S. 
* Comparison between the means for the enantiomers were carried out using Student's Nest for paired samples (N. S. = p>0.05). 
fi Comparison between respective means for young and elderly volunteers were carried out using Student's t-test 
for independent 
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A lower percentage of the dose, although not statistically significant, was 
recovered over the 24 hour urine collection period in the elderly (60.5 % vs. 72.3 %) 
with the overall stereochemical composition of the total material invariant between the 
two age groups (S/R: young = 0.81 and elderly = 0.87; Tables 6.9 and 6.11). 
The recovery values of flurbiprofen showed good correlation between the two 
volunteer groups for both enantiomers (Tables 6.9 and 6.11). However, the proportion 
of recovered flurbiprofen excreted as the acyl glucuronide is reduced in the elderly 
group such that it is no longer the primary component; i. e., for the R-enantiomer: 
acyl/free = 2.8 for the young and 0.99 for the elderly, and for the S-enantiomer: acyl/free 
= 2.7 for the young and 0.93 for the elderly. 
The total recovery of both enantiomers of the 4'-hydroxy metabolite were 
significantly decreased in the elderly. This was primarily due to the considerably 
reduced presence of the acyl glucuronide of (R)- and (S)-4'-hydroxyflurbiprofen in the 
recovered material for the elderly group and it is worth noting that the phenol conjugate, 
although a minor component, was recovered to a similar extent in both age groups. In 
addition, as observed with flurbiprofen, the quantities of the enantiomers of the 
4'-hydroxy metabolite recovered nonconjugated were greater in the elderly group such 
that elimination of the metabolite in the free form was quantitatively just as important as 
acyl glucuronidation for this age group, i. e., for the R-enantiomer: acyl/free = 3.1 for the 
young and 1.05 for the elderly, and for the S-enantiomer: acyl/free = 2.8 for the young 
and 0.95 for the elderly. 
3'-Hydroxy-4'-methoxyflurbiprofen is a relatively minor metabolite, however an 
interesting age-related alteration in the enantioselective excretion of this product as its 
phenol conjugates was detected. The recovery of both (R)- and (S)-3'-hydroxy-4'- 
methoxyflurbiprofen phenolic conjugates were lower in the elderly, but the decrease was 
only significant for the S-enantiomer which resulted in a reversal of the prominent 
enantiomer in the total recovered material, i. e. S/R: young = 1.17 and elderly = 0.91 
(Tables 6.9 and 6.11). 
This pattern of age-related differences in the excretion profile is reflected in the 
corresponding renal and metabolite formation clearances. Comparison of the renal 
clearances between the young and elderly for flurbiprofen (R: young = 1.2 and elderly = 
1.4; S: young = 0.9 and elderly = 1.1 ml/min) and for 4'-hydroxyflurbiprofen (R: young 
= 34.5 and elderly = 31.8; S: young = 18.4 and elderly = 
17.8 ml/min) showed no age- 
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related differences (Tables 6.5 and 6.6). However, metabolite formation clearances were 
all significantly reduced in the elderly being between two to three fold less than the 
corresponding values in the young group (Tables 6.10 and 6.12). It is worth noting that 
these age-related alterations in urinary excretion and formation clearances are not 
associated with enantioselective changes since the S/R ratios for the various parameters 
were consistent between the two age groups, this finding mirrors a similar observation 
with the serum pharmacokinetic data. 
6.4. Discussion 
Previous studies comparing the pharmacokinetics of flurbiprofen in different age 
groups are rare and are based on non-stereospecific drug determinations. These 
investigations were also performed with participants having underlying pathological 
conditions, and the findings of these studies suggest that age has a negligible influence 
on the disposition of flurbiprofen (Hamdy et al., 1980; Kean et al., 1992). However, the 
conclusions drawn by Hamdy et al. (1980) may be misleading due to limitations in the 
experimental design, assessment of age-related alterations in pharmacokinetics were 
performed in a retrospective manner with the experimental findings compared to those 
from a previous study using young healthy volunteers. The investigations carried out by 
Kean et al. (1992) were considerably more extensive and included examination of the 
urinary recoveries of flurbiprofen and its metabolites; nevertheless, the volunteers 
selected for the younger age group had a average age of 53 years and could be 
considered to be of semi-advanced age themselves and so the findings may not truly 
reflect the situation observed with a younger age group. 
Enantioselective disposition 
The results of the present study suggest that there are age-associated differences 
in 
the disposition of flurbiprofen since a greater number of enantioselective differences 
in 
the determined pharmacokinetic parameters were observed in the elderly compared to 
the young volunteers (Tables 6.1 and 6.5). Of significant 
importance, is the lower area 
under the curve (AUC) observed for (R)-flurbiprofen compared 
to (S)-flurbiprofen in the 
elderly (R: 69.5 vs. S: 79.3 µg/ml 
hr) and the corresponding degree of enantioselectivity 
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(S/R = 1.14) is in agreement with previous studies performed with healthy volunteers 
(Jamali et al., 1988,1991; Cefali et al., 1991; Knadler et al., 1992a; Geisslinger et al.. 
1994b). Such a difference in AUC for a pair of enantiomers following the oral 
administration of the drug may be due to enantioselectivity in bioavailability, systemic 
clearance or a combination of both. However, such differences are unlikely to be 
associated with differences in the systemic availability since absorption of most drugs 
through the gastrointestinal tract is a passive process governed primarily by the physico- 
chemical properties of the drug (Rowland and Tozer, 1995) and enantio selective 
presystemic metabolism is unlikely due to the low clearance of flurbiprofen. This seems 
a reasonable conclusion since the rapid and total systemic availability of flurbiprofen 
has been reported previously suggesting complete absorption and insignificant first-pass 
metabolism (Risdall et al., 1978; Szpunar et al., 1987). Thus the significant difference 
observed in the clearance of the two drug enantiomers, i. e., the slower clearance of 
(S)-flurbiprofen in comparison to (R)-flurbiprofen in the elderly, is responsible for the 
AUC of the pharmacologically more active S-enantiomer exceeding that of its antipode. 
This, together with the greater volume of distribution of (S)-flurbiprofen, is reflected in 
the significantly longer elimination half-life (t1/2, Z) of (S)-flurbiprofen and the 
enantiomeric ratio (S/R = 1.35) is in good agreement with the corresponding ratio for the 
AUCs. 
In the young, a comparable significant enantiomeric difference was only observed 
for t112,, and it would appear that the disposition of the drug exhibits age-related 
stereo selectivity. However, AUC and CL followed similar trends in the young 
volunteers to those observed in the elderly group with (S)-flurbiprofen having a larger 
AUC and lower CL than (R)-flurbiprofen and the degree of enantioselectivity for these 
two parameters were in fact comparable between the two groups (i. e. AUC S/R: young = 
1.17 and elderly = 1.14; and CL S/R: young = 0.86 and elderly = 0.88). It is possible that 
these differences did not achieve statistical significance in the young as a consequence 
of the much greater inter-subject variability observed for the S/R ratios of AUC and 
CL 
in the young (Table 6.2 and 6.6). 
The enantioselective serum kinetics of the metabolite, 4'-hydroxyflurbiprofen, 
has 
been investigated previously; but data analysis was restricted to the determination of the 
AUC values for the individual enantiomers (Knadler et al., 
1992a). In the current study, 
urinary recovery data was used to establish the oxidative metabolite 
fraction (Foy) for 
each enantiomer, i. e. the proportion of the 
dose that undergoes oxidation to form the 
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4'-hydroxy and 3'-hydroxy-4'-methoxy metabolites, which in combination with serum 
data enabled the determination of a more complete set of pharmacokinetic parameters. It 
is worth noting that the determination of Fo, t was based on the recovery of between 50 to 
75 % of the administered dose for the volunteers and the assumption is made that any 
unrecovered dose will be eliminated without influencing the determined FO,, value. This 
is acceptable as preliminary urinary excretion studies performed previously, using three 
volunteers, demonstrated that the proportion of oxidative metabolites present in 
recovered material was essentially invariant with increasing urinary collection period 
(see Chapter 5). Examination of the determined pharmacokinetic parameters revealed 
the same enantiomeric differences in both the elderly and young age groups (Tables 6.3 
and 6.7). The predominance of (S)-4'-hydroxyflurbiprofen in serum, as indicated by 
higher AUC and Cmax values for the (S)-enantiomer in both groups, is predominately as 
a consequence of the R-enantiomer being cleared significantly faster than its antipode in 
both groups. Stereoselective formation clearance favouring the R-enantiomer has a 
comparatively minor influence on the serum profiles since formation clearances were 
typical between 14 to 20 fold less than the associated total clearances (Tables 6.3,6.7, 
6.10 and 6.12). These observations are in contrast to those of Knadler et al. (1992a) 
were a lack of stereo selectivity in the disposition of 4'-hydroxyflurbiprofen was 
suggested based on the insignificant deviation of the S/R metabolite AUC ratio from 
unity. 
The above findings indicate that enantiomeric differences in the disposition of 
flurbiprofen stem predominantly from enantioselectivity in systemic clearance. Like 
other profen drugs, flurbiprofen is cleared almost exclusively by hepatic metabolism 
(Williams et al., 1993) and the clearance of such drugs is given by: 
CL = fU. CL. (Eqn. 6.8) 
where f is the fraction of drug unbound in the plasma and CLu is the unbound or 
intrinsic metabolic clearance of the drug from plasma (Rowland and Tozer, 1995). 
Therefore, differences in total clearance between enantiomers may be due either to 
differences in unbound clearance or in protein binding. 
The binding properties of flurbiprofen enantiomers have been investigated using 
equilibrium dialysis and ultrafiltration 
in plasma from healthy volunteers (Knadler et al. , 
1989). Modest stereoselective binding was indicated with the mean percent unbound of 
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the R-enantiomer being greater than that of the S-enantiomer, this is consistent with the 
higher total clearance of (R)-flurbiprofen observed in the current investigations. 
However, inter-individual variation in the enantiomeric ratio (S/R) of the free fraction 
was considerable, varying between 1.92 and 0.75 with a mean of 0.94. Moreover, a 
recent investigation demonstrated no significant difference in the plasma binding of 
flurbiprofen enantiomers and the mean enantiomeric ratio (S/R) of 1.23 was suggestive 
of higher free fractions of the S-enantiomer rather than its antipode (Blouin et al., 1993). 
Therefore, in contrast to ibuprofen, the enantioselectivity in plasma protein binding of 
flurbiprofen is not well defined and inter-individual variations in the enantiomeric ratio 
may be an important source of variability in the degree of stereoselectivity in disposition 
which could conceivably be responsible for a reversal in stereoselectivity in some 
individuals. 
To identify the principle pathways of flurbiprofen elimination, urinary recovery 
studies were performed and formation clearances determined for the metabolites to 
establish the relative contributions of the pathways to the overall enantioselectivity 
observed in the total clearance. Examination of the urinary excretion data indicates that 
the principle metabolites of flurbiprofen are 4'-hydroxyflurbiprofen and the glucuronide 
conjugate (Tables 6.9 and 6.11). The 4'-hydroxy metabolite is cleared predominantly in 
the form of the acyl glucuronide and further oxidation and methylation to yield 
3'-hydroxy-4'-methoxyflurbiprofen appears to be a comparatively minor elimination 
route. The preferential elimination of products with the R-configuration is reflected in 
the predominance of "R metabolites" recovered in the urine for both age groups; 
however in the young age group, the 3'-hydroxy-4'-methoxy metabolite, which accounts 
for only 4% of the dose, is excreted to a larger, but not significant, extent in the S-form. 
The formation clearance associated with oxidation to 4'-hydroxyflurbiprofen, as 
would be expected, shows substrate enantioselectivity favouring (R)-flurbiprofen in both 
the young and elderly groups (Tables 6.10 and 6.12). Such differences could clearly be 
caused by inherent stereoselectivity in functional oxidation, however this appears 
unlikely in this case since the mean S/R ratio for the oxidative metabolite 
fraction (F0X) 
were equal to unity for both age groups (Tables 
6.2 and 6.6). Furthermore, in vitro 
experiments carried out in order to characterise the 
kinetic parameters for the oxidation 
of (R)- and (S)-flurbiprofen, using 
human liver microsomes, highlighted a lack of 
stereoselectivity (Tracy et al., 1995). 
These studies, indicated that the enantiomers of 
flurbiprofen may exhibit stereoselectivity with respect to enzyme affinity 
(Km, R: 3.1 vs. 
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S: 1.9 µM) but have similar maximum formation velocities (Vm, R: 305 vs. S: 343 
pmol/min/mg protein) and with the racemate, enantiomer-enantiomer interactions 
results in decreased K,,, and V,,, for both enantiomers and an apparent loss of 
stereo selectivity. 
The formation clearances of flurbiprofen acyl glucuronide and 4'-hydroxy- 
flurbiprofen acyl glucuronide also displayed a preference for the R-enantiomers (Tables 
6.10 and 6.12). These findings show good correlation with in vitro data that indicates 
glucuronidation of flurbiprofen favours the R-enantiomer (Hamdoune et al., 1995). 
However, these findings must be interpreted with caution since it is also clear that 
enantioselective hydrolysis of acyl glucuronides may occur in tissue, plasma or both 
(Faed, 1984; Knadler and Hall, 1991). The formation clearances associated with acyl 
glucuronides must, therefore, be considered as net clearances reflecting a balance 
between formation and hydrolysis, which may in turn reflect the rate of elimination of 
the conjugate (Faed, 1984). 
However, having said that, the degree of enantioselectivity (i. e. S/R ratio) showed 
very little difference between the clearance of flurbiprofen via glucuronidation or 
oxidation in both age groups (Tables 6.10 and 6.12). This would suggest that modest or 
no enantioselectivity is observed in the metabolic processes and that enantioselectivity 
in protein binding, favouring a higher free fraction of (R)-flurbiprofen, is of greater 
significance. In contrast with 4'-hydroxyflurbiprofen, greater enantioselectivity was 
observed for elimination of the metabolite via conjugation than through further 
oxidation. This could possibly be as a consequence of a more prominent substrate 
enantioselectivity for the formation of the acyl glucuronide of the R-enantiomer being 
observed with 4'-hydroxyflurbiprofen than the parent drug. 
Age-associated differences 
Major age-related differences in the disposition of flurbiprofen appear to originate 
from a general reduction in clearance of the drug in the elderly and are observed with 
both enantiomers. The systemic clearances of (R)- and (S)-flurbiprofen in the elderly are 
62 % and 63 % respectively of the corresponding clearances in the young, and 
consequently the elderly have significant higher values 
for AUC (R: 69.5 vs. 42.3; S: 
79.3 vs. 49.5 µg/ml hr) and terminal elimination 
half lives for both enantiomers (R: 7.1 
vs. 4.5; S: 9.6 vs. 5.2 hr; Tables 
6.1 and 6.5). Similar age-related differences were 
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observed in the serum kinetics of the enantiomers of 4'-hydroxyflurbiprofen, the major 
metabolite (Tables 6.3 and 6.7). 
Such differences in the disposition of a low extraction drug such as flurbiprofen 
could be clearly be associated with age-related alterations in protein binding; however, 
in vitro studies have shown that the plasma protein binding of racemic flurbiprofen in 
elderly volunteers (>_ 65 years old) is not significantly different from normal subjects 
(Knadler et al., 1989). Moreover, if any age-related alterations in protein binding do 
occur then unbound fractions are likely to increase rather than decrease, with or without 
associated changes in stereoselectivity, since increasing age is associated with a 
decrease in serum albumin concentration (Wallace and Verbeeck, 1987; Woodhouse 
and Wynne, 1987). 
It is therefore likely that age-related changes in other factors alternate to protein 
binding, such as in renal function and/or drug metabolising capacity of the liver, play a 
more prominent role in the observed differences in flurbiprofen disposition between the 
two age groups. The reduced urinary recoveries of the total oxidative and conjugated 
metabolites in the elderly, but with concurrent higher recoveries of flurbiprofen and 
4'-hydroxyflurbiprofen in the free form suggest that reduced metabolic activity rather 
than a general decrease in renal elimination is the principle cause (Tables 6.9 and 6.11). 
Furthermore, the decreased elimination via oxidation and conjugation pathways is 
reflected in all the metabolite formation clearances being significantly lower in the 
elderly group (Tables 6.10 and 6.12). It is also worth noting that renal clearances of the 
enantiomers of flurbiprofen and 4'-hydroxyflurbiprofen displayed no age-related 
alterations (Tables 6.1,6.3,6.5 and 6.7). 
The affect of age on the drug metabolising capability of the liver is not well 
defined and the subject of much contention (Woodhouse and Wynne, 1987). The major 
physiological changes that occur with age which may influence hepatic drug elimination 
include an absolute (and relative to body weight) decrease in the size of liver and 
reduced regional blood flow to this organ (Kinirons and 
Crome, 1997). Results from in 
vitro studies have indicated that flurbiprofen oxidation to 
4'-hydroxyflurbiprofen is 
predominately mediated by cytochrome P450 
2C9 (CYP 2C9) (Tracy et al., 1996) and 
age related studies have indicated that generally clearance via 
CYP mediated 
metabolism is reduced in the elderly, which 
is consistent with our findings (Sotaniemi et 
al. 1997, Hammerlein et al., 1998). 
However, the effect of age on phase II metabolic 
reactions such as glucuronidation and methylation 
has not been the subject of extensive 
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research, but it has been suggested that glucuronidation is not generally affected by 
ageing (Mooney et al., 1985). The decreased clearance of ketoprofen in elderly 
volunteers, a drug principally eliminated via the formation of an acyl glucuronide, has 
been reported previously (Advenier et al., 1983; Dennis et al., 1985). Although, whether 
such changes were associated with decreased glucuronidation were not established. 
The decreased elimination of flurbiprofen via the oxidation and acyl 
glucuronidation pathways in the elderly appear not to be associated with stereoselective 
changes as indicated by the invariance of corresponding S/R ratios for metabolites 
recoveries between the two groups. This suggests that the oxidation and glucuronidation 
reactions are most probably carried out using single respective isoenzymes and any 
possible age-related alteration in protein binding is not expected to show 
stereoselectivity. However, in the case of the minor metabolite, 3'-hydroxy-4'- 
methoxyflurbiprofen, there appears to be a reversal in the stereoselectivity of 
elimination with age. i. e. the 3'-hydroxy-4'-methoxy metabolite is predominately 
excreted as phenolic conjugates of the S-enantiomer in the young and the R-enantiomer 
in the elderly. It is possible that phenolic conjugation of 3'-hydroxy-4'-methoxy- 
flurbiprofen to form either ether glucuronides and/or sulphate conjugates display 
opposing enantioselectivity such that the reduction in clearance with age is also 
associated with a change in the ratio of conjugation via the two pathways which results 
in a reversal in overall conjugation stereoselectivity. 
6.5. Conclusions 
Modest stereoselective differences were observed in the pharmacokinetics of the 
enantiomers of flurbiprofen following the administration of the racemic drug to healthy 
elderly volunteers. Enantiomeric differences in total clearance, favouring the faster 
elimination of the R-enantiomer (S/R = 0.88), resulted in higher values for AUC and 
tI i2, Z for the pharmacologically more potent 
(S)-flurbiprofen. In the young group, a 
similar statistical significant difference was seen for the ti/2, z, and comparable trends in 
AUC and CL were observed but did not reach statistical significance as a result of the 
greater inter-subject variation in enantioselectivity for these parameters. The primary 
pathway for flurbiprofen elimination is oxidation to form 4'-hydroxyflurbiprofen which 
accounted for about 36 % and 47 % of the recovered dose in the elderly and young 
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groups respectively. The same enantioselective differences in the serum kinetics of this 
metabolite were noticed in both age groups. Like the parent compound, enantioselective 
clearance of (R)-4'-hydroxyflurbiprofen was primarily responsible for the differences 
observed in AUC, tli2, Z and Cmax between the enantiomers. As would be expected there 
was a predominance of products with the R-configuration in urine and this pattern is 
reflected in the metabolic formation clearances which all displayed substrate 
stereo selectivity in favour of the R-enantiomer. 
Age-related differences were observed in the disposition of flurbiprofen largely as 
a consequence of the reduced clearance of the drug in the elderly. The reduced clearance 
is not associated with enantioselective alterations and thus similar age-related 
differences are observed for both enantiomers. Age-related decrease in hepatic function 
appears to be the primary cause resulting in reduced elimination via metabolism. The 
major outcome is that the elderly have greater exposure to the drug, as reflected by the 
AUCs for the enantiomers of flurbiprofen being approximately 60 % higher in this age 
group in comparison to the young; such differences could have major pharmacological 
and toxicological implications for the use of the drug in the elderly. 
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CHAPTER 7: 




General discussion and conclusions 
The prevalence of rheumatic diseases increases progressively with advancing age. 
Data from an interview survey indicate that self-reporting of arthritis by individuals 
living in the community increases from 337 per 1,000 among those aged between 55 to 
64 to nearly 600 per 1,000 for those aged 85 and older (Cohen and von Nostrand, 1995). 
Non steroidal anti-inflammatory drugs (NSAIDs) remain the mainstay of treatment for 
many rheumatic conditions, and the use of these agents is greatest in the elderly 
population; it has been estimated that 10% to 15% of those aged 65 and older take 
prescribed NSAIDs (Ray et al., 1993) and there may be a similar, if not greater, 
percentage using these medications "over the counter". 
Of increasing concern in recent years has been the adverse effects associated with 
the use of NSAIDs and this has been the subject of numerous epidemiological studies. A 
recent extensive meta-analysis, combining data from 49 different studies, indicated that 
on average 1 in 1200 patients taking NSAIDs for at least two months will die from 
gastrointestinal complications who would not have died had they not taken NSAIDs 
(Tramer et al., 2000). These calculations clearly suggest that chronic oral NSAIDs pose 
a substantial risk of death from gastrointestinal complications and could be responsible 
for 2000 deaths each year in the UK (Tramer et al., 2000). It is also generally accepted 
that the elderly are more prone than younger patients to the toxic effects of NSAIDs 
(Henry et al., 1993; Garcia Rodriguez and Jick, 1994; Wolfe et al., 1999), although few 
data exists to suggest that advanced age is an independent risk factor. However, the 
severity of the problem, together with its associated costs, has been highlighted in the 
study carried out by Cunningham et al. (1997), which demonstrated that NSAIDs were 
responsible for 28% of all drug related problems requiring hospitalisation of elderly 
people over a 9-month study period. 
The studies described in this thesis were stimulated by the following question: 
"Are the elderly at greater risk of NSAID-related adverse effects due to alterations in the 
disposition of NSAIDs in this population? ". Surprising there has been a scarcity of 
dispositional studies on NSAIDs designed to examine the influence of ageing and the 
limited data available is plagued by inconsistent findings. Furthermore, the majority of 
these studies have been of limited scope and not attempted 
to obtain a comprehensive 
picture of the disposition of the 
NSAID via different pathways or considered 
stereochemical aspects in the case of chiral 
NSAIDs. Ibuprofen and flurbiprofen are two 
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important chiral 2-arylpropionic acid derivatives used clinically as NSAIDs almost 
exclusively in their racemic form. Following the development and validation of 
appropriate stereospecific methodologies for the bioanalysis of these two NSAIDs and 
their major metabolites, the enantioselective disposition of the racemic drugs were 
investigated in the young and elderly to gain a clearer understanding of the influence of 
ageing. 
7.2. Stereospecific bioanalysis 
The various stereospecific analytical methods developed for the quantitative 
analysis of ibuprofen, flurbiprofen and their metabolites can be broadly categorised into 
two different chromatographic approaches: (a) indirect separation on an achiral reversed 
phase system following pre-column derivatization with the homo-chiral derivatizing 
reagent (HCDA), (R)-1-(naphthen-l-yl)ethylamine (NEA); or (b) direct separation on a 
polysaccharide CSP, i. e either cellulose tris(3,5-dimethyl phenylcarbamate) (Chiralcel 
OD) or amylose tris(3,5-dimethylphenylcarbamate) (Chiralpak AD), via normal phase 
HPLC. 
7.2.1 Indirect approach 
The indirect approach was adopted for the analysis of ibuprofen enantiomers in 
serum and urine, with a conventional, cheap and highly efficient reversed phase C18 
column used for the resolution of the fluorescent diastereomeric amides formed on 
reaction with (R)-NEA (Chapter 2). Derivatization was performed using CDI and HOBT 
as coupling reagents; which although required relatively long reaction times, was 
essentially quantitative and did not pose racemisation problems like those encountered 
with the mixed anhydride derivatization method (Hutt et al., 1994). 
The commercial availability of both enantiomers of NEA in high enantiomeric 
purity offers the flexibility to control the order of elution. In a reversed phase system, 
using (R)-NEA as the HCDA results in the diastereomeric amide derivative of 
(R)-ibuprofen eluting before that of (S)-ibuprofen and when (S)-NEA is used the elution 
order is reversed. For the assay methods, (R)-NEA was selected as the HCDA so that the 
(R)-ibuprofen derivative eluted first since (R)-ibuprofen concentrations were expected to 
be lower than those of the S-enantiomer in serum, and earlier elution would reduce the 
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effects of band broadening on a smaller peak and hence increase analytical sensitivity. It 
is also noteworthy, that under normal phase conditions, the order of elution is again the 
opposite of that for the reversed phase system (Hutt et al., 1994; Tan et al., 1999). 
A major drawback of the indirect approach, especially if a strong fluorophore or 
chromophore such as (R)-NEA is used, is that the excess chiral amine when injected 
onto the HPLC column will result in a large reagent peak that inevitably causes 
interference problems. Therefore a silica solid-phase extraction procedure was employed 
after derivatization, with the acidic silanol groups scavenging the unreacted amine 
whilst allowing the passage of the neutral diastereomeric amides. 
On the other hand, the fluorogenic properties of the naphthyl moiety allows for the 
use of a fluorescence detector and thus affords additional sensitivity. Comparison of the 
sensitivity, in terms of the minimal quantifiable limit, with those previously reported; 
indicates that the assay method used is more sensitive than those bioanalytical HPLC 
procedures based on CSPs (Nicoll-Griffith et al., 1988; Geisslinger et al., 1989; Li et 
al., 1993; Naidong and Lee, 1994; de Vries et al., 1994), equally if not more sensitive 
than those based on indirect approaches with UV detection (Lee et al., 1984; Avgerinos 
and Hutt, 1987; Mehvar et al., 1988) and equally sensitive with the methods based on 
fluorescence detection (Lemko et al., 1993; Lau, 1996). Furthermore, the comparatively 
long analysis time of the method used, is compensated by superior resolution 
characteristics and less peak interference from co-extracted endogenous substances than 
was evident for the methods cited in the literature. 
The general applicability of the approach for the indirect resolution of other chiral 
2-arylpropionic acids was also suggested. Using the same column and with adjustments 
in the mobile phase flow rate, the (R)-1-(naphthen-l-yl)ethylamide diastereomeric pairs 
for flurbiprofen and it's two major metabolites, 4'-hydroxyflurbiprofen and 3'-hydroxy- 
4'-methoxyflurbiprofen, could all be successfully baseline resolved as indicated by 
resolution factors greater than 2.0 (Chapter 4). In addition, a modest modification of the 
mobile phase composition would have allowed all three compounds to be analysed in a 
single chromatographic run. However, this was not attempted since the use of 
fluorescence detection exposed a major disadvantage of the indirect approach with the 
pair of derivatives formed for each analyte, 
in this case, displaying differential detector 
responses. The significant nature of the 
differences, with the peak area ratios for the 
diastereomeric pairs ranging from 0.35 to 0.82, rendered the approach 
inappropriate for 
application in quantitative analysis. 
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7.2.2 Direct approach 
The polysaccharide CSPs based on the tris(3,5-dimethylphenylcarbamate) 
derivative of cellulose (Chiralcel OD) and amylose (Chiralpak AD) show excellent 
enantioselectivity and have the ability to resolve a wide range of racemates having a 
variety of functional groups (Yashima and Okamato, 1997; Okamato and Yashmima, 
1998). However, their application in bioanalytical studies have been rather restricted 
because the columns are used under normal phase condition which necessitates the 
transfer of the analytes from the aqueous biological matrix to an organic phase prior to 
analysis. The presence of trace amounts of water may have detrimental effects by 
swelling or dissolving the polysaccharide-coat and any co-extracted endogenous 
material, which is likely to be strongly retained on the silica support, may cause even 
further damage. Thus for routine use in bioanalysis, the sample work-up procedure is 
critical to ensure the long-term stability, efficiency and selectivity of these costly CSP 
columns. 
Previous investigations on the enantiomeric resolution of 2-arylpropionic acids 
using Chiralcel OD and Chiralpak AD CSPs indicate that they have different chiral 
recognition properties since ketoprofen, flurbiprofen and tiaprofenic acid were only 
resolved on the Chiralpak AD column (Okamoto et al., 1989). Consistent with such 
observations, was our ability to resolve the enantiomers of ibuprofen successfully using 
the Chiralcel OD column (Chapter 2) but not with the Chiralpak AD phase (unpublished 
observations). Okamoto and Yashmina (1998) attributed the difference in chiral 
recognition ability between the two CSPs to the differences in their higher order 
structure. Possible structures are left-handed 3/2 and 4/1 helical chain conformations for 
tris(3,5-dimethylphenylcarbamates) of cellulose and amylose respectively (Okamoto and 
Yashmina, 1998). 
The direct resolution of ibuprofen enantiomers on the Chiralcel OD column was 
applied in methodology, using equilibrium dialysis and radiolabelled racemic ibuprofen, 
for the determination of unbound enantiomer concentrations in serum. Essentially, the 
individual enantiomer eluate fractions were collected, following isolation of ibuprofen 
from post-dialysis serum or buffer, for radiochemical analysis. Sample preparation was 
a simple one-step extraction procedure, which was deemed acceptable since only small 
aliquots of serum were used and the buffer samples, although of 
larger volume, were 
expected to be relatively free of contaminants. The use of radiolabelled 
drug is essential 
for the sensitive detection of enantiomeric differences at extremely 
low concentrations 
233 
Chapter 7 General discussion and conclusions 
and by using the direct chromatographic separation procedure, sample manipulation is 
considerably less than in previous methods employing the indirect approach (Evans et 
al., 1989; Tan et al., 1997a) and thus analyte loss and potential sources of error are kept 
to a minimum. 
In contrast to the parent drug, baseline resolution of both enantiomers of 
hydroxyibuprofen and for all four stereoisomers of carboxyibuprofen was achievable by 
use of the Chiralpak AD CSP (Chapter 2). However, the stereospecific analysis of these 
metabolites in urine was performed using a sequential achiral-chiral chromatographic 
approach to ensure that only "clean" samples were introduced into the Chiralpak AD 
column. The additional chromatographic step thus eliminated the need for a 
sophisticated sample purification procedure. This assay method had lower limits of 
quantification than the other reported chromatographic method, which was based on the 
indirect approach requiring the formation of (S)-1-phenylethylamide derivatives (Rudy 
et al., 1990). The throughput of the procedure could potentially be improved by column 
coupling and on line automation. With the use of a switching valve, the eluate fractions 
from the normal phase column containing the analytes can be diverted onto the CSP 
without detriment to chromatographic resolution since the mobile phases are similar, the 
only difference is that the proportion of ethanol in the mobile phase increases from 1.8% 
v/v to 8% v/v. Hence, diverting 1-2 ml of the achiral mobile phase onto the CSP should 
not influence resolution as there would be a concentration effect on the chiral column 
resulting in peak sharpening. 
The successful resolution of the enantiomers of 4'-hydroxyflurbiprofen and 
3'-hydroxy-4'-methoxyflurbiprofen on the Chiralpak AD CSP is a further indication of 
its versatility (Chapter 4). Unlike alternative CSPs such as those based on proteins, 
polysaccharide columns have a relatively high loading capacity so that large amounts of 
material could be injected on-column without appreciable loss of resolution. This 
coupled with the better than baseline resolution for these two flurbiprofen metabolites 
enabled on-column injections of up to 400 µg of racemic material. 
In this manner 
milligram quantities of the individual enantiomers could 
be isolated from the analytical 
column which allowed the chiroptical properties of the 
individual enantiomers of both 
compounds to be recorded for the first time. However, the assignment of stereochemical 
configurations using circular dichroism proved 
be more difficult than previously 
experienced with other 2-arylpropionic acids 
(Tan et al., 1997c; Hoult et al., 1999). This 
was primarily due to interference of the electronic 
transitions of the carboxyl group by 
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biphenyl-related signals, with the composite nature of the CD spectra further 
complicated by the influence of solvent and substitution on the biphenyl ring system. 
The assigned stereochemistry, which indicated that the elution order on the CSP was 
R- before the S-enantiomer for both metabolites, was subsequently confirmed by the 
analysis of urine extracts following the administration of the individual enantiomers of 
flurbiprofen to a healthy volunteer. 
The ability to separate and resolve the enantiomers of these metabolites and those 
of flurbiprofen together on the Chiralpak AD CSP within an acceptable run time, was 
appropriate for adaptation into an analytical method for the determination of both the 
drug and two major metabolites in urine (Chapter 5). To ensure the practicality of the 
approach for routine bioanalysis, a one-step extraction procedure was utilised which 
compromised optimal analyte recoveries to assure the CSP was exposed to 
"contaminant-free" extracts. Furthermore, simultaneous quantification of the analytes 
over differing concentration ranges was only made possible by the use of a dual, UV and 
fluorescence, detection method. A more sophisticated approach was also necessitated to 
quantify the conjugates than was used in the urine assay methods for ibuprofen and its 
metabolites, since the oxidative metabolites of flurbiprofen undergo conjugation of the 
phenolic hydroxyl in addition to acyl glucuronidation. For this purpose, an enzymatic- 
base hydrolysis combination method was employed, in addition to a base hydrolysis 
procedure. The serum assay method was confined to the analysis of the enantiomers of 
flurbiprofen and the 4'-hydroxy metabolite and so only required the use of fluorescence 
detection. However, the presence of interfering material in volunteer serum extracts, 
which was most likely to be drug-related, necessitated alteration in the mobile phase 
composition and the use of an alternative internal standard. 
7.3. Stereoselective disposition of ibuprofen and flurbiprofen 
Both ibuprofen and flurbiprofen demonstrated enantioselective disposition in 
humans, with the major enantiomeric differences for each drug evident in both the 
young and elderly (Chapters 3 and 6). However, comparison of the pharmacokinetic 
parameters of the two drugs clearly indicates that enantioselectivity 
in disposition is 
more apparent for ibuprofen than 
for flurbiprofen (Table 7.1). These differences in 
235 
Chapter 7 General discussion and conclusions 
enantiomeric disposition are primarily associated with enantioselectivity in plasma 
protein binding and/or metabolism of the drug. 
Table 7.1: Pharmacokinetic parameter ratios (SIR) based on total serum concentrations, 
following the oral administration of racemic ibuprofen (400 mg) or racemic flurbiprofen (100 mg) 
to healthy young volunteers t. 
Parameters Enantiomeric ratio (SIR) 
ibuprofen (n=8) flurbiprofen (n=4) 
Cmax 0.99 0.96 
Tmax 1.12 1.46 
tl/2, z 1.50 * 1.15 
AUC 1.28 * 1.17 
CL 1.27 * 0.86 
Vd 2.04 * 0.99 
% Unbound 2.09 * N. D. 
* p-value <0.05 for comparison between the means of enantiomers using Student's t-test for paired samples. 
t N. D. = not determined. 
7.3.1 Plasma protein binding 
The plasma protein binding of ibuprofen was shown to be extensive and 
stereoselective in favour of the R-enantiomer, with percentage unbound fractions of 
0.22% and 0.46% for (R)- and (S)-ibuprofen respectively following the administration of 
the racemic drug to young volunteers. The confinement of ibuprofen to the systemic 
circulation due to its high plasma protein binding results in typically low values for 
volume of distribution (Vd) for the enantiomers. The significantly greater apparent Vd 
for (S)-ibuprofen is indicative of its higher free levels; this enantioselectivity is lost 
when volume of distributions are based on unbound serum concentrations (Va) 
(Chapter 3). A characteristic feature of most NSAIDs is that they have a low hepatic 
extraction ratio, that is the intrinsic clearance of the drug is small relative to hepatic 
blood flow and only the unbound drug presented to the liver is available for clearance 
(Lin et al., 1987). Thus clearance of each ibuprofen enantiomer 
is directly proportional 
to their respective free fractions in the plasma, and so 
(S)-ibuprofen having a greater 
clearance than the R-antipode 
is primarily reflective of its lower association with plasma 
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protein. This central importance of protein binding is further emphasised when it is 
considered that unbound clearance displays opposite enantioselectivity to total 
clearance, i. e. shows preference for the R-enantiomer (Chapter 3). 
Investigations into the stereoselective protein binding of flurbiprofen were not 
performed during the course of these studies due to the non-availability of a 
radiolabelled form of the drug. The development of a method based on an alternative, 
non-radiochemical, detection approach was deemed unlikely to afford an acceptable 
degree of sensitivity, considering the serum concentrations of flurbiprofen were 
comparatively low due to the smaller administered dose, e. g. Cn, ax values for 
flurbiprofen enantiomers were approximately half those of the ibuprofen enantiomers. 
Previous, in-vivo studies have highlighted the extensive nature of the protein binding of 
flurbiprofen but painted an inconsistent picture with regards to enantioselectivity, each 
report suggesting modest preference for the opposing enantiomer (Knadler et al., 1989; 
Blouin et al., 1993). However, ex vivo determinations for healthy volunteers and 
ureamic patients both indicate that (S)-flurbiprofen is more tightly bound, with a mean 
enantiomeric ratio (S/R) of the free fraction of 0.87 and 0.81 in the two groups 
respectively (Knadler et al., 1992a, 1992b). It is noteworthy, that the enantiomeric ratios 
(S/R) for total clearance, having values of 0.86 and 0.88 for the young and elderly 
volunteers respectively in the present study, display close correlation to such degrees of 
enantioselectivity in protein binding. Therefore in comparison to ibuprofen, it would 
appear that enantioselectivity in protein binding of flurbiprofen is more modest and 
favours the opposite enantiomer of the drug. The limited difference in the protein 
binding of the flurbiprofen enantiomers is further suggested by the closeness of the 
enantiomeric ratio of Vd, based on total concentrations, to unity (Table 7.1). 
7.3.2 Metabolism 
A major difference in the disposition of the two drugs in humans, and primarily 
responsible for ibuprofen exhibiting greater enantioselectivity 
in its pharmacokinetics, is 
the metabolic inversion of (R)-ibuprofen to (S)-ibuprofen. 
The administration of the 
individual enantiomers of flurbiprofen to a volunteer 
during the preliminary 
investigations reported within this thesis did not result 
in the formation of their 
antipodes, indicating that chiral 
inversion of flurbiprofen does not occur to significant 
extent (Chapter 5). An observation 
in agreement with data reported in the literature 
(Jamali et al., 1988; Geisslinger et al., 
1994b). In contrast, the significance role played 
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by the chiral inversion reaction in the disposition of ibuprofen can be appreciated when 
it is considered that the unbound clearance of (R)-ibuprofen via inversion was 
approximately two-fold that by non-inversion pathways and equal to the unbound 
clearance of (S)-ibuprofen (Chapter 3). 
Like most 2-arylpropionic acid drugs, ibuprofen and flurbiprofen are excreted 
predominately in urine and mainly in the form of metabolites, i. e. the liver is the major 
organ involved in the elimination of the parent drug, while the kidneys are primarily 
responsible for the excretion of the products (Table 7.2). A common metabolic pathway 
for both drugs is conjugation of the carboxylic acid functional group to form acyl 
glucuronides. However, quantitatively the major route of elimination is oxidation; 
ibuprofen is metabolised in the iso-butyl side group to form hydroxy- and 
carboxyibuprofen and flurbiprofen undergoes aromatic oxidation to produce 
4'-hydroxyflurbiprofen. These oxidative metabolites also undergo phase II metabolism 
and all display a preference for glucuronic acid conjugation in the propionic acid side 
chain rather than conjugation at the introduced functional group. The 4'-hydroxy 
metabolite of flurbiprofen also undergoes further oxidation followed by methylation to 
yield 3'-hydroxy-4'-methoxyflurbiprofen, although this is only a minor elimination 
pathway (Table 7.2). 
Clearance of ibuprofen via the oxidation and glucuronidation metabolic pathways, 
exhibited substrate selectivity in favour of the S-enantiomer which was as result not only 
of the stereoselective protein binding but also inherent stereoselectivity in the metabolic 
pathways. The degree of enantioselectivity was quite varied between different metabolic 
pathways with the most marked effect noted for the formation of ibuprofen glucuronides 
(Table 7.2). Stereoselective clearance of flurbiprofen via oxidation and glucuronidation 
was also evident; however in this case, the enantiomeric differences were relatively 
modest and preference was for the R-enantiomer of the drug rather than 
its S-antipode. 
However, the magnitude of the enantioselectivity was not dissimilar between the two 
pathways and was comparable to the enantioselective ratios 
for the unbound fractions 
quoted above from previous dispositional studies. 
Therefore, it would appear that the in 
vivo metabolic fate of flurbiprofen, 
in contrast to ibuprofen, is not associated with 
significant enantioselectivity at the 
level of enzymatic oxidation and glucuronidation. 
The lack of enantiomeric differences in the oxidation of 
flurbiprofen is further suggested 
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by the relatively small deviation of the mean S/R ratio for the oxidative metabolite 
fraction (Fo,, ) from unity in both age groups (Chapter 6). Furthermore, in vitro 
investigations of the oxidative metabolism of flurbiprofen enantiomers are in agreement 
with these findings, suggesting a lack of stereo selectivity (Tracy et al., 1995). Similar in 
vitro studies of the glucuronidation of flurbiprofen, however, do suggest that the 
conjugation pathway is stereoselective in humans (Hamdoune et al., 1995); but 
application of such information to the clinical situation must be done with caution due 
to the unstable nature of the formed acyl glucuronides and thus the possible significance 
of stereoselective in vivo hydrolysis (Knadler and Hall, 1991). 
Table 7.2: Urinary excretion data (0-24 hr) following the oral administration of racemic 
ibuprofen (400 mg) or racemic flurbiprofen (100 mg) to healthy young volunteers. 
Urinary recovery (0-24 hr) 
Metabolite % of the dose ratio (SIR) 
Ibuprofen (n=8) 
free 1.02 15.5 
acyl glucuronide 11.1 11.5 
hydroxyibuprofen t 21.2 5.4 
carboxyibuprofen t 39.4 4.3 
Total 72.7 5.2 
Flurbiprofen (n=4) 
free 5.7 0.89 
acyl glucuronide 15.7 0.86 * 
4'-hydroxyflurbiprofen t 46.8 0.85 * 
3'-hydroxy-4'-methoxyflurbiprofen t 4.2 1.17 
Total 72.4 0.87 * 
* p-value <0.05 for comparison between the means of enantiomers using 
Student's Nest for paired samples 
total metabolite quantities, i. e. free plus conjugated. 
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7.4. Age-related alterations in the disposition of ibuprofen and 
flurbiprofen 
Ageing is a natural phenomenon associated with changes occurring at the basic 
cellular level, leading to altered physiological responses and a general decline in the 
function of major organs. These changes will affect the ability of the body to handle 
administered drugs and thus have the potential to cause alterations in both the 
pharmacokinetic and pharmacodynamic profiles of the drug in the elderly. Some of the 
physiological changes produced by ageing which may have important implications for 
altered pharmacokinetics are presented in Table 7.3. 
Table 7.3: Age-related physiological changes which have the potential to influence 
pharmacokinetic parameters. 
process factor effect 
Absorption gastic acid production reduced 
gastrointestinal blood flow reduced 
gastrointestinal motility reduced 
gastric emptying rate reduced 
Distribution body mass reduced 
proportion of body fat increased 
proportion of body water reduced 
plasma albumin reduced 
al-acid glycoprotein increased 
Metabolism liver mass reduced 
hepatic blood flow reduced 
hepatic metabolic capacity reduced 
Excretion glomerular filteration rate reduced 
renal plasma flow reduced 
renal tubular secretion reduced 
filteration fraction increased 
(Adapted from Cromarty, 1985; Dawling and Crome, 
1989; Hammerlein et al., 1998) 
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Advancing age appears to have an influence on the disposition of both ibuprofen 
and flurbiprofen; however, the nature of the changes are considerably different between 
the two drugs (Table 7.4). With regard to ibuprofen, age-related differences were only 
evident for the S-enantiomer. In comparison, ageing had an effect on both flurbiprofen 
enantiomers with the alterations being more marked than for (S)-ibuprofen, the extent of 
the changes were indifferent between the two enantiomers indicating that ageing has no 
influence on the enantioselectivity of flurbiprofen disposition (Table 7.4). As would be 
expected, of all the factors listed in Table 7.3, altered serum albumin binding and 
metabolic activity are the primary determinants of these age-related changes in drug 
disposition. 
Table 7.4: Effect of age on pharmacokinetic parameters, based on total serum concentrations, 
following the oral administration of racemic ibuprofen (400 mg) or racemic flurbiprofen (100 mg) 
to healthy young and elderly volunteers t. 
Ratio (elderly/young) 
Parameters ibuprofen flurbiprofen 
R -isomer S-isomer R-isomer S-isomer 
Cmax 1.03 0.88 * 1.21 1.20 
Tmax 0.69 0.62 1.44 0.96 
t1/2, z 1.13 1.38 
* 1.58 * 1.85 
AUC 1.25 1.07 1.64 * 1.60 
CL 0.81 0.96 0.62 * 0.63 
Vd 0.92 1.28 0.97 1.17 
% Unbound 1.00 1.15 * N. D. N. D. 
* p-value <0.05 for comparison between respective means for young and elderly volunteers using Student's t-test for indepedent 
samples. 
tn=8+8 for ibuprofen and 4+4 for flurbiprofen; N. D. = not determined. 
7.4.1 Plasma protein binding 
Ageing was associated with a significant stereoselective displacement of 
ibuprofen from binding sites on plasma protein leading to a 15% increase in the 
unbound fraction of the S-enantiomer with no concomitant change 
in the binding of the 
R-antipode (Table 7.4). In contrast, the binding of racemic flurbiprofen to plasma 
protein has been shown to be indifferent 
between healthy young and elderly volunteers 
(Knadler et al., 1989). The lack of significant age-related alterations 
in the free fraction 
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of flurbiprofen is also indicated in the present study by the comparatively minor 
differences in the Vd for the enantiomers between the two age groups. The observation 
that clearances were reduced to a similar extent for both enantiomers of flurbiprofen, 
rather than increased, in the elderly is further supportive of a lack of significant age 
related alteration in binding since any decrease in the serum levels of albumin with age 
is more likely to encourage higher free fractions and greater clearance of the drug. It is 
not surprising that the binding characteristics of flurbiprofen are not altered with age, 
since it has greater affinity for serum albumin, which is apparent when it is considered 
that unbound fractions of flurbiprofen are typically one order of magnitude less than 
those of ibuprofen (Evans et al., 1989; Knadler et al., 1989). 
7.4.2 Metabolism 
As ageing is associated with decreased liver perfusion and mass, hepatic 
metabolism would be expected to be reduced, this is reflected by the diminished 
clearance of both ibuprofen and flurbiprofen via oxidative pathways in the elderly. For 
ibuprofen, the impaired oxidative activity appeared to be stereoselective with the more 
prominent reductions evident for (S)-ibuprofen, such that the unbound formation 
clearances for the hydroxy- and carboxy- metabolites derived from this enantiomer were 
lower by 21% and 24% respectively in the elderly compared to the young (Chapter 3). 
Whereas in the case of the R-enantiomer, the unbound clearances for the hydroxy- and 
carboxy metabolites were reduced by only 15% and 8% respectively with advancing age 
(Chapter 3). Interestingly bienzymatic catalysis of ibuprofen oxidation has been 
suggested with CYP2C8 playing a minor, but significant, role alongside CYP2C9 
(Hamman et al., 1997). However, CYP2C8 shows opposing enantioselectivity to 
CYP2C9, favouring oxidation of (R)-ibuprofen, and thus it is possible that the age- 
related alterations are reflective of a comparatively greater decrease in CYP2C9 activity. 
Such alterations may have contributed to the overall unbound clearance of (S)-ibuprofen 
being 17 % lower in the elderly. With regards to flurbiprofen, the decrease in oxidative 
metabolism with age was more extensive than observed with ibuprofen and both 
enantiomers of the drug were equally effected. This is apparent when 
it is considered 
that the formation clearances of (R)- and (S)-4'-hydroxyflurbiprofen were reduced by 
51 % and 53% respectively in the elderly. In vitro 
investigations propose that CYP2C9 
may be the only isoenzyme involved to any substantial 
degree in flurbiprofen oxidation 
and it has been advocated that this reaction maybe a useful 
in vivo and in vitro probe for 
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this particular CYP isoenzyme (Tracy et al., 1996). Such a "metabolic burden" on a 
single enzyme is indicative of the dramatic and non-stereoselective nature of the 
changes in oxidative metabolism of flurbiprofen with age. 
It is also important to note that polymorphisms in the coding region of the 
CYP2C9 gene produce variants at amino acid residues 144 (Argl44Cys) and 359 
(Ile359Leu) of the CYP2C9 protein which can lead to differences in catalytic properties. 
For example, (S)-warfarin 7-hydroxylation, tolbutamide methylhydroxylation, and 
phenytoin 4'-hydroxylation are less efficiently catalysed by the Arg 144 -+ Cys 144 
variant of CYP2C9 (Miners and Birkett, 1998). Similarly, the Ile 359 -> Leu 359 variant 
exhibits reduced activity towards CYP2C9 substrates in vitro and in vivo where less 
than 1% of Caucasians, Chinese and African-Americans are homozygous at this gene 
locus and correspond to the tolbutamide poor metaboliser phenotype (Miners and 
Birkett, 1998). Approximately 20% of Caucasians are heterozygous for the mutation 
corresponding to the Cys144 variant of CYP2C9, but it is absent from Chinese 
individuals, and, therefore, the potential for significant interethnic differences in 
CYP2C9 activity exists (Miners and Birkett, 1998). Recently, it has been demonstrated 
that the Cys 144 variant of CYP2C9 displays intrinsic clearance values for ibuprofen 
hydroxylations markedly lower than those of the wild-type enzyme but exhibits 
comparable sulphaphenazole K; values (Hamman et al., 1997). The expression of this 
variant, therefore, would be expected to provide an additional source of interindividual 
variability in ibuprofen disposition. As yet no specific studies have been performed to 
detect any change in the proportions of CYP2C9 polymorphism phenotype in cross- 
sections of the population of different ages. 
Age-related differences in elimination via the glucuronidation pathway were only 
apparent for flurbiprofen, with the formation clearances for glucuronidation of both 
enantiomers of the drug being lower by 60% in the elderly. The lack of any similar age- 
associated alterations in the glucuronidation of ibuprofen would suggest that the 
reaction is mediated by different isoenzymes of the UDP-glucuronosyltransferase 
for the 
different drugs. 
Interestingly, the extent of (R)-ibuprofen undergoing metabolic inversion to the 
active S-enantiomer did not show age-related 
differences, with the young and elderly 
having F;, values of 0.68 and 0.66 respectively (Chapter 
3). It is therefore likely that 
expression of hepatic long chain 
fatty acid CoA synthetase, which modulates the rate- 
limiting step of the inversion process, is not altered significantly with advancing age. 
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Overall, it appears that change in the disposition of ibuprofen with age stems from 
a combination of an increase in the unbound fraction and a decrease in the unbound 
clearance, due to impaired oxidative metabolism, of the S-enantiomer. These factors 
operate in opposite directions such that at steady state the total serum concentrations 
would be similar between the two groups but unbound concentrations would be higher 
in the elderly, this is reflected by the elderly having a significantly greater AUC by 25% 
for unbound (S)-ibuprofen then the young (Chapter 3). Age-related differences in the 
disposition of flurbiprofen, on the other hand, seem to be primarily due to reduced 
clearance as a result of a general decline in hepatic metabolising capacity. Consequently, 
the elderly have greater exposure to both enantiomers of the drug with enantiomeric 
AUCs typically 60 % larger in this age group; parallel changes in unbound AUCs would 
be expected since age does not appear to have a major influence on the plasma protein 
binding of flurbiprofen. As it is the unbound concentrations of these drugs that are 
important for their pharmacodynamic effects, the elderly are therefore potentially 
exposed to increased effect and risk of toxicity at normal therapeutic doses. 
A variety of physiological and morphological changes occur in the ageing liver 
which may influence hepatic drug elimination. These include a decrease in size, as a 
proportion of body weight, from about 2.5% of bodyweight at age 50 to 1.6% of 
bodyweight at age 90; and a possible fall in blood flow from 1400 ml/min at age 30 to 
800 ml/min at age 75 (Woodhouse and Wynne, 1987). However, the effect of age on the 
drug metabolising capability of the liver per se is not clear with limited data available in 
the literature. There is "normally" considerable variation between healthy individuals in 
hepatic metabolism due to genetic factors, caffeine and cigarette consumption and 
nutritional status as well as age. 
Recently, the effect of age has been investigated on CYP-mediated metabolism in 
226 subjects with "equal" histopathological conditions (Sotaniemi et al., 1997). The 
subjects were classified by age in decades and the CYP contents of liver biopsy samples 
and the rate of antipyrine elimination from plasma assessed simultaneously. It appears 
that age has a reducing effect on oxidative drug metabolism in humans with CYP 
content (an in vitro parameter) altered stepwise, whereas antipyrine metabolism 
(an in 
vivo index) declined linearly after 40 years (Sotaniemi et al., 
1997). It is worth noting 
that other factors may also contribute to age related alterations 
in the rate of oxidative 
metabolism, which include the affinity of the relevant 
CYP450s for the drug, the 
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concentrations of CYP reductase and the integrity of the lipid domain (Dumas et al., 
1990). 
It has been suggested that the effect of ageing on phase II conjugation reactions 
appears to be less pronounced. Several authors have examined the effect of age upon in 
vitro UDP-glucuronyltransferase activities and have reported no change in Fischer 344 
rates or minimal changes only (10-20%) in Wistar rats (Woodhouse and James, 1990). 
Similarly sulphation of paracetamol in isolated hepatocytes was reported to be slightly 
decreased in old rats but not in old mice, when compared to young adults (Woodhouse 
and James, 1990). No data are available on the effects of age on these enzymes in 
human liver. 
7.4.3 Toxicological implications 
The changes in pharmacodynamic response with the altered pharmacokinetics of 
(S)-ibuprofen in the elderly were assessed by monitoring serum thromboxane B2 
concentrations (TXB2) as an indicator of cyclooxygenase-1 (COX-1) activity. COX-1 is 
constitutively expressed in many tissues including the gastrointestinal tract were it is 
responsible for the generation of cytoprotective prostaglandins (Vane et at, 1998). 
These prostaglandins provide protection to the gastrointestinal mucosa by reducing 
gastric acid production, increasing bicarbonate ion and mucus production, and 
maintaining blood flow to the intestinal mucosa (Soll, 1991). The pharmacodynamic 
investigations performed, indicate that the time-course of inhibitory activity on TXB2 
generation is in close correlation with serum unbound concentrations of (S)-ibuprofen 
(Chapter 5). The transient nature of the activity is reflective of the drug's ability to cause 
rapid reversible competitive inhibition of COX (Wu, 1998). Comparison of the TXB2 
profiles between the two age groups mirror the differences in the unbound 
(S)-ibuprofen serum profile and thus indicate that inhibitory activity has a more rapid 
onset and is longer-lived in the elderly in comparison to the young. The presence of 
significant residual activity after 24 hours post-dose in the elderly suggests that age- 
related changes in response may not be exclusively dose related but also due to 
attenuated sensitivity as a result of idiosyncratic pharmacodynamic alterations. For 
example, changes in enzyme number and affinity or blunted homeostatic mechanisms in 
the elderly could be possible associated factors (Hammerlein et al., 1998). The above 
findings suggest that altered disposition of ibuprofen in the elderly does increase the risk 
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of adverse reactions due to the strong relationship between activity and unbound serum 
concentration of (S)-ibuprofen. 
Although pharmacodynamic studies were not performed for flurbiprofen, the 
likelihood of toxicity in the elderly is more apparent than with ibuprofen since 
flurbiprofen enantiomers have comparatively longer elimination half-lives and age 
related alterations in disposition were more profound. This is also likely to be intensified 
by the fact that (S)-flurbiprofen has a more potent activity on COX; since in contrast to 
ibuprofen, flurbiprofen causes slowly-reversible time-dependent inactivation (Wu, 
1998). After the initial competitive inhibition of COX, flurbiprofen is believed to cause 
active site structural changes to facilitate slowly reversible inhibition; this phase of 
inhibition takes minutes to accomplish and, hence, is time-dependent. Furthermore, the 
increased exposure of the elderly to the R-enantiomer, which is relatively inactive in 
terms of COX inhibition, can not be assumed to be of little consequence. Since after 
long term administration of either the racemate or the individual enantiomers of 
flurbiprofen to rats, Wechter et al. (1993) found that the R-enantiomer alone did not 
elicit gastrointestinal lesions, but the racemate proved to be 2 to 4 fold more ulcerogenic 
in enantiomerically equivalent doses than the S-enantiomer. Recently, it has been shown 
that the R-enantiomer might exacerbate gastrointestinal toxicity in the rat by causing 
uncoupling of mitochondrial oxidative phosphorylation which consequently lead to 
increased intestinal permeability (Mahmud et al., 1998). Thus taking all these factors 
into consideration, it would seem that flurbiprofen should be used with considerable 
caution in the elderly population. 
It is also important to note that in addition to altered pharmacokinetics, increasing 
age is associated with many alterations in gastrointestinal physiology that may 
contribute to an increased risk of NSAID-induced gastrointestinal complications. Free 
radical scavenging functions are decreased, vascular integrity is diminished, and perhaps 
most important prostaglandin biochemistry is significantly altered (Solomon and 
Gurwitz, 1997). Studies in animals (Lee and Feldman, 1994) and humans have 
demonstrated reduced gastrointestinal prostaglandin levels with age. Goto et al. (1992) 
sampled the gastric mucosa in healthy volunteers for the concentration of 
four 
prostaglandins: 6-keto-prostaglandin Fla,, prostaglandin F2,,, prostaglandin 
E2 and 
prostaglandin D2. The concentrations found in individuals over 
70 years of age were half 
those of subjects less than 70. Cryer et al. (1992) also sampled the gastric mucosa 
from 
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healthy volunteers and found lower prostaglandin Fla, and prostaglandin E2 levels in 
volunteers aged 52 to 72 compared with younger subjects aged between 21 to 40. 
Ageing occurs at different rates, which may be influenced by genetic 
predisposition, e. g. type II diabetes, or by environmental and lifestyle factors; therefore 
the elderly can be viewed as a very diverse population group. In addition the ageing 
process is often superimposed by various disease conditions to which the elderly are 
more often susceptible e. g. renal dysfunction and musculoskeletal disorders. As a result 
of these multiple pathologies, the elderly are generally prescribed more drugs than the 
young, potentially leading to an increased risk of NSAID-related adverse reactions due 
to drug-disease and drug-drug interactions. Of primary importance, with regards to 
disposition of the NSAIDs, is if these interactions effect protein binding and/or 
metabolism, including the chiral inversion process. Thus the findings of this study 
should be considered with these factors also in mind. 
7.4.4 Concluding Remarks 
The results of the present study indicate age-related alterations in the disposition 
of both 2-arylpropionic acid drugs; such that the elderly have greater exposure to the 
unbound S-enantiomer of ibuprofen and both enantiomers in the case of flurbiprofen. 
These results taken collectively with the greater susceptibility to adverse reactions and 
the increased prevalence of certain comorbid conditions and concomitant drug therapies, 
suggest that the elderly are particularly at risk from the gastrointestinal complications of 
these well-established and widely-used NSAIDs. It is also obvious that many more 
studies investigating the age-related alterations in pharmacodynamic activity in 
combination with the enantiomeric pharmacokinetics of NSAIDs are necessary, to better 
appreciate the clinical implications of such changes and thus increase the safe and 
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Appendix 1: Demographic details and serum albumin concentrations for the young and elderly 
volunteers of the ibuprofen study. 
Ibuprofen study: Young 
Subject Sex Age Weight Height Albumin 
Code (years) (kg) (cm) (g/L) 
Iy l male 31 78.0 177 49.0 
Iy2 male 22 77.0 182 50.1 
Iy3 female 25 63.5 168 52.8 
Iy4 female 23 75.0 172 50.3 
Iy5 female 28 64.0 170 49.2 
ly6 female 23 77.0 180 56.5 
Iy7 male 20 84.0 187 50.6 
Iy8 male 21 67.0 177 51.0 
Mean - 24.1 73.2 176.6 51.2 
s. d. - 3.7 7.5 6.4 2.4 
Ibuprofen study: Elderly 
le l male 83 83.5 179 50.9 
Ie2 male 84 75.5 166 47.9 
Ie3 male 71 63.0 174 49.4 
Ie4 male 72 73.0 172 53.3 
Ie5 male 66 83.0 175 47.5 
Ie6 male 71 89.0 175 52.9 
Ie7 male 83 55.0 177 
46.1 
Ie8 female 75 58.0 157 52.2 
Mean - 75.6 72.5 
171.9 50.0 
s. d. - 6.8 
12.6 7.1 2.7 
Comparison of the means for weight, height and serum albumin concentration 
between the young and elderly groups using a 




Appendix 2: Serum concentrations (mcg/ml) for (R)- and (S)-ibuprofen in individual healthy young 
volunteers following the oral administration of 400 mg racemic ibuprofen. 
(R)-ibuprofen (mcg/ml) 
Firne (hr) lyl Iy2 Iy3 Iy4 Iy5 Iy6 Iy7 Iy8 mean s. d. 
0.25 7.94 0.00 0.17 1.43 0.47 0.11 0.00 0.00 1.27 2 -4 
0.50 13.05 0.00 2.73 1.82 2.59 0.38 0.45 0.14 2.65 4 35 
0.75 13.99 0.13 11.43 5.58 4.84 0.91 2.55 0.33 4.97 5 22 
1.00 16.13 0.19 14.02 10.00 7.49 1.55 3.40 0.52 6.66 623 
1.50 15.46 1.98 14.88 14.09 8.48 2.04 4.20 2.28 7.93 6.08 
2.00 14.49 3.78 13.33 15.78 17.23 2.12 4.06 13.43 10.53 6.1 2 
2.50 11.62 10.79 12.90 14.91 22.96 2.93 11.63 17.62 13.17 5 78 
3.00 11.16 15.21 12.68 14.26 19.38 3.00 11.02 17.42 13.02 4 99 
3.50 9.11 14.96 10.52 12.79 17.42 2.95 9.98 14.11 11.48 4 43 
4.00 5.39 14.58 7.26 11.69 12.78 3.67 8.70 11.54 9.45 3.82 
6.00 4.25 6.28 1.62 4.50 5.79 11.32 2.67 3.39 4.98 2.99 
8.00 1.63 3.59 0.50 2.30 1.91 3.48 1.40 0.92 1.97 1.12 
10.00 0.78 1.86 0.35 1.36 0.62 1.22 0.46 0.47 0.89 0.54 
24.00 0.00 0.00 0.00 0.00 0.00 0.09 0.00 0.00 0.01 0.03 
(S)-ibuprofen (mcg/ml) 
Time (hr) lyl Iy2 Iy3 Iy4 Iy5 Iy6 Iy7 Iy8 mean s. d. 
0.25 7.55 0.00 0.11 1.25 0.32 0.06 0.00 0.00 1.16 2.62 
0.50 13.63 0.00 2.72 1.76 2.01 0.28 0.48 0.13 2.63 4.56 
0.75 14.22 0.12 11.37 5.32 3.85 0.73 2.71 0.33 4.83 5.29 
1.00 16.78 0.31 14.02 9.32 6.04 1.27 3.93 0.57 6.53 6.30 
1.50 15.79 2.16 16.15 14.32 6.80 1.59 5.08 1.77 7.96 6.45 
2.00 14.55 4.00 16.23 14.93 13.19 1.74 5.21 11.64 10.19 5.65 
2.50 11.48 11.97 15.69 14.90 16.84 2.29 13.20 13.99 12.55 4 52 
3.00 10.81 15.88 15.16 13.55 14.35 2.31 13.65 14.12 12.48 4.37 
3.50 9.48 16.10 13.35 11.43 13.90 2.32 13.70 12.38 11.58 421 
4.00 5.47 15.45 12.12 11.00 10.44 2.95 12.51 9.50 9.93 
4.00 
6.00 5.05 7.41 7.99 7.58 7.91 16.14 8.01 6.77 8.36 
3.29 
8.00 2.29 5.15 4.20 3.38 4.01 11.83 3.70 3.45 4.75 
2 97 
10.00 1.08 1.89 2.60 1.95 1.90 7.44 2.07 1.49 
2.55 2 02 




Appendix 3: Serum concentrations (mcg/ml) for (R)- and (S)-ibuprofen in individual healthy 
elderly volunteers following the oral administration of 400 mg racemic ibuprofen. 
Time (hr) Iel Ie2 Ie3 
(R )-ibuprofen (mcg/ml) 
Ie4 Ie5 Ie6 Ie7 Ie8 mean s. d. 
0.25 1.45 3.62 1.20 2.05 2.57 0.46 4.02 10.71 3.26 124 
0.50 8.28 6.63 10.33 9.72 5.36 0.73 11.86 15.33 8.53 4 41 
0.75 12.00 8.75 12.96 11.38 9.20 1.37 15.35 18.36 11.17 5.06 
1.00 17.73 14.47 14.44 13.51 9.69 4.96 16.36 20.09 13.91 4 74 
1.50 17.85 14.80 13.82 14.57 11.46 9.03 17.18 21.44 15.02 3.86 
2.00 19.25 14.67 13.67 15.47 11.01 11.28 20.38 21.44 15.90 4 03 
2.50 18.40 13.39 12.80 15.42 11.27 11.99 16.39 20.19 14.98 3 18 
3.00 17.73 13.07 12.48 14.30 10.16 10.15 14.04 17.03 13.62 2.80 
3.50 13.90 12.04 12.03 13.83 9.89 9.24 12.17 16.65 12.47 2.36 
4.00 11.11 11.43 11.22 11.35 7.65 7.67 11.54 15.57 10.94 2.50 
6.00 4.35 5.43 4.40 3.32 2.29 3.09 3.41 6.74 4.13 1.43 
8.00 3.05 2.45 1.93 0.95 1.53 1.67 1.13 2.56 1.91 0.73 
10.00 2.33 1.03 1.17 0.38 0.77 0.67 0.21 1.29 0.98 0.66 
24.00 0.10 0.19 0.07 0.00 0.00 0.00 0.00 0.00 0.05 0.07 
(S)-ibuprofen (mcg/ml) 
Time (hr) Iel Ie2 Ie3 Ie4 Ie5 Ie6 Ie7 Ie8 mean s. d. 
0.25 1.25 3.21 1.03 1.77 2.50 0.31 2.60 8.40 2.63 2.51 
0.50 7.97 5.61 9.65 8.83 4.95 0.64 7.78 11.68 7.14 3.39 
0.75 10.41 7.68 13.44 10.36 8.55 1.38 10.53 13.48 9.48 3.86 
1.00 13.08 12.11 14.70 12.52 8.73 3.67 11.33 14.52 11.33 3.63 
1.50 16.48 13.44 14.17 13.23 11.38 7.48 11.77 15.58 12.94 2.80 
2.00 14.44 14.01 13.91 14.10 10.11 8.77 13.19 15.65 13.02 2.34 
2.50 13.62 12.81 12.90 12.58 9.29 10.33 10.49 14.30 12.04 1.78 
3.00 12.78 11.58 12.60 13.10 9.07 9.33 9.39 12.43 11.29 
1.73 
3.50 10.03 11.25 10.89 12.19 7.21 8.55 8.81 11.92 10.11 
1.77 
4.00 9.17 9.51 10.37 11.17 5.82 7.36 7.95 10.88 
9.03 1.86 
6.00 5.71 6.77 6.25 8.38 2.66 4.61 5.75 6.79 
5.87 1.69 
8.00 4.81 5.33 3.36 4.63 2.44 3.27 3.18 4.75 
3.97 1.03 
10.00 3.02 3.52 2.43 2.73 1.96 1.29 1.77 
2.62 2.42 0.72 
24.00 0.23 0.32 0.17 0.00 0.10 0.00 
0.00 0.00 0.10 0.13 
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Appendix 4: Cumulative urinary excretion of ibuprofen enantiomers in individual healthy, young 
volunteers following the oral administration of 400 mg racemic ibuprofen. 
total ibuprofen (% of administered dose) 
0-2hr 0-4 hr 0-6hr 0-8 hr 0-10hr 0-24hr 
Subject R S R S RS RS R S R S 
lyl 0.02 0.23 0.04 0.38 0.17 1.66 0.29 2.79 0.40 3.88 1.11 10.73 
Iy2 0.06 0.63 0.09 0.91 0.13 1.26 0.20 1.92 0.27 2.66 0.89 8.75 
Iy3 0.03 0.47 0.10 1.38 0.15 2.07 0.23 3.16 0.36 4.95 1.01 1404 
ly4 0.03 0.28 0.05 0.55 0.09 0.92 0.15 1.59 0.15 1.65 1.09 11.68 
Iy5 0.02 0.28 0.03 0.51 0.08 1.23 0.16 2.42 0.31 4.75 0.82 12 58 
1y6 0.18 2.27 0.26 3.31 0.29 3.70 0.33 4.26 0.42 5.40 0.87 1120 
1y7 0.14 1.63 0.22 2.51 0.32 3.63 0.35 3.95 0.39 4.43 0.67 7.63 
Iy8 0.05 0.61 0.10 1.14 0.15 1.71 0.28 3.16 0.49 5.64 1.13 12.98 
mean 0.07 0.80 0.11 1.34 0.17 2.02 0.25 2.91 0.35 4.17 0.95 11.20 
s. d. 0.06 0.75 0.08 1.05 0.09 1.07 0.08 0.93 0.10 1.38 0.16 2 15 
conjugated ibuprofen (% of administered dose) 
0-2hr 0-4hr 0-6hr 0 -öhr 0-10hr 0-24hr 
Subject R S R S R S R S R S R S 
lyl 0.02 0.22 0.04 0.36 0.16 1.58 0.28 2.65 0.39 3.69 1.07 10.19 
Iy2 0.05 0.57 0.08 0.82 0.12 1.14 0.18 1.74 0.25 2.41 0.81 7.92 
10 0.03 0.45 0.10 1.33 0.15 1.99 0.23 3.04 0.35 4.76 0.99 13 49 
1y4 0.03 0.25 0.05 0.49 0.09 0.82 0.14 1.41 0.14 1.47 1.02 10.39 
Iy5 0.02 0.26 0.03 0.47 0.08 1.12 0.15 2.21 0.29 4.33 0.78 11.48 
Iy6 0.17 2.14 0.25 3.12 0.28 3.49 0.32 4.02 0.41 5.09 0.84 10.57 
Iy7 0.13 1.45 0.20 2.24 0.29 3.23 0.32 3.52 0.35 3.95 0.61 6.79 
Iy8 0.04 0.52 0.09 0.97 0.13 1.46 0.25 2.70 0.44 4.81 1.00 11.08 
mean 0.06 0.73 0.10 1.22 0.16 1.85 0.23 2.66 0.33 3.81 
0.89 10.24 
s. d. 0.06 0.69 0.08 0.98 0.08 1.00 0.07 0.87 0.10 1.27 
0.16 2.08 
free ibuprofen (% of administered dose) 
0-2hr 0-4hr 0-6hr 0-8 hr 0-10hr 0-24hr 
Subject R S R S R S R S R S 
R S 
Iyl 0.00 0.01 0.00 0.02 0.01 0.08 0.01 0.14 0.02 
0.20 0.04 0.54 
Iy2 0.01 0.06 0.01 0.09 0.01 0.12 0.02 0.18 
0.02 0.25 0.08 0.83 
1y3 0.00 0.02 0.00 0.05 0.00 0.08 0.00 0.12 
0.01 0.19 0.02 0.55 
Iy4 0.00 0.03 0.00 0.06 0.01 0.10 0.01 0.18 
0.01 0.18 0.07 1.29 
Iy5 0.00 0.03 0.00 0.04 0.00 0.11 0.01 0.21 
0.02 0.42 0.05 1.10 
1y6 0.01 0.13 0.01 0.19 0.01 0.21 0.01 
0.24 0.01 0.31 0.03 0.63 
Iy7 0.01 0.18 0.02 0.28 0.03 0.40 0.03 
0.43 0.04 0.49 0.07 0.84 
Iy8 0.01 0.09 0.01 0.17 0.02 0.25 0.03 
0.46 0.06 0.83 0.13 1.90 
n 00 0 0 07 01 0 0.11 0.01 
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Appendix 5: Cumulative urinary excretion of hydroxyibuprofen enantiomers in individual healthy 
young volunteers following the oral administration of 400 mg racemic ibuprofen. 
total hydroxyibuprofen (% of administered dose) 
0-2hr 0-4 hr 0-6hr 0-8 hr 0-10hr 0-24 hr 
Subject R S R S R S R S R S R S 
lyl 0.10 0.37 0.16 0.60 0.67 2.60 1.13 4.37 1.58 6.08 4.36 16.80 
1y2 0.17 1.27 0.25 1.63 0.35 2.27 0.53 3.46 0.73 4.79 2.40 15.77 
ly3 0.08 0.62 0.24 1.80 0.35 2.69 0.54 4.12 0.85 6.44 2.40 18.29 
1y4 0.06 0.41 0.13 0.83 0.21 1.37 0.37 2.37 0.38 2.45 2.72 17 40 
1y5 0.10 0.44 0.18 0.80 0.44 1.93 0.86 3.81 1.69 7.49 4,47 19.84 
Iy6 0.61 4.26 0.89 6.20 0.99 6.93 1.14 7.98 1.45 10.13 3.00 20.99 
Iy7 0.73 3.98 1.13 6.14 1.63 8.86 1.77 9.64 1.98 10.81 3.42 18.64 
1y8 0.18 0.73 0.33 1.37 0.49 2.06 0.91 3.82 1.63 6.81 3.74 15 65 
mean 0.25 1.51 0.41 2.42 0.64 3.59 0.91 4.95 1.29 6.88 3.31 1792 
s. d. 0.26 1.64 0.38 2.35 0.46 2.74 0.45 2.50 0.56 2.71 0.82 1.89 
conjugated hydroxyibuprofen (% of administered dose) 
0-2hr 0-4hr 0-6hr 0-8hr 0-10hr 0-24hr 
Subject R S R S R S R S R S R S 
lyl 0.02 0.22 0.03 0.36 0.14 1.58 0.24 2.65 0.34 3.69 0.93 10.20 
Iy2 0.07 0.79 0.10 1.14 0.14 1.58 0.21 2.41 0.29 3.34 0.95 10.99 
Iy3 0.02 0.41 0.06 1.18 0.08 1.77 0.13 2.71 0.20 4.24 0.56 12.04 
Iy4 0.01 0.25 0.02 0.51 0.03 0.84 0.06 1.46 0.06 1.51 0.45 10.68 
Iy5 0.02 0.23 0.04 0.42 0.09 1.00 0.18 1.98 0.35 3.89 0.94 10.29 
Iy6 0.08 1.94 0.12 2.82 0.13 3.15 0.15 3.63 0.19 4.61 
0.40 9.55 
1yy7 0.12 2.17 0.18 3.35 0.26 4.84 0.29 5.26 0.32 5.90 
0.55 10.18 
1y8 0.01 0.32 0.02 0.61 0.03 0.91 0.05 1.69 0.09 
3.01 0.21 6.92 
mean 0.04 0.79 0.07 1.30 0.11 
1.96 0.16 2.72 0.23 3.77 0.62 10.11 
s. d. 0.04 0.80 0.06 1.15 0.07 
1.38 0.08 1.23 0.11 1.28 0.28 1.48 
free hydroxyibuprofen (% of administered dose) 



















































































































































Appendix 6: Cumulative urinary excretion of carboxyibuprofen stereoisomers in individual healthy 
young volunteers following the oral administration of 400 mg racemic ibuprofen. 
total carboxyibuprofen (% of administered dose) 
0-2hr 0-4hr 0-6hr 0-8hr 0-10hr 0-24hr 
Subject R S R S R S R S R S R S 
Iyl 2'R- 0.11 0.28 0.18 0.46 0.78 1.98 1.31 3.34 1.83 4.64 5.05 12.82 
2'S- 0.06 0.33 0.10 0.54 0.42 2.36 0.71 3.97 0.99 5.52 2.72 15.26 
1y2 2'R- 0.33 0.91 0.48 1.32 0.67 1.84 1.02 2.80 1.42 3.87 4.66 12 74 
2'S- 0.23 1.23 0.34 1.78 0.47 2.48 0.72 3.78 0.99 5.23 3.26 17.21 
1y 3 2'R- 0.13 0.45 0.38 1.33 0.57 1.98 0.87 3.03 1.36 4.74 3.87 13,47 
2'S- 0.07 0.54 0.21 1.57 0.31 2.35 0.48 3.60 0.75 5.63 2.13 15.99 
Iy4 2'R- 0.10 0.29 0.21 0.59 0.34 0.97 0.59 1.69 0.61 1.74 4.32 12.37 
2'S- 0.06 0.36 0.11 0.72 0.19 1.19 0.32 2.07 0.33 2.14 2.36 15.18 
1y5 2'R- 0.13 0.42 0.24 0.75 0.58 1.82 1.15 3.58 2.25 7.04 5.97 18.65 
2'S- 0.09 0.48 0.16 0.87 0.38 2.10 0.74 4.15 1.46 8.16 3.86 21.61 
Iy6 2'R- 0.89 3.50 1.30 5.10 1.45 5.71 1.67 6.57 2.12 8.33 4.39 17.27 
2'S- 0.58 4.59 0.85 6.69 0.95 7.48 1.09 8.62 1.39 10.93 2.88 22.66 
Iy7 2'R- 1.02 3.32 1.57 5.12 2.27 7.38 2.47 8.03 2.77 9.01 4.77 15.53 
2'S- 0.54 3.76 0.83 5.80 1.19 8.36 1.30 9.09 1.45 10.21 2.47 17.59 
Iy8 2'R- 0.18 0.53 0.33 0.99 0.50 1.49 0.92 2.76 1.65 4.92 3.78 11.31 
2'S- 0.14 0.73 0.27 1.37 0.40 2.07 0.74 3.82 1.32 6.82 3.04 15.67 
mean 2'R- 0.36 1.21 0.59 1.96 0.90 2.90 1.25 
3.98 1.75 5.54 4.60 14.27 
2'S- 0.22 1.50 0.36 2.42 0.54 3.55 0.76 4.89 1.09 6.83 2.84 17.65 
s. d 2'R- 0.38 1.37 0.54 1.97 0.65 2.32 0.59 
2.16 0.66 2.42 0.70 2,60 




Appendix 6: continued 
0-2hr 
conjugated carboxyibuprofen (% of administere 
0-4hr 0-6hr 0-8 hr 
d dose) 
0-10hr 0-24hr 
Subject R S R S R S R S R S R 
lyl 2'R- 0.04 0.10 0.06 0.17 0.26 0.70 0.43 1.19 0.61 1.65 1.68 4 56 
2'S- 0.01 0.12 0.02 0.20 0.09 0.87 0.16 1.46 0.23 2.03 0.62 x. 60 
1y2 2'R- 0.12 0.30 0.18 0.44 0.25 0.61 0.39 0.93 0.54 1.29 1.77 . 12; 
2'S- 0.05 0.44 0.08 0.64 0.11 0.89 0.17 1.36 0.23 1.88 0.77 6.1 
1y3 2'R- 0.03 0.11 0.10 0.35 0.15 0.52 0.23 0.79 0.35 1.24 1.01 3.52 
2'S- 0.01 0.16 0.03 0.47 0.05 0.70 0.08 1.08 0.12 1.69 0.35 4.80 
ºv4 2'R- 0.02 0.07 0.06 0.15 0.09 0.25 0.16 0.44 0.16 0.44 1.15 3.1- 
2'S- 0.01 0.10 0.02 0.20 0.03 0.33 0.05 0.57 0.05 0.59 0.38 4.21 
Iy5 2'R- 0.04 0.16 0.08 0.28 0.20 0.69 0.41 1.34 0.79 2.64 2.11 7.01 
2'S- 0.03 0.18 0.05 0.33 0.11 0.80 0.21 1.58 0.42 3.11 1.10 8.23 
Iy6 2'R- 0.16 0.35 0.24 0.51 0.27 0.57 0.31 0.66 0.39 0.83 0.81 1.72 
2'S- 0.06 0.92 0.10 1.34 0.11 1.50 0.12 1.74 0.16 2.20 0.34 4.56 
1y7 2'R- 0.19 0.71 0.29 1.09 0.42 1.57 0.46 1.71 0.51 1.92 0.88 3.31 
2'S- 0.07 0.81 0.10 1.25 0.14 1.79 0.15 1.94 0.16 2.19 0.29 3.77 
Iy8 2'R- 0.01 0.02 0.02 0.05 0.03 0.07 0.05 0.13 0.09 0.22 0.20 0 52 
2'S- 0.01 0.04 0.02 0.08 0.02 0.13 0.05 0.23 0.08 0.41 0.20 0.95 
mean 2'R- 
2'S- 






































free carboxyibuprofen (% of administered dose) 
0-2hr 0-4hr 0-6hr 0-8hr 0-1 0hr 0-2 4hr 
Subject R S R S R S R S R S R S 
lyl 2'R- 0.07 0.18 0.12 0.29 0.52 1.28 0.88 2.15 1.22 2.99 3.37 8.26 
2'S- 0.05 0.21 0.08 0.34 0.33 1.49 0.55 2.51 0.76 3.49 2.10 9.66 
Iy2 2'R- 0.21 0.61 0.30 0.88 0.42 1.23 0.63 1.87 0.88 2.58 2.89 8.49 
2'S- 0.18 0.79 0.26 1.14 0.36 1.59 0.55 2.42 0.76 3.35 2.49 11.04 
1y3 2'R- 0.10 0.34 0.28 0.98 0.42 1.46 0.64 2.24 1.01 3.50 2.86 9.95 
2'S- 0.06 0.38 0.18 1.10 0.26 1.65 0.40 2.52 0.63 3.94 1.78 11.19 
1y4 2'R- 0.08 0.22 0.15 0.44 0.25 0.72 0.43 1.25 0.45 1.30 3.17 9.20 
2'S- 0.05 0.26 0.09 0.52 0.16 0.86 0.27 1.50 0.28 1.55 1.98 10.97 
Iy5 2'R- 0.09 0.26 0.16 0.47 0.38 1.13 0.74 2.24 1.46 4.40 
3.86 11.64 
2'S- 0.06 0.30 0.11 0.54 0.27 1.30 0.53 2.57 1.04 5.05 
2.76 13.38 
1y6 2'R- 0.73 3.15 1.06 4.59 1.18 5.14 1.36 5.91 1.73 
7.50 3.58 15.55 
2'S- 0.52 3.67 0.75 5.35 0.84 5.98 0.97 6.88 1.23 
8.73 2.54 18.10 
Iy7 2'R- 0.83 2.61 1.28 4.03 1.85 5.81 2.01 6.32 
2.26 7.09 3.89 12.22 
2'S- 0.47 2.95 0.73 4.55 1.05 6.57 1.15 7.15 
1.29 8.02 2.22 13.82 
1y8 2'R- 0.17 0.51 0.31 0.94 0.47 1.42 0.87 
2.63 1.56 4.70 3.58 10.79 
2'S- 0.13 0.69 0.25 1.29 0.38 1.94 0.69 
3.59 1.24 6.41 2.84 14 1 
2'R- 0 29 0 99 46 0 1.58 0.69 2.27 0.95 








0.31 1.85 0.46 2.67 0.64 3.64 
0.90 5.07 2.34 12 St, 
s. d 2'R- 0.31 1.19 0.45 1.71 
0.55 2.00 0.51 1.92 0.56 2.15 
0.40 2.40 
2'S- 0.19 1.36 0.28 1.95 0.31 2.25 




Appendix 7: Cumulative urinary excretion of ibuprofen enantiomers in individual healthy elderly 
volunteers following the oral administration of 400 mg racemic ibuprofen. 
total ibuprofen (% of administered dose) 
0-2hr 0-4hr 0-6hr 0-8 hr 0-10hr 0-24hr 
Subject R S R S R S R S R S R S 
lel 0.07 1.08 0.12 1.74 0.12 1.74 0.17 2.51 0.20 2.94 0.75 1107 
1e2 0.24 2.78 0.37 4.25 0.42 4.86 0.51 5.87 0.57 6.61 1.13 13.02 
1e3 0.03 0.33 0.06 0.58 0.10 1.06 0.15 1.59 0.23 2.45 0.79 8 37 
Ie4 0.03 0.44 0.06 0.82 0.09 1.24 0.14 1.87 0.35 4.75 1.38 18.74 
1e5 0.11 1.08 0.21 1.95 0.30 2.84 0.39 3.72 0.51 4.84 1.50 14 2O 
1e6 0.04 0.47 0.09 0.96 0.11 1.20 0.13 1.40 0.17 1.87 0.63 6.77 
1e7 0.07 0.66 0.16 1.49 0.21 1.98 0.27 2.48 0.32 2.94 0.96 8.93 
Ie8 0.03 0.28 0.07 0.56 0.09 0.76 0.16 1.32 0.23 1.94 1.16 9 58 
mean 0.08 0.89 0.14 1.54 0.18 1.96 0.24 2.60 0.32 3.54 1.04 1134 
s. d. 0.07 0.82 0.11 1.21 0.12 1.34 0.14 1.54 0.15 1.68 0.31 3.86 
conjugated ibuprofen (% of administere d dose) 
0-2hr 0-4 hr 0-6hr 0-8 hr 0-10hr 0-24hr 
Subject R S R S R S R S R S R S 
Iel 0.06 1.02 0.11 1.65 0.11 1.65 0.16 2.38 0.18 2.79 0.69 10.50 
1e2 0.23 2.66 0.35 4.06 0.40 4.64 0.48 5.61 0.54 6.31 1.06 12 44 
Ie3 0.03 0.31 0.06 0.55 0.09 1.00 0.14 1.50 0.22 2.31 0.74 7.90 
1e4 0.03 0.38 0.05 0.71 0.08 1.07 0.12 1.62 0.31 4.10 122 16.19 
Ie5 0.10 1.01 0.20 1.82 0.28 2.65 0.36 3.47 0.47 4.52 1.39 13.26 
leb 0.04 0.43 0.08 0.88 0.10 1.09 0.12 1.28 0.15 1.70 0.57 6.17 
1e7 0.06 0.55 0.14 1.24 0.18 1.65 0.23 2.07 0.28 2.45 0.83 7.45 
Ie8 0.03 0.25 0.06 0.51 0.08 0.69 0.15 1.19 0.21 1.76 1.06 8.67 
mean 0.07 0.83 0.13 1.43 0.16 1.81 0.22 2.39 0.29 3.24 0.94 10.32 
s. d. 0.07 0.80 0.10 1.17 0.12 1.30 0.13 1.50 0.14 1.61 
0.28 3.42 
free ibuprofen (% of administered dose) 
0-2hr 0-4hr 0-6hr 0-8hr 0-10hr 0-24hr 
Subject R S R S R S R S R 
S R S 
Iel 0.01 0.06 0.01 0.09 0.01 0.09 0.02 0.13 0.02 
0.15 0.07 0.57 
Ie2 0.01 0.13 0.02 0.19 0.03 0.22 0.03 0.26 0.03 
0.30 0.07 0.58 
1c3 0.00 0.02 0.00 0.03 0.01 0.06 0.01 0.09 
0.02 0.14 0.05 0.47 
1e4 0.00 0.06 0.01 0.11 0.01 0.17 0.02 0.25 
0.04 0.65 0.16 2 55 
1e5 0.01 0.07 0.02 0.13 0.02 0.19 0.03 0.25 
0.04 0.32 0.11 0. y4 
1e6 0.00 0.04 0.01 0.09 0.01 0.11 0.01 
0.13 0.02 0.17 0.06 0.60 
1e7 0.01 0.11 0.02 0.25 0.03 0.33 0.04 
0.41 0.04 0.49 0.13 148 
1e8 0.00 0.03 0.01 0.05 0.01 0.07 0.01 
0.13 0.02 0.19 0.10 0. »1 
01 0 06 0 01 0 0.12 0.02 0.15 0.02 






01 0 07 0 0.01 0.09 0.01 0.11 
0.01 0.18 0.04 0.11 
s. d. . . . . 
28 
Appendix 
Appendix 8: Cumulative urinary excretion of hydroxyibuprofen enantiomers in individual healthy 
elderly volunteers following the oral administration of 400 mg racemic ibuprofen. 
total hydroxyibuprofen (% of administered dose) 
0-2hr 0-4hr 0-6hr 0-8hr 0.10hß n ,. 
Subject R S R S R S R S R S R S 
Iel 0.28 1.48 0.46 2.39 0.46 2.39 0.66 3.45 0.77 4 04 190 15 24 
1e2 0.37 2.69 0.57 4.11 0.65 4.70 0.78 5.68 0.88 6.39 1 74 1260 
1e3 0.07 0.37 0.12 0.64 0.21 1.17 0.32 1.77 0.49 2.73 1.68 9.32 
le4 0.07 0.43 0.13 0.81 0.20 1.23 0.30 1.84 0.77 4.68 3.04 18.5 I 
1e5 0.26 1.34 0.46 2.43 0.68 3.54 0.88 4.64 1.15 6.03 3.37 17.71 
1e6 0.25 1.36 0.51 2.80 0.63 3.51 0.74 4.09 0.99 5.46 3.58 19.81 
1e7 0.24 1.12 0.53 2.52 0.71 3.35 0.89 4.21 1.05 4.99 IN 1i 14 
1e8 0.13 0.61 0.26 1.22 0.36 1.65 0.62 2.86 0.91 4.21 4.51 20.82 
mean 0.21 1.18 0.38 2.12 0.49 2.69 0.65 3.57 0.88 4.82 3.00 16.14 
s. d. 0.11 0.75 0.18 1.16 0.21 1.28 0.23 1.36 0.20 1.18 0.94 3 86 
conjugated hydroxyibuprofen (% of administered dose) 
0-2hr 0-4hr 0-6hr 0 -öhr 0-10hr 0-24hr 
Subject R S R S R S R S R S R S 
Iel 0.06 0.95 0.10 1.54 0.10 1.54 0.14 2.22 0.17 2.60 0.62 9.79 
1e2 0.02 1.72 0.03 2.63 0.03 3.01 0.04 3.64 0.04 4.09 0.08 8.06 
1e3 0.02 0.24 0.04 0.42 0.07 0.77 0.11 1.16 0.17 1.79 0.57 6.12 
1e4 0.01 0.22 0.01 0.41 0.02 0.62 0.03 0.93 0.07 2.36 0.26 9,32 
Ie5 0.04 0.79 0.07 1.43 0.10 2.09 0.14 2.73 0.18 3.55 0.52 10.43 
1e6 0.04 0.80 0.08 1.65 0.09 2.07 0.11 2.42 0.15 3.23 0.53 11.70 
1e7 0.02 0.49 0.04 1.10 0.06 1.46 0.07 1.84 0.09 2.17 0.27 6.60 
1e8 0.02 0.37 0.04 0.73 0.05 0.99 0.08 1.71 0.12 2.52 0.59 12.46 
mean 0.03 0.70 0.05 1.24 0.06 1.57 0.09 2.08 0.12 
2.79 0.43 9.31 
s. d. 0.02 0.50 0.03 0.74 0.03 0.80 0.04 0.87 
0.05 0.77 0.20 2.27 
free hydroxyibuprofen (% of administered dose) 
0-2hr 0-4hr 0-6hr 0-8hr 0-10hr 
0-24hr 
Subject RSRSRSRSRSRS 
lel 0.22 0.53 0.36 0.85 0.36 0.85 0.52 1.23 
0.61 1.44 2.28 5.45 
Ie2 0.35 0.97 0.54 1.48 0.62 1.69 0.75 2.05 
0.84 2.31 1.66 4 54 
1e3 0.04 0.13 0.08 0.22 0.14 0.40 0.21 
0.61 0.33 0.94 1.11 3.20 
Ie4 0.07 0.22 0.12 0.40 0.18 0.61 0.28 
0.91 0.70 2.33 2.77 9.19 
1e5 0.22 0.55 0.39 1.00 0.57 1.46 0.75 
1.91 0.97 2.48 2.86 7.28 
1e6 0.21 0.56 0.43 1.15 0.54 1.44 
0.63 1.67 0.84 2.24 3.05 
8.11 
1e7 0.22 0.63 0.49 1.42 0.65 1.89 
0.81 2.37 0.96 2.81 2 92 
8.54 
1e8 0.12 0.25 0.23 0.49 0.31 0.66 
0.54 1.15 0.79 1.69 3.92 
8.36 
0 18 48 0 0 33 0.88 0.42 1.13 
0.56 1.49 0.76 2.03 2.57 
6.83 
mean . . . 
20 0 56 0 0.22 0.61 
0.21 0.62 0.87 217 
s. d. 0.10 0.27 0.17 0.47 . . 
ý ( 
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Appendix 9: Cumulative urinary excretion of carboxyibuprofen stereoisomers in individual health% 
elderly volunteers following the oral administration of 400 mg racemic ibuprofen. 
0-2hr 
total carboxyibuprofen (% 
0-4hr 0-6hr 
of administered dose) 
0-8hr 0-10hr 0-24hr 
Subject R S R S R S R S R S R S 
Iel 2'R- 0.52 1.54 0.83 2.48 0.83 2.48 1.20 3.58 1.41 4.20 5.31 15.84 
2'S- 0.38 1.83 0.62 2.94 0.62 2.94 0.89 4.25 1.05 4.98 3.95 18.78 
1e2 2'R- 0.56 1.69 0.86 2.58 0.99 2.95 1.19 3.57 1.34 4.01 2.64 7.91 
2'S- 0.45 2.24 0.69 3.43 0.79 3.92 0.95 4.74 1.07 5.33 2.11 10.50 
Ie3 2'R- 0.12 0.36 0.20 0.62 0.37 1.14 0.56 1.71 0.86 2.64 2.92 9.01 
2'S- 0.09 0.46 0.16 0.80 0.29 1.46 0.44 2.20 0.67 3.40 2.30 11.60 
1e4 2'R- 0.10 0.29 0.18 0.54 0.27 0.82 0.40 1.24 1.03 3.14 4.06 12.42 
2'S- 0.05 0.35 0.09 0.65 0.14 0.99 0.21 1.49 0.54 3.78 2.11 14.93 
Ie5 2'R- 0.32 0.98 0.58 1.78 0.85 2.59 1.11 3.39 1.45 4.41 4.25 12.94 
2'S- 0.26 1.33 0.48 2.42 0.70 3.52 0.91 4.61 1.19 6.00 3.48 17.60 
Ie6 2'R- 0.40 1.10 0.83 2.26 1.04 2.83 1.21 3.30 1.62 4.42 5.88 
16.01 
2'S- 0.23 1.31 0.47 2.69 0.59 3.37 0.69 3.93 0.92 5.25 3.32 
19.02 
Ie7 2'R- 0.33 0.78 0.74 1.77 0.98 2.35 1.23 2.95 1.46 
3.49 4.42 10.61 
2'S- 0.21 0.98 0.47 2.21 0.63 2.94 0.79 3.69 0.93 4.38 
2.83 13.28 
1e8 2'R- 0.12 0.41 0.32 0,81 0.43 1.11 0.75 1.91 
1.10 2.82 5.45 13.91 
2'S- 0.16 0.54 0.24 1.08 0.32 1,47 0.56 2.54 
0.82 3.74 4.07 18.48 
2'R 31 0 0 89 57 0 61 1 0.72 2.03 0.96 2.71 
1.28 3.64 4.37 12.33 
mean - . . . . 
2'S- 0.23 1.13 0.40 2.03 0.51 2.58 0.68 
3.43 0.90 4.61 3.02 15.52 
s. d 2'R- 0.18 0.53 0.29 0.84 
0.31 0.86 0.34 0.94 0.26 0.72 1.17 
2.98 
2'S- 0.14 0,68 0.22 1.05 0.23 1.11 0.26 
1.21 0.22 0.92 0.80 3.42 
-87 
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Appendix 9: continued 
conjugated carboxyibuprofen (% of administe red dose) 
0-2hr 0-4hr 0-6hr 0-8 hr 0-10hr 0--4 hr 
Subject R S R S R S R S R S R S 
let 2'R- 0.12 0.35 0.47 1.60 0.47 1.60 0.68 2.31 0.80 2.71 102 1023 
2'S- 0.05 0.46 0.40 1.91 0.40 1.91 0.57 2.77 0.67 3.21 2,52 12,22 
1e2 2'R- 0.13 0.20 0.20 0.30 0.23 0.34 0.27 0.41 0.31 0.46 0.61 0.91 
2'S- 0.03 0.33 0.05 0.52 0.06 0.59 0.07 0.71 0.08 0.80 0.16 1.57 
1e3 2'R- 0.03 0.05 0.04 0.09 0.07 0.16 0.11 0.24 0.17 0.37 0 57 1 27 
2'S- 0.00 0.09 0.01 0.16 0.01 0.29 0.02 0.44 0.03 0.68 0.10 
_211 
1e4 2'R- 0.04 0.08 0.02 0.15 0.09 0.22 0.14 0.35 0.36 0.87 1.41 3 44 
2'S- 0.01 0.12 0.01 0.22 0.02 0.35 0.03 0.52 0.08 1.32 0.28 5I1 
1e5 2'R- 0.01 0.14 0.01 0.26 0.03 0.37 0.03 0.49 0.05 0.64 0.14 I87 
2'S- 0.02 0.21 0.04 0.39 0.06 0.57 0.07 0.74 0.09 0.98 0.26 2.85 
1e6 2'R- 0.10 0.26 0.21 0.53 0.26 0.66 0.30 0.77 0.41 1.04 1 49 3 ,5 
2'S- 0.04 0.36 0.08 0.73 0.10 0.92 0.12 1.08 0.16 I44 0.56 519 
1e7 2'R- 0.03 0.01 0.07 0.03 0.09 0.04 0.11 0.04 0.13 0.05 0.39 0.16 
2'S- 0.00 0.05 0.00 0.12 0.01 0.16 0.01 0.19 0.01 0.24 0.02 0.71 
1e8 2'R- 0.00 0.08 0.08 0.15 0.11 0.21 0.19 0.35 0.28 0.53 1 40 2.60 
2'S- 0.06 0.11 0.04 0.22 0.05 0.30 0.09 0.52 0.12 0.77 0.62 3.79 
mean 2'R- 0.06 0.15 0.14 0.39 0.17 0.45 0.23 0.62 0.31 0.83 1.13 3.03 
2'S- 0.03 0.22 0.08 0.53 0.09 0.64 0.12 0.87 0.16 1.18 0.57 4- 
s. d 2'R- 0.05 0.12 0.15 0.51 0.15 0.50 0.20 0.71 0.23 0.82 0.92 3.16 
2'S- 0.02 0.15 0.13 0.59 0.13 0.57 0.18 0.81 0.21 0.91 0.82 3.60 
free carboxyibuprofen (% of administered dose) 
0-2hr 0-4hr 0-6hr 0-8hr 0-10hr 0-2-4hr 
Subject R S R S R S R S R S R S 
Iel 2'R- 0.40 1.19 0.36 0.88 0.36 0.88 0.52 1.27 0.61 1.49 2.29 5.61 
2'S- 0.33 1.37 0.22 1.03 0.22 1.03 0.32 1.48 0.38 1.74 1.43 6,56 
1e2 2'R- 0.43 1.49 0.66 2.28 0.76 2.61 0.92 3.16 1.03 3.55 2.03 7.00 
2'S- 0.42 1.91 0.64 2.91 0.73 3.33 0.88 4.03 0.99 4.53 1.95 8.93 
Ie3 2'R- 0.09 0.31 0.16 0.53 0.30 0.98 0.45 1.47 0.69 2.27 2.35 7.74 
2'S- 0.09 0.37 0.15 0.64 0.28 1.17 0.42 1.76 0.64 2.72 2.20 
9.29 
1e4 2'R- 0.06 0.21 0.16 0.39 0.18 0.60 0.26 0.89 0.67 2.27 
2.65 8.98 
2'S- 0.04 0.23 0.08 0.43 0.12 0.64 0.18 0.97 0.46 2.46 
1.83 9.72 
1e5 2'R- 0.31 0.84 0.57 1.52 0.82 2.22 1.08 2.90 1.40 
3.77 4.11 11.07 
2'S- 0.24 1.12 0.44 2.03 0.64 2.95 0.84 3.87 1.10 
5.02 3.22 14.75 
1e6 2'R- 0.30 0.84 0.62 1.73 0.78 2.17 0.91 2.53 
1.21 3.38 439 1-1 26 
2'S- 0.19 0.95 0.39 1.96 0.49 2.45 0.57 2.85 
0.76 3.81 2.76 13.83 
1e7 2'R- 0.30 0.77 0.67 1.74 0.89 2.31 1.12 
2.91 1.33 3.44 4.03 10.45 
2'S- 0.21 0.93 0.47 2.09 0.62 2.78 0.78 
3.50 0.92 4 14 2 81 12 57 
1e8 2'R- 0.12 0.33 0.24 0.66 0.32 0.90 
0.56 1.56 0.82 2.29 4.05 
1131 
2'S- 0.10 0.43 0.20 0.86 0.27 1.17 0.47 
2.02 0.70 - 
97 3.45 14 na 
m n 2'R- 0 25 0 75 43 0 1.22 
0.55 1.58 0.73 2.09 0.97 
2.81 3 24 9.30 
ea . . . 
42 0 94 1 0.56 2.56 
0.74 3.42 2 46 11.39 
2'S- 0.20 0.91 0.32 1.49 . . 
d s 2'R- 14 0 0.45 0.22 0.69 
0.29 0.81 0.32 0.88 
0.32 0.83 0.99 2 35 
. . 
23 0 04 1 0.26 1.16 
0.25 1.13 0.71 '. 07 
2'S- 0.13 0.57 0.19 0.87 . . 
SS 
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Appendix 10: Demographic details and serum albumin concentrations for the young and elderly 
volunteers of the flurbiprofen study. 
Flurbiprofen study: Young 
Subject Sex Age Weight Height 
Code (years) (kg) (cm) 
Fy 1 female 26 73.0 173 
Fy2 male 29 65.0 168 
Fy3 male 28 64.0 172 
Fy4 female 24 69.0 170 
Mean - 26.8 67.8 170.8 
s. d. - 2.2 4.1 2.2 
Flurbiprofen study: Elderly 
Fe l female 72 54.5 155 
Fe2 male 82 74.0 175 
Fe3 male 87 75.5 173 
Fe4 female 73 59.0 164 
Mean - 78.5 65.8 
166.8 
s. d. - 7.2 10.6 
9.2 
Comparison of the means for weight and height between the young and elderly groups using a 
T-test for independent samples, 
revealed no significant age-related differences. 
-o9 
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Appendix 11: Serum concentrations (mcg/ml) for (R)- and (S)-flurbiprofen and (R)- and (S)- 
4'-hydroxyflurbiprofen in individual healthy young volunteers following the oral administration of 
100 mg racemic flurbiprofen. 
Time (hr) Fyl 
(R)-flurbiprofen (mcg/ml) 
Fy2 Fy3 Fy4 mean s. d. Fyl 
(S)-flurbiprofen (mcg/ml) 
Fy2 Fy3 Fy4 mean s. d. 
0.50 0.42 3.81 1.56 2.11 1.98 1.41 0.38 3.75 1.53 2.15 1 95 1 40 
1.00 5.13 8.47 4.47 4.09 5.54 2.00 4.70 8.20 4.28 4.01 5.30 196 
1.50 6.05 8.85 7.74 4.64 6.82 1.85 5.40 8.34 7 42 4.52 6 42 176 
2.00 6.34 8.07 7.21 4.57 6.55 1.50 5.47 7.40 7.51 4 76 6 29 1 38 
3.00 6.15 5.95 5.16 4.26 5.38 0.86 5.51 5.36 5.74 4.83 5 36 0.39 
4.00 4.84 4.30 4.16 3.87 4.29 0.41 4.70 3.97 4.51 4.50 4 42 031 
5.00 3.76 3.40 3.04 3.23 3.36 0.31 3.53 3.17 3.48 4 00 3 55 0 34 
6.00 2.66 2.53 2.39 2.60 2.55 0.12 2.70 2.54 2.80 3.27 2 83 031 
7.00 2.25 1.86 1.93 2.03 2.02 0.17 2.43 1.92 2.29 2.65 _ 32 031 
8.00 1.81 1.53 1.59 1.71 1.66 0.12 1.99 1.58 1.92 2.36 196 032 
10.00 1.28 1.10 1.25 1.25 1.22 0.08 1.41 1.10 1.49 2.04 1 51 0.39 
12.00 0.88 0.74 0.75 0.94 0.83 0.10 1.00 0.80 0.96 1.54 1 08 0.32 
24.00 0.12 0.11 0.15 0.23 0.15 0.05 0.19 0.16 0.23 0.42 0.25 012 
(R)-4'-hydroxyflurbiprofen (mcg/ml) (S)-4'-hydroxyflurbiprofen (mcg/ml) 
Time (hr) Fyl Fy2 Fy3 Fy4 mean s. d. Fyl Fy2 Fy3 Fy4 mean s. d. 
0.50 0.03 0.11 0.05 0.02 0.05 0.04 0.04 0.14 0.09 0.04 0 08 0 05 
1.00 0.20 0.36 0.29 0.21 0.27 0.08 0.34 0.45 0.47 0.29 0.39 009 
1.50 0.34 0.54 0.52 0.27 0.42 0.13 0.50 0.69 0.85 0.37 0 60 021 
2.00 0.43 0.93 0.59 0.28 0.56 0.28 0.59 1.33 0.95 0.39 0.82 041 
3.00 0.41 0.76 0.54 0.29 0.50 0.20 0.57 1.06 0.84 0.37 071 
030 
4,00 0.43 0.59 0.40 0.25 0.42 0.14 0.49 0.77 0.68 0.32 
0 57 0 20 
5.00 0.21 0.30 0.16 0.16 0.21 0.07 0.23 0 34 0.25 0 
20 0.26 0 06 
6.00 0.15 0.20 0.13 0.13 0.15 0.03 0.18 0.23 0.20 
0.17 0 20 0 03 
7.00 0.14 0.16 0.10 0.11 0.13 0.03 0.18 0.19 0.17 
0.14 0.17 0 02 
8 00 0.12 0.14 0.08 0.08 0.11 0.03 0.16 0.17 
0.15 0.12 0 15 0 02 
10.00 0.10 0.10 0.06 0.07 0.08 0.02 0.15 
0.13 0.12 0.11 0.13 002 
12.00 0.07 0.07 0.05 0.05 0.06 0.01 0.14 
0.09 0.09 0.08 0.10 0 03 
24.00 0.02 0.02 0.02 0.02 0.02 0.00 0.07 
0.04 0.05 0.05 0.05 0.01 
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Appendix 12: Serum concentrations (mcg/ml) for (R)- and (S)-flurbiprofen and (R)- and (S)- 
4'-hydroxyflurbiprofen in individual healthy elderly volunteers following the oral administration of 
100 mg racemic flurbiprofen. 
Time (hr) Fel 
(R)-}lurbiprofen (mcg/ml) 
Feg Fe3 Fe4 mean s. d. Fel 
(S)-flurbiprofen (mcg/ml) 
Fe2 Fe3 Fe4 mean s. d. 
0.50 0.00 0.00 7.46 0.24 1.93 3.69 0.00 0.00 7.15 0.20 1.84 3 54 
1.00 0.30 0.34 8.12 4.13 3.22 3.73 0.26 0.30 7.69 4.04 1 07 1 1i 
1.50 1.13 1.67 7.89 7.51 4.55 3.65 1.07 1.52 7.22 7.12 4 23 140 
2.00 9.27 3.18 7.36 8.93 7.19 2.80 8.56 2.94 6.69 8.19 6 60 257 
3.00 10.93 5.57 6.56 6.95 7.50 2.36 10.18 5.12 5.99 6.58 6 97 2.22 
4.00 8.74 4.63 4.59 5.02 5.75 2.01 9.27 4.80 4.51 5 25 5 96 2 23 
5 00 7.14 4.22 3.98 4.36 4.93 1.48 8.02 4.30 4.02 4.68 5 26 186 
6.00 5.86 3.56 3.59 3.33 4.09 1.19 6.90 3 79 3.75 3.70 4 54 1 58 
7.00 4.70 3.00 3.06 3.14 3.48 0.82 5.67 3.25 3.21 3.44 3.89 119 
8.00 4.15 2.78 2.95 2.69 3.14 0.68 5.01 3.00 3.00 2.91 148 I02 
10.00 3.36 2.03 2.42 2.35 2.54 0.57 4.06 2.21 2.52 2.47 2 82 0 84 
12.00 2.88 1.72 1.94 1.81 2.09 0.54 3.66 1.89 2 17 1.96 2 42 0 84 
24.00 0.89 0.72 0.72 0.43 0.69 0.19 1.61 0.85 1.03 0.71 1.05 0 40 
(R)-4'-hydroxyflurbiprofen (mcg/mI) (S)-4'-hyd roxyflu rbipro fen (mcg/mI) 
Time (hr) Fel Fe2 Fe3 Fe4 mean s. d. Fel Feg Fei Fe4 mean s. d. 
0.50 0.00 0,00 0.14 0.00 0.04 0.07 0.00 0.00 0.18 0.00 0 05 009 
1.00 0.00 0.00 0.25 0.08 0.08 0.12 0.00 0.00 0.29 0.11 010 0.14 
1.50 0.05 0.09 0.59 0.28 0.25 0.25 0.08 0.14 0.74 0.38 0 34 0 30 
2.00 0.36 0.19 0.61 0.42 0.40 0.17 0.51 0.29 0.77 0.55 0 53 020 
3.00 0.63 0.35 0.63 0.49 0.53 0.13 0.92 0.52 0.74 0.62 070 
0.17 
4.00 0.71 0.44 0.51 0.42 0.52 0.13 0.93 0.56 0.55 0.48 063 
0.20 
5.00 0.41 0.48 0.47 0.37 0.43 0.05 0.52 0.61 0.48 0.42 
0.51 008 
6.00 0.34 0.24 0.27 0.21 0.27 0.06 0.44 0.27 0.26 0.24 
0 30 009 
7.00 0.27 0.21 0.25 0.18 0.23 0.04 0.37 0.24 0.25 
0.21 0.27 0 07 
8.00 0.23 0.21 0.24 0,16 0.21 0.04 0.34 0.23 0.24 
0.20 0 25 006 
10.00 0.18 0.17 0.23 0.14 0.18 0.04 0.28 0.20 
0.24 0.17 0.22 0.05 
12.00 0.16 0.16 0.18 0.12 0.16 0.03 0.26 0.18 
0.19 0.16 0.20 004 
24.00 0.07 0.08 0.08 0.05 0.07 0.01 0.14 
0.11 0.10 0.09 0.11 002 
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Appendix 13: Cumulative urinary excretion of flurbiprofen enantiomers in individual health', 
young volunteers following the oral administration of 100 mg racemic flurbiprofen. 
total flurbiprofen (% of administered dose) 
0-2hr 0-4hr 0-6hr 0-8hr 0-10hr 0-12hr 0-22 hr 0- 24hr 
Subject R S R S R S RS RS R S R S R S 
Fyl 0.71 0.68 1.40 1.33 2.16 2.05 3.33 3.16 5.15 4.88 6.90 6.54 11.76 11.15 12 82 1_ 16 
Fy2 0.66 0.58 2.31 2.04 3.99 3.53 5.34 4.72 5.80 5.13 6.26 5.54 7.74 6.85 8.50 - 5_ 
Fy3 0.21 0.17 2.09 1.70 3.95 3.21 5.23 4.25 6.01 4.89 6.55 5.32 10.47 8 52 10.65 866 
Fy4 0.29 0.24 0.41 0.34 1.31 1.08 3.73 3.08 5.14 4.25 7.37 6.09 13.12 10.85 1373 1135 
mean 0.47 0.42 1.55 1.35 2.85 2.47 4.41 3.80 5.53 4.79 6.77 5.87 10.77 9.34 11 42 991 
0.26 0.25 0.86 0.74 1.34 1.12 1.03 0.81 0.45 0.38 0.48 0.55 2 29 2 04 2 34 2 19 
conjugated flurbiprofen (% of administered dose) 
0-2 hr 0-4hr 0-6hr 0-8hr 0-10hr 0-I2hr 0-22 hr 0-2 4hr 
Subject R S R S R S RS RS R S R S R S 
Fyl 0.43 0.41 0.85 0.80 1.31 1.23 2.01 1.90 3.12 2.95 4.17 3.95 7.12 6.73 776 7.34 
Fy2 0.54 0.48 1.90 1.69 3.29 2.92 4.40 3.91 4.79 4.25 5.16 4.58 6.38 5.66 7.01 6 22 
Fy3 0.16 0.13 1.65 1.34 3.12 2.53 4.14 3.35 4.76 3.85 5.18 4.19 8.29 671 8 43 6.82 
Fy4 0.22 0.18 0.31 0.26 1.00 0.82 2.86 2.35 3.94 3.23 5.65 4.64 10.06 826 10.53 864 
mean 0.34 0.30 1.18 1.02 2.18 1.88 3.35 2.88 4.15 3.57 5.04 4.34 7 96 6 84 8 43 726 
s. d. 0.18 0.17 0.73 0.63 1.19 1.01 1.12 0.91 0.79 0.59 0.62 0.33 1.61 1.07 1.51 1.03 
free flurbiprofen (% of administered dose) 
0-2hr 0-4hr 0-6hr 0-8 hr 0-10hr 0-12hr 0-22 hr 
0- 24hr 
Subject R S R S R S RS RS R S 
R S R S 
Fyl 0.28 0.27 0.55 0.53 0.85 0.81 1.31 1.25 2.03 1.94 2.72 2.59 
4.64 4.42 506 4 82 
Fy2 0.12 0.10 0.40 0.35 0.70 0.61 0.94 0.82 1.02 0.89 1.10 
0.96 1.36 118 149 130 
Fy3 0.04 0.04 0.43 0.36 0.82 0.68 1.09 0.90 1.25 1.04 1.36 
1.13 2.18 181 2 222 1 84 
Fy4 0.07 0.06 0.09 0.08 0.30 0.26 0.87 0.74 1.20 1.01 1.72 

































Appendix 14: Cumulative urinary excretion of 4'-hydroxyflurbiprofen enantiomers in individual 
healthy young volunteers following the oral administration of 100 mg racemic flurbiprofen. 
total 4'-hydroxyfiurbiprofen (% of administered dose) 
0-2hr 0-4hr 0-6hr 0-Shr 0-10hr 0-12 hr 0-22 hr 0- : 4hr 
Subject R S R S R S RS RS R S R S 
Fyl 1.44 1.18 2.82 2.31 4.35 3.56 6.70 5.49 10.37 8.50 13.89 11 39 23.69 1a 41 25 83 21 
Fy2 2.07 1.72 7.24 6.01 12.53 10.39 16.74 13.88 18.20 15.10 19.63 16.28 24 27 20.13 2666 22 11 
Fy3 0.45 0.40 4.56 4.05 8.62 7.67 11.42 10.16 13.13 11.68 1431 12.73 22 88 2035 23 2- 20 - 
Fy4 0.54 0.46 0.76 0.65 2.43 2.08 6.94 5.95 9.56 8.19 13.71 11.74 2441 2091 25 55 21 88 
mean 1.12 0.94 3.84 3.25 6.98 5.93 10.45 8.87 12.82 10.87 15.39 13.03 23.81 20_20 2i 3; 11 46 
s. d. 0.77 0.63 2.75 2.30 4.51 3.80 4.72 3.95 3.90 3.23 2.84 2.24 0.70 0.62 1.45 065 
4'-hydroxyflurbiprofen acyl-conjugate (% of administered dose) 
0-2 hr 0-4 hr 0-6hr 0-8hr 0-10hr 0-12hr 0-22 hr 0-24hr 
Subject R S R S R S R S R S R S R S R S 
Fy1 0.87 0.71 1.71 1.38 2.63 2.14 4.06 3.30 6.29 5.10 8.42 6.83 14.36 11.65 15.66 1270 
Fy2 1.52 1.25 5.33 4.36 9.21 7.55 12.31 10.08 13.38 10.96 14.43 11.82 1784 14 62 19.60 16.06 
Fy3 0.35 0.30 3.52 3.01 6.65 5.69 8.81 7.54 10.14 8.67 11.04 9.44 1766 15 10 1796 15 36 
Fy4 0.41 0.34 0.58 0.48 1.85 1.53 5.29 4.37 7.29 6.02 10.46 8.64 18.61 15 37 19.48 1609 
mean 0.79 0.65 2.78 2.31 5.09 4.23 7.62 6.32 9.28 7.69 11.09 9.18 17.12 14 19 18.18 15 05 
s. d. 0.54 0.44 2.08 1.72 3.46 2.87 3.72 3.09 3.19 2.66 2.50 2.07 1 88 1.72 184 
160 
4'-hydroxyflurbiprofen phenol-conjugate (% of administered dose) 
0-2hr 0-4hr 0-6hr 0-8 hr 0-10hr 0-l2hr 0-22 
hr 0-24hr 
Subject R S R S RS RS RS RS 
R S R ý' 
FyI 0.04 0.00 0.09 0.00 0.13 0.00 0.20 0.00 0.31 0.00 
0.42 0.00 0.72 0.00 0.78 0.00 
Fy2 0.26 0.21 0.90 0.73 1.55 1.27 2.07 1.70 2.25 1.84 
2.43 1.99 3.00 2.46 3 30 2 70 
Fy3 0.01 0.02 0.14 0.16 0.26 0.31 0.34 0.41 0.39 
0.47 0 42 0.51 0.68 0.82 0 69 0 83 
Fy4 0.01 0.01 0.01 0.02 0.04 0.05 0.12 0.14 0.16 
0.19 0.23 0.27 0.41 049 0 43 051 
0 08 0 06 28 0 0 23 0.49 0.41 0.68 0.56 0.78 










0.35 0.71 0.59 0.93 0.78 0.99 0.83 1.04 
























free 4'-hydroxyflurbiprofen (% of administered dose) 
0-10hr 0-12hr 0-6hr 0-Shr ý 
SRS 
RSRSR 
1.58 1.43 2.44 2.20 3.78 
3.40 5.06 4.56 
1.77 1.58 2.37 2.11 2.57 
2.29 2.78 2.47 
1.71 1.67 2.27 2.21 2.61 
2.54 2.84 2.77 
0.54 0.50 1.53 1.44 2.11 
1.98 3.03 2.83 
1.40 1.29 2.15 1.99 2.77 
2.55 3.42 3.16 
0.58 0.54 0.42 0.37 
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Appendix 15: Cumulative urinary excretion of 3'-hydroxy-4'-methoxyflurbiprofen enantiomers in 
individual healthy young volunteers following the oral administration of 100 mg racemic 
flurbiprofen. 
total 3'-hydroxy-4'-methoxyflurbiprofen (% of administered dose) 
0-2hr 0-44hr 0-6hr 0-8 hr 0-10hr 0-12hr 0-22 hr 0- 24hr 
Subject R S R S RS RS RS RS R S R S 
FyI 0.13 0.13 0.25 0.26 0.39 0.40 0.59 0.62 0.92 0.96 1.23 1.29 2.10 2.20 2.29 2 40 
Fy2 0.13 0.20 0.47 0.70 0.81 1.22 1.08 1.63 1.18 1.77 1.27 1.91 1.57 2.36 1 73 2 59 
Fy3 0.04 0.04 0.40 0.44 0.75 0.83 0.99 1.10 1.14 1.26 1 24 1.38 1.98 2.20 2.02 2 24 
Fy4 0.03 0,04 0.05 0.05 0.15 0.17 0.44 0.47 0.61 0.65 0.87 0.93 1.55 1.66 163 I74 
mean 0,08 0.10 0.29 0.36 0.52 0.65 0.78 0.96 0.96 1.16 1.15 1.38 1.80 2.11 1 91 22 24 
s. d. 0.05 0.08 0.19 0.28 0.31 0.47 0.31 0.52 0.26 0.48 0.19 0.40 0.28 0.30 0.30 0.37 
3'-hydroxy-4'-methoxyflurbiprofen acyl-conjugate (% of administered dose) 
0-2hr 0-4hr 0-6hr 0-8 hr 0-10hr 0-12hr 0-22 hr 0-24hr 
Subject RSRSRSRSRSRSRSRS 
Fy l 0.003 0.002 0.006 0.004 0.009 0.006 0.014 0.009 0.021 0.013 0.029 0.018 0.049 0 030 0.053 0.033 
Fy2 0.005 0.004 0.017 0.015 0.030 0.026 0.040 0.035 0.044 0.038 0.047 0.041 0.058 0.051 0 064 0.056 
Fy3 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Fy4 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0000 
mean 0.002 0.002 0.006 0.005 0.010 0.008 0.013 0.011 0.016 0.013 0.019 0.015 0.027 0.020 
0 029 0,022 
s. d. 0.002 0.002 0.008 0.007 0.014 0,013 0.019 0.017 0.021 0.018 0.023 0.020 0.031 
0.025 0.034 0027 
3'-hydroxy-41-methoxyllurbiprofen phenol-conjug ate (% of administered dose) 
0-2hr 0-4hr 0-6hr 0-8hr 0-10hr 0-12hr 
0-22 hr 0-24hr 
Subject R S R S RS RS R S R 
S R S R S 
Fyl 0.12 0.13 0.24 0.25 0.37 0.39 0.56 0.59 0.87 0.92 1.17 
1.23 1.99 210 217 229 
Fy2 0.13 0.20 0.45 0.68 0.77 1.18 1.03 1.58 1.12 1.72 
I21 1.86 1.50 2.29 165 2.52 
Fy3 0.04 0.04 0.40 0.44 0.75 0.83 0.99 1.10 1.14 1.26 
1.24 1.38 1.98 2.20 2.02 2 24 
Fy4 0.03 0.04 0.05 0.05 0.15 0.17 0.44 0.47 0.61 0.65 
0.87 0.93 1.55 1.66 1.63 1 74 
an 0 08 0 10 0 28 0 36 0.51 0.64 0.76 
0.94 0.94 1.14 1.12 1.35 1.76 










0.27 0.30 0.46 0.30 0.51 0.25 0.46 
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biprofen (% of administered dose) 
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Appendix 16: Cumulative urinary excretion of flurbiprofen enantiomers in individual healthy 
elderly volunteers following the oral administration of 100 mg racemic flurbiprofen. 
total flurbiprofen ( % of administered dose) 
0-2hr 0-4 hr 0-6hr 0-8hr 0-10hr 0-12hr 0-22 hr 0-24hr 



























































































conjugated flurbiprofen (% of administered dose) 
0-2hr 0-4hr 0-6hr 0-8 hr 0-10hr 0-12hr 0-22 hr 0-24hr 



























































































free flurbiprofen (% of administered dose) 
0-2hr 0-4hr 0-6hr 0-8hr 0-10hr 0-12hr 0-22 hr 0-24hr 




























































































Appendix 17: Cumulative urinary excretion of 4'-hydroxyflurbiprofen enantiomers 
in individual 
healthy elderly volunteers following the oral administration of 
100 mg racemic flurbiprofen. 
total 4'-hydroxyflurbiprofen (% of administered dose) 
0-2hr 0-4 hr 0-6hr 0-8 hr 0-1 0hr 0-12hr 0-22 hr 
0-24hr 
Subject R S R S R S R S R S R S R 







































































































4'-hydroxyflurbiprofen acyl-conjugate (% of administered dose ) 
0-2hr 0-4hr 0-6hr 0-8hr 0-10hr 0-12hr 0-22 hr 0-24hr 







































































































4'-hydroxyflurbiprofen phenol-conjugate (% of administered dose) 
0-2hr 0-4hr 0-6hr 0-8hr 0-10hr 0-12hr 0-22 hr 0-24hr 







































































































free 4'-hydroxyllurbiprofen (% of administered dose) 
0-2hr 0-4hr 0-6hr 0-8hr 0-10hr 0-12hr 0-22 hr 0-24hr 
Subject R S R S R S RS RS R S R S R S 
Fel 1.43 1.23 1.63 1.40 2.01 1.73 2.26 1.94 2.74 2 35 3.16 2.72 9.70 8.34 11.36 9.76 
Feg 1.03 0.94 1.22 1.11 1.56 1.43 216 1.98 2.77 2.53 2.90 2.65 6.57 6.02 712 6.52 
Fe3 0.04 0.03 0.10 0.08 0.16 0.13 0.21 0.17 0.32 0.25 0.45 0.36 1.64 1.30 1.93 1.53 
Fe4 2.07 1.69 3.02 2.46 4.32 3.52 5.33 4.35 6.93 5.65 7.69 6.27 15.89 12.96 16.51 13.47 
mean 1.14 0.97 1.49 1.26 2.01 1.70 2.49 2.11 3.19 2.70 3.55 3.00 8.45 7.16 9.23 782 
s. d. 0.85 0.70 1.21 0.98 1.73 1.40 2.12 1.72 2.75 2.23 3.02 2.44 5.97 4.85 6.20 5.07 
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Appendix 18: Cumulative urinary excretion of 3'-hydroxy-4'-methoxyflurbiprofen enantiomers in 
individual healthy elderly volunteers following the oral administration of 100 mg racemic 
flurbiprofen. 
total 3'-hydroxy-4'-methoxyflurbiprofen (% of administered dose) 
0-2hr 0-4hr 0-6hr 0-8hr 0-10hr 0-12hr 0-22 hr 0-24hr 
Subject RSRSRSRSRSRSRSRS 
Fel 0.17 0.14 0.19 0.16 0.24 0.20 0.27 0.23 0.32 0.27 0.37 0.32 1.15 0.97 1.34 1.14 
Feg 0.25 0.22 0.30 0.26 0.39 0.33 0.54 0.45 0.68 0.58 0.72 0.61 1.63 1.38 1.76 1.49 
Fe3 0.04 0.04 0.11 0.10 0.17 0.15 0.22 0.20 0.33 0.30 0.47 0.42 1.71 1.53 2.01 1.80 
Fe4 0.13 0.15 0.19 0.21 0.27 0.30 0.33 0.38 0.43 0.49 0.48 0.54 0.98 1.12 1.02 1.16 
mean 0.15 0.14 0.20 0.18 0.26 0.25 0.34 0.31 0.44 0.41 0.51 0.47 1.37 1.25 1.53 1.40 
s. d. 0.09 0.07 0.08 0.07 0.09 0.08 0.14 0.12 0.17 0.15 0.15 0.13 0.36 0.25 0.44 0.31 
3'-hydroxy-4'-methoxyllurbiprofen acyl-conjugate (% of administered dose) 
0-2hr 0-4hr 0-6hr 0-8hr 0-10hr 0-12hr 0-22 hr 0-24hr 
Subject R S R S RS RS RS RS R S R S 
Fel 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Feg 0.006 0.005 0.007 0.006 0.009 0.008 0.013 0.011 0.017 0.014 0.018 0.015 0.040 0.033 0.043 0.036 
Fe3 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Fe4 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
mean 0.002 0.001 0.002 0.002 0.002 0.002 0.003 0.003 0.004 0.003 0.004 0.004 0.010 0.008 0.011 0.009 
s. d. 0.003 0.003 0.004 0.003 0.005 0.004 0.007 0.005 0.008 0.007 0.009 0.007 0.020 0.017 0.022 0.018 
3'-hydroxy-4'-methoxyflurbiprofen phenol-conjugate (% of administered dose) 
0-2hr 0-4hr 0-6hr 0-8 hr 0-10hr 0-12hr 0-22 hr 0-24hr 
Subject RSRSRSRSRSRSRSRS 
Fel 0.17 0.14 0.19 0.16 0.24 0.20 0.27 0.23 0.32 0.27 0.37 0.32 1.15 0.97 1.34 114 
Fe2 0.24 0.20 0.28 0.24 0.36 0.31 0.50 0.43 0.64 0.55 0.67 0.57 1.53 1.30 1.66 1.41 
Fe3 0.04 0.04 0.11 0.10 0.17 0.15 0.22 0.20 0.33 0.30 0.47 0.42 1.71 1.53 2.01 1.80 
Fc4 0.13 0.15 0.19 0.21 0.27 0.30 0.33 0.38 0.43 0.49 0.48 0.54 0.98 1.12 1.02 1.16 
mean 0.14 0.13 0.19 0.18 0.26 0.24 0.33 0.31 0.43 0.40 0.50 0.46 1.34 1.23 1.51 1.38 
s. d. 0.08 0.07 0.07 0.06 0.08 0.08 0.12 0.11 0.15 0.14 0.13 0.12 0.34 0.24 0.42 
031 
free 3'-hydroxy-4'-methoxyflurbiprofen (% of administered dose) 
0-2hr 0-4hr 0-6hr 0-8 hr 0-10hr 0-12hr 0-22 hr 0-24hr 
Subject RSRSRSRSRSRSRSRS 
Fe l 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
0.000 
Feg 0,009 0.008 0.011 0.009 0.014 0.012 0.019 0.016 0.024 0.021 0.025 0.022 0.057 0.050 0.062 
0.054 
Fe3 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
0.000 0.000 
Fe4 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
0.000 0.000 
mean 0.002 0.002 0.003 0.002 0.003 0.003 0.005 0.004 0.006 0.005 
0.006 0.005 0.014 0.012 0 016 0.013 
s. d. 0.004 0.004 0.005 0.005 0.007 0.006 0.009 0.008 0.012 0.010 
0.013 0.011 0.029 0.025 0 031 002, 
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